OA18996A - Substituted Spirocyclic Inhibitors of Autotaxin - Google Patents
Substituted Spirocyclic Inhibitors of Autotaxin Download PDFInfo
- Publication number
- OA18996A OA18996A OA1201600370 OA18996A OA 18996 A OA18996 A OA 18996A OA 1201600370 OA1201600370 OA 1201600370 OA 18996 A OA18996 A OA 18996A
- Authority
- OA
- OAPI
- Prior art keywords
- methyl
- decan
- triazaspiro
- fluoro
- dioxo
- Prior art date
Links
- 102100016621 ENPP2 Human genes 0.000 title claims description 41
- 101700057276 ENPP2 Proteins 0.000 title claims description 41
- 230000002401 inhibitory effect Effects 0.000 title claims description 27
- 239000003112 inhibitor Substances 0.000 title claims description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 219
- -1 synthesis Substances 0.000 claims abstract description 78
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 206010061218 Inflammation Diseases 0.000 claims abstract description 12
- 230000003176 fibrotic Effects 0.000 claims abstract description 12
- 230000004054 inflammatory process Effects 0.000 claims abstract description 12
- 230000001684 chronic Effects 0.000 claims abstract description 10
- 206010064190 Cholestatic pruritus Diseases 0.000 claims abstract description 9
- 210000004698 Lymphocytes Anatomy 0.000 claims abstract description 9
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 9
- 230000001404 mediated Effects 0.000 claims abstract description 8
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 175
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 91
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 82
- 229910020008 S(O) Inorganic materials 0.000 claims description 61
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 53
- 229910052739 hydrogen Inorganic materials 0.000 claims description 45
- 229910052757 nitrogen Inorganic materials 0.000 claims description 45
- 125000005843 halogen group Chemical group 0.000 claims description 44
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 42
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 42
- 239000005711 Benzoic acid Substances 0.000 claims description 41
- 235000010233 benzoic acid Nutrition 0.000 claims description 41
- 229910052760 oxygen Inorganic materials 0.000 claims description 38
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 34
- 125000005842 heteroatoms Chemical group 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 19
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 claims description 17
- 208000002193 Pain Diseases 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 16
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 15
- 206010016654 Fibrosis Diseases 0.000 claims description 14
- 206010029331 Neuropathy peripheral Diseases 0.000 claims description 14
- 230000004761 fibrosis Effects 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 8
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 claims description 7
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 claims description 7
- 238000005755 formation reaction Methods 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- PWXJULSLLONQHY-UHFFFAOYSA-M N-phenylcarbamate Chemical compound [O-]C(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-M 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- ILVXOBCQQYKLDS-UHFFFAOYSA-N Pyridine-N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 5
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 4
- 210000004185 Liver Anatomy 0.000 claims description 4
- 206010027476 Metastasis Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 102100015381 PTGS2 Human genes 0.000 claims description 4
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
- 239000002464 receptor antagonist Substances 0.000 claims description 4
- KIYAHTYTVMZFTM-UQBPGWFLSA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C1)F KIYAHTYTVMZFTM-UQBPGWFLSA-N 0.000 claims description 3
- CWSQVYFGLYCBFT-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F CWSQVYFGLYCBFT-OAQYLSRUSA-N 0.000 claims description 3
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims description 3
- 108009000252 Lung fibrosis Proteins 0.000 claims description 3
- 206010025650 Malignant melanoma Diseases 0.000 claims description 3
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims description 3
- 201000003741 gastrointestinal carcinoma Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 210000000056 organs Anatomy 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- QWEWLLNSJDTOKH-UHFFFAOYSA-N 1,3-thiazole-2-carboxamide Chemical compound NC(=O)C1=NC=CS1 QWEWLLNSJDTOKH-UHFFFAOYSA-N 0.000 claims description 2
- DDLPGTOHZZKQLP-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC(C(F)(F)F)=CC=C1F DDLPGTOHZZKQLP-UHFFFAOYSA-N 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000006673 Asthma Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- JQXPNFVKZCESQZ-RUZDIDTESA-N C(#N)CN1C(N(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)C2=CC=C(C=C2)OC)=O Chemical compound C(#N)CN1C(N(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)C2=CC=C(C=C2)OC)=O JQXPNFVKZCESQZ-RUZDIDTESA-N 0.000 claims description 2
- OGGLMNLWYAICPS-HOYKHHGWSA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)[C@@H](C)OC)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)[C@@H](C)OC)C1)F OGGLMNLWYAICPS-HOYKHHGWSA-N 0.000 claims description 2
- YXAWXHAIPIUYAF-RUZDIDTESA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=CC=4N(C=3)C(=NC=4)C)=O)C)=O)CC2)C(C)C)C=1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=CC=4N(C=3)C(=NC=4)C)=O)C)=O)CC2)C(C)C)C=1)F YXAWXHAIPIUYAF-RUZDIDTESA-N 0.000 claims description 2
- PYZWTJUUYLSWCJ-AREMUKBSSA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(OCC(=O)O)C=C3)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(OCC(=O)O)C=C3)C)=O)CC2)C(C)C)C1)F PYZWTJUUYLSWCJ-AREMUKBSSA-N 0.000 claims description 2
- FEEIXHTXTABLRV-JOCHJYFZSA-N C(C1=CC=CC=C1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound C(C1=CC=CC=C1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O FEEIXHTXTABLRV-JOCHJYFZSA-N 0.000 claims description 2
- UBCHOWVYKLDUSP-RUZDIDTESA-N C1(CC1)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=CC1 Chemical compound C1(CC1)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=CC1 UBCHOWVYKLDUSP-RUZDIDTESA-N 0.000 claims description 2
- GNLVIJDIHHCHMW-LJQANCHMSA-N C1(CC1)CN1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound C1(CC1)CN1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O GNLVIJDIHHCHMW-LJQANCHMSA-N 0.000 claims description 2
- IBGQJSIESRIIGY-RUZDIDTESA-N C1(CC1)CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)C1=CC=C(C(=O)O)C=C1 Chemical compound C1(CC1)CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)C1=CC=C(C(=O)O)C=C1 IBGQJSIESRIIGY-RUZDIDTESA-N 0.000 claims description 2
- XYFFYFXZKIBNEK-OAQYLSRUSA-N C1(CCCCC1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound C1(CCCCC1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O XYFFYFXZKIBNEK-OAQYLSRUSA-N 0.000 claims description 2
- WFHYLAWROUXHOF-RUZDIDTESA-N C1(CCCCC1)[C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=CC=C2)=O)C)=O)CC1)NC(C1=CC(=CC=C1)C)=O Chemical compound C1(CCCCC1)[C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=CC=C2)=O)C)=O)CC1)NC(C1=CC(=CC=C1)C)=O WFHYLAWROUXHOF-RUZDIDTESA-N 0.000 claims description 2
- OEARUEAHUJSOKP-XMMPIXPASA-N CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(NC2COC2)C=C1 Chemical compound CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(NC2COC2)C=C1 OEARUEAHUJSOKP-XMMPIXPASA-N 0.000 claims description 2
- XNSIWDJGVGEHNG-KRZHYRLCSA-N CC([C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)OC([2H])([2H])[2H])=O)C)=O)CC1)NC(C1=CC(=CC(=C1)F)C(F)(F)F)=O)C Chemical compound CC([C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)OC([2H])([2H])[2H])=O)C)=O)CC1)NC(C1=CC(=CC(=C1)F)C(F)(F)F)=O)C XNSIWDJGVGEHNG-KRZHYRLCSA-N 0.000 claims description 2
- YEBVGOIYHPKGTI-HSZRJFAPSA-N CC=1OC2=C(N=1)C=C(C=C2)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound CC=1OC2=C(N=1)C=C(C=C2)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O YEBVGOIYHPKGTI-HSZRJFAPSA-N 0.000 claims description 2
- QQXOMARFNQGCBI-HSZRJFAPSA-N COC1=CC=C(CN2C(=O)N(C)C(=O)C22CCN(CC2)C(=O)[C@H](NC(=O)C2=C(F)C=CC(=C2)C(F)(F)F)C(C)C)C=C1 Chemical compound COC1=CC=C(CN2C(=O)N(C)C(=O)C22CCN(CC2)C(=O)[C@H](NC(=O)C2=C(F)C=CC(=C2)C(F)(F)F)C(C)C)C=C1 QQXOMARFNQGCBI-HSZRJFAPSA-N 0.000 claims description 2
- 206010058019 Cancer pain Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 2
- FWQXBPDCDUMPMX-OAQYLSRUSA-N ClC1=CC=C(C=C1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound ClC1=CC=C(C=C1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O FWQXBPDCDUMPMX-OAQYLSRUSA-N 0.000 claims description 2
- XTHYGPKTTMYUHE-JOCHJYFZSA-N ClC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=C(C=1)C(F)(F)F Chemical compound ClC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=C(C=1)C(F)(F)F XTHYGPKTTMYUHE-JOCHJYFZSA-N 0.000 claims description 2
- QRTLPAYPYOBWKI-OAQYLSRUSA-N ClC=1C=C(C=CC1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound ClC=1C=C(C=CC1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O QRTLPAYPYOBWKI-OAQYLSRUSA-N 0.000 claims description 2
- 206010009905 Collagen-vascular disease Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims description 2
- 229960001334 Corticosteroids Drugs 0.000 claims description 2
- 108010037464 Cyclooxygenase 1 Proteins 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- KFTMKTOJVHOBGJ-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC4=CN(N=C4C=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC4=CN(N=C4C=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F KFTMKTOJVHOBGJ-HSZRJFAPSA-N 0.000 claims description 2
- WVJFJUVNPHYXQD-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=[N+](C=C3)[O-])=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=[N+](C=C3)[O-])=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F WVJFJUVNPHYXQD-HXUWFJFHSA-N 0.000 claims description 2
- SVIMIKSMBLUDTA-OBFZPWGMSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3CCC(CC3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3CCC(CC3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F SVIMIKSMBLUDTA-OBFZPWGMSA-N 0.000 claims description 2
- CJYDPDOXVLTDPZ-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=C4C=NN(C4=CC3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=C4C=NN(C4=CC3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F CJYDPDOXVLTDPZ-HSZRJFAPSA-N 0.000 claims description 2
- ZGWXCVZYJDJXBF-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=CC4=C(NC(O4)=O)C=3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=CC4=C(NC(O4)=O)C=3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F ZGWXCVZYJDJXBF-OAQYLSRUSA-N 0.000 claims description 2
- JZWGMGWQHXSVTH-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=NC(=CC=3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=NC(=CC=3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F JZWGMGWQHXSVTH-OAQYLSRUSA-N 0.000 claims description 2
- KJHTYHAUNFWGTP-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC=C(C=C3)S(=O)(=O)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC=C(C=C3)S(=O)(=O)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F KJHTYHAUNFWGTP-HSZRJFAPSA-N 0.000 claims description 2
- XSPPBSRUOZLLIM-FDDCHVKYSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3[C@@H](C)C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3[C@@H](C)C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F XSPPBSRUOZLLIM-FDDCHVKYSA-N 0.000 claims description 2
- LLXKRJNAHLSYTL-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=CC=C1C Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=CC=C1C LLXKRJNAHLSYTL-HSZRJFAPSA-N 0.000 claims description 2
- QJCCUDVULRJUPE-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)B(O)O)C)=O)CC2)C(C)C)C=CC=C1C Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)B(O)O)C)=O)CC2)C(C)C)C=CC=C1C QJCCUDVULRJUPE-HSZRJFAPSA-N 0.000 claims description 2
- IWULRNJVGTUITM-UZUQRXQVSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F IWULRNJVGTUITM-UZUQRXQVSA-N 0.000 claims description 2
- 208000005017 Glioblastoma Diseases 0.000 claims description 2
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims description 2
- 102100004188 LIPC Human genes 0.000 claims description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 2
- 229940065725 Leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims description 2
- 208000002780 Macular Degeneration Diseases 0.000 claims description 2
- KWOKRNLQLCBPBQ-JOCHJYFZSA-N O1C=NC2=C1C=CC(=C2)N2C(N(C(C21CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound O1C=NC2=C1C=CC(=C2)N2C(N(C(C21CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O KWOKRNLQLCBPBQ-JOCHJYFZSA-N 0.000 claims description 2
- VQJKWNQTZOTJSH-GJFSDDNBSA-N OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(NC2CNC2)C=C1 Chemical compound OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(NC2CNC2)C=C1 VQJKWNQTZOTJSH-GJFSDDNBSA-N 0.000 claims description 2
- 102100006335 PTGS1 Human genes 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 108010058868 Phospholipases A1 Proteins 0.000 claims description 2
- XIPFMBOWZXULIA-UHFFFAOYSA-N Pivalamide Chemical compound CC(C)(C)C(N)=O XIPFMBOWZXULIA-UHFFFAOYSA-N 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 102000015433 Prostaglandin Receptors Human genes 0.000 claims description 2
- 108010050183 Prostaglandin Receptors Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims description 2
- 206010038436 Renal failure acute Diseases 0.000 claims description 2
- 206010038444 Renal failure chronic Diseases 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010050207 Skin fibrosis Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 101710040537 TNF Proteins 0.000 claims description 2
- 108010016133 acylglycerol kinase Proteins 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 230000003110 anti-inflammatory Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 125000005418 aryl aryl group Chemical group 0.000 claims description 2
- 201000001320 atherosclerosis Diseases 0.000 claims description 2
- 230000003182 bronchodilatating Effects 0.000 claims description 2
- 239000000168 bronchodilator agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002559 chemokine receptor antagonist Substances 0.000 claims description 2
- 201000000522 chronic kidney disease Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- RHJVIGLEIFVHIJ-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1[CH]CCCC1 RHJVIGLEIFVHIJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 230000001861 immunosuppresant Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 201000009251 multiple myeloma Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims description 2
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrugs Drugs 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims description 2
- 229960004365 benzoic acid Drugs 0.000 claims 9
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 6
- 241000157985 Uta Species 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000003936 benzamides Chemical compound 0.000 claims 2
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 1
- 229940050390 Benzoate Drugs 0.000 claims 1
- BYUJUUYDYMRQPL-AREMUKBSSA-N C(#N)COC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)=O)C Chemical compound C(#N)COC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)=O)C BYUJUUYDYMRQPL-AREMUKBSSA-N 0.000 claims 1
- AJASGMZXUFJNGO-AREMUKBSSA-N C(C)(=O)NC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)=O)C Chemical compound C(C)(=O)NC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)=O)C AJASGMZXUFJNGO-AREMUKBSSA-N 0.000 claims 1
- QYGDBEKYTXDNBG-GBXCKJPGSA-N C(C)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)[C@H](C)OC)C=CC1 Chemical compound C(C)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)[C@H](C)OC)C=CC1 QYGDBEKYTXDNBG-GBXCKJPGSA-N 0.000 claims 1
- GJGLRORVXVDGLT-XMMPIXPASA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)C(C)C)C1)F GJGLRORVXVDGLT-XMMPIXPASA-N 0.000 claims 1
- CSUDRQYUGZFSQX-XMMPIXPASA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CN(C(C=C3)=O)C)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CN(C(C=C3)=O)C)C)=O)CC2)C(C)C)C1)F CSUDRQYUGZFSQX-XMMPIXPASA-N 0.000 claims 1
- LMBIYMSSVZDHLJ-XMMPIXPASA-N C1(CC1)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C1)F Chemical compound C1(CC1)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C1)F LMBIYMSSVZDHLJ-XMMPIXPASA-N 0.000 claims 1
- CVJCFLXYSPTJMF-RUZDIDTESA-N C1(CC1)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)C(C)C)C=1)F Chemical compound C1(CC1)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)C(C)C)C=1)F CVJCFLXYSPTJMF-RUZDIDTESA-N 0.000 claims 1
- AVCLPPIOIMVHKM-AREMUKBSSA-N C1(CCCC1)[C@H](C(=O)N1CCC2(C(N(C(N2CC=2C=C3N=CC=NC3=CC2)=O)C)=O)CC1)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O Chemical compound C1(CCCC1)[C@H](C(=O)N1CCC2(C(N(C(N2CC=2C=C3N=CC=NC3=CC2)=O)C)=O)CC1)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O AVCLPPIOIMVHKM-AREMUKBSSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- BYITUQUWMVRENA-OAQYLSRUSA-N CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(OC(F)(F)F)C=C1 Chemical compound CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(OC(F)(F)F)C=C1 BYITUQUWMVRENA-OAQYLSRUSA-N 0.000 claims 1
- LREGJECKQRKIRO-HSZRJFAPSA-N CC([C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)OCC)=O)C)=O)CC1)NC(C1=CC(=CC(=C1)F)C(F)(F)F)=O)C Chemical compound CC([C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)OCC)=O)C)=O)CC1)NC(C1=CC(=CC(=C1)F)C(F)(F)F)=O)C LREGJECKQRKIRO-HSZRJFAPSA-N 0.000 claims 1
- OODKHHDCOOFVEO-JOCHJYFZSA-N CC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=CN=1 Chemical compound CC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=CN=1 OODKHHDCOOFVEO-JOCHJYFZSA-N 0.000 claims 1
- GFEIJPUCUOEGQN-JOCHJYFZSA-N CC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C=3C=NC=CC=3)C)=O)CC2)C(C)C)C=CC=1 Chemical compound CC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C=3C=NC=CC=3)C)=O)CC2)C(C)C)C=CC=1 GFEIJPUCUOEGQN-JOCHJYFZSA-N 0.000 claims 1
- HIDNZZJXDDHNIT-HSZRJFAPSA-N CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)C)=O)=O)C2=CC=C(C(=O)O)C=C2 Chemical compound CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)C)=O)=O)C2=CC=C(C(=O)O)C=C2 HIDNZZJXDDHNIT-HSZRJFAPSA-N 0.000 claims 1
- DGQSCTYDBGYFLL-XMMPIXPASA-N CN1CN(C2=CC=C(C=C2)C(O)=O)C2(CCN(CC2)C(=O)[C@H](NC(=O)C2=C(F)C=CC(=C2)C(F)(F)F)C2CCCC2)C1=O Chemical compound CN1CN(C2=CC=C(C=C2)C(O)=O)C2(CCN(CC2)C(=O)[C@H](NC(=O)C2=C(F)C=CC(=C2)C(F)(F)F)C2CCCC2)C1=O DGQSCTYDBGYFLL-XMMPIXPASA-N 0.000 claims 1
- BMPQFGJILDCURA-NZQKXSOJSA-N CO[C@H]([C@H](C(=O)N1CCC2(C(N(CN2C2=CC=CC=C2)C)=O)CC1)NC(C1=CC(=CC=C1)C)=O)C Chemical compound CO[C@H]([C@H](C(=O)N1CCC2(C(N(CN2C2=CC=CC=C2)C)=O)CC1)NC(C1=CC(=CC=C1)C)=O)C BMPQFGJILDCURA-NZQKXSOJSA-N 0.000 claims 1
- VLNHDIUXVAENAZ-OAQYLSRUSA-N ClC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)Cl Chemical compound ClC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)Cl VLNHDIUXVAENAZ-OAQYLSRUSA-N 0.000 claims 1
- VHXSAZIFLREOKP-JOCHJYFZSA-N ClC1=C(C(=O)O)C=CC(=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C Chemical compound ClC1=C(C(=O)O)C=CC(=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C VHXSAZIFLREOKP-JOCHJYFZSA-N 0.000 claims 1
- ZBMKHKUSHQYCES-HSZRJFAPSA-N ClC1=C(CN2C(N(C(C22CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O)C=CC(=C1)OC Chemical compound ClC1=C(CN2C(N(C(C22CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O)C=CC(=C1)OC ZBMKHKUSHQYCES-HSZRJFAPSA-N 0.000 claims 1
- PUDOGKJIUDKIDW-OAQYLSRUSA-N ClC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=CC1Cl Chemical compound ClC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=CC1Cl PUDOGKJIUDKIDW-OAQYLSRUSA-N 0.000 claims 1
- FRPWXZRVHMHXCN-OAQYLSRUSA-N FC(OC=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C1)F)F Chemical compound FC(OC=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C(=O)O)C=C3)=O)C)=O)CC2)C(C)C)C1)F)F FRPWXZRVHMHXCN-OAQYLSRUSA-N 0.000 claims 1
- DPEYSCNSVHLKSC-JOCHJYFZSA-N FC(OC=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=1)F)F Chemical compound FC(OC=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=1)F)F DPEYSCNSVHLKSC-JOCHJYFZSA-N 0.000 claims 1
- PDFLRDQOOPRETN-JOCHJYFZSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC(=CC=C3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC(=CC=C3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F PDFLRDQOOPRETN-JOCHJYFZSA-N 0.000 claims 1
- NICOGKFOAIXLOQ-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)C(F)(F)F)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)C(F)(F)F)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F NICOGKFOAIXLOQ-OAQYLSRUSA-N 0.000 claims 1
- JVAMAQLUVPYFRN-JOCHJYFZSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=CC=C1C Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=CC=C1C JVAMAQLUVPYFRN-JOCHJYFZSA-N 0.000 claims 1
- ICGDCTCMAMLBLT-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=NC=CC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=NC=CC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F ICGDCTCMAMLBLT-HXUWFJFHSA-N 0.000 claims 1
- HNOOHVKPFGVHJU-LJQANCHMSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=NN(C=3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=NN(C=3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F HNOOHVKPFGVHJU-LJQANCHMSA-N 0.000 claims 1
- BHOCDSKRDCALBO-JOCHJYFZSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC(=NC=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC(=NC=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F BHOCDSKRDCALBO-JOCHJYFZSA-N 0.000 claims 1
- NAYGITXNXIHYHT-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC=4N(C=C3)C=CN=4)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC=4N(C=C3)C=CN=4)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F NAYGITXNXIHYHT-HSZRJFAPSA-N 0.000 claims 1
- OFTYQIXWGCTZEP-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3CCOCC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3CCOCC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F OFTYQIXWGCTZEP-OAQYLSRUSA-N 0.000 claims 1
- QMXYZPVXWVDPON-XMMPIXPASA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=C4N=CC=NC4=CC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=C4N=CC=NC4=CC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F QMXYZPVXWVDPON-XMMPIXPASA-N 0.000 claims 1
- NIPMGVAATRVWNE-XMMPIXPASA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=CC4=C(N=C(O4)C)C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=CC4=C(N=C(O4)C)C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F NIPMGVAATRVWNE-XMMPIXPASA-N 0.000 claims 1
- XSPPBSRUOZLLIM-WZONZLPQSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3[C@H](C)C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3[C@H](C)C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F XSPPBSRUOZLLIM-WZONZLPQSA-N 0.000 claims 1
- GMXMCKXBUPLWRK-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=C(C=C1)OC Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C(=O)O)C=C3)C)=O)CC2)C(C)C)C=C(C=C1)OC GMXMCKXBUPLWRK-HSZRJFAPSA-N 0.000 claims 1
- UIAGFPZXZVFJAN-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)S(=O)(=O)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)S(=O)(=O)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F UIAGFPZXZVFJAN-HSZRJFAPSA-N 0.000 claims 1
- YRPBCYXITJJJIU-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=C(C=C1)C Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=C(C=C1)C YRPBCYXITJJJIU-HSZRJFAPSA-N 0.000 claims 1
- SKIMFNPYHUYVFV-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C=3C=C(C=CC3)B(O)O)C)=O)CC2)C(C)C)C=CC=C1C Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C=3C=C(C=CC3)B(O)O)C)=O)CC2)C(C)C)C=CC=C1C SKIMFNPYHUYVFV-HSZRJFAPSA-N 0.000 claims 1
- DBEAPVRCIGSENG-OAQYLSRUSA-N N=1NN=NC1C1=CC=C(C=C1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound N=1NN=NC1C1=CC=C(C=C1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O DBEAPVRCIGSENG-OAQYLSRUSA-N 0.000 claims 1
- MSXIOGSTPFCARR-JOCHJYFZSA-N N=1NN=NC1C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C Chemical compound N=1NN=NC1C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C MSXIOGSTPFCARR-JOCHJYFZSA-N 0.000 claims 1
- OGEVRNIAJCFHBG-AREMUKBSSA-N NC(COC1=CC=C(C=C1)N1CN(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)CC)F)=O)=O)=O)C)=O Chemical compound NC(COC1=CC=C(C=C1)N1CN(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)CC)F)=O)=O)=O)C)=O OGEVRNIAJCFHBG-AREMUKBSSA-N 0.000 claims 1
- GTUGLGLYOBKYGH-VQIWEWKSSA-N OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)c1cc(ccc1F)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)c1ccc(OCCN(C)C)cc1 Chemical compound OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)c1cc(ccc1F)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)c1ccc(OCCN(C)C)cc1 GTUGLGLYOBKYGH-VQIWEWKSSA-N 0.000 claims 1
- JRVBKZVVCIANHI-GJFSDDNBSA-N OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)c1cc(ccc1F)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(CCN(C)C)C2=O)c1ccc(cc1)C(O)=O Chemical compound OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)c1cc(ccc1F)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(CCN(C)C)C2=O)c1ccc(cc1)C(O)=O JRVBKZVVCIANHI-GJFSDDNBSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 328
- 150000003839 salts Chemical class 0.000 abstract description 10
- 239000011780 sodium chloride Substances 0.000 abstract description 10
- 239000000543 intermediate Substances 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 230000002194 synthesizing Effects 0.000 abstract description 4
- 208000004296 Neuralgia Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 500
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 417
- 239000007787 solid Substances 0.000 description 383
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 364
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 338
- 239000000243 solution Substances 0.000 description 311
- 238000005160 1H NMR spectroscopy Methods 0.000 description 259
- 230000002829 reduced Effects 0.000 description 252
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 242
- 235000019439 ethyl acetate Nutrition 0.000 description 167
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 148
- 238000006243 chemical reaction Methods 0.000 description 142
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 136
- 239000012044 organic layer Substances 0.000 description 131
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 126
- 229910052938 sodium sulfate Inorganic materials 0.000 description 126
- 235000011152 sodium sulphate Nutrition 0.000 description 126
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 108
- 239000005457 ice water Substances 0.000 description 103
- 239000002904 solvent Substances 0.000 description 91
- 238000010898 silica gel chromatography Methods 0.000 description 85
- 238000000034 method Methods 0.000 description 82
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 76
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 76
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 75
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 72
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 69
- 239000003208 petroleum Substances 0.000 description 68
- 238000003756 stirring Methods 0.000 description 59
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 58
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 56
- 238000007792 addition Methods 0.000 description 55
- 239000003921 oil Substances 0.000 description 51
- 235000019198 oils Nutrition 0.000 description 51
- 101700046984 CDK20 Proteins 0.000 description 48
- 238000001914 filtration Methods 0.000 description 40
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 40
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 39
- 238000000746 purification Methods 0.000 description 30
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 29
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 29
- 239000002244 precipitate Substances 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- FKBFHOSFPRWJNV-UHFFFAOYSA-N [dimethylamino-(3-oxidotriazolo[4,5-b]pyridin-3-ium-1-yl)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2[N+](=C(N(C)C)N(C)C)N=[N+]([O-])C2=N1 FKBFHOSFPRWJNV-UHFFFAOYSA-N 0.000 description 24
- 239000012065 filter cake Substances 0.000 description 24
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 24
- 239000000725 suspension Substances 0.000 description 23
- 238000010791 quenching Methods 0.000 description 22
- 230000000171 quenching Effects 0.000 description 22
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 21
- 229910000027 potassium carbonate Inorganic materials 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 235000015320 potassium carbonate Nutrition 0.000 description 19
- 238000002953 preparative HPLC Methods 0.000 description 19
- HTUHXGLKWIWJTR-SNVBAGLBSA-N (2R)-2-[[2-fluoro-5-(trifluoromethyl)benzoyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@H](C(O)=O)NC(=O)C1=CC(C(F)(F)F)=CC=C1F HTUHXGLKWIWJTR-SNVBAGLBSA-N 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- 239000001184 potassium carbonate Substances 0.000 description 18
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 17
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 15
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 15
- 235000019270 ammonium chloride Nutrition 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 241000282326 Felis catus Species 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 10
- QDKFWFRVAQGVLI-UHFFFAOYSA-M N1CNCC11CCN(CC1)C(=O)[O-] Chemical compound N1CNCC11CCN(CC1)C(=O)[O-] QDKFWFRVAQGVLI-UHFFFAOYSA-M 0.000 description 9
- LEIMLDGFXIOXMT-UHFFFAOYSA-N Trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 229910000033 sodium borohydride Inorganic materials 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- WOUCSYNEFIEFNV-UHFFFAOYSA-N hydron;[1-(2-phenylethyl)piperidin-4-yl] benzoate;chloride Chemical compound Cl.C=1C=CC=CC=1C(=O)OC(CC1)CCN1CCC1=CC=CC=C1 WOUCSYNEFIEFNV-UHFFFAOYSA-N 0.000 description 8
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 8
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 8
- WRJWRGBVPUUDLA-UHFFFAOYSA-N Chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 7
- KVVMXWRFYAGASO-UHFFFAOYSA-M azetidine-1-carboxylate Chemical compound [O-]C(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-M 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000008079 hexane Substances 0.000 description 7
- ILAHWRKJUDSMFH-UHFFFAOYSA-N Boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cells Anatomy 0.000 description 6
- 150000002829 nitrogen Chemical group 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- ALBOFFXGHBTZSA-LLVKDONJSA-N (2R)-2-[(2-fluoro-3-methylbenzoyl)amino]-3-methylbutanoic acid Chemical compound CC(C)[C@H](C(O)=O)NC(=O)C1=CC=CC(C)=C1F ALBOFFXGHBTZSA-LLVKDONJSA-N 0.000 description 5
- GKASDNZWUGIAMG-UHFFFAOYSA-N Triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- 238000010189 synthetic method Methods 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- IFYWBEDKWLNJTM-UHFFFAOYSA-N 3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;hydrochloride Chemical compound Cl.C1CNCCC21C(=O)N(C)CN2C1=CC=CC=C1 IFYWBEDKWLNJTM-UHFFFAOYSA-N 0.000 description 4
- IPBXLTHOJUWUIJ-UHFFFAOYSA-N 3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decane-2,4-dione;hydrochloride Chemical compound Cl.C1CNCCC21C(=O)N(C)C(=O)N2C1=CC=CC=C1 IPBXLTHOJUWUIJ-UHFFFAOYSA-N 0.000 description 4
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- DSIRTMPQIVXJGI-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)OC)C#N Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)OC)C#N DSIRTMPQIVXJGI-UHFFFAOYSA-N 0.000 description 4
- BATXBDIAUCCELA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)C(N)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)C(N)=O)C)=O)CC1 BATXBDIAUCCELA-UHFFFAOYSA-N 0.000 description 4
- AIPKEPCUXGMQEE-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C12CCNCC2)=O)C)=O Chemical compound Cl.C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C12CCNCC2)=O)C)=O AIPKEPCUXGMQEE-UHFFFAOYSA-N 0.000 description 4
- 229910004373 HOAc Inorganic materials 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N Trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N [(2R)-3-acetyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000001808 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- KUGLDBMQKZTXPW-NUBCRITNSA-N methyl (2R)-2-amino-3-methylbutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)C(C)C KUGLDBMQKZTXPW-NUBCRITNSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000001187 sodium carbonate Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- HODWPRQQRJVYGG-LLVKDONJSA-N (2R)-3-methyl-2-[(3-methylbenzoyl)amino]butanoic acid Chemical compound CC(C)[C@H](C(O)=O)NC(=O)C1=CC=CC(C)=C1 HODWPRQQRJVYGG-LLVKDONJSA-N 0.000 description 3
- YRCGAHTZOXPQPR-UHFFFAOYSA-M 2-ethylnonanoate Chemical compound CCCCCCCC(CC)C([O-])=O YRCGAHTZOXPQPR-UHFFFAOYSA-M 0.000 description 3
- YHOYYHYBFSYOSQ-UHFFFAOYSA-N 3-methylbenzoyl chloride Chemical compound CC1=CC=CC(C(Cl)=O)=C1 YHOYYHYBFSYOSQ-UHFFFAOYSA-N 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- PSTDHCWYBBDDSK-UHFFFAOYSA-N Br.CN1C(=O)N(Cc2ccc(cc2)C#N)C2(CCNCC2)C1=O Chemical compound Br.CN1C(=O)N(Cc2ccc(cc2)C#N)C2(CCNCC2)C1=O PSTDHCWYBBDDSK-UHFFFAOYSA-N 0.000 description 3
- MRVISGVUICZVHZ-HHHXNRCGSA-N C(C)(C)(C)OC(=O)N1CC(C1)NC1=CC=C(C=C1)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound C(C)(C)(C)OC(=O)N1CC(C1)NC1=CC=C(C=C1)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O MRVISGVUICZVHZ-HHHXNRCGSA-N 0.000 description 3
- SDDGOOXEAMHSOO-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(C#N)NC=1C=C2C=NNC2=CC=1 Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(C#N)NC=1C=C2C=NNC2=CC=1 SDDGOOXEAMHSOO-UHFFFAOYSA-N 0.000 description 3
- WDTOENJUPDDZAF-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(C(N)=O)NC1=CC=C(C=C1)Br Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(C(N)=O)NC1=CC=C(C=C1)Br WDTOENJUPDDZAF-UHFFFAOYSA-N 0.000 description 3
- SYGQPIYWVFQCPY-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)C#N)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)C#N)C)=O)CC1 SYGQPIYWVFQCPY-UHFFFAOYSA-N 0.000 description 3
- LQZZXBWNRGKVGX-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C2=CC=C(C=C2)OC)=O)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C2=CC=C(C=C2)OC)=O)=O)CC1 LQZZXBWNRGKVGX-UHFFFAOYSA-N 0.000 description 3
- WECFQTXIHDOCRA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2CC2CC2)=O)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2CC2CC2)=O)=O)CC1 WECFQTXIHDOCRA-UHFFFAOYSA-N 0.000 description 3
- YXTBPQNTBMEZTB-GFCCVEGCSA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)O)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)O)C(C)C)C1)F YXTBPQNTBMEZTB-GFCCVEGCSA-N 0.000 description 3
- GUXRKOGGQHNTIY-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2)=O)C)=O)CC1 Chemical compound C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2)=O)C)=O)CC1 GUXRKOGGQHNTIY-UHFFFAOYSA-N 0.000 description 3
- GRIZPACFGLDLIG-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)O)=O)C)=O)CC1 Chemical compound C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)O)=O)C)=O)CC1 GRIZPACFGLDLIG-UHFFFAOYSA-N 0.000 description 3
- WNZZCFYRMROUMP-HSZRJFAPSA-N C(N)(=O)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C(=CC=C2)C)F)=O)=O)=O)C Chemical compound C(N)(=O)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C(=CC=C2)C)F)=O)=O)=O)C WNZZCFYRMROUMP-HSZRJFAPSA-N 0.000 description 3
- IZKYDFLRAAPPQE-CQSZACIVSA-N C1(CCCCC1)[C@H](C(=O)O)NC(C1=CC(=CC=C1)C)=O Chemical compound C1(CCCCC1)[C@H](C(=O)O)NC(C1=CC(=CC=C1)C)=O IZKYDFLRAAPPQE-CQSZACIVSA-N 0.000 description 3
- UDZHMKJRHGZCGG-UHFFFAOYSA-N CC=1C=C(C(=O)NC(C(=O)O)C2CCOCC2)C=CC=1 Chemical compound CC=1C=C(C(=O)NC(C(=O)O)C2CCOCC2)C=CC=1 UDZHMKJRHGZCGG-UHFFFAOYSA-N 0.000 description 3
- ATEYDVFDXSKYOB-LLVKDONJSA-N COC([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O Chemical compound COC([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O ATEYDVFDXSKYOB-LLVKDONJSA-N 0.000 description 3
- LDZCACILIBPLQU-GFCCVEGCSA-N COC([C@@H](C(C)C)NC(C1=CC(=CC=C1)C)=O)=O Chemical compound COC([C@@H](C(C)C)NC(C1=CC(=CC=C1)C)=O)=O LDZCACILIBPLQU-GFCCVEGCSA-N 0.000 description 3
- PKIJKKJZABCKII-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)OC(C1=CC=C(C=C1)N1C(N(C(C12CCNCC2)=O)C)=O)=O Chemical compound Cl.C(C1=CC=CC=C1)OC(C1=CC=C(C=C1)N1C(N(C(C12CCNCC2)=O)C)=O)=O PKIJKKJZABCKII-UHFFFAOYSA-N 0.000 description 3
- QQRJKHSCUCGNAH-UHFFFAOYSA-N Cl.CN1CN(C2(C1=O)CCNCC2)C2=CC=C(C#N)C=C2 Chemical compound Cl.CN1CN(C2(C1=O)CCNCC2)C2=CC=C(C#N)C=C2 QQRJKHSCUCGNAH-UHFFFAOYSA-N 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- FDAWOYJCBVRUDO-QYGXFBIXSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3CC(C3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3CC(C3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F FDAWOYJCBVRUDO-QYGXFBIXSA-N 0.000 description 3
- SRJOCJYGOFTFLH-UHFFFAOYSA-N Isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 3
- VUVGYHUDAICLFK-UHFFFAOYSA-N Perosmic oxide Chemical compound O=[Os](=O)(=O)=O VUVGYHUDAICLFK-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000037348 biosynthesis Effects 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- WTVNFKVGGUWHQC-UHFFFAOYSA-N decane-2,4-dione Chemical compound CCCCCCC(=O)CC(C)=O WTVNFKVGGUWHQC-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- CBUDZRZIGMEWPU-YSMPRRRNSA-N methyl (2Z)-2-[[3-[[3-cyano-4-methyl-6-(trifluoromethyl)pyridin-2-yl]sulfanylmethyl]-4-methoxyphenyl]methylidene]-5-[4-(dimethylamino)phenyl]-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate Chemical compound O=C1N2C(C=3C=CC(=CC=3)N(C)C)C(C(=O)OC)=C(C)N=C2S\C1=C/C(C=1)=CC=C(OC)C=1CSC1=NC(C(F)(F)F)=CC(C)=C1C#N CBUDZRZIGMEWPU-YSMPRRRNSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 230000001131 transforming Effects 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- GUMINBOCIUCMJL-UHFFFAOYSA-N (3-phenylmethoxycyclobutyl)methanol Chemical compound C1C(CO)CC1OCC1=CC=CC=C1 GUMINBOCIUCMJL-UHFFFAOYSA-N 0.000 description 2
- LQLGKCHDVVPGRT-UHFFFAOYSA-N (3-phenylmethoxycyclobutyl)methyl methanesulfonate Chemical compound C1C(COS(=O)(=O)C)CC1OCC1=CC=CC=C1 LQLGKCHDVVPGRT-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-Dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- IAWQUHCVFXQBMC-UHFFFAOYSA-N 1,3-benzoxazol-5-amine Chemical compound NC1=CC=C2OC=NC2=C1 IAWQUHCVFXQBMC-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-Hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- KSQLNMJXRMQLEG-UHFFFAOYSA-N 1-benzyl-4-(cyclopropylmethylamino)piperidine-4-carbonitrile Chemical compound C1CC(C#N)(NCC2CC2)CCN1CC1=CC=CC=C1 KSQLNMJXRMQLEG-UHFFFAOYSA-N 0.000 description 2
- ROCSEYQVAGEUMU-UHFFFAOYSA-N 2,2-diethylbutane-1,1,1-triolate Chemical compound CCC(CC)(CC)C([O-])([O-])[O-] ROCSEYQVAGEUMU-UHFFFAOYSA-N 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N 3-Methylbutanoic acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- NNJSDVWFUJMHSO-UHFFFAOYSA-N 5-ethyl-2-fluorobenzoic acid Chemical compound CCC1=CC=C(F)C(C(O)=O)=C1 NNJSDVWFUJMHSO-UHFFFAOYSA-N 0.000 description 2
- MNEOLRFGVQZMLA-UHFFFAOYSA-N 5-nitro-1,3-benzoxazole Chemical compound [O-][N+](=O)C1=CC=C2OC=NC2=C1 MNEOLRFGVQZMLA-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N Adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 2
- GAHAORRDBVBAPJ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(C#N)NC1=CC=C(C=C1)Br Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(C#N)NC1=CC=C(C=C1)Br GAHAORRDBVBAPJ-UHFFFAOYSA-N 0.000 description 2
- SCVUZWWWMAPPRU-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(C#N)NC=1C=CC2=C(N=CO2)C=1 Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(C#N)NC=1C=CC2=C(N=CO2)C=1 SCVUZWWWMAPPRU-UHFFFAOYSA-N 0.000 description 2
- HFYGISWDWJNTLB-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC(=NC=C2)O)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC(=NC=C2)O)=O)C)=O)CC1 HFYGISWDWJNTLB-UHFFFAOYSA-N 0.000 description 2
- GPNGSTGBUDAMNV-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C(=O)O)C=C2)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C(=O)O)C=C2)=O)C)=O)CC1 GPNGSTGBUDAMNV-UHFFFAOYSA-N 0.000 description 2
- BYOPNQOEDNNTKG-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=NC=C2)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=NC=C2)=O)C)=O)CC1 BYOPNQOEDNNTKG-UHFFFAOYSA-N 0.000 description 2
- YXEDDJIPWHFHAZ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2CCC(CC2)OC)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2CCC(CC2)OC)=O)C)=O)CC1 YXEDDJIPWHFHAZ-UHFFFAOYSA-N 0.000 description 2
- LJWJLZLFECFSHM-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2CC2CC(C2)OC)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2CC2CC(C2)OC)=O)C)=O)CC1 LJWJLZLFECFSHM-UHFFFAOYSA-N 0.000 description 2
- NRBQZDXLVILEIS-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2CC2CC(C2)OCC2=CC=CC=C2)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2CC2CC(C2)OCC2=CC=CC=C2)=O)C)=O)CC1 NRBQZDXLVILEIS-UHFFFAOYSA-N 0.000 description 2
- DDGDZFFHSTYJSB-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C(=O)O)C=C2)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C(=O)O)C=C2)C)=O)CC1 DDGDZFFHSTYJSB-UHFFFAOYSA-N 0.000 description 2
- TZHZZUDHZUSHJA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)N)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)N)C)=O)CC1 TZHZZUDHZUSHJA-UHFFFAOYSA-N 0.000 description 2
- AIWVSUBUVALELS-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)O)C)=O)CC1 AIWVSUBUVALELS-UHFFFAOYSA-N 0.000 description 2
- DIDHUZSBHMELII-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C2=CC=C(C=C2)C(=O)OC)=O)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C2=CC=C(C=C2)C(=O)OC)=O)=O)CC1 DIDHUZSBHMELII-UHFFFAOYSA-N 0.000 description 2
- XVEVFQDPENSLGR-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C2=CC=C(C=C2)OC)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C2=CC=C(C=C2)OC)C)=O)CC1 XVEVFQDPENSLGR-UHFFFAOYSA-N 0.000 description 2
- LOVOSGLSVNCCMB-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NCN2C2=CC(=CC=C2)Cl)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NCN2C2=CC(=CC=C2)Cl)=O)CC1 LOVOSGLSVNCCMB-UHFFFAOYSA-N 0.000 description 2
- WFZYPGVYWFOYEL-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NCN2C2=CC=C(C=C2)Br)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NCN2C2=CC=C(C=C2)Br)=O)CC1 WFZYPGVYWFOYEL-UHFFFAOYSA-N 0.000 description 2
- IZYSHHCPXDNKHA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NCN2C2=CC=C(C=C2)C(=O)OC)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NCN2C2=CC=C(C=C2)C(=O)OC)=O)CC1 IZYSHHCPXDNKHA-UHFFFAOYSA-N 0.000 description 2
- KIYAHTYTVMZFTM-KBMIEXCESA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N([C@H](N3C3=CC=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C1)F KIYAHTYTVMZFTM-KBMIEXCESA-N 0.000 description 2
- KTOMLKZVNNYBLC-AREMUKBSSA-N C(C)OC(CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC(=C2)C)F)=O)=O)C2=CC=CC=C2)=O Chemical compound C(C)OC(CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=CC(=CC(=C2)C)F)=O)=O)C2=CC=CC=C2)=O KTOMLKZVNNYBLC-AREMUKBSSA-N 0.000 description 2
- OLKPUYYYNAVLGE-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)N)=O)C)=O)CC1 Chemical compound C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)N)=O)C)=O)CC1 OLKPUYYYNAVLGE-UHFFFAOYSA-N 0.000 description 2
- YRWJXOMBVJMHMM-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)NC2CN(C2)C(=O)OC(C)(C)C)=O)C)=O)CC1 Chemical compound C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)NC2CN(C2)C(=O)OC(C)(C)C)=O)C)=O)CC1 YRWJXOMBVJMHMM-UHFFFAOYSA-N 0.000 description 2
- LEQNBKIUGXBMTP-UHFFFAOYSA-N CC=1C=C(C(=O)NC(C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C2CCOCC2)C=CC=1 Chemical compound CC=1C=C(C(=O)NC(C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C2CCOCC2)C=CC=1 LEQNBKIUGXBMTP-UHFFFAOYSA-N 0.000 description 2
- NYLKTDGFIYPAJX-JOCHJYFZSA-N CC=1C=C(C(=O)N[C@@H](C(N2CCC3(COC(N3C3=CC=CC=C3)=O)CC2)=O)C(C)C)C=CC1 Chemical compound CC=1C=C(C(=O)N[C@@H](C(N2CCC3(COC(N3C3=CC=CC=C3)=O)CC2)=O)C(C)C)C=CC1 NYLKTDGFIYPAJX-JOCHJYFZSA-N 0.000 description 2
- QAERKTUSUHHSGT-UHFFFAOYSA-N COC(C(C1CCOCC1)NC(C1=CC(=CC=C1)C)=O)=O Chemical compound COC(C(C1CCOCC1)NC(C1=CC(=CC=C1)C)=O)=O QAERKTUSUHHSGT-UHFFFAOYSA-N 0.000 description 2
- HQTPWERZTKULDL-UHFFFAOYSA-N COC(NC1=CC=C(C=C1)N1C(N(C(C12CCNCC2)=O)C)=O)=O Chemical compound COC(NC1=CC=C(C=C1)N1C(N(C(C12CCNCC2)=O)C)=O)=O HQTPWERZTKULDL-UHFFFAOYSA-N 0.000 description 2
- REXZRKVSHFOVJY-CYBMUJFWSA-N COC([C@@H](C(C)C)NC(C1=C(C=CC(=C1)CC)F)=O)=O Chemical compound COC([C@@H](C(C)C)NC(C1=C(C=CC(=C1)CC)F)=O)=O REXZRKVSHFOVJY-CYBMUJFWSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VOLSRGHOVRKEKR-UHFFFAOYSA-N Cl.BrC1=CC=C(C=C1)N1CN(C(C12CCNCC2)=O)C Chemical compound Cl.BrC1=CC=C(C=C1)N1CN(C(C12CCNCC2)=O)C VOLSRGHOVRKEKR-UHFFFAOYSA-N 0.000 description 2
- DVTMIPFVPWWLJV-GNAFDRTKSA-N Cl.C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)N)=O)=O)C)=O Chemical compound Cl.C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)N)=O)=O)C)=O DVTMIPFVPWWLJV-GNAFDRTKSA-N 0.000 description 2
- PDAHLAFJCZBDJG-UHFFFAOYSA-N Cl.C1(CCCCC1)N1C(N(C(C12CCNCC2)=O)C)=O Chemical compound Cl.C1(CCCCC1)N1C(N(C(C12CCNCC2)=O)C)=O PDAHLAFJCZBDJG-UHFFFAOYSA-N 0.000 description 2
- JVLPHMQUKCMZNW-UHFFFAOYSA-N Cl.CN1C(N(C2(C1=O)CCNCC2)C2=CC=C(C(=O)O)C=C2)=O Chemical compound Cl.CN1C(N(C2(C1=O)CCNCC2)C2=CC=C(C(=O)O)C=C2)=O JVLPHMQUKCMZNW-UHFFFAOYSA-N 0.000 description 2
- YISYEKGFDVXRFR-UHFFFAOYSA-N Cl.CN1C(N(C2(C1=O)CCNCC2)C2=CC=C(C=C2)[N+](=O)[O-])=O Chemical compound Cl.CN1C(N(C2(C1=O)CCNCC2)C2=CC=C(C=C2)[N+](=O)[O-])=O YISYEKGFDVXRFR-UHFFFAOYSA-N 0.000 description 2
- WSFHNQHIUBJNQS-UHFFFAOYSA-N Cl.CN1C(N(C2(C1=O)CCNCC2)C2=CC=NC=C2)=O Chemical compound Cl.CN1C(N(C2(C1=O)CCNCC2)C2=CC=NC=C2)=O WSFHNQHIUBJNQS-UHFFFAOYSA-N 0.000 description 2
- RCBFIMHUYSXGFW-UHFFFAOYSA-N Cl.CN1CN(C2(C1=O)CCNCC2)C2=CC=C(C(=O)N)C=C2 Chemical compound Cl.CN1CN(C2(C1=O)CCNCC2)C2=CC=C(C(=O)N)C=C2 RCBFIMHUYSXGFW-UHFFFAOYSA-N 0.000 description 2
- ARPPGVQFALGDFM-UHFFFAOYSA-N Cl.CN1CN(C2(C1=O)CCNCC2)C2=CC=C(C=C2)NC(C)=O Chemical compound Cl.CN1CN(C2(C1=O)CCNCC2)C2=CC=C(C=C2)NC(C)=O ARPPGVQFALGDFM-UHFFFAOYSA-N 0.000 description 2
- XKPZXXVIAFDYCT-UHFFFAOYSA-N Cl.COC1CCC(CC1)N1C(N(C(C12CCNCC2)=O)C)=O Chemical compound Cl.COC1CCC(CC1)N1C(N(C(C12CCNCC2)=O)C)=O XKPZXXVIAFDYCT-UHFFFAOYSA-N 0.000 description 2
- BUQUATZPZHRSFL-UHFFFAOYSA-N Cl.N1N=CC2=CC(=CC=C12)N1CN(C(C12CCNCC2)=O)C Chemical compound Cl.N1N=CC2=CC(=CC=C12)N1CN(C(C12CCNCC2)=O)C BUQUATZPZHRSFL-UHFFFAOYSA-N 0.000 description 2
- CAKQNJGHSUJCEV-UHFFFAOYSA-N Cl.N=1NN=NC1C1=CC=C(C=C1)N1C(N(C(C12CCNCC2)=O)C)=O Chemical compound Cl.N=1NN=NC1C1=CC=C(C=C1)N1C(N(C(C12CCNCC2)=O)C)=O CAKQNJGHSUJCEV-UHFFFAOYSA-N 0.000 description 2
- AEOGPETYCDHTTQ-UHFFFAOYSA-N Cl.O1C=NC2=C1C=CC(=C2)N2C(N(C(C21CCNCC1)=O)C)=O Chemical compound Cl.O1C=NC2=C1C=CC(=C2)N2C(N(C(C21CCNCC1)=O)C)=O AEOGPETYCDHTTQ-UHFFFAOYSA-N 0.000 description 2
- YIHKQVVAQIJGNW-MUTAZJQDSA-N Cl.[2H]C([2H])([2H])Oc1ccc(cc1)N1C(=O)N(C)C(=O)C11CCNCC1 Chemical compound Cl.[2H]C([2H])([2H])Oc1ccc(cc1)N1C(=O)N(C)C(=O)C11CCNCC1 YIHKQVVAQIJGNW-MUTAZJQDSA-N 0.000 description 2
- VFQXVTODMYMSMJ-UHFFFAOYSA-N Isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- UGHRRXXJNLINJN-VQIWEWKSSA-N OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(OCC2CNC2)C=C1 Chemical compound OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)C1=CC=C(OCC2CNC2)C=C1 UGHRRXXJNLINJN-VQIWEWKSSA-N 0.000 description 2
- BHAAPTBBJKJZER-UHFFFAOYSA-N P-Anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N Potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 101710030983 RNF138 Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M Sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 101710029702 TICAM1 Proteins 0.000 description 2
- 101710021425 TRIM69 Proteins 0.000 description 2
- 102100003447 TRIM69 Human genes 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N Titanium isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- NMUKISKKAYOKAK-UHFFFAOYSA-M [O-]C(=O)N1CCC2(CC1)NC(=O)NC2=O Chemical compound [O-]C(=O)N1CCC2(CC1)NC(=O)NC2=O NMUKISKKAYOKAK-UHFFFAOYSA-M 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 2
- HGOPYEWWZGZVJI-UHFFFAOYSA-N benzyl 2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CC2(C(NC(=O)N2)=O)CCN1C(=O)OCC1=CC=CC=C1 HGOPYEWWZGZVJI-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000029578 entry into host Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 2
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 2
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 230000000644 propagated Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- NHAKTECXIBGECS-UHFFFAOYSA-N tert-butyl 1-(4-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1=CC(OC)=CC=C1N1C2(CCN(CC2)C(=O)OC(C)(C)C)C(=O)NC1 NHAKTECXIBGECS-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- WAMWSIDTKSNDCU-SSDOTTSWSA-N (2R)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@H](N)C1CCCCC1 WAMWSIDTKSNDCU-SSDOTTSWSA-N 0.000 description 1
- SZXBQTSZISFIAO-SSDOTTSWSA-N (2R)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-SSDOTTSWSA-N 0.000 description 1
- VWSUOKFUIPMDDX-NKWVEPMBSA-N (2R,3S)-3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CO[C@@H](C)[C@H](C(O)=O)NC(=O)OC(C)(C)C VWSUOKFUIPMDDX-NKWVEPMBSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- USBLZEFCYGBDBO-UHFFFAOYSA-N 1,3,8-triazaspiro[4.5]decane-2,4-dione;hydrochloride Chemical compound Cl.N1C(=O)NC(=O)C11CCNCC1 USBLZEFCYGBDBO-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- XBTOSRUBOXQWBO-UHFFFAOYSA-N 1H-indazol-5-amine Chemical compound NC1=CC=C2NN=CC2=C1 XBTOSRUBOXQWBO-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- QBAYIBZITZBSFO-UHFFFAOYSA-N 2-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C(F)(F)F QBAYIBZITZBSFO-UHFFFAOYSA-N 0.000 description 1
- VLZVIIYRNMWPSN-UHFFFAOYSA-N 2-Amino-4-nitrophenol Chemical compound NC1=CC([N+]([O-])=O)=CC=C1O VLZVIIYRNMWPSN-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- DGNAETGARNTCIL-UHFFFAOYSA-N 2-fluoro-3-methylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1F DGNAETGARNTCIL-UHFFFAOYSA-N 0.000 description 1
- LIFKXWNFWIUMJT-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC=C1F LIFKXWNFWIUMJT-UHFFFAOYSA-N 0.000 description 1
- SVEQHRSELNPKJJ-UHFFFAOYSA-N 2-methoxypyridin-4-amine Chemical compound COC1=CC(N)=CC=N1 SVEQHRSELNPKJJ-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-Oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- XPUFVYIUPYNLPD-UHFFFAOYSA-N 3-fluoro-5-methylbenzoic acid Chemical compound CC1=CC(F)=CC(C(O)=O)=C1 XPUFVYIUPYNLPD-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- HODWPRQQRJVYGG-UHFFFAOYSA-N 3-methyl-2-[(3-methylbenzoyl)amino]butanoic acid Chemical compound CC(C)C(C(O)=O)NC(=O)C1=CC=CC(C)=C1 HODWPRQQRJVYGG-UHFFFAOYSA-N 0.000 description 1
- YNNOFVDQHAHVFG-UHFFFAOYSA-N 3-phenylmethoxycyclobutane-1-carboxylic acid Chemical compound C1C(C(=O)O)CC1OCC1=CC=CC=C1 YNNOFVDQHAHVFG-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FQXQBFUUVCDIRK-UHFFFAOYSA-N 3-trifluoromethylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1 FQXQBFUUVCDIRK-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-Bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-Nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- FBXGQDUVJBKEAJ-UHFFFAOYSA-N 4H-oxazin-3-one Chemical compound O=C1CC=CON1 FBXGQDUVJBKEAJ-UHFFFAOYSA-N 0.000 description 1
- 102100017923 ACOT12 Human genes 0.000 description 1
- 101710008266 ACOT12 Proteins 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N Allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- BVYYDEKYMCUJBZ-XMMPIXPASA-N C(#N)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C(=CC=C2)C)F)=O)=O)=O)C Chemical compound C(#N)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C(=CC=C2)C)F)=O)=O)=O)C BVYYDEKYMCUJBZ-XMMPIXPASA-N 0.000 description 1
- DSWPYXJSXDRMLQ-RUZDIDTESA-N C(#N)CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)C2=CC=CC=C2 Chemical compound C(#N)CN1CN(C2(C1=O)CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)C2=CC=CC=C2 DSWPYXJSXDRMLQ-RUZDIDTESA-N 0.000 description 1
- KFGNJVIGLYFLND-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(C#N)NC1=CC(=CC=C1)Cl Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(C#N)NC1=CC(=CC=C1)Cl KFGNJVIGLYFLND-UHFFFAOYSA-N 0.000 description 1
- MMNWNPBLZSZYBH-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC(=NC=C1)OC)C(N)=O Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC(=NC=C1)OC)C(N)=O MMNWNPBLZSZYBH-UHFFFAOYSA-N 0.000 description 1
- QVAXHGOCYXFCIW-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC2=C(NC(O2)=O)C=C1)C#N Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC2=C(NC(O2)=O)C=C1)C#N QVAXHGOCYXFCIW-UHFFFAOYSA-N 0.000 description 1
- YGNGSBREWOHUMA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)C(=O)OC)C#N Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)C(=O)OC)C#N YGNGSBREWOHUMA-UHFFFAOYSA-N 0.000 description 1
- KYZRXNLDSCFSAY-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)C(=O)OC)C(N)=O Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)C(=O)OC)C(N)=O KYZRXNLDSCFSAY-UHFFFAOYSA-N 0.000 description 1
- MKGNJQSRKQKKKO-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)OC)C(N)=O Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)OC)C(N)=O MKGNJQSRKQKKKO-UHFFFAOYSA-N 0.000 description 1
- HSIIXVXTSGPOEL-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)[N+](=O)[O-])C#N Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)[N+](=O)[O-])C#N HSIIXVXTSGPOEL-UHFFFAOYSA-N 0.000 description 1
- BDBIAAZHIAQIRE-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)[N+](=O)[O-])C(N)=O Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=C(C=C1)[N+](=O)[O-])C(N)=O BDBIAAZHIAQIRE-UHFFFAOYSA-N 0.000 description 1
- NCTIHFMOMGFBLQ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=CC=C1)CO Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(NC1=CC=CC=C1)CO NCTIHFMOMGFBLQ-UHFFFAOYSA-N 0.000 description 1
- QKPYLVKCFVPACU-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)(NC=1C=C2C=NN(C2=CC=1)COCC[Si](C)(C)C)C#N Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)(NC=1C=C2C=NN(C2=CC=1)COCC[Si](C)(C)C)C#N QKPYLVKCFVPACU-UHFFFAOYSA-N 0.000 description 1
- GPLTVAVDEWWYFT-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC(=NC=C2)OC)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC(=NC=C2)OC)=O)C)=O)CC1 GPLTVAVDEWWYFT-UHFFFAOYSA-N 0.000 description 1
- WOJSGWVFKPDRHM-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC(=NC=C2)OS(=O)(=O)C(F)(F)F)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC(=NC=C2)OS(=O)(=O)C(F)(F)F)=O)C)=O)CC1 WOJSGWVFKPDRHM-UHFFFAOYSA-N 0.000 description 1
- VHMFQJKDNYCRIE-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)C#N)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)C#N)=O)C)=O)CC1 VHMFQJKDNYCRIE-UHFFFAOYSA-N 0.000 description 1
- VZYWAOURFXYQOC-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)C(=O)OC)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)C(=O)OC)=O)C)=O)CC1 VZYWAOURFXYQOC-UHFFFAOYSA-N 0.000 description 1
- BVAUFGCBZRJRGV-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)C(=O)OC)=O)CCBr)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)C(=O)OC)=O)CCBr)=O)CC1 BVAUFGCBZRJRGV-UHFFFAOYSA-N 0.000 description 1
- APKAWEMBTQIXLM-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)[N+](=O)[O-])=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)[N+](=O)[O-])=O)C)=O)CC1 APKAWEMBTQIXLM-UHFFFAOYSA-N 0.000 description 1
- MRNNILOUSRRAFP-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C=2C=CC3=C(N=CO3)C=2)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2C=2C=CC3=C(N=CO3)C=2)=O)C)=O)CC1 MRNNILOUSRRAFP-UHFFFAOYSA-N 0.000 description 1
- ZJHMHNHHAHOXCB-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2CC2CC(C2)O)=O)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(C(N2CC2CC(C2)O)=O)C)=O)CC1 ZJHMHNHHAHOXCB-UHFFFAOYSA-N 0.000 description 1
- QWUPDRKBVJUNGN-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)C(=O)OC)CCN(C)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)C(=O)OC)CCN(C)C)=O)CC1 QWUPDRKBVJUNGN-UHFFFAOYSA-N 0.000 description 1
- SUJOJJFVULOWHX-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)C2=NNC=N2)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)C2=NNC=N2)C)=O)CC1 SUJOJJFVULOWHX-UHFFFAOYSA-N 0.000 description 1
- YNCWQCCUIPAVEL-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)C=2N=NNN=2)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(N(CN2C2=CC=C(C=C2)C=2N=NNN=2)C)=O)CC1 YNCWQCCUIPAVEL-UHFFFAOYSA-N 0.000 description 1
- KAQRMDGACFBJEN-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C2=CC(=C(C=C2)O)N)=O)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C2=CC(=C(C=C2)O)N)=O)=O)CC1 KAQRMDGACFBJEN-UHFFFAOYSA-N 0.000 description 1
- HDJPDABCTZWWIS-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C2=CC(=NC=C2)OC)=O)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C2=CC(=NC=C2)OC)=O)=O)CC1 HDJPDABCTZWWIS-UHFFFAOYSA-N 0.000 description 1
- FSQBKIVHXLJAAA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C=2C=CC3=C(N=CO3)C2)=O)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NC(N2C=2C=CC3=C(N=CO3)C2)=O)=O)CC1 FSQBKIVHXLJAAA-UHFFFAOYSA-N 0.000 description 1
- ZQVRZDYSBNRPGA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(C(NCN2C=2C=C3C=NN(C3=CC=2)COCC[Si](C)(C)C)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C(NCN2C=2C=C3C=NN(C3=CC=2)COCC[Si](C)(C)C)=O)CC1 ZQVRZDYSBNRPGA-UHFFFAOYSA-N 0.000 description 1
- CVXCEPBXIZNYNI-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CCC2(COC(N2C2=CC=CC=C2)=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(COC(N2C2=CC=CC=C2)=O)CC1 CVXCEPBXIZNYNI-UHFFFAOYSA-N 0.000 description 1
- FDMPIRZDCYAKSK-YADARESESA-N C(C)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)[C@H](C)OC)C=C(C=1)F Chemical compound C(C)C=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)[C@H](C)OC)C=C(C=1)F FDMPIRZDCYAKSK-YADARESESA-N 0.000 description 1
- RTIHBKINNPLROJ-HSZRJFAPSA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C1)F RTIHBKINNPLROJ-HSZRJFAPSA-N 0.000 description 1
- LAAYUKAQBBWYLR-RUZDIDTESA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)NS(=O)(=O)C)C)=O)CC2)C(C)C)C=1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)NS(=O)(=O)C)C)=O)CC2)C(C)C)C=1)F LAAYUKAQBBWYLR-RUZDIDTESA-N 0.000 description 1
- UPMJDGRLZVVPFX-RUZDIDTESA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)OC)C)=O)CC2)C(C)C)C=1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)OC)C)=O)CC2)C(C)C)C=1)F UPMJDGRLZVVPFX-RUZDIDTESA-N 0.000 description 1
- GOECOLXTEALSPU-YADARESESA-N C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)[C@H](C)OC)C1)F Chemical compound C(C)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)[C@H](C)OC)C1)F GOECOLXTEALSPU-YADARESESA-N 0.000 description 1
- VNOMDZYUHYQSCO-MUUNZHRXSA-N C(C)OC(COC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)=O)C)=O Chemical compound C(C)OC(COC1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)CC)F)=O)=O)=O)C)=O VNOMDZYUHYQSCO-MUUNZHRXSA-N 0.000 description 1
- BWSIWBLHEPRLRT-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)NC(=O)OC)=O)C)=O)CC1 Chemical compound C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)NC(=O)OC)=O)C)=O)CC1 BWSIWBLHEPRLRT-UHFFFAOYSA-N 0.000 description 1
- GSIQCECTWFVLNZ-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)OCC2CN(C2)C(=O)OC(C)(C)C)=O)C)=O)CC1 Chemical compound C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)OCC2CN(C2)C(=O)OC(C)(C)C)=O)C)=O)CC1 GSIQCECTWFVLNZ-UHFFFAOYSA-N 0.000 description 1
- DAYRLROUUVCIQC-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)[N+](=O)[O-])=O)C)=O)CC1 Chemical compound C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2C2=CC=C(C=C2)[N+](=O)[O-])=O)C)=O)CC1 DAYRLROUUVCIQC-UHFFFAOYSA-N 0.000 description 1
- LFYKFDTWFWSDGN-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2CC2=CC=C(C=C2)C#N)=O)C)=O)CC1 Chemical compound C(C1=CC=CC=C1)OC(=O)N1CCC2(C(N(C(N2CC2=CC=C(C=C2)C#N)=O)C)=O)CC1 LFYKFDTWFWSDGN-UHFFFAOYSA-N 0.000 description 1
- GXTJTMSNIPLUEK-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C(=O)OC(C)(C)C)=O)C)=O Chemical compound C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C(=O)OC(C)(C)C)=O)C)=O GXTJTMSNIPLUEK-UHFFFAOYSA-N 0.000 description 1
- MHXYHDLOSGZGGZ-AREMUKBSSA-N C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(=O)OC(C)(C)C)=O)=O)C)=O Chemical compound C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(=O)OC(C)(C)C)=O)=O)C)=O MHXYHDLOSGZGGZ-AREMUKBSSA-N 0.000 description 1
- KIBBQMUFFRTOAS-GDLZYMKVSA-N C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C11CCN(CC1)C([C@@H](C(C)C)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O)=O)=O)C)=O KIBBQMUFFRTOAS-GDLZYMKVSA-N 0.000 description 1
- YIPKBYQEYHKEHN-MUUNZHRXSA-N C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=NC=CC=C2)=O)=O)=O)C)=O Chemical compound C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=NC=CC=C2)=O)=O)=O)C)=O YIPKBYQEYHKEHN-MUUNZHRXSA-N 0.000 description 1
- ANHDLZKAIXZCMD-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)NC1(CCN(CC1)C(=O)OC(C)(C)C)C#N Chemical compound C(C1=CC=CC=C1)OC(=O)N1N=CC2=CC(=CC=C12)NC1(CCN(CC1)C(=O)OC(C)(C)C)C#N ANHDLZKAIXZCMD-UHFFFAOYSA-N 0.000 description 1
- IMDCEXZKOIPWHX-GDLZYMKVSA-N C(C1=CC=CC=C1)OC(C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound C(C1=CC=CC=C1)OC(C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O IMDCEXZKOIPWHX-GDLZYMKVSA-N 0.000 description 1
- RIBHIMIYEIPLAE-JOCHJYFZSA-N C(N)(=O)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C Chemical compound C(N)(=O)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C RIBHIMIYEIPLAE-JOCHJYFZSA-N 0.000 description 1
- UISRURNJKGWKBC-XMMPIXPASA-N C1(CC1)C(=O)NC1=CC=C(C=C1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O Chemical compound C1(CC1)C(=O)NC1=CC=C(C=C1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C)=O UISRURNJKGWKBC-XMMPIXPASA-N 0.000 description 1
- CQXUXMITFAPFPB-IQGLISFBSA-N C1(CC1)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)[C@@H](C)OC)C=1)F Chemical compound C1(CC1)C=1C=CC(=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=C(C=C3)OC)=O)C)=O)CC2)[C@@H](C)OC)C=1)F CQXUXMITFAPFPB-IQGLISFBSA-N 0.000 description 1
- FEQGCIWMINOGHQ-HSZRJFAPSA-N C1(CCCC1)[C@H](C(=O)N1CCC2(C(N(C(N2C2=CN(C(C=C2)=O)C)=O)C)=O)CC1)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O Chemical compound C1(CCCC1)[C@H](C(=O)N1CCC2(C(N(C(N2C2=CN(C(C=C2)=O)C)=O)C)=O)CC1)NC(C1=C(C=CC(=C1)C(F)(F)F)F)=O FEQGCIWMINOGHQ-HSZRJFAPSA-N 0.000 description 1
- RUOHCNVILPLZAB-UHFFFAOYSA-M C1(CCCCC1)N1C(N(C(C11CCN(CC1)C(=O)[O-])=O)C)=O Chemical compound C1(CCCCC1)N1C(N(C(C11CCN(CC1)C(=O)[O-])=O)C)=O RUOHCNVILPLZAB-UHFFFAOYSA-M 0.000 description 1
- YVWMYJOXTKDKMW-OAQYLSRUSA-N CC([C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=CC=C2)=O)C)=O)CC1)NC(C1=CC(=CC=C1)C(F)(F)F)=O)C Chemical compound CC([C@H](C(=O)N1CCC2(C(N(C(N2C2=CC=CC=C2)=O)C)=O)CC1)NC(C1=CC(=CC=C1)C(F)(F)F)=O)C YVWMYJOXTKDKMW-OAQYLSRUSA-N 0.000 description 1
- HNDOKECUHRYOFY-UHFFFAOYSA-N CC1N(C)C(=O)C2(CCNCC2)N1C1=CC=C(C=C1)C(=O)OCC1=CC=CC=C1 Chemical compound CC1N(C)C(=O)C2(CCNCC2)N1C1=CC=C(C=C1)C(=O)OCC1=CC=CC=C1 HNDOKECUHRYOFY-UHFFFAOYSA-N 0.000 description 1
- LEQNBKIUGXBMTP-VWLOTQADSA-N CC=1C=C(C(=O)N[C@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C2CCOCC2)C=CC1 Chemical compound CC=1C=C(C(=O)N[C@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C2CCOCC2)C=CC1 LEQNBKIUGXBMTP-VWLOTQADSA-N 0.000 description 1
- NSBSPXKDMKAISE-XMMPIXPASA-N CN(C(C1=CC(=CC=C1)C)=O)[C@@H](C(=O)N1CCC2(C(N(CN2C2=CC=CC=C2)C)=O)CC1)C(C)C Chemical compound CN(C(C1=CC(=CC=C1)C)=O)[C@@H](C(=O)N1CCC2(C(N(CN2C2=CC=CC=C2)C)=O)CC1)C(C)C NSBSPXKDMKAISE-XMMPIXPASA-N 0.000 description 1
- OKZORNQRMTXUEA-UHFFFAOYSA-M CN(C)C=NC(=O)C1=CC=C(C=C1)N1CN(C(C11CCN(CC1)C(=O)[O-])=O)C Chemical compound CN(C)C=NC(=O)C1=CC=C(C=C1)N1CN(C(C11CCN(CC1)C(=O)[O-])=O)C OKZORNQRMTXUEA-UHFFFAOYSA-M 0.000 description 1
- WNGGVNLXXCHXLF-UHFFFAOYSA-N CN1CN(C2(C1=O)CCNCC2)C2=CC=C(C=C2)NC2COC2 Chemical compound CN1CN(C2(C1=O)CCNCC2)C2=CC=C(C=C2)NC2COC2 WNGGVNLXXCHXLF-UHFFFAOYSA-N 0.000 description 1
- KPYNEPNUIWWVBW-RUZDIDTESA-N COC(C1=CC=C(C=C1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)CCN(C)C)=O)=O Chemical compound COC(C1=CC=C(C=C1)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)CCN(C)C)=O)=O KPYNEPNUIWWVBW-RUZDIDTESA-N 0.000 description 1
- QKNXAXGHTVYQJQ-GFCCVEGCSA-N COC([C@@H](C(C)C)NC(C1=CC(=CC(=C1)C)F)=O)=O Chemical compound COC([C@@H](C(C)C)NC(C1=CC(=CC(=C1)C)F)=O)=O QKNXAXGHTVYQJQ-GFCCVEGCSA-N 0.000 description 1
- JMGCKVCCTINCEW-UHFFFAOYSA-M CS(=O)(=O)OCC1CN(C1)C(=O)[O-] Chemical compound CS(=O)(=O)OCC1CN(C1)C(=O)[O-] JMGCKVCCTINCEW-UHFFFAOYSA-M 0.000 description 1
- BOVRBJIKOACTQN-UHFFFAOYSA-N Cl.C(C)OC(CN1CN(C2(C1=O)CCNCC2)C2=CC=CC=C2)=O Chemical compound Cl.C(C)OC(CN1CN(C2(C1=O)CCNCC2)C2=CC=CC=C2)=O BOVRBJIKOACTQN-UHFFFAOYSA-N 0.000 description 1
- UXUBGTXSWGYPQI-UHFFFAOYSA-N Cl.C(C)OC(COC1=CC=C(C=C1)N1CN(C(C12CCNCC2)=O)C)=O Chemical compound Cl.C(C)OC(COC1=CC=C(C=C1)N1CN(C(C12CCNCC2)=O)C)=O UXUBGTXSWGYPQI-UHFFFAOYSA-N 0.000 description 1
- ZIIJERLVLBETKE-UHFFFAOYSA-N Cl.CC1N(C2(C(N1C)=O)CCNCC2)C2=CC=C(C(=O)OCC1=CC=CC=C1)C=C2 Chemical compound Cl.CC1N(C2(C(N1C)=O)CCNCC2)C2=CC=C(C(=O)OCC1=CC=CC=C1)C=C2 ZIIJERLVLBETKE-UHFFFAOYSA-N 0.000 description 1
- CJVWOXHLAZETRN-UHFFFAOYSA-N Cl.CN(CCN1CN(C2(C1=O)CCNCC2)C2=CC=C(C(=O)OC)C=C2)C Chemical compound Cl.CN(CCN1CN(C2(C1=O)CCNCC2)C2=CC=C(C(=O)OC)C=C2)C CJVWOXHLAZETRN-UHFFFAOYSA-N 0.000 description 1
- JRJPEHCWBIWZLG-UHFFFAOYSA-N Cl.COC(C1=CC=C(C=C1)N1C(N(C(C12CCNCC2)=O)CCN(C)C)=O)=O Chemical compound Cl.COC(C1=CC=C(C=C1)N1C(N(C(C12CCNCC2)=O)CCN(C)C)=O)=O JRJPEHCWBIWZLG-UHFFFAOYSA-N 0.000 description 1
- KDPJSZWBEYYGGM-UHFFFAOYSA-N Cl.ClC=1C=C(C=CC1)N1CN(C(C12CCNCC2)=O)C Chemical compound Cl.ClC=1C=C(C=CC1)N1CN(C(C12CCNCC2)=O)C KDPJSZWBEYYGGM-UHFFFAOYSA-N 0.000 description 1
- PYFYPWVBEJICJJ-UHFFFAOYSA-N Cl.N=1NN=NC1C1=CC=C(C=C1)N1CN(C(C12CCNCC2)=O)C Chemical compound Cl.N=1NN=NC1C1=CC=C(C=C1)N1CN(C(C12CCNCC2)=O)C PYFYPWVBEJICJJ-UHFFFAOYSA-N 0.000 description 1
- HEQMBSJYJNODGD-XFULWGLBSA-N Cl.N[C@@H](C(=O)N1CCC2(C(N(C(N2C2=CC=CC=C2)=O)C)=O)CC1)C(C)C Chemical compound Cl.N[C@@H](C(=O)N1CCC2(C(N(C(N2C2=CC=CC=C2)=O)C)=O)CC1)C(C)C HEQMBSJYJNODGD-XFULWGLBSA-N 0.000 description 1
- YJSVSYAAIWLGOX-KUARMEPBSA-N Cl.N[C@@H](C(=O)N1CCC2(C(N(CN2C2=CC=CC=C2)C)=O)CC1)[C@H](C)OC Chemical compound Cl.N[C@@H](C(=O)N1CCC2(C(N(CN2C2=CC=CC=C2)C)=O)CC1)[C@H](C)OC YJSVSYAAIWLGOX-KUARMEPBSA-N 0.000 description 1
- FLHHNKLGKZDSCR-JOCHJYFZSA-N ClC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CN(C(C=C3)=O)C)C)=O)CC2)C(C)C)C=C(C=1)C(F)(F)F Chemical compound ClC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CN(C(C=C3)=O)C)C)=O)CC2)C(C)C)C=C(C=1)C(F)(F)F FLHHNKLGKZDSCR-JOCHJYFZSA-N 0.000 description 1
- UIEWINQXMGLYAY-JOCHJYFZSA-N ClC=1C=C(CN2C(N(C(C23CCN(CC3)C([C@@H](C(C)C)NC(C3=C(C=CC(=C3)C(F)(F)F)F)=O)=O)=O)C)=O)C=CC1 Chemical compound ClC=1C=C(CN2C(N(C(C23CCN(CC3)C([C@@H](C(C)C)NC(C3=C(C=CC(=C3)C(F)(F)F)F)=O)=O)=O)C)=O)C=CC1 UIEWINQXMGLYAY-JOCHJYFZSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N Decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N Dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 108010000659 EC 1.1.3.17 Proteins 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N Ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N Ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- TXPSXZIHPCEXFF-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F TXPSXZIHPCEXFF-OAQYLSRUSA-N 0.000 description 1
- WBYXLXUXBRZQMG-LJQANCHMSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=NN(C=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=NN(C=C3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F WBYXLXUXBRZQMG-LJQANCHMSA-N 0.000 description 1
- FXWGYDPLALEKQP-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3CCOCC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3CCOCC3)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F FXWGYDPLALEKQP-HXUWFJFHSA-N 0.000 description 1
- WNXSJVVSLRKTOJ-OAQYLSRUSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=C4C(=NC3)NC=C4)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C=3C=C4C(=NC3)NC=C4)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F WNXSJVVSLRKTOJ-OAQYLSRUSA-N 0.000 description 1
- IMHHPEPUHQCPDX-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC(=CC=C3)S(=O)(=O)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC3=CC(=CC=C3)S(=O)(=O)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F IMHHPEPUHQCPDX-HSZRJFAPSA-N 0.000 description 1
- UJMHKSRNVUZPTN-JOCHJYFZSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=NC(=CC=3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3C=NC(=CC=3)OC)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F UJMHKSRNVUZPTN-JOCHJYFZSA-N 0.000 description 1
- JNXAQUUKDDPRNR-HXUWFJFHSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3SC=C(N3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3CC=3SC=C(N3)C)=O)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F JNXAQUUKDDPRNR-HXUWFJFHSA-N 0.000 description 1
- UGGCRELAIDTUIN-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC(=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC(=C(C(=O)O)C=C3)C)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F UGGCRELAIDTUIN-HSZRJFAPSA-N 0.000 description 1
- SYMAHTMNWKYCSK-HSZRJFAPSA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC(=C(C(=O)O)C=C3)OC)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC(=C(C(=O)O)C=C3)OC)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F SYMAHTMNWKYCSK-HSZRJFAPSA-N 0.000 description 1
- QUJPPYISLDYWBK-RUZDIDTESA-N FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)NC3COC3)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F Chemical compound FC1=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=C(C=C3)NC3COC3)C)=O)CC2)C(C)C)C=C(C=C1)C(F)(F)F QUJPPYISLDYWBK-RUZDIDTESA-N 0.000 description 1
- MTJUBQAUVHBHKK-HSZRJFAPSA-N FC1=C(C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=C1)C Chemical compound FC1=C(C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=C1)C MTJUBQAUVHBHKK-HSZRJFAPSA-N 0.000 description 1
- QBMVYVJWNKXVLA-OAQYLSRUSA-N FC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=CC1 Chemical compound FC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(C(N3C3=CC=CC=C3)=O)C)=O)CC2)C(C)C)C=CC1 QBMVYVJWNKXVLA-OAQYLSRUSA-N 0.000 description 1
- LRPMEFKJMWMCGK-HSZRJFAPSA-N FC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=C(C1)C Chemical compound FC=1C=C(C(=O)N[C@@H](C(=O)N2CCC3(C(N(CN3C3=CC=CC=C3)C)=O)CC2)C(C)C)C=C(C1)C LRPMEFKJMWMCGK-HSZRJFAPSA-N 0.000 description 1
- PZAOANXPKWANOY-LLVKDONJSA-N FC=1C=C(C(=O)N[C@@H](C(=O)O)C(C)C)C=C(C1)C Chemical compound FC=1C=C(C(=O)N[C@@H](C(=O)O)C(C)C)C=C(C1)C PZAOANXPKWANOY-LLVKDONJSA-N 0.000 description 1
- 102000003688 G-protein coupled receptors Human genes 0.000 description 1
- 108090000045 G-protein coupled receptors Proteins 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 244000232488 Jessenia polycarpa Species 0.000 description 1
- 235000002407 Jessenia polycarpa Nutrition 0.000 description 1
- 102100003077 LPAR1 Human genes 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N Methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-Methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- LCJOQRSTIMFYCP-HSZRJFAPSA-N N1N=C(N=C1)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C Chemical compound N1N=C(N=C1)C1=CC=C(C=C1)N1CN(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=C(C=CC(=C2)C(F)(F)F)F)=O)=O)=O)C LCJOQRSTIMFYCP-HSZRJFAPSA-N 0.000 description 1
- TWKSGEPTRAKZPK-OAQYLSRUSA-N N1N=CC2=CC(=CC=C12)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=NC=CC=C2)=O)=O)=O)C)=O Chemical compound N1N=CC2=CC(=CC=C12)N1C(N(C(C12CCN(CC2)C([C@@H](C(C)C)NC(C2=NC=CC=C2)=O)=O)=O)C)=O TWKSGEPTRAKZPK-OAQYLSRUSA-N 0.000 description 1
- 101700000165 NLP2 Proteins 0.000 description 1
- 101700040193 NPP2 Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- AATZXTDEFPCGCL-UHFFFAOYSA-M O=C1NC2(C(N1C)=O)CCN(CC2)C(=O)[O-] Chemical compound O=C1NC2(C(N1C)=O)CCN(CC2)C(=O)[O-] AATZXTDEFPCGCL-UHFFFAOYSA-M 0.000 description 1
- NINPXZCUJKZPPO-VQIWEWKSSA-N OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(CN(CCN(C)C)C2=O)C1=CC=C(C=C1)C(O)=O Chemical compound OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)C1=C(F)C=CC(=C1)C(F)(F)F)C(=O)N1CCC2(CC1)N(CN(CCN(C)C)C2=O)C1=CC=C(C=C1)C(O)=O NINPXZCUJKZPPO-VQIWEWKSSA-N 0.000 description 1
- QKJHBYYCKYKXCI-GNAFDRTKSA-N OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)c1cc(ccc1F)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)c1ccc2nc(C)[nH]c2c1 Chemical compound OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)c1cc(ccc1F)C(F)(F)F)C(=O)N1CCC2(CC1)N(C(=O)N(C)C2=O)c1ccc2nc(C)[nH]c2c1 QKJHBYYCKYKXCI-GNAFDRTKSA-N 0.000 description 1
- SIHVYINVDLUUCJ-UFTMZEDQSA-N OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)c1cc(ccc1F)C(F)(F)F)C(=O)N1CCC2(CC1)N(CN(C)C2=O)c1ccc(OCCN(C)C)cc1 Chemical compound OC(=O)C(F)(F)F.CC(C)[C@@H](NC(=O)c1cc(ccc1F)C(F)(F)F)C(=O)N1CCC2(CC1)N(CN(C)C2=O)c1ccc(OCCN(C)C)cc1 SIHVYINVDLUUCJ-UFTMZEDQSA-N 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N Picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 101710015542 Pp1-87B Proteins 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- JKVRTUCVPZTEQZ-UHFFFAOYSA-N Tributyltin azide Chemical compound CCCC[Sn](CCCC)(CCCC)N=[N+]=[N-] JKVRTUCVPZTEQZ-UHFFFAOYSA-N 0.000 description 1
- YHBHQYRDAVETGQ-UHFFFAOYSA-N Triton X 100 Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCCCCCCCCCO)C=C1 YHBHQYRDAVETGQ-UHFFFAOYSA-N 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- IRMJSOUZKXJYPI-VPYROQPTSA-N [2H]C([2H])([2H])OC1=CC=C(C=C1)N1C(=O)N(C)C(=O)C11CCN(CC1)C(=O)OC(C)(C)C Chemical compound [2H]C([2H])([2H])OC1=CC=C(C=C1)N1C(=O)N(C)C(=O)C11CCN(CC1)C(=O)OC(C)(C)C IRMJSOUZKXJYPI-VPYROQPTSA-N 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N [N-]=C=O Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- WPVJDVZITHRFHI-UHFFFAOYSA-M [O-]C(=O)N1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1 Chemical compound [O-]C(=O)N1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1 WPVJDVZITHRFHI-UHFFFAOYSA-M 0.000 description 1
- SJZAPSHKTOTRBQ-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-1-yl)methylidene]-dimethylazanium Chemical compound C1=CC=C2[N+](=C(N(C)C)N(C)C)N=NC2=N1 SJZAPSHKTOTRBQ-UHFFFAOYSA-N 0.000 description 1
- PDKXJKWLFFZPPF-UHFFFAOYSA-N [dimethylamino-(3-oxidotriazolo[4,5-b]pyridin-3-ium-1-yl)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(C(N(C)C)=[N+](C)C)N=[N+]([O-])C2=N1 PDKXJKWLFFZPPF-UHFFFAOYSA-N 0.000 description 1
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 230000002917 arthritic Effects 0.000 description 1
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 description 1
- VZOVOHRDLOYBJX-UHFFFAOYSA-N benzyl 4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)CCN1C(=O)OCC1=CC=CC=C1 VZOVOHRDLOYBJX-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HXSNGAHNYZBZTH-UHFFFAOYSA-N cyclopropylmethanamine;hydrochloride Chemical compound Cl.NCC1CC1 HXSNGAHNYZBZTH-UHFFFAOYSA-N 0.000 description 1
- 230000003436 cytoskeletal Effects 0.000 description 1
- MKJDUHZPLQYUCB-UHFFFAOYSA-N decan-4-one Chemical compound CCCCCCC(=O)CCC MKJDUHZPLQYUCB-UHFFFAOYSA-N 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- BKNZVLSJCYPDLJ-UHFFFAOYSA-N methyl 2-amino-2-(oxan-4-yl)acetate;hydrochloride Chemical compound Cl.COC(=O)C(N)C1CCOCC1 BKNZVLSJCYPDLJ-UHFFFAOYSA-N 0.000 description 1
- 230000001617 migratory Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 101710031992 pRL90232 Proteins 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 108060002036 pde-2 Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- FSDNTQSJGHSJBG-UHFFFAOYSA-N piperidine-4-carbonitrile Chemical compound N#CC1CCNCC1 FSDNTQSJGHSJBG-UHFFFAOYSA-N 0.000 description 1
- 101710035540 plaa2 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- OCFVSFVLVRNXFJ-UHFFFAOYSA-N potassium hydride Inorganic materials [H-].[K+] OCFVSFVLVRNXFJ-UHFFFAOYSA-N 0.000 description 1
- 230000002206 pro-fibrotic Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- BHSCFWOFSDZQIK-UHFFFAOYSA-N tert-butyl 3-(2-ethoxy-2-oxoethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)N(CC(=O)OCC)CN2C1=CC=CC=C1 BHSCFWOFSDZQIK-UHFFFAOYSA-N 0.000 description 1
- WFYWNZAFKBBGCF-UHFFFAOYSA-N tert-butyl 3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound O=C1N(C)C(=O)NC11CCN(C(=O)OC(C)(C)C)CC1 WFYWNZAFKBBGCF-UHFFFAOYSA-N 0.000 description 1
- ZBTCTIDRZAHCCK-UHFFFAOYSA-N tert-butyl 3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21C(=O)N(C)CN2C1=CC=CC=C1 ZBTCTIDRZAHCCK-UHFFFAOYSA-N 0.000 description 1
- VMKIXWAFFVLJCK-UHFFFAOYSA-N tert-butyl 3-oxoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C1 VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- INQOMBQAUSQDDS-FIBGUPNXSA-N trideuterio(iodo)methane Chemical compound [2H]C([2H])([2H])I INQOMBQAUSQDDS-FIBGUPNXSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
Abstract
The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
Description
SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN CROSS-REFERENCE TO RELATED APPLICATIONS
This application daims the benefit under 35 U.S.C. 119(e) of LES. Provisional Patent Application No. 61/975,123, filed on April 4,2014 and entitled ‘Substituted Spirocydic Inhibitors Of Autotaxin And Their Préparation And Use In The Treatment Of LPA-Dependent Or LPA-Mediated Diseases. The entire contents of the above-referenced application is incorporated herein by référencé.
FIELD AND BACKGROUND
Autotaxin (ATX) is a secreted enzyme of the edonucleotide pyrophosphatase/phosphodiesterase family, and is also known as Edonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP-2 or NPP2). ATX plays a rôle in driving pathological conditions, induding fibrosis, arthritic inflammation, neurodegeneration, neuropathie pain, and cancer. ATX is the fundamental regulator of the conversion of Lysophosphatidylcholine (LPC) to Lysophosphatidic Add (LPA). LPA is a bioadive lipid that affeds migration, prolifération, and survival of various cell types.
Inhibition of ATX has been shown to reduce LPA levels in pathological settings. Redudion of LPA may provide therapeutic benefits in diseases with unmet medical need, induding cancer, lymphocyte homing, chronic inflammation, neuropathie pain, fibrotic diseases such as Idiopathic Pulmonary Fibrosis (IPF), thrombosis, and cholestatic pruritus which are caused, mediated and/or propagated by increased LPA levels and/or adivation of ATX.
Fibrotic diseases are chronic, débilitât)ng and often léthal pathologies driven by a dysregulated response to tissue or organ injury. Fibrosis can develop in the liver, kidney, lung, denmis, vasculature, gut and other sites. Fibrosis develops due to action of pathways induding growth fadors, cytokines, integrin and lipids.
ATX, LPA, and LPA Receptor (LPAR) pathways hâve been implicated in fibrotic disease. For example, profiling studies show increased levels of ATX, LPA and LPARs in various rodent models of fibrosis and in human patient fluids and biopsy tissue. LPA can induce proliférative, survival, and chemotadic responses in transformed ceti fines, indicating that LPA may exert pro-inflammatory and profibrotic responses in cells known to be critical in fibrotic disease, induding: fibroblasts, smooth muscle cells, macrophages, épithélial and endothélial cells, and leukocytes. Gene-targeted mouse models hâve implicated LPARs in fibrosis pathogenesis. Inhibitors of LPARs indicate that antagonism of receptors within this pathway blocked or reversed fibrosis in the lung, liver, kidney and skin in rodents. Cell typespecific gene targeting studies hâve showed that ATX plays a role in the development of lung fibrosis and inflammatory arthritis.
ATX and LPA hâve also been implicated in tumor progression and metastasis. ATX may be responsible for increased LPA levels in ascites and plasma of ovarian cancer patients since ATX couverts LPC to LPA. Increased levels of LPA, attered receptor expression and altered responses to LPA may contribute to initiation, progression or outcome of ovarian cancer. LPA has also been linked to prostate, breast, melanoma, head and neck, bowel, brain and thyroid cancers.
LPA has been shown to promote tumor cell survival, prolifération, invasion and migration into neighboring tissues, which can resuit in the formation of métastasés. Additionally, LPA promûtes cytoskeletal remodeling that may enhance migratory and invasive properties of cells, which may contribute to cancer metastasis, These biological and pathobiological processes of LPA are initiated through the activation of G-protein coupled receptors.
Transcriptome analyses of more than 350 normal tissues and more than 1700 malignant tissues demonstrate that ATX is expressed in a variety of carcinomas and sarcomas, underscoring the potential contribution of LPA to metastatic disease.
Accordingly, when treating patients with diseases, such as cancer, lymphocyte homing, chronic inflammation, neuropathie pain, fibrotic diseases, thrombosis, and cholestatic pruritus it is désirable to lower LPA levels. This can be accomplished through inhibition of enzymes involved in LPA biosynthesis, such as ATX.
Since ATX is expressed in tumors and affects tumor cell prolifération and invasion into neighboring tissues both of which can lead to the formation of métastasés, ATX is a target for anti-tumor therapy. Moreover, in angiogenesis, ATX, taken with other anti-angiogenetic factors, brings about blood vessel formation. Angiogenesis supplies tumors with nutrients during tumor growth. Therefore, inhibition of angiogenesis is a target for anti-tumor therapy, leading to starvation of a tumor.
ATX has also been implicated in nerve injury-induced neuropathie pain. LPA biosynthesis, through ATX, is the source of LPA for LPA1 receptor-mediated neuropathie pain. Therefore, targeted inhibition of ATX-mediated LPA biosynthesis may represent a novel treatment to prevent nerve injuryinduced neuropathie pain.
Various publications refer to compounds that are capable of inhibiting ATX, including: WO2013061297, WO2012166415, US20120100592, W02012024620. WQ2011116867, WO2011017350, WO2011006569, WO2010115491, WO2010115491, W02010112124, W02010112116, WO2010063352, US20100016258, and WO2009151644.
Accordingly, there remains a need for ATX inhibitors having the potential to reach the clinic and obtain regulatory approval for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, such as cancer, lymphocyte homing, chronic inflammation, neuropathie pain, fibrotic diseases, thrombosis, and cholestatic pruritus which are caused, mediated and/or propagated by increased LPA levels and/or the activation of ATX.
SUMMARY
The présent invention includes certain substituted compounds described herein, their salts, préparations thereof, pharmaceutical compositions and formulations thereof, and methods of treating disease such as cancers therewith.
The présent invention includes compounds of Formula I and pharmaceutically acceptable salts thereof:
wherein X1 is selected from C-i-zaocyi, C=O, NR3, or Ο; X2 is selected from Ci-2aikyi, C-O, NR3, or O; X3 is selected from Ci-2aw, C=O, NR3, O or CR10R11; R1, R3. R2a, R4, R10 and R11 are each independently optionally substituted; and m and n are each independently selected from 0,1 or 2. Any of the above can be further substituted. Compounds of Formula I inhibit ATX.
In some embodiments, compounds of the présent invention are inhibitors of ATX. In some embodiments, compounds of the présent invention are sélective inhibitors of ATX.
In some embodiments, the présent invention includes a method for the treatment of at least one of cancer, lymphocyte homing, chronic inflammation, neuropathie pain, fibrotic diseases, thrombosis, and cholestatic pruritus comprising administering to a subject in need thereof a therapeutically effective amount of a compound or sait of the compound of Formula I that binds to and inhibits ATX providing a réduction in LPA levels.
Embodiments of the présent invention include the compounds herein, pharmaceutically acceptable salts thereof, any physical forms thereof including solvatés and hydrates, préparation ofthe compounds, intermediates, and pharmaceutical compositions and formulations thereof.
DETAILED DESCRIPTION
In some embodiments, the présent invention concems compounds and salts thereof of Formula I, as shown below and defined herein.
A compound according to Formula I:
o
I or a pharmaceutically acceptable sait thereof, wherein:
X1 and X2 are each independently selected from one or more of Ci-2aikyi, C=O, NR3, or O;
X3 is independently selected from one or more of Ci-2aikyi, C=O, NR3, O, orCR10R11;
m and n are each independently selected from 0, 1 or 2;
R1 is selected from Co.i2alkyl-, Cwcycloalkyl-Co^alkyl-, C3-i2heterocycloalkyl-Co.i2alkyl-, arylCo-nalkyl-, aryl-C3-i2Cycloalkyl-, aryl-C3.i2heterocycloalkyl-, heteroaryI-Co-i2alkyl-, heteroaryl-Csi2cycloalkyl-, or heteroaryl-C^heterocycloalkyl-, any of which is optionally substituted with one or more independent G1 substituents;
R2 is selected from Co-i2alkyl—. C3-i2cycloalkyl-Co-i2alkyl-, C3-i2heterocycloalkyl-Co-i2alkyl-, arylCo-i2alkyl-, aryl-C3.i2cycloalkyl-, aryl-C3-i2heterocycloalkyl-, heteroaryl-Co valkyl-, heteroaryl-Cj. i2cycloalkyl-, or heteroaryl-C3-i2heterocycloalkyl-, any of which is optionally substituted with one or more independent G2 substituents;
R2a is selected from Ct^alkyl-, C3-i2Cycloalkyl-Co-i2alkyl-, Ca-^heterocycloalkyl-Co-^alkyl-, aryl— Co-i2alkyl-, aryl-C3-i2cycloalkyl-, aryl-C3-i2heterocycloalkyl-, heteroaryl-Conalkyl-, heteroaryl-Cai2cycloalkyl—, or heteroaryl-Ca-iaheterocycloalkyl-, any of which is optionally substituted with one or more independent G2a substituents;
R2 and R2a are each independentiy a linear structure, or, R2 and R2a are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(0)mi;
R3 is selected from Co-^alkyl-, C3-i2cycloalkyl-Co-i2alkyl-, C3-i2heterocycloalkyl-Co-i2alkyl-, aryl— Co-i2alkyi-, aryl-Ca-iîcycloalkyl-, aryl-C^heterocycloalkyl-, heteroaryl-Co-i2alkyl-, heteroaryl-Cai2cycloalkyl-, or heteroaryi-C^heterocycloalkyl-, any of which is optionally substituted with one or more independent G3 substituents;
R4 is selected from Ccusaïkyl— C3.i2cycloalkyl-C<n2alkyl-, C3.i2heterocycloalkyl-Co-i2alkyl-, aryl— Co-i2alkyl-, aryl-Cs-iscycloalkyl-, aryl-C3.i2heterocycloalkyl-, heteroaryl-Co-i2alkyl-, heteroaryl-Csi2cycloalkyl-, heteroaryl-C3-i2heterocycloalkyl-, or pyridine-N-oxide, any of which is optionally substituted with one or more independent G4 substituents;
G1, G2, G2a, G3, and G4 are each independentiy selected from one or more of H, D, halo, -CN, CD3, -OCD3, -oxo-, -CF3, -OCFs, -OCHF2, -NR5R6, -NO2, -B(OH)2, -PO(OR12)2, -PO(OR12)R13, CONR12OH, -Co-i2alkyl, -C2-i2alkenyl, -C2-i2alkynyl, C3-i2cycloalkyl-Co-i2alkyl-, Cs-uheterocycloalkyl-Cl· i2alkyl-, aryl-Co-^alkyl-, heteroaryl-Co-i2alkyl-, -OCo-i2alkyl, -S(O)mR12, -C(O)R12, -C(O)NR12R13, C(O)-C(O)NR12R13, -C(O)OR12, -C(O)-C(O)OR12, -OC(O)R12, -NR12C(O)R13, -NR12C(O)OR13, NR12S(O)2R13, -(CR14R1S)C(O)R13, -(CR14R15)C(O)OR12, -(CR14R15)C(O)NR12R13, (CR14R15)niS(O)2NR12R13, -(CR14R15)niNR12R13, -(CR14R15)niOR12, -(CR14R15)niS(O)n2 R12, NR16C(O)NR12R13, -NR16S(O)2NR12R13 or-NR16S(O)NR12R13, any of which is optionally substituted with one or more independent Q1 substituents;
Q1 is selected from H, D, halo, —CN, —CD3, —OCDa, —oxo—, —CFj, —OCFs, —OCHF2, —NO2, — B(OH)2, -PO(OR17)2, -PO(OR17)R18, NR17R16, -CONR17OH, Co-i2alkyl-, -C2-i2 alkenyl, -C2-i2alkynyl, aryl-Co-i2alkyl-, heteroaryl-Co-valkyl-, C3-i2cycloalkyi-Co-i2alkyl-, C3.i2heterocycloalkyl-Co-i2alkyl-, aryl— Co-i2cycloalkyl-, heteroaryl-C3-i2cycloalkyl-, C3-i2heterocycioalky!-C3-i2cycloalkyl-, C3-i2cycloalkyl-C3i2cycloalkyl-, Ci-i2alkyl-C3-i2heterocycloa[kyl-, C3.i2heterocycloalkyl-C3-i2heterocycloalkyl-, aryl-Cs. i2heterocycloalkyl—, heteroaryl—C3-i2heterocyc[oalkyî—, —OCo-i2alkyl, —C(O)-C(O)NR R , —C(O)C(O)OR17, -OC(O)R17, -NR17C(O)R18, -NR17S(O)2R18, -(CR19R20)n3C(O)R17, -(CR19R20)n3C(O)OR17, (CR19R2D)n3C(O)NR17R18, -(CR19R20)n3S(O)2NR17R18, -(CR19R20)n3NR17R18, -(CR19R20)n3OR17, (CR19R20)n3S(O)n4R17, -NR21C(O)NR17R18, -NR21S(O)2NR17R18 or -NR21S(O)NR17R10, any of which is optionally substituted with one or more independent Q2 substituents;
Q2 is selected from one or more of H, D, halo, —CN, —oxo—, —CDs, —OCD3, —CF3, —OCF3, — OCHF2, -NO2, -B(OH)2, -PO(OR27)2i -PO(OR27)R28, -CONR27OH. -CONR27R28Co-i2alky1-, -C2-i2 alkenyl, -C2-12 alkynyl, -OCo-i2alkyl, aryl-Co-i2alkyl-, heteroaryl-Co-^alkyl-, C3.i2cycloalkyl-Co-i2alkyl-, C3-i2heterocycloalkyl-Co-i2alkyl-, aryl-Co-i2cycloalkyl- heteroaryl-C3-i2cycloaikyl-, C3-i2heterocycloalkylC3.i2cycloalkyl-, C3-i2cycloalkyl-C3-i2cycloaikyl-, Ci-i2alkyl-C3-i2heterocycloalkyl-, C3-i2heterocycloalkylC3-i2heterocycloalkyl-, aryl—C3-i2heterocycloalkyl—, heteroaryl—C3-i2heterocycloa1ky1—, —C(O)C(O)NR27R28, -C0.12alkylC(O)OR27, -C(O)-C(O)OR27, -CC(O)R27, -NR27C(O)R28, -NR27C(O)OR28, NR27S(O)2R28, -(CR2aR30)n5C(O)R27, -(CR29R30)n5C(O)OR27, -(CR29R30)n5C(O)NR27R28, (CR29R30)n5S(O)2NR27R28. -(CR29R30)n5NR27R28, -(CR^R^sOR27, -(CR29R30)n5S(O)n6R27. NR30C(O)NR27R2B, -NR30S(O)2NR27R28 or-NR30S(O)NR27R28 substituents, any of which may be optionally substituted;
Rs, R6, R10, R11, R12, R13, R14, R15, and R16 are each independently selected from one or more of H, Ci-eaikyl—, Cïecycloalkyl-Co-ealkyl-, C^eheterocycloalkyl-Co^alkyl-, aryl-Co^alkyl-, aryl-Csecycloalkyl-, aryl-Cs-eheterocycloalkyl-, heteroaryl-Ci-ealkyi-, heteroaryl-Cs-acycfoalkyl- or heteroarylCj^heterocycloalkyl- any of which may be optionally substituted;
R17, R18, R19, R20, R21, R27, R28, R29, and R30 are each independently selected from H, Ci-ealkyl—, Cs-acycloalkyl-CiMalkyl-, Cs-eheterocycloalkyl—Coealkyl—, aryl-Co-ealkyl-, aryl-Cs-ecycloalkyl-, aryl-Caeheterocycloalkyl-, heteroaryl-Ci^alkyl-, heteroaryl-Cïecycloalkyl- or heteroaryl-C^heterocycloalkyl-, any of which may be optionally substituted;
-NR5R6 and -NR12R13 are each independently a linear structure, or, R5 and R6, or R12 and R13, respectively, are taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m2;
-CR10R11 and -CR14R15 are each independently a linear structure, or, R10 and R11, or R14 and R15 respectively, are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more heteroatoms selected from O, N, or S(O)m3;
-CR19R20 is a linear structure, or, R19 and R20 are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m<
-NR17R18 is a linear structure, or, R17 and R18 are taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)ms;
-CR^R30 is a linear structure, or, R29 and R30 are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)me;
-NR27R28 is a linear structure, or, R27 and R2Sare taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)mz;
wherein m1, m2, m3, m4, m5, m6, m7, n1, n2, n3, n4, n5 and n6 are each independently selected from 0, 1 or 2;
or a pharmaceutically acceptable sait, solvaté or a prodrug thereof.
in some embodiments of Formula I:
R1 is selected from one of Cs-Bcycloalkyl-Coaalkyl-, Ca-sheterocycloalkyl-Co-salkyl-, aryl-Coaaikyl—, or heteroaryl-Cc ealkyl-;
G1 is selected from one of H, halo, -CN, -oxo-, -CF3, -OCF3, -OCHF2, -NR5R6, -NO2, -OCr>. aalkyl, -S(O)niR12, -B(OH)2, -Cn-ealkyl, -C2-aalkenyl, -C2-8alkynyl, C^cycloalkyl-Co salkyl-.Csaheterocycloalkyl-Co-ealkyl-, aryl-Co^alkyl-, or heteroaryl-Co aalky!-.
In some embodiments of Formula I:
G1 is selected from 0 to 3 of H, halo, -CN, -oxo-, -CF3, -OCF3, -OCHF2, -NR5R6, -NO2, -OCoealkyl, -S(O)mR12, -B(OH)2, -Coaalkyl, -C^salkenyl, -C2-aalkynyl, Cs-ecycloalkyl-Co-aalkyl-CseheterocycIoalkyl-Ccksalkyl-, aryl—Co-ealkyl-, or heteroaryl-Co-salkyl-, ln some embodiments of Formula I:
R2 is selected from Co-aalkyl-, C^ecycloalkyl-Co-ealkyl-, or C^heterocycloalkyi-Co^alkyl-;
R2a is Co-ealkyl-;
G2 is selected from one or more of H, halo, -CN, -CD3, -OCD3, -CF3, -OCF3, -OCHF2, or -OCoealkyl;
R2 and R2a are each independently a linear structure, or, R2 and R2a are taken together with the carbon atom to which they are attached to forrn a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, or N.
In some embodiments of Formula I:
G2 is selected from 0 to 3 of H, halo, -CN, -CÜ3, -OCD3, -CF3, --OCF3, -OCHF2, or-OCo-ealkyl.
In some embodiments of Formula I:
R3 is selected from Coealkyl-, Cs^cycloalkyl-Co-ealkyl-, or Cs-aheterocycloalkyl-Co-ealkyl-;
G3 is selected from one or more of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF3, OCHF2, -NR5R®, -Co-ealkyl, -C2-ealkenyl, -C2-ealkyny1, -O Co-ealkyl, -S(O)mR12, -C(O)R12, -C(O)NR12R13, or-C(0)OR12
In some embodiments of Formula I:
G3 is selected from 0 to 3 of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CFa. -OCF3, -OCHF2, — NR5R6, -Co-ealkyl, -C2-aalkenyl, -C2-aalkynyl, -OCo-aalkyl, -S(O)mR12, -C(O)R1Z, -C(O)NR12R13, orC(O)OR12
In some embodiments of Formula I:
R4 is selected from Co-aalkyl-, Cs-scycloalkyl-Cs-ealkyl-, Cs-eheterocycloalkyl-Co-ealkyl-, aryl-Coeatkyt-, heteroaryl-Co-ealkyl-, heteroaryl-Cs-ecycloalkyl·-, heteroaryl-C3.eheterocycloalkyl-, or pyridine-Noxide;
G4 is selected from one or more of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF3, OCHF2, -NR5R6, -NO2, -B(OH)2, -CONR12OH, -Co-ealkyl, Ca-acycloalkyl-Cc-aalkyl-, C^heterocycloalkylCoealkyl-, aryl-Co aalkyl-, heteroaryl-Coeaikyl-, -OCo-ealkyl, -S(O)niR12, -C(O)R12, -C(O)NR12R13, C(0)-C(O)NRl2R13, -C(O)OR12, -C(O)-C(O)OR12, -OC(O)R12, -NR12C(O)R13, -NR12C(O)OR13, (CR14R15)C(O)R13, -(CR14R15)niS(O)2NR12R13, -(CR14R15)mNRl2R13, -(CR14R15)mOR12, (CR14R15)niS(O)n2 R12, or -NR16C(O)NR12R13.
In some embodiments of Formula I:
G4 is selected from 0 to 3 of H, D, halo, —CN, —CD3, -OCD3, —oxo—, -CF3, —OCF3, —OCHF2, — Nr5r6. _no2i -B(OH)2, -CONR12OH, -Co-aalkyl, Ceecycloalkyi-Co-ealkyl-, Ca-eheterocycloalkyl-Coealkyi, aryl-Co-ealkyl-, heteroaryl-Coaalkyl-, -OCo-ealkyl, -S(O)mR12, -C(O)R12, -C(O)NR12R13, -C(O)C(O)NR12R13, -C(O)OR12, -C(O)-C(O)OR12, -OC(O)R12, -NR12C(O)R13, -NR12C(O)OR13, (CR14R15)C(O)R13, —(CR14R15)niS(O)2NR12R13, -(CR14R15)mNR12R13, ~(CR14R15)niOR12, (CR14R15)niS(O)n2 R12, or -NR16C(O)NR12R13.
In some embodiments of Formula l:
Q1 is selected from H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF3, -OCHF2, NR17R18, Coealkyl-, aryl-Co-ealkyl-, heteroaryl-Co-ealkyl-, Cs-ecycloalkyl-Co-ealkyl-, Caeheterocycloalkyl-Co-salkyl-, aryl-Co-ecycloalkyl-, heteroaryl-Csecycloalkyl-, Cs-aheterocycloalkyl-Cs-scycloalkyl-, Cs-ecycloaikyl-Csecycloalkyl-, Ci-ealky1-C3-eheterocycloalkyl-, Cs-eheterocycloalkyl-Cs-eheterocycloalkyl-, aryl-Cseheterocycloalkyl-, heteroaryl-Cs-eheterocycloalkyl-, -OCœalkyl, -C(0)-C(O)NR17R18, -C(O)-C(O)OR17, -OC(O)R17, -NR17C(O)R18, -NR17S(O)2R18, -(CR19R2°)n3C(O)R17, -(CR19R20)n3C(O)OR17, 6 (CR19R20)n3C(O)NR17R18, -(CR19R20)n3S(O)2NR17R18, -(CRlsR2ü)n3NR17R18, -(CR19R20)n3OR17, (CR19R20)n3S(O)MR17, -NR21C(O)NR17R18, -NR21S(O)2NR17R18, or-NR21S(0)NR17R18.
In some embodiments of Formula I:
R1 is selected from one of C^cycloalkyl-Coealkyl-, C^heterocycloalkyl-Cwalkyl-, aryl-Coealkyl-, or heteroaryl-Co-ealkyl-;
G1 is selected from one of H, halo, -CN, -oxo-, -CF3, -OCFa, -OCHF2, -NR5R6, -NO2, -OCoealkyl, -S(O)niR12, -B(OH)2, —Cœalkyl, -C2-6alkenyl, -C2-6alkynyl, C3-6cyc1oalkyl-CtM>alkyl-,C3eheterocycloalkyl-Co^alkyl-, aryl-Co-ealkyl-, or heteroaryl-Co-ealkylIn some embodiments of Formula 1:
G1 is selected from 0 to 2 of H, halo, -CN, -oxo-, -CF3, -OCFa, —OCHF2, -NR5R6, -NO2, -OCosalkyl, -S(O)mR12, -B(OH)2, -Coealkyl, -C2-6alkenyl, -C2-ealkynyl, Cs-ecycloalkyl-CMalkyl-.C^ eheterocycloalkyl-Cc-ealkyl-, aryl-Co-ealkyl-, or heteroaryl-Co-ealkylIn some embodiments of Formula I:
R2 is selected from Coealkyl-, C^ecycloalkyl-Co-ealkyl-, or Cseheterocycloalkyl-Co-ealkyl-;
R2a is Co-ealkyl-;
G2 is selected from one or more of H, halo, -CN, -CD3, -OCD3, -CF3, -OCF3, -OCHF2, or -OCoealkyl;
R2 and R2a are each independently a linear structure, or, R2 and R2a are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionalty inctudes one or more additional heteroatoms selected from O, or N.
In some embodiments of Formula l:
R2 and R2a are each independently a linear structure, or, R2 and R2a are taken together with the carbon atom to which they are attached to form a 4-6 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, or N.
In some embodiments of Formula I:
G2 is selected from O to 2 of H, halo, -CN, -CD3, -OCD3, —CF3, -OCF3, -OCHF2, or-OCo-ealkyl.
In some embodiments of Formula I:
R3 is selected from Cwsalkyl-, C^cycloalkyl-CMalkyl-, or Cs-eheterocycloalkyl-Co-ealkyl-;
G3 is selected from one or more of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF3, OCHF2, -NR5Rs, -Co-ealkyl, -C2-ealkenyl, -C2-6a1kynyl, -OCo-salkyl, -S(O)mR12, -C(O)R12, -C(O)NR12R13, or-C(O)OR12
In some embodiments of Formula I:
G3 is selected from 0 to 2 of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF3, -OCHF2, NR5R6, -Co-ealkyl, -C2-ealkenyl, -C2-6alkynyl, -OCo-ealkyl, -S(O)mR12, -C(O)R12, -C(O)NR12R13, orC(O)OR12
In some embodiments of Formula I:
r< is selected from Cwalkyl-, Cs-ecycloalkyl-Cœalkyl-, Cs-eheterocycloalkyl-Cû-ealkyl-, aryl-Coealkyl-, heteroaryl-Co-6alkyl-, heteroaryl-C3 ecycloalkyl-, heteroaryl-C^heterocycloalkyl-, or pyridine-Noxide;
G4 is selected from one or more of H, D, halo, -CN, -CD3, -OCD3| -oxo-, -CF3, -OCF3, OCHF2, -NR5R6, -NO2, -B(OH)2, -CONR12OH, -Co-saikyl, Cs-ecycloalkyl-Cœealkyl-, C^eheterocycloalkylCo-ealkyl-, aryl-Co-ealkyl-, heteroaryl-Coealkyl-, -OCoealkyl, -S(O)niR12, -C(O)R12, -C(O)NR12R13,
C(O)*C(O)NR12R13, -C(O)OR12, -C(O)-C(O)OR12, -OC(O)R12, -NR12C(O)R13, -NR12C(O)OR13, (CR14R15)C(O)R13, -(CR14R15)mS(O)2NR12R13, -(CR14R15)mNR12R13, -(CR14R15)mOR12, (CR14R15)mS(O)n2 R12, or-NR16C(0)NR12R13.
In some embodiments of Formula I:
G4 is selected from 0 to 2 of H, D, halo, -CN, -CD3, -OCDs, -oxo-, -CF3, -OCF3, -OCHF2, NR5R6, -NO2, ~B(OH)2, -CONR12OH, -Cosalkyl, Csecycloalkyl-Coeaikyl-, CMheterocycloalkyl-CtMalkyl, aryl-Co-ealkyl—, heteroaryl-Cosalkyl—, -OCo-ealkyl, -S(O)niR12, —C(O)R12, -C(O)NR12R13, —C(O)C(O)NR12R13, -C(O)OR12, -C(O)-C(O)OR12, -OC(O)R12. -NR12C(O)R13, -NR12C(O)OR13 (CR14R15)C(O)R13, -(CR’4R15)niS(O)2NR12R13, -(CR14R15)niNR12R13, -(CR14R15)mOR12, (CR14R15)mS(O)n2 R12, or -NR16C(O)NR12R13.
In some embodiments of Formula I:
Q1 is selected from H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCFa, -OCHF2, NR17R18, Coealkyl-, aryl-Caealkyl- heteroaryl-Co-ealkyl-, Cyecycloalkyl-Co-ealkyl-, Ca-eheterocycloalkyl-Co^alkyl-, aryl-Co-ecycloalkyl-, heteroaryl-Cj-ecycloalkyl-, C^heterocycloalkyl-Cs-ecycloalkyl-, Cs-ecycloalkyl-Csecycloalkyl-, Ci salkyl-C^heterocycloalkyl-, C^heterocycloalkyl-Cs-eheterocycloalkyl-, aryl-Cseheterocycloalkyl—, heteroaryl—Cssheterocycloalkyl-, -OCo-ealkyl, -C(O)-C(O)NR17R10, -C(O)-C(O)0R17, ~OC(O)R17, -NR17C(O)R18, -NR17S(O)2R18, -(CR19R20)n3C(O)R17, -(CR19R2û)n3C(O)OR17, (CR1sR20)n3C(O)NR17Rie, -(CR’9R20)n3S(O)2NR17R18, -(CR19R20)n3NR17R1B, -(CR19R20)n3OR17, (CR19R20)n3S(O)n4R17, -NR21C(O)NR17R1S, -NR21S(O)2NR17R10, or-NR21S(O)NR17R18.
In some embodiments of Formula I:
R2 is selected from methyl, ethyl, propyl, isopropyl, or one of the following groups:
and R2a is selected H, methyl, ethyl, propyl, isopropyl; or
R2 and R2a are taken together with the carbon atom to which they are attached to forni one of the following groups:
ln some embodiments of Formula I:
R1 îs selected from one of Cecycloalkyl-Co^alkyl-, Ceheterocycloalkyl-Ccrealkyl-, 6-memberedaryl-Co-ealkyl-, or S-membered-heteroaryl-Co-ealkyl-, wherein the 4-position of R1 is hydrogen, and wherein R1 is optionally substituted by one or more G1 substituents at the 2, 3, 5 and 6 positions.
In some embodiments of Formula I:
-NR5R6 and -NR12R13 are each independently a linear structure, or, R5 and R6, or R12 and R13, respectively, are taken together with the nitrogen atom to which they are attached to fomn a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m2i
-CR10R11 and -CR14R15 are each independently a linear structure, or, R10 and R”, or Ru and R15 respectively, are taken together with the carbon atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more heteroatoms selected from O, N, orS(0)m3;
_CR19R20 is a linear structure, or, R19 and R20 are taken together with the carbon atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m<
-NR17R18 is a linear structure, or, R17 and R18 are taken together with the nitrogen atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(0)m5;
_CR29R30 js a |inear structure, or, R29 and R30 are taken together with the carbon atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)me;
-NR27R20 is a linear structure, or, R27 and R28 are taken together with the nitrogen atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m7;
wherein m2, m3, m4, m5, m6, and m7 are each independently selected from 0, 1 or 2.
In some embodiments of Formula I, compounds of the présent invention are a subgenus of
Formula I, having the Formula la:
R3
wherein X3 is selected from C=O, or CR10R11.
In some embodiments of Formula la, R2a is hydrogen. In other embodiments of Formula la, R2 is d.ualkyl-, C3-i2cycloalkyl-, or Ci.i2heteroalkyl any of which is optionally substituted with one or more independent G2 substituents (e.g., methyl, ethyl, iso-propyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl). In certain embodiments of Formula la, R1 is aryl or heteroaryl, any of which is optionally substituted with one or more independent G1 substituents. In other embodiments, of Formula la, R is aryl. In certain embodiments of Formula la, the 4-position of said aryl is H, and wherein the 2, 3, 5 and 6 positions of said aryl are optionally substituted by one or more G1 substituents. In some embodiments of Formula la, said 2, 3, 5, and 6 positions are optionally substituted with halo (e.g., fluoro, chloro, bromo), Ci-ealkyl (e.g., methyl, ethyl, CF3), Ci^heteroalkyl (e.g., methoxy, trifluoromethoxy). or C^cycloalkyi (e.g., cyclopropyl). In some embodiments, R1 is 3-methyl-phenyl, 3-methyl-4-fluoro-phenyl, 2-fluoro-5-ethylphenyl, 2-fluoro-5-trifluoromethyl-phenyl, 3-fluoro-5-methyl-phenyl, 2-fluoro-5-cyclopropyl-phenyl, 2fluoro-5-chloro-phenyl, 3,5-dichloro-phenyl, 2-fluoro-5-methyl-phenyl, 3-chloro-5-trifluoromethyl-phenyl, 2fluoro-5-trifluromethoxy-phenyl, 2-fluoro-5-difluoromethoxy-phenyl, 3-fluoro-5-ethyl-phenyl, 3-cyclopropyl, 3-ethyl-phenyl, 2-fluoro-3-methyl-phenyl, or 2-fluoro-5-methoxy-phenyl.
In other embodiments of Formula la, R3 is Ci-i2alkyl orCi-i2heteroalkyl. In certain embodiments of Formula la, R3 is Ci-i2alkyl (e.g., methyl,
οΛ θΝ)
In other embodiments of Formula la,
Çh3 °· CH,
R3 is Ci-i2heteroalkyl (e.g. Cl*3 or 0 ), in some embodiments of Formula la, R4 is Ci-iaalkyl (e.g., iso-butyl), CMcycloalkyl (e.g., cyclopentyl or cyclohexyl), aryl (e.g., phenyl, 4-methoxy-phenyl, 3-fluoro-4-methoxy-phenyl, 4-cyanophenyl, 3-cyano-phenyl, 3-methoxy-phenyl, 4-trifluoromethoxy-phenyl, 3-chloro-phenyl, 3-bromo-phenyl, 4-deutero-phenyl, 4-trifluoromethyl-phenyl, 4-carboxy-phenyl, 4-chloro-phenyl, 4-fluoro-phenyl, 4-methylphenyl, 3,4-dichloro-phenyl, 4-ethoxy-phenyl, 4-trideuteromethoxy-phenyl, 4-carboxymethyl-phenyl, 4(oxetan-3-ylmethoxy)-phenyl,4-(2-hydroxyethoxy)-phenyl, 4-boronic acid-phenyl, 3-methoxy-4-carboxyphenyl, 3-chloro-4-carboxy-phenyl, 4-carboxamide-phenyl, 4-oxyacetic acid-phenyl, 4-oxyacetamidephenyl, 4-cyanomethyl-phenyl, 4-(2-dimethylamino-ethoxy)-phenyl, 4-acetamido-phenyl, 4-methylsulfnamido-phenyl,4-methylcarbamate-phenyl, benzo[d][1,3]-dioxof-5-yl, 2-chloro-phenyl, 4methylsulfonyl-phenyl, 3-methyl-l-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl, 4-(oxetan-3-ylamino)phenyl, 4-(1H-1,2,4-triazo!-3-yl)-phenyl, 4-(2H-tetrazol-5-yl)-phenyl) heteroaryl (e.g. 4-pyridyl, 1-methyl1H-indazol-5-yl, 2-methyl-2H-indazoyl-5-yl, 1-imidazo[1,2a]pyridine-6-yl, 3-methylimidazo[1,5a]pyridine-6yl, 1H-pyrrolo[2,3b]pyridine-5-yl, 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl, 1-methyl-6-oxo-1,6dihydropyridin-3-yl, 5-benzofuranyl, 2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl, 1 H-benzo[d][1,2,3]triazol-5-yl, 1H-indazoyl-5-yl, 1H-indol-5-yl, 3-pyridyl) aryl-C^alkyl (e.g., 4-cyanobenzyl, benzyl, 4-fluorobenzyl, 4methoxybenzyl, 4-chlorobenzyl, 3-cyano-benzyl, 3-chloro-benzyl. 2-fluoro-5-methoxy-benzyl, 2-fluoro-4methoxy-benzyl, 2-chloro-4-methoxy-benzyl), heteroaryl-Ci ealkyl (e.g., (2,3-dihydrobenzo[b][1,4]dioxin-6yl)-methyl, (6-methoxypyridin-3-yi)-methyl, (qulnoxalin-6-yl)-methyl, (3-methyi-2-oxo-2,3dihydrobenzo[d]oxazol-5-yl)-methyl, (pyrimidin-2-yl)-methyl, (2-methylbenzo[d]oxazol-5-yl)-methyl), or Cai2heterocycloalkyl (e.g., 1-methyl-6-oxo-1,6-dihydropyridin-3-yl) any of which is optionally substituted with one or more independent Q1 substituents.
In some embodiments of Formula la, X3 is C=O. in other embodiments of Formula la, X3 is CR,0R11 wherein R10 is hydrogen and R11 is hydrogen or methyl.
In some embodiments of Formula I, compounds of the présent invention are a subgenus of
Formula I, having the Formula Ih:
Rs
lh wherein X3 is selected from C=O, or CR10R11.
In some embodiments of Formula I:
the 4-position of the phenyl ring in Formula lh is H, and wherein the 2, 3, 5 and 6 positions of the phenyl ring in Formula lh are optionally substituted by one or more G1 substituents.
In some embodiments of Formula I:
R3 is selected from methyl, ethyl, propyl, isopropyl, -(CH2)i-3-cyclopropyl, Csacycloalkyl, -(CH2)i3CN. -(CH2)i-3C(O)OH, or-(CH2)i.3S(0)2Me.
In some embodiments of Formula I:
X1 is selected from Ci-2aM C=O;
X2 is selected from Ci-2aii<yi, NR3, or O;
X3 is selected from C=O or CR10R11;
R10 and R11 are each independently equal to H or Cvealkyl;
m and n are each equal to 1.
In some embodiments, the compounds of Formula I are inhibitors of ATX.
In some embodiments, the compound of Formula I is any one of the compounds described herein (e.g., any one of the compounds described in Examples 1 to 246)
In some embodiments, the present invention includes a pharmaceutical composition comprising the compound or sait of any one of the compounds of Formula l, formulated wîth or without one or more pharmaceutical carriers.
In some embodiments, the present invention includes a method for the treatment of at least one of cancer, lymphocyte homing, chronic inflammation, neuropathie pain, fibrotic diseases, thrombosis, and cholestatic pruritus mediated at least in part by ATX comprising administering to a subject in need thereof a therapeutically effective amount of a compound or sait of the compound of Formula I.
In some embodiments, the present invention includes a method for the treatment of at least one of cancer, lymphocyte homing, chronic inflammation, neuropathie pain, fibrotic diseases, thrombosis, and cholestatic pruritus comprising administering to a subject in need thereof a therapeutically effective amount of a compound or sait of the compound of Formula l that binds to and inhibits ATX providing a réduction in LPA levels.
In some embodiments, the present invention includes a method of treating fibrosis, inflammation, cancer, angiogenesis, or pain in a mammal comprising administering a therapeutically effective amount of a compound according to Formula I. or a pharmaceutically acceptable sait thereof, to the mammal in need thereof.
In some embodiments, the present invention includes a method of treating lung fibrosis, asthma, chronic obstructive pulmonary disease (COPD), renal fibrosis, acute kidney injury, chronic kidney disease, liver fibrosis, skin fibrosis, fibrosis of the gut, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer, colon cancer, bowel cancer, head and neck cancer, melanoma, multiple myeloma, chronic lymphocytic leukemia, B cell lymphome, T cell lymphoma, cancer pain, tumor metastasis, transplant organ rejection, scleroderma, ocularfibrosis, âge related macular degeneration (AMD), diabetic retinopathy, collagen vascular disease, atherosclerosis, Raynaud's phenomenom, rheumatoid arthritis, osteoarthritis or neuropathie pain in a mammal comprising administering a therapeutically effective amount of a compound according Formula l, or a pharmaceutically acceptable sait thereof, to the mammal in need thereof.
In some embodiments, the présent invention further includes administering to the mammal one or more additional therapeutically active agents selected from: corticosteroids, immunosuppressants, analgésies, anti-cancer agents, anti-inflammatories, non-steroidal anti-inflammatories, dual cyclooxygenase-1 and -2 inhibitors, cyclooxygenase-2 sélective inhibitors, TNFa blockers, kinase inhibitors, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, prostaglandin receptor antagonists, prostaglandin formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase A1 inhibitors, phospholipase A2 inhibitors, lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, and LPA receptor antagonists.
In some embodiments of Formula I, compounds are présent as a material in substantially pure form.
In some embodiments of Formula I, compounds are selected from any one of the Examples herein or a pharmaceutically acceptable sait thereof.
Each variable définition above includes any subset thereof and the compounds of Formula I include any combination of such variables or variable subsets.
The présent invention includes the compounds and salts thereof, their physical fomns, préparation ofthe compounds, useful intermediates, and pharmaceutical compositions and formulations thereof.
The compounds of the présent invention and the temn “compound in the daims include any pharmaceutically acceptable salts or solvatés, and any amorphous or crystal forms, ortautomers, whether or not specifically recited in context.
The present invention includes ail isomers ofthe compounds. Compounds may hâve one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where a compound of the invention contains an alkenyl or alkenylene group, géométrie cisrtrans (or Z/E) isomers are possible. Where the compound contains, for example, a keto or oxime group or an aromatic moiety, tautomeric isomerism ('tautomerism') can occur. A single compound may exhibit more than one type of isomerism.
The present invention includes any stereoisomers, even if not specifically shown, individually as well as mixtures, géométrie isomers, and pharmaceutically acceptable salts thereof. Where a compound or stereocenter is described or shown without definitive stereochemistry, it is to be taken to embrace ail possible individual isomers, configurations, and mixtures thereof. Thus, a material sample containing a mixture of stereoisomers would be embraced by a recitation of either of the stereoisomers or a recitation without definitive stereochemistry. Also contemplated are any cis/trans isomers ortautomers of the compounds described.
The present invention includes ail stereoisomers, géométrie isomers and tautomeric forms ofthe inventive compounds, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. When a tautomer ofthe compound of Formula I exists, the compound of Formula I ofthe present invention indudes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula la:
wherein R1, R2, R2a, R3, R4. X3. m and n are as previously described for a compound of Formula I.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula Ib:
wherein R1, R2, R2a. R3, R4, R10, R11, ni and n are as previously described for a compound of Formula I.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula le.
wherein R1, R2, R2a, X1 - X3. G4, m and n are as previously described for a compound of Formula I and wherein E99 is equal to 0,1, 2, or 3.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula Id.
Id wherein R1, R3, R2a, R3, R4, m and n are as previously described for a compound of Formula I. In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula le;
le wherein R1, R2, R2a, X1 - X3. G4, m and n are as previously described for a compound of Formula l, wherein Y1-Y4 and Z1-Z6 are each independently selected from one or more of Co-zalkyl, O, N or S and wherein E99 is equal to 0,1,2, or 3.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula If:
If wherein R1, R2, R2a, R3, G4, m and n are as previously described for a compound of Formula I, wherein Y1-Y4 and Z1-Z6 are each independently selected from one or more of Co^alkyl, O, N or S and wherein E99 is equal to 0,1.2, or 3.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula Ig:
ig wherein R1, R2, R2a, R3, R10, R11, G4, m and n are as previously described for a compound of Formula I, wherein Y'-Y4 and Z1-Z6 are each independently selected from one or more of Crwalkyl, O, N or S and wherein E99 is equal to 0,1,2, or 3.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula Ih:
ih wherein R2, R2a, R3, R4, X3, G1, m and n are as previously described for a compound of Formula I.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula li:
R3
li wherein R2, R2a, R3, R4. R10, R11, G1, m and n are as previously described for a compound of Formula I.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula Ij:
wherein R2, R2a, X1 - X3, G1, G4, m and n are as previously described for a compound of Formula I and wherein E99 is equal io 0,1,2, or 3.
In an embodiment, a compound according to Formula l and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula Ik:
Ik wherein R2, R2a, R3, R4, G1, m and n are as previously described for a compound of Formula I. 15
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula II:
wherein R2, R2a, X1 -X3, G1, G4, m and n are as previously described for a compound of Formula I, wherein Y1-Y4 and Z1-Z6 are each independently selected from one or more of Ctwalkyl, O, N or S and wherein E99 is equal to 0,1,2, or 3,
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula Im:
Im wherein R2, R2a, R3, G1, G4, m and n are as previously described for a compound of Formula I, wherein Y'-Y4 and Z1-Z6 are each independently selected from one or more of Co-2alkyl, O, N or S and wherein E99 is equal to 0. 1,2, or 3.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula In:
R3
In wherein R2, R2a, R3, R10, R11, G1, G4, m and n are as previously described for a compound of Formula I, wherein Y1-Y4 and Z1-Z5 are each independently selected from one or more of Co^alkyl, O, N or S and E99 is equal to 0,1, 2, or 3.
In an embodiment, a compound according to Formula I and above embodiments is provided, wherein the compound of Formula I is represented by the compound of Formula lo:
la wherein R2, R2a, R3, R4, X3, G1, m and π are as previously described for a compound of Formula I.
The présent invention includes the compounds, intermediates, examples and synthetic methods described herein. Compounds of Formula I are prepared according to reaction schemes described herein. Unless otherwise indicated, the substituants in the schemes are defined as above.
Synthetic Methods
Compounds of the présent invention include the intermediates, examples, and synthetic methods described herein.
The compounds of Formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are familiarto those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art [such as those methods disclosed in standard reference books such as the Compendium of Organic Synthetic Methods, Vol. I-VI (Wiley-lnterscience), or the Comprehensive Organic Transformations, by R. C. Larock (Wiley-lnterscience)]. Preferred methods include, but are not limited to, those described below.
During any of the following synthetic sequences it may be necessary and/or désirable to protect sensitive or reactive groups on any of the molécules concemed. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991, and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.
Compounds of Formula I, ortheir pharmaceuticaliy acceptable salts, can be prepared according to the reaction Schemes discussed hereinbelow and the general skill in the art. Unless otherwise indicated, the substituents in the Schemes are defined as above. Isolation and purification of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.
When a general or exemplary synthetic procedure is referred to, one skilled in the art can readily determine the appropriate reagents, if not indicated, extrapolating from the general or exemplary procedures. Some of the general procedures are given as examples for preparing spécifie compounds. One skilled in the art can readily adapt such procedures to the synthesis of other compounds. Représentation of an unsubstituted position in structures shown or referred to in the general procedures is for convergence and does not preclude substitution as described elsewhere herein. For spécifie groups that can be présent, either as groups in the general procedures or as optional substituents not shown, refer to the descriptions in the remainder of this document, including the daims, summary and detailed description.
A general procedure for the synthesis of compounds of Formula I is shown in Scheme 1.
Scheme 1 :
where R1, R2, R2a, R4, X1, X2, and X3 are as defined previously for compound of Formula l and A1 - OH, alkoxy, or a suitable leaving group such as imidazole.
In a typical préparation, of a compound of Formula I, a compound of Formula II and lia were reacted under suitable amide coupling conditions. Suitable conditions include but are not limited to treating compounds of Formula II (when A1=OH) and lia with coupling reagents such as DCC or EDC in conjunclion with DMAP, HOBt, HOAt, and the like. Moreover, HATU in the presence of diisopropylethyl amine (DIPEA) can be used. Suitable solvents for use in the above process included, but were not limited to, ethers such as THF, glyme, and the like; DMF; DMSO; MeCN; halogenated solvents such as chloroform or DCM. If desired, mixtures of these solvents were used, howeverthe preferred solvents were DCM and DMF. The above process was carried out at températures between about 0° C and about 100° C. Preferably, the reaction was carried out at about rt. The above process was preferably carried out at or about atmospheric pressure aithough higher or iower pressures may be used if desired. Substantially equimoiar amounts of reactants were preferably used aithough higher or Iower amounts may be used if desired. Additionally, other suitable reaction conditions for the conversion of a carboxylic acid derived compound such as compound of Formula II to an amide such as compound of Formula I can be found in Larock, R. C. Comprehensive Organic Transformations, 2nd ed.; Wiley and Sons: New York. 1999, pp 1941-1949. Compounds of Formula lia are either commercially available, are synthesized by known chemical procedures or are described in detail withîn.
A general procedure for the synthesis of compounds of Formula II is shown in Scheme 2.
Scheme 2:
O
where R1, R2, and R2a are as defined previously for compound of Formula I, A1 - OH, and A2 OH, alkoxy, or a suitable leaving group such as Cl or imidazole.
In a typical préparation, of a compound of Formula II, a compound of Formula III and IV were reacted under suitable amide coupling conditions. Suitable conditions include but are not limited to treating compounds of Formula IV (when A1=OH) and compounds of Formula lli with coupling reagents such as DCC or EDC in conjunction with DMAP, HOBt, HOAt, and the like. Moreover, HATU in the presence of DIPEA may be used. Suitable solvents for use in the above process include, but are not limited to, ethers such as THF, glyme, and the like; DMF; DMSO; MeCN; halogenated solvents such as chloroform or DCM. If desired, mixtures of these solvents may be used, howeverthe preferred solvents were DCM and DMF. The above process was carried out at températures between about 0° C and about 100° C. Preferabiy, the reaction was carried out at or about rt. The above process was preferably carried out at about atmospheric pressure although higher or lower pressures may be used if desired. Substantially equimolar amounts of reactants were preferably used although higher or lower amounts may be used if desired. Altematively, compounds of Formula lll and IV (where A2 = suitable leaving group such as Cl) were reacted with bases such as NaOH, TEA or DIPEA and the like in conjunction with DMAP and the like. Suitable solvents for use in this process included, but were not limited to, ethers such as THF, glyme, and the like; DMF; DMSO; MeCN; halogenated solvents such as chloroform or DCM; or alcohois or water. If desired, mixtures of these solvents may be used, howeverthe preferred solvent was DCM. The above process was carried out at températures between about —20’ C and about 40 C. Preferably, the reaction was carried out between 0° C and 25° C. The above process to produce was preferably carried out at about atmospheric pressure although higher or lower pressures were used if desired. Substantially equimolar amounts of compounds of Formula lll and IV and base and sub-stoichiometric amounts of DMAP were preferably used although higher or lower amounts may be used if desired. Additionally, other suitable reaction conditions for the conversion of a carboxylic acid derived compound such as compound of Formula 11 to an amide such as compound of Formula I can be found in Larock, R. C. Comprehensive Organic Transformations, 2nd ed.; Wiley and Sons: New York, 1999, pp 1941-1949. Compounds of Formula lll and IV as well as lia are either commercially avaiiable, are synthesized by known chemical procedures or are described in detail within.
A typical préparation of lia is shown in Scheme 3 wherein, PG = suitable protecting group.
Scheme 3:
o
Q ♦ r4-nh2 N 2
PG
H NC N-R*
PG
CH(OEt)a
lia
Another typical préparation of lia is shown in Scheme 4 wherein, PG = suitable protecting group.
Scheme 4:
â
Another typical préparation of lia is shown in Scheme 5 wherein, PG - suitable protecting group.
Scheme 5 + (NH4)2CO3 kcn
PG
Préparations and Intermedîates
Example 1:
(R)-N-(1-Cyclohexyl-2-(3-methyl-2,4-dioxo-1-phenyl-1,3l8-triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-3methylbenzamide
Représentative scheme:
HOAc,
O.. ?-cl
1) 'N O
DCM.Ot
2) HCl ElOH
3) (BoC),O. KjCO,
CH3I
NaH. DMF r.t 30 rnins
HCl, daoxane
DCM, î.t
HA TU, DIPEA
h2n-Voh
O
a q. NaOH (20%), 0°C
fert-Butyl-4-cyano-4-(phenylamino)piperidine-1-carboxylate
CN
To a solution of aniline (0.5 g, 0.005 mol) in acetic acid (20 mL) was added terAbutyl-4-oxopiperidine-1carboxylate (1.0 g, 0.005 mol). The resulting mixture was cooled to 0°C and trimethyIsilyl cyanide (0.49 g, 0.005 mol) was added. The resulting solution was stirred overnight at room température. Saturated aqueous ammonium chloride solution was added (50 mL). The mixture was extracted with ethyl acetate (3 * 50 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : petroleum ether = 1:1 to afford terf-butyl-4-cyano-4-(phenylamino)piperidine-1carboxylate as a white solid (1.3 g, 86%).
LCMS (ESI): m/z = 302.2 [M+H]+.
fert-Butyl-2,4-d'Oxo-1-phenyl-1,3,8-triazaspiroI4.5]decane-8-€arboxylate
To a solution of tert-butyl-4-cyano-4-(phenylamino)piperidine-1-carboxyIate (0.45 g, 0.0015 mol) in dichloromethane was added chlorosulfonyl isocyanate (0.32 g, 0.00224 mol) at 0°C. After stirring for 30 minutes at 0°C, the reaction was quenched with a 5% aqueous hydrochioric acid solution (2 mL). The solvent was removed under reduced pressure and éthanol (10 mL) was added. The mixture was stirred for 30 minutes at 80°C. The solvent was removed under reduced pressure and the residue was dissolved in tetrahydrofuran (20 mL) and the pH of the mixture was adjusted to pH 8 by addition of a 10% aqueous potassium carbonate solution. Then di-fert-butyl-dicarbonate (0.5 g, 0.00229 mol) in tetrahydrofuran (20 mL) was added. After stim'ng ovemight, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with ethyl acetate . petroleum ether 10:1 to afford fert-butyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (300 mg, 41%).
LCMS (ESI): m/z = 346.2 [M+Hf.
1H-NMR (300 MHz, DMSO-de): δ = 1.25 (s, 9H), 1.34-1.51 (m, 2H), 1.95-2.04 (m, 2H), 3.21-3.25 (m, 2H), 3.67-3.78 (m, 2H), 7.19-7.33 (m, 2H), 7.40-7.53 (m, 3H), 10.99-11.2 (s, br, 1H).
fert-Buty1-3-methyl-2,4-dioxO1-phenyl-1,3,84riazaspiro[4.5]decane-8-carboxylate
XRX-000102-00-001 -C
To a solution of fert-butyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate (200 mg, 0.000579 mol) in N,N-dimethylformamide (5 mL) was added sodium hydride (23 mg, 60% in oii. 0.0006 mol) at 0°C. After stirring for 15 minutes, iodomethane (83 mg, 0.00057 mol) was added. The resulting mixture was stirred for 15 minutes. The reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 * 50 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:3 to afford tert-butyl-3-methyl-2,4-dioxo-1· phenyl-1,3,8-triazaspiro[4.5Jdecane-8-carboxylate as a white solid (140 mg, 67%).
LCMS (ESI): m/z = 360.2 [M+H]\ 1H-NMR (300 MHz, DMSO-de): δ = 1.30 (s, 9H), 1.38-1.58 (m, 2H), 1.97-2.04 (m, 2H), 2.89 (s, 3H), 3.213.25 (m, 2H), 3.78-3.82 (m, 2H), 7.26-7.29 (m. 2H), 7.45-7.51 (m, 3H).
3-Methyl-1-phenyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride
XRX-000102-00-001-d
A solution of ferf-butyl-3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxy!ate (140 mg, 0.000389 mol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 3-methyl-1-phenyl-1,3,8triazaspiro[4.5]decane-2,4-dione hydrochloride as a white solid (92 mg, 80%).
LCMS (ESI): m/z = 260.1 [M+Hf.
(R)-2-Cyclohexyl-2-(3-methylbenzamido)acetic acid
XRX-000102-00-001 -e
To a solution of (R)-2-amino-2-cyclohexylacetic acid (100 mg, 0.636 mmol) in a 20% aqueous sodium hydroxide solution (2 mL) was added dropwise 3-methylbenzoyl chloride (110 mg, 0.709 mmol) at 0°C. The mixture was stirred for 10 minutes before the reaction was quenched with ice-water (10 mL). The pH of the mixture was adjusted to 1 by addition of a 37% aqueous hydrochloric acid solution. The mixture was extracted with ethyl acetate (3 * 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 20:1 to afford (R)-2-cyclohexyl-2(3-methylbenzamido)acetic acid as a colorless oii (87 mg, 50%).
LCMS (ESl): m/z = 276.2 [M+H]+.
(R)-N-(1-Cyclohexyl-2-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-3methylbenzamide
To a mixture of 3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (20 mg, 0.000068 mol) and (R)-2-cyclohexyl-2-(3-methylbenzamido) acetic acid (35 mg, 0.000119 mol) in dichloromethane (5 mL) was added 1-[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridmium-3-oxide hexafluorophosphate (HATU) (146 mg, 0.00038 mol) and N.N-diisopropylethylamine (83 mg, 0.00064 mol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol= 15:1 to afford (R)-N-(1-cyclohexyl-2(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxoethy1)-3-methylbenzamide as a white solid (8.4 mg, 23%).
LCMS (ESl): m/z = 517.2 [M+H]\ ’H-NMR (400 MHz, CD3OD): δ = 1.04-1.88 (m, 15H), 2.40 (s, 3H), 3.09 (s, 3H), 3.46-3.47 (m, 1H), 3.924.51 (m, 3H), 4.83-4.85 (m, 1H), 7.15-7.52 (m, 9H).
The following 24 compounds were synthesized following the general procedure described above:
Exemple 2:
(R)-3-Fluoro-N-(3-methyl-1-{3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1 oxobutan-2-yl)benzamide
3.5 mg, yield: 9%, white solid.
LCMS (ESl): m/z = 481.2 [M+H]*.
1H-NMR (400 MHz, CDaOD): δ = 0.72-0.97 (m, 6H), 1.70-2.25 (m, 5H), 3.09 (s, 3H), 3.46-3.47 (m, 1H), 4.51-3.92 (m, 3H), 4.85-4.83 (m, 1H), 7.52-7.15 (m, 9H).
Example 3:
(R)-2-Fluoro-3-methyl-N-(3-methyl-1-(3-methyl-2,4-dioxo-1 -phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-
-oxobutan-2-yl)benzamide
mg, yield: 29%. white solid.
LCMS (ESl): m/z = 495.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.9-1.05 (m, 6H), 1.69-2.11 (m, 5H), 2.39 (s, 3H), 3.09 (s, 3H), 3.58-4.51 (m, 4H), 4.89-4.91 (m, 1H), 7.05-7.65 (m, 8H).
Example 4:
2-Fluoro-3-methyl-N-((2R,3R)-3-methyl-1-(3-methyl-2l4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-
8-yl)-1 -oxopentan-2-yl)benzamide
mg, yield: 13%, white solid.
LCMS (ESI): m/z = 509.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.81-0.98 (m, 6H), 1.23-1.92 (m, 7H), 2.32 (s, 3H), 3.09 (s, 3H), 3.333.47 (m, 1H), 3.92-3.95 (m, 1H), 4.32-4.40 (m, 1H), 4.47-4.50 (m, 1H), 4.97-5.01 (m, 1H), 7.05-7.65 (m,
8H).
Example 5:
(R)-N-(1-(3-(Cyanomethyl)-1-(4-methoxyphenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-ethyl-2-fluorobenzamide
44.3 mg, yield: 47%, white solid.
LCMS (ESI): m/z = 564.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.79-1.01 (m, 6H), 1.24-1.27 (m, 3H), 1.66-1.74 (m, 1 H), 1.82-2.24 (m,
4H), 2.67-2.73 (m, 2H), 3.41-3.46 (m. 1H). 3.77 (s, 2H), 3.85-3.93 (m, 2H), 4.2-4.32 (m, 1H). 4.42-4.56 (m, 1H), 4.62 (s, 2H), 4.84-4.86 (m, 1H), 6.60-7.57 (m, 7H).
Example 6:
(R)-2-F1uoro-N-(1-(1-(3-fluoro-4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
58.0 mg, yield: 29%. white solid.
LCMS (ESI): m/z = 596.9 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.82-1.02 (m, 6H), 1.67-2.20 (m, 5H), 3.07 (s, 3H), 3.45-3.51 (m, 1H),
3.84 (s, 2H), 3.92-3.97 (m, 2H), 4.19-4.29 (m, 1H), 4.41-4.53 (m, 1H), 4.84-4.88 (m, 1H), 6.99-8.50 (m, 7H).
Example 7:
(R)-N-{1-(1-(4-Cyanophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trif1uoromethyl)benzamide
CN
75.8 mg, yield: 44.9%, white solid.
LCMS (ESI): m/z = 573.9 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 0.89-1.05 (m, 6H), 1.74-1.81 (m, 1H), 1.92-2.14 (m, 4H), 3.16 (s, 3H), 3.48-3.53 (m, 1H), 4.00-4.13 (m, 2H), 4.43-4.67 (m, 1H), 4.97-5.03 (m, 1H), 7.27-7.40 (m, 3H). 7.26-7.73 (m, 1H), 7.70-7.81 (m, 3H), 8.25-8.34 (m. 1H).
Example 8:
(R)-N-('l-{1-(3-Cyanophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-loxobutan-2-yl)-2-fluoro-5-(trif1uoromethyl)benzamide
64.7 mg, yield: 31%, white solid.
LCMS (ESI): m/z = 573.9 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 0.89-1.05 (m, 6H), 1.72-1.78 (m, 1H), 1.96-2.12 (m, 4H), 3.16 (s, 3H),
3.48-3.55 (m, 1H), 3.99-4.12 (m, 2H), 4.65-4.68 (m, 1H), 4.92-5.05 (m, 1H), 7.25-7.30 (m, 1H), 7.39-7.71 (m, 6H), 8.15-8.34 (m, 1 H).
Example 9:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(4-(methylsulfonyl)phenyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yi)-1-oxobutan-2-y1)-5-(trifluoromethyl)benzamide
51.0 mg, yield: 30%, white solid. LCMS (ESI): m/z = 627 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.80-1.03 (m, 6H), 1.71-2.28 (m, 5H), 3.09-3.19 (m, 6H), 3.48-3.54 (m,
1H), 3.95-4.02 (m, 1 H), 4.21-4.55 (m, 2H), 4.84-4.89 (m, 1H), 7.42-8.55 (m, 8H).
Example 10:
(R)-2-Fluoro-N-(1-(1-(3-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro(4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
44.0 mg, yield: 29%, white solid.
LCMS (ESI): m/z = 579 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.80-1.03 (m, 6H), 1.71-2.28 (m, 5H), 3.09 (s, 3H), 3.46-3.53 (m, 1H),
3.75-3.84 (m, 3H), 3.75-3.99 (m, 1H), 4.18-4.52 (m, 2H), 4.84-4.88 (m, 1H), 6.79-8.53 (m, 8H).
Example 11:
(/?)-2-Fluoro-N-(3-methyl-1-{3-methyl-1-{3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
13.9 mg, yield: 20%, white solid.
LCMS (ESI): m/z = 619.7 [M+H]L
Ή-NMR (400 MHz, CD3OD): δ = 0.80-1.06 (m, 6H), 1.36 (m, 1H), 1.69-1.95 (m, 1H), 2.00-2.23 (m, 3H), 3.08 (s, 3H), 3.29 (s, 2H), 3.43 (s, 1H), 3.49 (m, 1H), 3.92-3.99 (m, 1H), 4.17-4.31 (m. 1H), 4.39-4.53 (m, 1H), 4.84 (m, 1H), 7.00-7.44 (m, 4H), 7.78-8.01 (m, 2H).
Example 12:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(1-methyl-1H-indazol-5-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
35.8 mg, yieid: 26%, white solid.
LCMS (ESI): m/z = 603.2 [M+H]+.
1H-NMR (400 MHz, CDCb): δ = 0.79-1.04 (m, 6H), 1.79-2.12 (m, 5H), 3.16 (s, 3H), 3.49-3.59 (m, 1H), 4.02-4.15 (m, 5H), 4.60-4.63 (m, 1H), 4.99-5.03 (m, 1H), 7.12-7.23 (m, 2H), 7.43-7.59 (m, 3H), 7.71-7.76 (m, 1H), 8.01-8.07 (m, 1 H), 8.16-8.31 (m, 1H).
Example 13: (R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(2-methyl-2H-indazol-5-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
17.4 mg, yieid: 33%, white solid.
LCMS (ESI): m/z = 603.2 [M+Hf.
1H-NMR (400 MHz, CDCb): δ = 0.80-1,04 (m, 6H), 1.83-2.13 (m, 5H), 3.16 (s, 3H), 3.49-3.55 (m, 1H), 4.03-4.08 (m, 2H), 4.26-4.31 (m, 3H), 4.60-4.63 (m, 1H), 4.99-5.02 (m, 1H), 7.00-7.23 (m, 2H), 7.42-7.54 (m. 2H), 7.72-7.84 (m, 2H), 7.96-8.02 (m, 1H), 8.18-8.34 (m, 1H).
Example 14:
(R)-2-Fluoro-N-(1-(1-(imidazo[1,2-alpyridin-6-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiroi4.5]decan-8yl)-3-methyl-1-oxobutan-2-yi)-5-(trifluoromethyl)benzamide trifiuoroacetic acid sait
45.6 mg, yieid: 26%, white solid.
LCMS (ESI): m/z = 589.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ= 0.85-1.04 (m, 6H), 1.77-2.33 (m, 5H), 3.14 (s, 3H), 3.46-3.55 (m, 1H), 3.93-4.01 (m, 1H), 4.18-4.31 (m, 1H), 4.46-4.59 (m, 1H), 4.70-4.72 (m, 1H), 7.33-7.48 (m, 1H), 7.70-8.54 (m, 6H), 9.00 (s, 1H).
Example 15:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(3-{methylsuifonyl)phenyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
73.4 mg, yield: 43%, white solid.
LCMS (ESI): m/z = 626.9 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.79-1.02 (m, 6H), 1.65-1.86 (m, 1H), 2.01-2.28 (m, 4H), 3.09 (s, 2H), 3.11 (s, 3H), 3.20 (s, 1H), 3.46-3.53 (m, 1H), 3.93-3.99 (m, 1H), 4.21-4.30 (m, 1H), 4.43-4.55 (m, 1H), 4.80-4.84 (m, 1H), 7.39-7.47 (m, 1H), 7.62-8.10 (m, 6H), 8.42-8.53 (m, 1H).
Example 16:
(R)-2-Fluoro-N-{3-methyl-1-(3-methyl-1-(1-methyl-1H-pyrazol-3-yl)-2,4-dioxo-1,3,8 triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
128.0 mg, yield: 70%, white solid.
LCMS (ESI): m/z = 553.0 [M+H]\ 1H-NMR (400 MHz, CD3OD): δ = 1.02-1.06 (m, 6H), 1.89-2.73 (m, 5H). 3.07 (s, 3H), 3.45-3.52 (m, 1H),
3.82-3.94 (m, 3H), 3.82-4.00 (m, 1H), 4.27-4.30 (m, 1H), 4.89-4.52 (m, 1H), 4.85-4.97 (m, 1H), 6.35-6.47 (m, 1H). 7.43-7.55 (m. 2H), 7.87-7.89 (m, 1H), 7.99-8.05 (m, 1H).
Example 17:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-{1-methyl-1H-pyrazol-4-yl)-2,4-dioxo-1,3,8triazaspiro[4.5ldecan-8-yl)-1-oxobutan-2-yl)-5-{trifluoromethyl)benzamide
159.5 mg, yield: 81%, white solid.
LCMS (ESI): m/z = 553.0 [M+H]\ 1H-NMR (400 MHz, CD3OD): ô= 0.89-1.04 (m, 6H), 1.76-2.15 (m, 5H), 3.06 (s, 3H), 3.32-3.48 (m, 1H), 3.82-4.00 (m, 4H), 4.27-4.31 (m, 1H), 4.52-4.56 (m, 1H), 4.85-4.90 (m, 1H), 7.42-7.51 (m, 2H), 7.75-7.80 (m, 1H), 7.87-7.90 (m, 1H), 7.99-8.03 (m, 1H).
Example 18:
(R)-5-Ethy l-2-fluoro-N-(3-methyl-1 -(3-methyl-1 -(3-methy limidazo[1,5-a]py ridin-6-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide
16.0 mg, yield: 30%, white solid.
LCMS (ESI): m/z = 563.1 [M+H]’.
1H-NMR (400 MHz, CD3OD): δ = 0.86-1.03 (m, 6H), 1.20-1.31 (m, 3H), 1.75-1.78 (m, 1H), 2.07-2.24 (m, 3H), 2.31-2.33 (m, 1H), 2.61-2.66 (m, 2H), 2.59 (s, 2H), 2.87 (s, 1H), 3.13 (s, 3H), 3.47-3.51 (m, 1H), 3.97-4.02 (m, 1H), 4.23-4.31 (m, 1H), 4.47-4.56 (m, 1H), 4.75-4.78 (m, 1H), 6.99-7.05 (m, 2H), 7.21-7.34 (m, 2H), 7.55-7.99 (m, 2H), 8.50 (m, 1H).
Example 19:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(2-methyl-1H-benzo[d]imidazol-6-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-{trifluoromethyl)benzamide trifluoroacetic acid sait
12.7 mg, yield: 9%, white solid. LCMS (ESI): m/z = 603.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 0,76-1.01 (m, 6H), 1.72-2.30 (m, 5H), 2.84-2.90 (m, 3H), 3.12 (s, 3H), 3.49-3.55 (t, 1H), 3.93-4.01 (t, 1H), 4.16-4.54 (m, 2H), 4.80-4.82 (m, 1H), 7.34-7.51 (m, 2H), 7.70-8.08 (m, 4H).
Example 20:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
56.3 mg, yield: 32%, white solid.
LCMS (ESI): m/z = 589.2 [M+H]+.
1H-NMR (400 MHz, CDCh): δ = 0.79-1.04 (m, 6H), 1.75-2.18 (m, 5H), 3.18 (s. 3H), 3.47-3.53 (t, 1H), 3.98-4.04 (m, 2H), 4.63-4.66 (m, 1H), 4.97-5.02 (m, 1H), 6.55-6.61 (m, 1H), 7.17-7.22 (m, 1H), 7.42-7.49 (m, 2H), 7.68-7.77 (m, 1H), 7.82-7.85 (m, 1H). 8.05-8.10 (m. 1H), 8.14-8.34 (m, 1H).
Example 21:
(R)-N -(1-(1 -{3,4-Dihydro-2H-benzo[b][1,4]oxazin-7-yl)-3-methyl-2,4-dtoxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1 -oxobutan-2-yl)-2-fluoro-5-(trifiuoromethyl)benzamide
59.9 mg, yield: 27%, white solid.
LCMS (ESI): m/z = 606.2 [M+H]‘.
1H-NMR (400 MHz. CD3OD): δ = 0.84-1.00 (m, 6H), 1.69-2.15 (m, 5H), 3.05 (s, 3H), 3.23-3.40 (m, 3H). 3.89-3.93 (m, 1H), 4.19-4.23 (m, 3H), 4.43-4.56 (m, 1H). 4.88-4.94 (m, 1H), 6.54-6.65 (m, 3H), 7.40-7.42 (m, 1 H), 7.86-8.03 (m,2H).
Example 22:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-146-0X0-1 .e-dihydropyridin-a-yl)-! ,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
22.8 mg, yield: 14%, white solid.
LCMS (ESI): m/z = 566.2.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.89-1.00 (m, 6H), 1.69-2.13 (m, 5H), 3.04 (m, 3H), 3.31-3.48 (m, 1H), 3.88-3.94 (m, 2H), 4.26-4.28 (m, 2H), 4.52-4.55 (m, 2H). 6.50-6.70 (m, 1H), 7.35-7.42 (m, 3H), 7.94-8.03 (m, 2H).
Example 23:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyM-(1-methyl-6-oxo-1,6-dihydropyridin-3-y1)-214-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyi)benzamide
O
34.8 mg, yield: 45%, white solid.
LCMS (ESI): m/z = 580.2 [M+Hf.
1H-NMR (400 MHz. CD3OD): δ = 0.90-1.04 (m, 6H). 1.70-1.87 (m, 1H), 1.99-2.18 (m, 4H), 3.07 (s, 3H),
3.44-3.60 (m, 4H), 3.90-3.96 (m, 1H), 4.22-4.32 (m, 1H), 4.46-4.58 (m, 1H), 4.84-4.88 (m. 1H), 6.49-6.62 (m, 1 H), 7.36-7.48 (m, 2H), 7.74-8.02 (m, 3H).
Example 24:
(R)-N-(1-Cyclopentyl-2-(3-methyl-1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2,4-dioxo-1,3,8 triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-2-fluoro-5-(trifluoromethyl)benzamide
66.1 mg, yield: 30%, white solid. LCMS (ESI): m/z = 606.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 1.14-1.83 (m, 9H), 1.99-2.16 (m, 3H), 2.36-2.40 (m, 1H). 3.07 (s, 3H),
3.44-3.61 (m, 4H), 3.91-3.94 (m, 1H), 4.29-4.38 (m, 1H), 4.47-4.57 (m, 1H), 4.79-4.88 (m, 1H), 6.47-6.62 (m, 1H), 7.36-7.47 (m, 2H), 7.74-7.98 (m, 3H).
Example 25:
(R)-2-Fluoro-N-(1-(1-(6-methoxypyridin-3-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
O
50.0 mg, yield: 40%, white solid.
LCMS (ESl): m/z = 580.2 [M+H]\ 1H-NMR (400 MHz, CDCI3): δ = 0.95-1.05 (m, 6H), 1.69-1.73 (m, 1H), 1.82-2.00 (m, 3H), 2.03-2.16 (m,
1H), 3.15 (s, 3H), 3.45-3.52 (m, 1H), 3.87-4.12 (m, 5H), 4.52-4.64 (m, 1 H), 4.98-5.09 (m, 1 H), 6.78-6.87 (m, 1H), 7.29-7.36 (m, 1H), 7.36-7.50 (m, 1H), 7.70-7.81 (m, 1 H). 7.99-8.10 (m, 1H). 8.25-8.39 (m, 1H).
Example 26:
(R)-2-Fiuoro-W43-methyl-143-methyl-2A<lioxo-144^trffluoromethoxy)phenyl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
12.8 mg, 16% yield, yellow solid.
LRMS: m/z = 616 [M+Hf.
Ή-NMR (400 MHz, CD3OD): δ = 7.94-7.84 (m, 2H). 7.51-7.26 (m, 5H), 4.88-4.80 (m, 1H), 4.58-4.42 (m,
1H), 4.34-4.19 (m, 1H). 4.02-3.89 (m, 1H), 3.55-3.44 (m, 1H), 3.10 (s, 3H), 2.28-1.94 (m, 4H), 1.76-1.64 (m, 1 H), 1.01 (dd, J = 11.8, 6.7 Hz, 4H), 0.92 (d, J = 6.7 Hz, 1 H), 0.79 (d, J = 6.7 Hz, 1 H).
Example 27:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(5-benzofuran)-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)-5-(trifluoromethyl)benzamîde
30 mg, 28% yield, yeltow solid.
LRMS; m/z = 588 [M+H]*.
1H-NMR (400 MHz, DMSO-de): δ = 8.72 (dd, J= 30.5, 8.8 Hz, 1H), 8.08 (d, J~ 30.8,1H), 7.94 (s, 1H), 7.86-7.61 (m, 2H), 7.56-7.34 (m, 2H), 7.18 (dd, J = 49.9, 8.6 Hz, 1H), 6.98 (d, J = 49.5 Hz, 1H), 4.67 (t, J = 8.4 Hz, 1H), 4.44-3.62 (m, 4H), 3.29 (m, 1H), 3.00 (s, 3H). 2.25-2.09 (m, 2H), 1.70-1.48 (m, 2H), 0.8910 0.56 (m, 6H).
Example 28:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(2-oxo-2l3-dihydrobenzo[dloxazol-6-yl)-1)3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
Représentative scheme:
Représentative general procedure:
tert-Butyl-4-cyano-4-(2-oxo-2,3-dihydrobenzoid]oxazol-6-ylamino) piperidine-1-carboxylate
CN
To a solution of 6-aminobenzo[d]oxazo1-2(3H)-one (6 g, 0.04 mol) in acetic acid (100 mL) was added tertbuty1-4-oxopiperidine-1-carboxylate (8.83 g. 0.04 mol). The resulting mixture was cooled to 0°C and trimethylsilyl cyanide (5.99 g, 0,06 mol) was added. The resulting solution was stirred ovemight at room température. Saturated aqueous ammonium chloride solution was added (50 mL). The mixture was 10 extracted with ethyl acetate (3 χ 100 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 10:1 to afford tert-butyl-4-cyano-4-(2-oxo-2,3dihydrobenzo[d]oxazol-6-ylamîno)piperidine-1-carboxylate as a white solid (10 g, 71%).
LCMS (ESI): m/z = 359.1 [M+H]+.
tert-Butyl^-{3-ailyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-ylamîno)^-cyanopiperidine-1-carboxylate
CN
To a solution of tert-butyl-4-cyano-4-(2-oxo-2,3-dihydrobenzo[d]oxazo!-6-ylannino)piperidine-1-carboxylate (1.0 g, 0.0027 mol) in Ν,Ν-dimethylformamide (10 mL) was added sodium hydride (0.2 g, 60% in oil, 0.00521 mol) at 0°C. After stirring for 15 minutes, 3-bromoprop-1-ene (0.35 g, 0.0029 mol) was added. The resulting mixture was stirred for 15 minutes at room température and the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:10 to afford terî-butyl-4-(3-allyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-ylamino)-4-cyanopiperidine-1-carboxylate as a thick oil (600 mg, 58%).
LCMS (ESI); m/z = 399.2 [M+Hf.
tert-Butyl-143-allyl-2-oxo-2,3-dihydrobenzo[dJoxazol-6-yl}-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate
To a solution of fert-butyl-4-(3-allyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-ylamino)-4-cyanopiperidine-1carboxylate (0.6 g, 0.0015 mol) in dichloromethane (10 mL) was added chlorosulfonyl isocyanate (0.32 g, 0.0023 mol) at 0°C. After stirring for 30 minutes at 0°C, the reaction was quenched with a 5% aqueous hydrochloric acid solution (5 mL). The solvent was removed under reduced pressure and éthanol (10 mL) was added. The mixture was stimed for 30 minutes at 80°C. The solvent was removed under reduced pressure and the residue was dissolved in tetrahydrofuran (20 mL). The pH of the resulting mixture was adjusted to 8 by addition of a 15% aqueous potassium carbonate solution. To the resulting mixture was added di-iert-butyl-dicarbonate (213 g, 0.0015 mol). After stirring ovemight, the solvent was removed under reduced pressure and the residue was extracted with ethyl acetate (3*10 mL). The combined organic layers were dried over anhydrous sodium sulfate The solvent was removed under reduced pressure to afford tert-butyl-1-(3-allyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate as a yellow oil (400 mg, crude), which was used directly without any further purification.
LCMS (ESl): m/z = 443.2 [M+H]+.
1H-NMR (300 MHz, CDCh): δ = 1.46 (s, 9H), 1.73-1.84 (m, 2H), 2.10-2.23 (m, 2H), 3.17-3.30 (m, 2H), 3.92-4.11 (m, 2H), 4.35-4.46 (m, 2H), 5.20-5.34 (m, 2H), 5.79-6.01 (m, 2H), 6.78-6.93 (m, 3H).
tert-Butyl-l-P-allyl^-oxo-a.S-dihydrobenzoIdloxazol-e-ylJ-S-methyl^-dioxo-I.S.e triazaspiro[4.5]decane-8-carboxylate
To a solution of fert-butyl-1-(3-allyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (400 mg, crude) in N.N-dimethylformamide (10 mL) was added sodium hydride (138 mg, 60% in oit, 0.00343 mol) at 0°C. Afier stirring for 15 minutes, iodomethane (220 mg, 0.0015 mol) was added. The resulting mixture was stirred for 15 minutes at room température and the réaction was quenched with ice-water (10 mL). The mixture was extracted with ethyi acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eiuting with dichloromethane : methanol = 10:1 to afford fert-butyl-1-(3-allyl-2-oxo-2,3-dihydrobenzoid]oxazol-6-yi)-3methy1-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a brown solid (240 mg, 35% overtwo steps).
LCMS (ESl): m/z = 457.2 [M+H]+.
’H-NMR (300 MHZ. CDCb): 6-1.40 (s. 9H). 1.67-1.94 (m. 4H). 3.11 (s. 3H). 3.44-3.58 (m. 2H). 3.93-4.08 (m. 2H), 4 44-4 53 (m, 2H). 5.31-5.47 (ni. 2H). 5.81-5.94 (m. 1H). 6.90-7.05 (m. 3H).
(R)-Methyl-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoate
O
To a solution of 2-fluoro-5-(trifluoromethyl)benzoic acid (15.0 g, 0.072 mol) in dichloromethane (500 mL) was added sequentially D-valine methyl ester hydrochloride (12.0 g, 0.072 mol), 1[bis(dimethylamino)methylenel-1 H-1 ^S-triazoloK.S-bJpyridinium-S-oxide hexafluorophosphate (HATU) (41 g, 0.11 mol) and N.N-diisopropylethylamine (23.3 g, 0.18 mol). Before quenching with ice-water (50 mL) the reaction was stirred for 1 hour. The mixture was extracted with dichloromethane (3 * 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography eiuting with ethyl acetate : petroleum ether = 1:5 to afford (R)-methyl-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3methylbutanoate as a thick oil (18.6 g, 81% )
LCMS (ESI): m/z = 322,1 [M+H]*.
1H-NMR (300 MHz, CD3OD): δ = 1.05 (dd, J = 6.8, 4.3 Hz, 6H), 2.22-2.35 (m, 1H), 3.79 (s, 3H), 4.58 (d, J = 6.0 Hz, 1 H), 7.46 (t, J = 9.4 Hz, 1 H), 7.89 (m, 1 H), 8.00 (dd, J = 6.2, 2.1 Hz, 1 H).
(R)-2-(2-Fluoro-5-(trifluoromethyl)benzamido)-3-niethylbutanoic acid
O .OH
To a solution of (R)-methyl-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoate (18.6 g, 0.058 mol) in tetrahydrofuran (50 mL) was added an aqueous lithium hydroxide solution (44 mL, 2.0 M, 0.088 mol). Before quenching with ice-water (20 mL), the reaction was stirred 1 hour. The pH of the solution was adjusted to 3 by addition of a 5% aqueous hydrochloric acid solution (5%). The mixture was filtered and the filter cake was washed with petroleum ether (30 mL) and dried under reduced pressure to afford (R)-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoic acid as a white solid (16.7 g, 94%). LCMS (ESI): m/z = 308.1 [M+Hf.
1H-NMR (300 MHz, DMSO): ô = 0.95 (dd, J = 6.7, 4.7 Hz, 6H), 2.13-2.17 (m, 1H), 4.31-4.35 (m, 1H), 7.52-7.55 (m. 1H), 7.58-7.85 (m, 2H), 12.77 (br, 1H).
.(1 -(3-Allyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-3-methyl-2,4-dioxo-1,3,8tnazaspiro[4.5ldecan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(tnfluoromethyl)benzamide
A solution of terf-buty1-1-(3-allyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-3-methyl-2.4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (100 mg. 0.228 mmol) in hydrochloric acid in dioxane (6.0 M, 5 mL) was stirred for 30 minutes. The solvent was removed under reduced pressure. To the residue was added dichloromethane (5 mL), (R)-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoic acid (79 mg, 0.26 mmol), i-[bis(dimethylamino)methyleneJ-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (146 mg, 0.38 mmol) and N.N-diisopropylethylamine (83 mg, 0.64 mmol). The reaction was stirred for 2 hours before it was quenched by addition of with ice-water (10 mL). The mixture was extracted with ethyl acetate (3x10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prepTLC (dichloromethane : methanol = 15:1) to afford (R)-N-(1-(1-(3-allyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6yl)-3-methyl-2l4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yi)-2-fluoro-5(trifluoromethyl)benzamide as a white solid (120 mg, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 646.1 [M+H]+.
(R)-2-Fluoro-N-(3-methyl-1-(3-methyi-2,4-dioxo-1-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
To a solution of (R)-N-(1-(1-(3-al1yl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-y1)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide (120 mg, crude) in dioxane/fert-BuOH (1:1) (10 ml_) was added a solution of osmium tetroxide in tert-BuOH (0.5 mL, 0.1%) and N-methylmorpholine-N-oxide (170 mg, 1.45 mmol). After stirring for 30 minutes, to the resulting solution was added sodium periodate (300 mg, 1.4 mmol). Before the reaction was quenched by addition of ice-water (10 mL), the mixture was heated at reflux for 1 hour. The solvent was removed under reduced pressure. The residue was extracted with ethyl acetate (3 χ 50 mL). The combined orgamc layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 10:1 to afford (R)-2-fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-1l3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide as a white solid (8.0 mg, 5% overtwo steps).
LCMS (ESI): m/z = 606.1 [M+H]*.
1H-NMR (400 MHz, CD3OD): 5 = 0.80-1.01 (m, 6H), 1.70-1.91 (m, 2H), 2.05-2.22 (m, 3H), 3.09 (s, 3H), 3.45-3.50 (m, 1H), 3.86-3.93 (m, 1H), 4.16-4.25 (m, 1H), 4.40-4.48 (m, 1H), 4.81-4.85 (m, 1H), 7,02-7.08 (m, 3H), 7.30-7.37 (m. 1H), 7.79-7.85 (m, 3H), 8.41-8.56 (m, 1H).
The following 5 compounds were synthesized following the general procedure described above from tert-butyl-1-(3-aUyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5Jdecane-8-carboxylate (prepared as described in Example 28-d):
Example 29: (R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
NH
39.3 mg, yield: 32%, white solid. LCMS (ESI): m/z = 606.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.79-1.00 (m, 6H), 1.73-2.16 (m, 5H), 3.08 (s, 3H), 3.44-3.48 (m, 1H), 3.82-3.95 (m, 1H), 4.16-4.24 (m, 1H), 4.39-4.46 (m, 1H), 4.81-4.86 (m, 1H), 6.95-7.05 (m, 2H), 7.15-7.45 (m, 2H), 7.81-7.85 (m,2H).
Example 30:
(R)-2-Fluoro-N-(3-methyl-1 -(3-methyl-2,4-dioxo-1 -(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-
1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
This compound was prepared following the general procedure described above using 4-allyl-7-amino-2Hbenzo[b][1,4]oxazin-3(4H)-one
O
22.5 mg, yield: 13%, white solid.
LCMS (ESI): m/z = 620.2 [M+H]+.
’H-NMR (400 MHz. CD3OD): δ = 0.83-1.01 (m, 6H), 1.71-1.74 (m, 1H), 1.84-2.10 (m, 4H), 3.07 (s, 3H), 3.45-3.51 (m, 1H), 3.91-3.97 (m, 1H), 4.18-4.24 (m, 1H), 4.39-4.63 (m, 3H), 5.32-5.42 (m, 1H), 6.80-6.94 (m, 3H), 7.32-7.47 (m, 1H), 7.86-8.48 (m, 2H).
Example 31:
(R)-5-Ethyl-2-fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-
1,3,8-triazaspiro[4.5ldecan-8-yl)-1-oxobutan-2-yl)benzamide
23.4 mg, yield: 39%, white solid.
LCMS (ESI): m/z = 566.2 [M+H]*.
Ή-NMR (400 MHz, CDCb): δ = 0.87-1.07 (m, 6H), 1.21-1.23 (m, 3H), 1.25-1.99 (m, 8H, 3H), 2.65 (m. 2H), 3.16 (s, 3H), 3.48-3.50 (m. 1H), 3.92-3.97 (m, 2H), 4.67-4.69 (m, 1H), 5.13-5.07 (m, 1H), 6.87-7.02 (m, 1H), 6.99-7.05 (m, 2H), 7.29-7.33 (m, 2H), 7.54-7.74 (m, 2H), 9.37 (m, 1H),
Example 32:
(R)-N-(1-(1-(1H-Benzo[d][1,2,3]triazof-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro [4.5]decan-8-yl)-3methyl-1 -oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benz- amide
Λ π hn-n mg, 20% yield, white solid.
LCMS (ESI): m/z = 590.1 [M+H]+.
1H-NMR (400 MHz, CDsOD): δ = 0.69 (d, J= 6.8 Hz, 1H), 0.85 (d, J= 6.7 Hz, 1H), 0.95-0.99 (m, 4H), 1.75-2.25 (m, 5H), 3.12 (s, 3H), 3.47-3.57 (m, 1H), 3.93-4.02 (m, 1H), 4.20-4.32 (m, 1H), 4.49-4.56 (m, 1H), 4.78-4.84 (m, 1H), 7.16-7.46 (m, 2H), 7.72-8.03 (m, 4H).
Example 33:
(R)-N-(3-Methyl-1-(3-niethyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5ldecan-8-yl)-1-oxobutan-2-yl)-3(trifluoromethyl)benzamide
Représentative scheme:
HN
BocHN
-OH
HATU, D1PEA, DCM, r.t a
b
Example 1-d
HATU. DIPEA, DCM, r.t
XRX-000131-00-001
Représentative general procedure:
(R)-tert-Butyl-3-methyi-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1 oxobutan-2-ylcarbamate
To a mixture of 3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (prepared as described in Example 1-d) (513 mg, 1.73 mmol) in dichloromethane (30 mL) was added (R)-2-(tertbutoxycarbony!amino)-3-methylbutanoicacid (411 mg, 0.00026 mol), 1-[bis(dimethylamino)methylene]1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (900 mg, 2.36 mmol) and N,Ndiisopropylethylamîne (605 mg, 4.6 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water. The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:5 to afford (R)-fert-butyl-3-methyl-1-(3-methyl-2,4-dioxo-1phenyl-1,3,8-triazaspiro(4.5]decan-8-yl)-1-oxobutan-2-ylcarbamate as a colorless oil (650 mg, 81%). LCMS (ESI): m/z = 459.2 [M+H]+.
1H-NMR (300 MHz, CDCh): δ = 0.65-0.92 (m, 6H), 1.34 (s, 6H), 1.44 (s, 3H), 1.59-1.94 (m, 4H), 3.11 (s, 3H), 3.34-3.51 (m, 1H), 3.83-3.94 (m,2H), 4.27-4.44 (m, 1H), 4.49-4.61 (m, 1H), 5.15-5.17 (m, 1H), 7.057.19 (m, 2H). 7.40-7.45 (m, 3H).
(R)-8-(2-Amino-3-methylbutanoyl)-3-methyl-1-pheny1-1,3l8-triazaspiro[4.5]decane-2,4-dione hydrochloride
A solution of tert-butyl-3-methyl-1-(4-nitrophenyl)-2.4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (458 mg, 1.98 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford (R)-8-(2-amtno-3methylbutanoyl)-3-methyl-1-phenyI-1,3.8-triazaspiroi4.5]decane-2,4-dione hydrochloride as a white solid (250 mg, 46%).
LCMS (ESI): m/z = 359.2 [M+Hf.
(R)-N-(3-Methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-3(trifluoromethyl)benzamide
To a mixture of (R)-8-(2-amino-3-methylbutanoyl)-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decane-2,4dione hydrochloride (52 mg, 0.132 mmol) in dichloromethane (2 mL) was added 3(trifluoromethyl)benzoic acid (23 mg, 0.12 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2.3-triazolo[4,5b]pyridinium-3-oxide hexafluorophosphate (HATU) (68 mg, 0.17 mmol) and N.N-diisopropylethylamine (31 mg, 0.24 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:5 to afford (R)-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8triazaspiroi4.5]decan-8-yl)-1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide as a white solid (34.4 mg, 49%). LCMS (ESI): m/z = 531.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.92-1.00 (m, 6H), 1.97-2.19 (m, 5H), 3.08 (s, 3H), 3.91-4.48 (m, 4H), 4.77-4.91 (m, 1H), 7.17-7.33 (m, 4H), 7.84-8.07 (m, 4H), 8.12-8.14 (m, 1H).
The following 18 compounds were synthesized following the general procedure described above: Example 34:
(R)-3-Ethyl-2-fluoro-N-(3-methy 1-143-methyl-2,4-dioxo-1 -pheny 1-1,3,8-triazaspiro[4.5]decan-8-yl)-1 oxobutan-2-yl)benzamide
31.2 mg, yieid: 51%, white solid.
LCMS (ESI): m/z = 509.2 [M+HJ*.
1H-NMR (400 MHz, CD3OD): δ = 0.79-1.09 (m, 6H), 1.17-1.33 (m, 3H), 1.60-2.24 (m, 5H), 2.73 (m, 2H),
3.09 (s, 3H), 3.48 (m, 1H), 3.83-4.04 (m, 1H), 4.24-4.30 (m, 1H), 4.37-4.52 (m, 1H), 4.85-4.89 (m, 1H), 7.10-7.59 (m, 8H).
Example 35:
(R)-3,4-Dichloro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-ptienyl-1,3,8-triazaspiro[4.5]decan-8-y 1)-1oxobutan-2-yl)benzamide
Cl
Cl
33.9 mg, yield; 50%, white solid.
LCMS (ESI): m/z = 531.2, 533.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.71-0.90 (m, 6H), 1.58-2.30 (m, 5H), 3.09 (s, 3H), 3.48 (m, 1H), 3.844.01 (m, 1H), 4.17-4.58 (m, 2H), 4.74 (m, 1H), 7.17-7.84 (m, 8H).
Example 36:
(R)-2,5-Dichloro-N-{3-methyl-143-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5ldecan-8-yl)-1oxobutan-2-yl)benzamide
Cl
34.4 mg, yield: 51%. white solid.
LCMS (ESI): m/z = 531.2, 533.2 [M+H]L 1H-NMR (400 MHz, CD3OD): δ = 0.71-1.10 (m, 6H), 1.61-2.25 (m, 5H), 3.10 (s, 3H), 3.46-3.49 (m, 1H), 3.81-4.04 (m, 1H), 4.11-4.58 (m, 2H), 4.74-4.77 (m, 1H), 7.12-7.57 (m, 8H).
Example 37:
5-Ethyl-2-fluoro-N-((2R,3S)-3-methoxy-1-(3-methyl-214-dioxo-1-phenyl-1,3,8-tnazaspiro[4.5îdecan8-yl)-1 -oxobutan-2-yl)benzamide
19.8 mg, yield: 29%, white solid.
LCMS (ESI): m/z = 525.2 [M+Hf.
’H-NMR (400 MHz, CD3OD): δ = 1.22-1.31 (m, 6H), 1.66-2.83 (m, 6H), 3.03 (m, 4H). 3.38 (s, 2H). 3.514.51 (m, 5H), 5.01-5.17 (m, 1H), 6.73-7.76 (m, 8H).
Example 38:
3-Ethyl-5-fluoro-N-((2Rl3S)-3-methoxy-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-
8-yl)-1-oxobutan-2-yl)benzamide
36.0 mg, yield; 54%, white solid.
LCMS (ESI): m/z = 525.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.00-1.19 (m, 6H), 1.66-2.71 (m, 6H), 3.08 (s, 3H), 3.11 (s, 1H), 3.30 (s, 2H), 3.46-4.47 (m, 5H), 5.03-5.11 (m, 1H), 6.69-7.76 (m, 8H).
Example 39: (R)-5-Ethyl-2-fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide
10.0 mg, yield: 17%, white solid.
LCMS (ESI): m/z = 509.2 [M+H]+.
1H-NMR (400 MHz, CDsOD): δ = 0.79-1.09 (m, 6H), 1.26-1.30 (m, 3H), 1.57-2.27 (m, 5H), 2.63-2.75 (m, 2H), 3.09 (s, 3H), 3.42-3.56 (m. 1H), 4.14-4.32 (m. 2H). 4.37-4.53 (m, 1H), 4.82-4.88 (m. 1H). 7.05-7.61 (m, 8H).
Example 40: 5-Ethyl-2-fluoro-N-((2R,3R)-3-methoxy-1-{1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide
O
10.0 mg, yield: 15%, white solid. LCMS (ESI): m/z = 555.2 [M+H]*.
1H-NMR (400 MHz, CDaOD): δ = 1.02-1.27 (m, 6H), 1.65-2.05 (m, 4H), 2.66-2.73 (m, 2H), 3.08 (s, 3H), 3.12-3.20 (m, 1H), 3.44-3.47 (m, 1H), 3.52-3.88 (m, 6H), 4.17-4.25 (m, 1H), 4.31-4.49 (m, 1H), 5.06-5.17 (m, 1H), 6.93-7.20 (m, 5H), 7.39-7.57 (m, 2H).
Example 41:
3-Fluoro-N-((2R,3R)-1-(1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-trîazaspiro[4.51decan-8-yl)-3 met h y I-1-oxo pentan-2-y I )-5-methy Ibe nza m i de
12.8 mg, yield: 11%, white solid.
LCMS (ESI): m/z = 539.2 IM+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.67-0.98 (m, 6H), 1.12-1.25 (m, 1H), 1.45-1.48 (m, 1 H), 1.62-2.15 (m,
5H), 2.41 (s, 3H). 3.07 (s, 3H), 3.47-3.51 (m. 1H), 3.75 (s, 2H), 3.84 (s, 1H), 3.85-4.51 (m, 3H), 4.89-4.91 (m, 1H), 6.84-7.52 (m, 7H).
Example 42:
(R)-5-Cyclopropyl-2-fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiroI4.5]decan
8-yl)-1-oxobutan-2-yl)benzamide
XRX-000155-00-001
34.0 mg, yield: 39%, white solid.
LCMS (ESI): m/z = 521.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.67-0.98 (m, 10H), 1.65-2.15 (m, 6H), 3.08 (s. 3H), 3.47-3.51 (m, 1H),
3.91-3.94 (m, 1H), 4.23-4.49 (m, 2H), 4.80-4.90 (m, 1H), 7.05-7.51 (m, 8H).
Example 43:
(R)-5-Chloro-2-fluoro-N-(3-methyl-1 -(3-methyl-2,4-dioxo-1 -phenyl-1,3,8-triazaspiro[4.5Jdecan-8-yl)1 -oxobutan-2-yl)benzamide
XRX-000166-00-001
42.0 mg, yield: 48%, white solid.
LCMS (ESI): m/z = 515.2[M+H]+.
1H-NMR (400 MHz, CD3OD): 5 = 0.76-1.01 (m, 6H), 1.65-2.15 (m, 5H), 3.09 (s, 3H), 3.47-3.51 (m, 1 H}, 3.90-3.95 (m, 1H), 4.17-4.47 (m, 2H), 4.80-4.82 (m, 1H), 7.22-7.75 (m, 8H).
Example 44:
(R)-2-Fluoro-N-(3-methyl-1 -(3-methyl-2,4-dioxo-1 -phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1 oxobutan-2-yl)-5-(trifluoromethyl)benzamide
26.9 mg, yield: 55%, white solid.
LCMS (ESI): m/z = 549.2 [M+HJ+.
1H-NMR (400 MHz, CD3OD): δ = 0.77-1.03 (m, 6H), 1.68-2.22 (m, 5H), 3.09 (s, 3H), 3.46-3.53 (m, 1 H). 3.93-3.99 (m, 1H), 4.18-4.30 (m, 1H), 4.40-4.52 (m, 1H), 4.83-4.86 (m, 1H), 7.23-7.53 (m, 6H), 7.85-8.02 (m. 2H).
Example 45:
(R)-5-Cyclopropyl-2-fluoro-N-(1 -(1 -(4-methoxyptienyl)-3-methy l-2,4-dioxo-1,3,8 triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)benzamide
O
23.0 mg, yield: 36%, white solid.
LCMS (ESI): m/z = 551.2 (M+Hf.
iH-NMR (400 MHz, CD3OD): δ = 0.68-0.98 (m, 10H), 1.86-2.16 (m, 6H), 3.32 (s, 3H), 3.47-3.51 (m, 1H) 3.75-3.77 (m, 2H), 3.81-3.88 (m, 1H), 3.93-4.49 (m, 3H). 4.84-4.90 (m, 1H), 6.88-7.34 (m. 7H).
Example 46:
(R)-3-Ethyl-N-(3.metliyl-1-(3-<nethyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiroI4.S]decan-S-yl)-1 oxobutan-2-yl)benzamide
29.5 mg, yield: 50%, white solid.
LCMS (ESI): m/z = 491 [M+Hf.
’H-NMR (400 MHz, CD3OD): δ = 0.72-0.97 (m, 6H), 1.23-1.28 (m, 3H), 1.60-2.18 (m, 5H), 2.67-2.73 (m, 2H), 3.07 (s, 3H), 3.49-3.52 (m, 1H), 3.90-4.00 (m, 1H), 4.31-4.49 (m, 2H), 4.76-4.88 (m, 1H), 7.16-7.49 (m, 8H).
Example 47:
(R)-3-Ethyl-5-fluoro-N-(3-methyi-1 -f3-methyl-2,4-dioxo-1 -pheny 1-1,3,8-triazaspîro[4.5]decan-8-y l)-1 oxobutan-2-yl)benzamide
27.6 mg, yield: 45%, white solid.
LCMS (ESI): m/z = 509 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.71-0.96 (m, 6H), 1.24 (m, 3H), 1.65-1.68 (m, 1H), 1.91-2.09 (m, 4H), 2.70-2.72 (m, 2H) 3.07 (s, 3H), 3.45-3.47 (m, 1H), 3.90-3.96 (m, 1H), 4.30-4.47 (m, 2H), 4.73 (m, 1H).
7.14-7.50 (m, 9H).
Example 48:
(R).3,5-Dichloro-N-(3-methyl-1-(3-methyl-2l4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide
18.5 mg, yield: 29%, white solid.
LCMS (ESI): m/z = 531 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.71-0.96 (m. 6H), 1.63-1.73 (m, 1H), 1.81-2.61 (m, 4H), 3.08 (s. 3H),
3.47 (m, 1H), 3.89 (m, 1H), 4.22-4.51 (m, 2H), 4.71 (m, 1H), 7.18-8.65 (m. 8H.
Example 49:
5-Cyclopropyl-2-fluoro-N-((2R,3R)-3-methoxy-1-(1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8 triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide
Ο
XRX-100063-00-001
27.2 mg, yield: 31%, white solid.
LCMS (ESI): m/z = 567 [M+H]\ 1H-NMR (400 MHz, CD3OD): δ = 0.70-0.82 (m, 2H), 0.91-1.03 (m, 4H), 1.14-1.32 (m, 2H), 1.60-1.79 (m,
H), 1.83-2.17 (m, 4H), 2.99-3.11 (m, 3H), 3.13-3.15 (m. 2H), 3.71-4.01 (m, 6H), 4.14 (m, 1H). 4.47-4.49 (m, 1H), 5.03-5.26 (m, 1H), 6.95-7.01 (m, 1H), 7.02-7.33 (m, 5H), 7.50-7.71 (m, 1H).
Example 50:
(R)-5-Ethyl-2-fluoro-N-(1-(1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-
3-methyl-1-oxobutan-2-yl)benzamide
O-,
43.7 mg, yield: 68%, white solid.
LCMS (ESI): m/z = 539 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.74-1.08 (m. 6H), 1.21-1.38 (m, 3H), 1.60-1.75 (m, 1H), 1.78-2.25 (m,
4H), 2.62-2.80 (m, 2H), 3.08 (s, 3H), 3.41-3.48 (m, 1H), 3.56-3.76 (m. 2H), 3.84-3.93 (m, 1H), 4.18-4.27 (m, 2H), 4.48-4.86 (m, 2H), 6.90-6.92 (m, 1H), 7.00-7.26 (m, 4H), 7.45 (m, 2H).
Example 51:
(R)-2-F!uoro-N-(1-(1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
40.0 mg, yield: 47%, white solid. LCMS (ESI): m/z = 579 [M+H]\ 1H-NMR (400 MHz, CDsOD): δ = 0.79-1.
(m, 6H), 1.66-2.17 (m, 5H), 3.06 (s, 3H), 3.49 (m, 1H), 3.75 (s,
2H), 3.85 (s, 1H), 3.94-4.22 (m, 2H). 4.44-4.50 (m. 1H), 4.86-4.94 (m. 1H), 6.90-6.93 (m, 1H), 7.13 (m, 3H), 7.43 (m, 1H), 7.94 (m, 2H).
Example 52:
( R)-N-(1-(1-(1 H-indazol-5-y l)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
XRX-100166-00-001
Représentative scheme:
K2CO3. Cw-a
2) HCl, EtOH/ί Jh
3) (BûcJjO, KjCOi r t. cb-rmiQht
CHjl
PdlC.
MeOH. ri. 3h
Représentative general procedure: tert-Butyl-4-(1 H-indazol-5-ylamino)-4-cyanopiperidine-1 -carboxylate
CN
XRX-100166-00-001 -a
To a solution of 1 H-indazol-5-amine (25.0 g, 0.19 mol) in acetic acid (300 mL) was added tert-butyl-4oxopiperidine-1-carboxylate (45.0 g. 0.22 mol). The resulting mixture was cooled to 0°C and trimethylsilyl cyanide (37.0 g, 0.37 mol) was added. The resulting solution was stirred ovemight at room température. Saturated aqueous ammonium chloride solution (500 mL) was added. The resulting mixture was filtered and the filter cake was washed with water (3 « 50 mL) to afford tert-butyl-4-(1 H-indazol-5-ylamino)-4cyanopiperidine-1-carboxylate as a brown solid (60.0 g, 93%).
LCMS (ESl): m/z = 342.1 [M+Hf.
1H-NMR (300 MHz, DMSO-de): δ = 1.41 (s, 9H), 1.76-1.85 (m, 2H), 2.20-2.24 (m, 2H), 3.15 (t, J = 10.8 Hz, 2H), 3.78-3.82 (m, 2H), 5.74 (s, 1H), 6.95-7.05 (m, 1H), 7.12-7.20 (m, 1H), 7.29-7.42 (m, 1H), 7.92 (s, 1H), 12.8 (br, 1H).
Benzyl-5-((1-(tert-butoxycarbonyl)-4-cyanopiperidin-4-yl)amino)-1H-indazole-1-carboxylate
XRX-100166-00-001 -b
To a solution of fert-butyl-4-(1H-indazol-5-ylamino)-4-cyanopiperidine-1-carboxylate (60.0 g, 0.18 mol) in tetrahydrofuran : water (300 mL, 1:1) was added potassium carbonate (57.0 g, 0.41 mol) and benzyl chlorofomnate (53.0 g, 0.31 mol) at 0°C. After stirring ovemight, the organic layer was isolated and the aqueous was extracted with ethyl acetate (3 χ 100 mL). The combined layers were washed with water (3 x 50 mL) and brine (3 χ 50 mL). The organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : dichloromethane : petroleum ether= 1:2:2 to afford benzyl-5-((1-(tertbutoxycarbonyl)-4-cyanopiperidin-4-yl)amino)-1H-indazole-1-carboxylateas a brown solid (60.0 g, 70%). LCMS (ESI): m/z = 476.1 [M+Hf.
Benzyl-5-(8-(iert-butoxycarbonyl)-2,4-<lioxo-1,3l8-triazaspiro[4.5]decan-1-yl)-1H-indazole-1carboxylate
XRX-100165-00-001 -c
To a solution of benzyl-5-((1-(terf-butoxycarbonyl)-4-cyanopiperidin-4-yl)amino)-1H-indazole-1carboxylate (10.0 g, 0.021 mol) in dichloromethane (200 mL) was added chlorosulfonyl isocyanate (20 mL, 0.23 mol) at 0°C. After stining for 30 minutes at 0°C, the reaction was quenched by addition of a 5% aqueous hydrochloric acid solution (100 mL). The solvent was removed under reduced pressure and éthanol (100 mL) was added. The mixture was stirred for 30 minutes at 80°C. The solvent was removed under reduced pressure and the residue was added to tetrahydrofuran (20 mL) and the pH was adjusted to 8 by addition of a 15% aqueous potassium carbonate solution. Then di-fert-butyl-dicarbonate (5.9 g, 0.027 mol) in tetrahydrofuran (100 mL) was added. After stirring ovemight, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 50 :1 to afford benzyl-5-(8-(fert-butoxycarbonyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate as a yellow solid (3.0 g, 27%).
LCMS (ESI): m/z = 520.1 [M+Hf.
1H-NMR (300 MHz, CDCb): δ = 1.36 (s, 9H), 1.74-1.81 (m, 2H), 1.96-2.00 (m, 2H), 3.43-3.55 (m, 2H), 4.02 (br, 2H), 5.56 (s, 2H), 7.25-7.41 (m, 5H), 7.51-7.57 (m, 3H), 8.21 (s, 1H), 8.29-8.32 (d, 1H, J = 9.2 Hz).
Benzyl-S-tS-ftert-butoxycarbonylJ-S-methyi^, 4-dioxo-1,3,8-triazaspiroi4.5]decan-1-yl)-1H-indazole-
1-carboxylate
XRX-100165-00-001-d
To a solution of benzyl-5-(8-(fert-butoxycarbonyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)-1 H-indazole1-carboxylate (10.0 g, 0.019 mol) in N,N-dimethylformamide (100 ml_) was added potassium carbonate (5.32 g, 0.039 mol) at 0°C. After stirring for 15 minutes, iodomethane (1.58 ml_, 0.025 mol) was added. After stirring for 1 hour, the reaction was quenched by addition of ice-water (50 mL). The mixture was extracted with ethyl acetate (3 * 50 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 40 :1 to afford benzyl-5-(8-(fertbutoxycarbonyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate as a white solid (7.5 g, 73%).
LCMS (ESI): m/z = 534.1 [M+H]+.
1H-NMR (300 MHz, CDCh): δ = 1.35 (s, 9H), 1.72-1.77 (m, 4H), 1.86-1.90 (m, 2H), 3.11 (s, 3H), 3.51 (br, 2H), 3.86-4.10 (m, 2H), 5.55 (s, 2H), 7.29 (dd, 1H, J = 8.9 Hz, J = 1.9 Hz), 7.40 (m, 3H), 7.53 (m, 3H), 8.20 (d, 1 H, J = 0.7 Hz), 8.28 (d, 1 H, J = 8.6 Hz).
Benzyl-5-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate hydrochloride
XRX-100165-00-001 -e
A solution of benzyl-5-(8-(tert-butoxycarbonyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)-1Hindazole-1-carboxylate (3.50 g, 0.00657 mol) in hydrochloric acid in dioxane (10 mL, 6.0 M) was stirred 1 hour. The mixture was filtered, and the filter cake was washed with petroleum ether (3 χ 10 mL) to afford benzyl-5-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate hydrochloride as a white solid (1.98 g, 70%).
LCMS (ESI): m/z = 434.1 [M+Hf.
(R)-Benzyl-5-(8-(2-(2-fluoro-5-(trifIuoromethyl)benzamido)-3-inethylbutanoyl)-3-methyl-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-1 -y 1)-1 H-indazole-1-carboxylate
To a solution of benzyl-5-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate hydrochloride (5.0 g, 0.011 mol) in dichloromethane (100 mL) was added sequentially (R)-2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 26-f) (2.9 g, 0.0094 mol), 1 -[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-blpyridinium-3-oxide hexafluorophosphate (HATU) (5.33 g, 0.01406 mol), N,N-diisopropylethylamine (3.0 g, 0.024 mol). The reaction was stirred for 2 hours before quenching with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 χ 50 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-benzyl-5-(8-(2-(2-fIuoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3methyl-2,4-dioxo-1,3,8-triazaspiroI4.5]decan-1-yl)-1H-îndazole-1-carboxylate as a white solid (5.1 g, 76%).
LCMS (ESI): m/z = 723.0 [M+H]+.
(R)-N-(1 -(1 -(1 H-lndazol-5-yi)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)-2-fiuoro-5-(trifluoromethyl)benzamide
XRX-100165-00-001
A mixture of (R)-benzyl-5-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methyl butanoyl)-3-methyl-2,4dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate (350 mg, 0.48 mmol) and palladium on carbon (50 mg, 5%) in methanol (50 mL) was stirred for 3 hours under a hydrogen atmosphère. The resulting mixture was filtered and the filter cake was washed with methanol (5*10 mL). The filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (acetonitrile and water, acetonitrile from 5% to 60%) to afford (R)-N-(1-(1-(1H-indazo!-5-yl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1 -oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide as a white solid (78 mg, 27%).
LCMS (ESI): m/z = 589.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.67-0.99 (m, 6H), 1.74-2.26 (m, 5H), 3.11 (s, 3H), 3.48-3.54 (m, 1H), 3.94-4.00 (m, 1H), 4.18-4.52 (m, 2H), 4.80-4.84 (m, 1H), 7.16-7.68 (m, 3H), 7.75-7.87 (m, 2H), 7.87-8.15 (m, 1H), 8.46-8.51 (m, 1H).
The following 22 compounds were synthesized folîowing the general procedure described above:
Example 53:
(R)-N-{1 -{1 -(1 H-lndazol-6-y l)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
XRX-100207-00-001
73.2 mg, yield: 30%, white solid.
LCMS (ESI): m/z = 589.0 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.79-1.04 (m, 6H), 1.84-2.13 (m, 5H). 3.18 (s, 3H), 3.48-3.54 (m, 1H), 4.02-4.06 (m, 2H), 4.60-4.64 (m, 1 H), 4.97-5.01 (m, 1H), 6.91-6.96 (m, 1H), 7.15-7.24 (m, 1H), 7.42-8.01 (m, 4H), 8.13-8.34 (m, 1H).
Example 54:
(R)-IM-(1 -(1-(1 H-lndazol-5-yl)-3-methy1-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-
XRX-100276-00-001
29.7 mg, yield: 37%, white solid.
LCMS (ESI): m/z = 561.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): ô = 0.63-1.00 (m, 10H), 1.72-2.25 (m, 6H), 3.11 (s, 3H), 3.47-3.53 (m, 1H), 3.93-3.99 (m, 1H), 4.16-4.51 (m, 2H), 4.80-4.82 (m, 1H), 6.89-7.11 (m, 1H), 7.17-7.30 (m, 2H), 7.40-7.53 (m, 1H), 7.65-7.67 (m, 1H), 7.77-8.03 (m, 1H), 8.10-8.15 (m, 1H).
Example 55:
( R)-N-{1 -(1 -(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)-5-ethyl-2-fluorobenzamide
XRX-100277-00-001
29.4 mg, yield: 46%, white solid.
LCMS (ESI): m/z = 549.2 [M+H]+.
1H-NMR (400 MHz, CD3OD); δ = 0.67-1.04 (m, 6H), 1.18-1.31 (m, 3H), 1.73-2.25 (m, 5H), 2.58-2.70 (m, 2H), 3.10 (s, 3H), 3.47-3.50 (m, 1H), 3.93-3.99 (m, 1H), 4.16-4.51 (m, 2H), 4.81-4.88 (m, 1H), 6.90-6.94 (m, 1H), 7.09-7.17 (m, 1H), 7.24-7.35 (m, 2H), 7.51-7.56 (m, 1H), 7.65-7.77 (m, 1H), 8.03-8.15 (m, 1H).
Example 56:
(R)-N-(1 -(141 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-3-methyl-1 oxobutan-2-yl)-2-fluoro-5-methylbenzamide
XRX-100278-00-001
25.2 mg, yield: 39%, white solid.
LCMS (ESI): m/z = 535.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.66-0.97 (m, 6H), 1.72-2.34 (m, 8H), 3.10 (s, 3H), 3.45-3.54 (m, 1H),
3.92-3.98 (m, 1H), 4.25-4.50 (m, 2H), 4.80-4.82 (m, 1H). 6.86-7.09 (m, 1H), 7.17-7.28 (m, 3H), 7.50-7.52 (m, 1H), 7.64-7.76 (m, 1H). 8.04-8.15 (m, 1H).
Example 57:
(R)-N424141H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1 -cyclopentyl-2 oxoethyl)-2-fluoro-54trifluoromethyl)benzamide
XRX-100415-00-001
33.7 mg, yield: 41%, white solid.
LCMS (ESI): m/z = 615.2 [M+H]*.
’H-NMR (400 MHz, CDCb): δ = 1.23-1.96 (m, 10H), 2.09-2.23 (m, 2H), 2.34-2.40 (m, 1H), 3.10 (s, 3H),
3.48-3.54 (m, 1H), 3.92-4.00 (m, 1H), 4.30-4.33 (m, 1H), 4.47-4.51 (m, 1H), 4.83-4.84 (m, 1H), 7.14-7.30 (m. 2H), 7.39-7.52 (m, 1H), 7.66-7.68 (m, 1H), 7.74-7.86 (m, 2H), 7.96-8.15 (m, 1H).
Example 58:
(R)-N-(2-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-cyclobutyl-2oxoethyl)-2-fluoro-5-(trifluoromethyl)benzamide
XRX-100430-00-001
33.6 mg, yield: 41%, white solid.
LCMS (ESI): m/z = 601.2 [M+H]+.
1H-NMR (400 MHz, CDCh): δ = 1.58-1.88 (m, 10H), 2.54-2.77 (m, 1H), 3.18 (s, 3H), 3.48-3.54 (m, 1H),
3.92-4.09 (m, 2H), 4.48-4.61 (m, 1H), 5.09-5.12 (m, 1H), 7.00-7.35 (m, 3H), 7.44-7.62 (m, 2H), 7.71-7.74 (m, 1 H), 7.98-8.08 (m, 1H).
Example 59:
(R)-N-(1-(1 -(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)-3-(trifluoromethyl)benzamide (This compound was obtained as the des-chloro by-product of Example 57)
XRX-100433-00-001
6.9 mg, yield: 11%, white solid.
LCMS (ESI): m/z = 571.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.61-0.62 (m, 1H), 0.86-0.88 (m, 1H), 0.94-1.09 (m, 4H), 1.75-2.25 (m,
5H), 3.10 (s, 3H), 3.46-3.53 (m, 1H), 3.92-3.99 (m, 1H), 4.42-4.52 (m, 2H), 4.74-4.78 (m, 1H), 7.15-7.29 (m. 1H), 7.47-7.51 (m, 1H), 7.58-7.67 (m, 2H), 7.77-7.96 (m, 2H), 8.01-8.18 (m, 2H).
Example 60:
(R)-N-(1-(1-(1 W-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-y!)-3-methyl-1oxobutan-2-yl)-3-chloro-5-(trifluoromethyl)benzaniide
XRX-100462-00-001
8.8 mg, yield: 14%, white solid.
LCMS (ESI): m/z = 605.2 [M+Hf.
1H-NMR (400 MHz, CDsOD): δ = 0.85-0.87 (m, 1H), 0.95-0.99 (m,4H), 1.06-1.08 (m, 1H), 1.70-1.78 (m, 1H), 1.89-1.99 (m, 1H), 2.07-2.34 (m, 3H), 3.10 (s, 3H), 3.50-3.54 (m, 1H), 3.91-3.99 (m, 1H), 4.23-4.52 (m, 2H), 4.74-4.77 (m, 1H), 7.14-7.17 (m, 1H), 7.48-7.50 (m, 1H), 7.64-7.65 (m, 1H), 7.77-7.89 (m. 3H), 7.97-7.98 (m, 1H), 8.07-8.15 (m, 1H).
Example 61:
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-<lioxo-1l3,84riazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yî)-2-methyl-5-(trifluoromethyl)benzamide
XRX-100474-00-001
22.0 mg, yield: 54%, white solid.
LCMS (ESI): m/z = 585.2 [M+Hf.
1H-NMR (400 MHz, CDsOD): δ= 0.58-1.10 (m, 6H), 1.70-1.89 (m, 3H), 2.10-2.12 (m, 4H), 2.34-2.43 (m, 1H), 3.12 (s, 3H), 3.51-3.54 (m, 1H), 3.98-4.00 (m, 1H), 4.17-4.62 (m, 2H), 4.78-4.82 (m, 1H), 7.17-7.25 (m, 2H), 7.40-7.44 (m, 1H), 7.50-7.84 (m, 3H), 8.00-8.10 (m, 1H).
Example 62:
(R)-N-(1-(1-(1 H-lndazol-5-yl)-3-methy1-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethoxy)benzamide
18.4 mg, yield: 28%, white solid.
LCMS (ESI): m/z = 605.2 [M+H]‘.
Ή-NMR (400 MHz, CD3OD): δ = 0.67-0.97 (m, 6H), 1.71-2.12 (m, 5H), 3.10 (s, 3H), 3.47-3.50 (m, 1H), 3.91-3.96 (m, 1H), 4.15-4.23 (m, 1H), 4.38-4.48 (m, 1H), 4.81-4.83 (m, 1H), 7.07-7.41 (m, 6H), 8.03-8.15 (m. 1H).
Example 63:
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-methoxybenzamide
XRX-100486-00-001
22.2 mg, yield: 34%, white solid.
LCMS (ESI): m/z = 551.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.67-0.68 (m, 1H), 0.80-0.82 (m, 1H), 0.95-0.97 (m, 4H), 1.72-1.79 (m, 1H), 1.88-1.92 (m, 1H), 2.07-2.23 (m, 3H), 3.10 (s, 3H), 3.46-3.52 (m, 1H), 3.76-3.80 (m, 3H), 3.92-3.98 (m, 1H), 4.15-4.27 (m, 1H), 4.37-4.51 (m, 1H), 4.81-4.83 (m, 1H), 6.90-7.28 (m, 4H), 7.50-7.66 (m, 1H), 7.64-7.76 (m, 1H), 8.03-8.15 (m, 1H).
Example 64:
(R)-N-(1 -(1 -{1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)-5-(difluoromethoxy)-2-fluorobenzamide
3.5 mg, 6.7% yield, white solid.
LCMS (ESI): m/z = 507.2 [M+Hf.
’H-NMR (400 MHz, CD3OD): δ = 0.67-0.98 (m, 6H). 1.73-1.79 (m, 1H), 1.88-1.91 (m, 1H), 1.95-2.09 (m, 3H), 3.33 (s, 1H), 3.11 (s, 2H), 3.48-3.54 (m, 1H), 3.93-3.96 (m, 1H), 4.16-4.28 (m, 1H), 4.37-4.52 (m, 1H), 4.79-4.88 (m. 1H), 6.63-6.81 (m, 1H), 6.99-7.06 (m, 1H), 7.21-7.32 (m, 2H), 7.48-7.55 (m, 1H), 7.687.78 (m, 1H), 8.03-8.15 (m, 1H), 8.26-8.31 (m, 1H).
Example 65:
(R)-N-(1-(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5Idecan-8-yl)-3-methyl-1oxobutan-2-yl)-2,5-dichlorobenzamide
XRX-100601 -00-001
41.2 mg, 29% yield, white solid.
LCMS (ESI): m/z = 571.1,573.1 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.63-1.00 (m, 6H), 1.68-2.23 (m, 5H), 3.10 (s, 3H), 3.32-3.51 (m, 1H),
3.92-3.98 (m, 1H), 4.17-4.50 (m, 2H), 4.72-4.77 (m, 1H). 7.14-7.21 (m, 2H), 7.26-7.35 (m, 1H), 7.43-7.46 (m, 1H), 7.53-7.76 (m, 2H), 8.03-8.15 (m, 1H).
Example 66:
(R)_N-(1-(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2,5-difluorobenzamide hn-n
XRX-100502-00-001
20.9 mg, 31.3% yield, white solid.
LCMS (ESI): m/z = 539.1 [M+H]+.
’H-NMR (400 MHz, CD3OD): δ = 0.67-0.98 (m, 6H), 1.72-1.80 (m, 1H), 1.88-1.95 (m, 1H), 2.08-2.24 (m, 3H), 3.10 (s, 1H), 3.46-3.53 (m, 1H), 4.15-4.29 (m, 1H), 4.48-4.52 (m, 1H), 4.80-4.81 (m, 1H), 4.90-4.91 (m, 1H), 7.00-7.07 (m, 4H), 7.65-7.74 (m, 1H), 8.03-8.15 (m, 2H).
Example 67:
(R)-N -( 1 -(1 -(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)-1 -admantanecarboxly amide
HN
XRX-100503-00-001
2.5 mg, 10.3% yield, white solid.
LCMS (ESI): m/z = 561.3 [M+Hf.
1H-NMR (400 MHz, CD3OD); δ = 0.58-0.88 (m, 6H), 1.45-1.92 (m, 20H), 3.32 (s, 3H), 3.43-3.53 (m, 1H), 3.85-3.93 (m, 1H), 4.05-4.25 (m, 1H), 4.38-4.55 (m, 1H), 4.84-4.88 (m, 1H), 7.00-7.12 (m, 1H), 7.22-7.29 (m, 1H), 7.62-7.67 (m, 1H), 8.13-8.14 (m, 1H).
Example 68:
(RJ-N-fl^l-flH-Indazol-S-yO-S-methyl^^-dioxo-I.S.S-triazaspiro^.SJdecan-e-yO-S-methyl-loxobutan-2-yl)-2-chloro-5-(trifluoromethyl)benzamide
XRX-1 00605-00-001 mg, 67% yield, white solid.
LCMS (ESI): m/z = 605.1,607.1 [M+H]4.
1H-NMR (400 MHz, CD3OD): δ = 0.99-0.66 (m, 6H), 1.71-1.80 (m, 1H), 2.00-2.28 (m, 4H), 3.12 (s, 3H),
3.48-3.58 (m, 1H), 3.94-4.05 (m, 1H), 4.34-4.54 (m, 2H), 4.74-4.82 (m, 1H), 7.18-7.34 (m, 1H), 7.40-7.45 (m. 1H), 7.68-7.78 (m, 3H), 8.00-8.16 (m, 1H).
Example 69:
(S)-N-(1 -(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
81.1 mg, 57% yield, white solid.
LCMS (ESI): m/z = 589.2 [M+Hf.
Ή-NMR (400 MHz, CD3OD): δ = 0.67-0.99 (m, 6H), 1.74-2.16 (m, 5H), 3.11 (s, 3H), 3.48-3.55 (m, 1H), 3.94-4.52 (m, 3H), 481-4.89 (m, 1H), 7.16-7.21 (m, 1H), 7.28-7.41 (m, 1H), 7.52-7.54 (m, 1H), 7.66-7.68 (m, 1H), 7.76-7.87 (m, 2H), 7.99-8.02 (m, 1H).
Example 70:
N-ia-fl-tlH-Indazol-S-yO-a-methyl^^-dioxo-I^.S-triazaspfro^.Sldecan-e-ylJ-Z-oxoethylJ^-fluoro-S(trifluoromethyl)benzamide
14.9 mg, 15% yield, white solid.
LCMS (ESI); m/z = 547.1 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 1.80-2.13 (m, 5H), 3.10 (s, 3H), 3.42-3.61 (m, 1H), 3.83-3.91 (m, 2H), 4.21-4.23 (m, 2H), 4.39-4.49 (m, 1H), 7.20-7.23 (m, 1H), 7.34-7.40 (m, 1H), 7.60-7.63 (m, 1H). 7.71-7.72 (m, 1H), 7.82-7.83 (m, 1H), 8.09-8.11 (m, 2H).
Example 71:
M-(14141 H-lndazo!-5-yl)-3-methyl-2,4-dioxo-1,3l8-triazaspiro[4.5]decane-8- carbonyljcyclopropyl)-
2-f1uoro-5-(trifluoromethyl)benzamide
HN-N
36.8 mg, 11% yield, white solid.
LCMS (ESI): m/z = 573.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 1.26-1.36 (m, 4H). 1.76-1.84 (m, 2H), 2.10-2.13 (m, 2H), 3.10 (s, 3H), 3.59-3.80 (m, 2H), 4.31-4.35 (m, 2H), 7.15-7.22 (m, 2H), 7.48-7.50 (m, 1H), 7.64-7.65 (m, 1H), 7.76-7.83 (m. 2H), 8.01 (s, 1H).
Example 72:
(R)_N-{1 4141 H-indazol-5-yl)-3-methyi-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8- yl)-1 -oxopropan-2yl)-2-fluoro-5-(trifluoromethyl)benzamide
22.2 mg, 14% yield, white solid.
LCMS (ESI): m/z = 561.1 [M+H]*.
1H-NMR (400 MHz, CDaOD): δ = 1.23-1.37 (m, 3H), 1.78-2.13 (m, 4H), 3.11 (s, 3H), 3.50-3.53 (m, 1H),
3.96-4.08 (m, 2H), 4.46-4.49 (m, 1H), 5.02-5.04 (m, 1H), 7.22-7.29 (m, 1H), 7.41-7.59 (m, 1H), 7.717.78.(m, 1H), 7.86-7.91 (m, 2H), 8.07-8.15 (m, 2H).
Example 73:
N-(3-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carbonyl)oxetan-3-yl)-2fluoro-5-(trifluoromethy1)benzamîde
4.8 mg, 6% yield, yellow solid.
LRMSm/i= 588 [M+Hf.
’H-NMR (400 MHz, DMSO-de): δ = 8.61 (s, 1H), 8.51 (d, J= 8.7 Hz, 1H), 8.27 (d, J = 3.7 Hz, 1H), 8.158.09 (m, 1H), 7.94 (d, J= 1.4 Hz, 1H), 7.71 (t, J= 9.0 Hz, 1H), 7.65 (dd, J = 8.7, 1.9 Hz, 1H), 4.76 (dd, J = 16.3, 6.0 Hz, 2H), 4.29 (dd, J = 28.0, 6.2 Hz, 2H), 3.64-3.44 (m, 2H), 3.28 (m, 2H), 3.01 (s, 3H), 2.21-2.08 (m, 2H), 1.79-1.58 (m, 2H).
Example 74:
N_0 -(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-2-methyl-1oxopropan-2-yl)-2-f1uoro-5-(trifluoromethyl)benzamide
23.8 mg, 14% yield, white solid.
LCMS (ESI): m/z = 597.1 [M+Naf.
iH-NMR (400 MHz, CD3OD): Ô= 1.47 (s, 6H), 1.68-1.84 (m, 2H), 2.01-2.05 (m, 2H), 3.06 (s, 3H), 3.553.87 (br, 2H), 4.39-4.50 (m, 2H), 7.03-7.06 (m, 1H), 7.29-7.42 (m, 2H), 7.53-7.54 (m, 1H), 7.67-7.69 (m, 1H), 7.81-7.84 (m, 1H), 7.93-7.94 (m, 1H).
Example 75:
(R)-N-(1-(1-(Cyclopropylmethyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
Représentative scheme:
NHjHCl
KCN, MeOH/water
°c îicl
1) ''N'^O DCM. 0°C
2) HCl. EtOH
3) Pd/C, MeOH
4) (BocfeO, K2CO3,
CH3I
DMF, NaH, r.t
1) HCl, dioxane
Example 28-f
HATU, DCM, DIPEA, r.t
Représentative general procedure:
1-Benzyl-4-(cyclopropylmethylamino)piperidine-4-carbonitrile
CN
XRX-100267-00-001 -a
To a mixture of cyclopropylmethanamine hydrochloride (500 mg, 4.7 mmol) in methanol : water (9:1,50 mL) was added 1-benzylpiperidin-4-one (700 mg, 3.7 mmol) and potassium cyanide (200 mg, 3.0 mmol). The resulting mixture was stirred ovemight. The reaction was quenched with aqueous potassium carbonate (10%, 30 mL). The resulting mixture was extracted with ethyl acetate (3 * 100 mL). The combined organic layers were dried over with anhydrous sodium sulfate The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 10:1 to afford l-benzyl-4-(cyclopropylmethylamino)piperidine-4-carbonitrile as a yellow oil (450 mg, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 377.2 [M+Hf.
tert-Butyl-1-(cyclopropylmethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
BocN
XRX-100267-00-001-b
To a solution of 1-benzyl-4-(cyclopropylmethylamino)piperidine-4-carbonitrile (450 mg, crude) in dichloromethane was added chlorosulfonyl isocyanate (300 mg, 2.11 mmol) at 0°C. After stirring for 30 minutes at 0°C, the reaction was quenched with a 5% aqueous hydrochloric acid solution (5 mL). The solvent was removed under reduced pressure and éthanol (10 mL) was added. The mixture was stirred for 30 minutes at 80°C. The solvent was removed under reduced pressure. The residue was dissolved in methanol. After stirring for 5 minutes, 5% palladium on carbon (150 mg, 50% wet with water) was added. The resufting mixture was stirred under a hydrogen atmosphère for 1 hour. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was added to tetrahydrofuran (20 mL) and the pH was adjusted to 8 by addition of aqueous potassium carbonate (15%). Then di-fert-butyl-dicarbonate (300 mg, 1.37 mmol) in tetrahydrofuran (20 mL) was added. After stirring ovemighi, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 10:1 to afford tert-butyl-1(cyclopropylmethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a yellow oil (200 mg, 13% over two steps).
LCMS (ESI): m/z = 324.2 [M+Hf. tert-Butyl-l-icyclopropylmethyO-a-methyl-Z^-dioxo-l^.e-triazaspiro^.Sldecane-e-carboxylate
BocN
XRX-100267-00-001 -C
To a solution of tert-butyl-1-(cyclopropylmethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (200 mg, 0.61 mmol) in N,N-dimethylfomnamide (2 mL) was added sodium hydride (50 mg, 60% in oil, 1.30 mmol) at 0°C. After stirring for 15 minutes, iodomethane (100 mg, 0.74 mmol) was added. The resulting mixture was stirred for 15 minutes at room température and the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-HPLC (acetonitrile and water, acetonitrile from 5% to 50%) to afford tert-butyl-l-(cyclopropylmethyl)-
3-methyl-2,4-dioxo-1,3,8-triazaspiro(4.5]decane-8-carboxylate as a white solid (110 mg, 52%).
LCMS (ESI): m/z = 338.2 [M+Hf.
1H-NMR (300 MHz, CDCb): δ = 0.29-0.35 (m, 2H), 0.46-0.57 (m, 2H), 1.45 (s, 9H), 1.56-1.69 (m, 3H), 1.83-1.94 (m, 2H), 2.98 (s, 3H), 3.08 (d, J= 6.9 Hz, 2H), 3.37-3.56 (m, 2H), 3.96-4.12 (m, 2H).
(R)-N-(1-(1-(Cyclopropylmethyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fïuoro-5-(trif1uoromethyl)benzamide
A solution of fert-butyi-1-(cyclopropylmethyl)-3-methyi-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (110 mg, 0.35 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The solvent was removed under reduced pressure. To the residue was added dichloromethane (5 mL), (R)-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Exampie28-f) (100 mg, 0.34 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxide hexafluorophosphate (HATU) (150 mg, 0.39 mmol) and N,N-diisopropylethylamine (150 mg, 1.16 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (5 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-N(1-(1-(cyclopropylmethyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methy!-1-oxobutan-2-yl)-
2-fluoro-5-(trifluoromethyl)benzamide as a white solid (44.6 mg, 24%).
LCMS (ESl): m/z = 527.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 0.29-0.33 (m, 2H), 0.46-0.54 (m, 3H), 1.04-1.11 (m, 6H), 1.75-1.84 (m, 2H), 1.95-2.05 (m, 1H), 2.15-2.19 (m, 1H), 2.35-2.41 (m, 1H), 3.01 (s, 3H), 3.17-3.20 (m, 2H), 3.42-3.48 (m, 1H), 3.92-3.95 (m, 1H), 4.11-4.33 (m, 1H), 4.57-4.60 (m, 1H), 4.90-4.95 (m, 1H), 7.41-7.48 (m, 1H). 7.91 (s, 1H), 8.04-8.06 (m, 1H), 8.56 (s, 1H).
The following 5 compounds were synthesized following the general procedure described above: Example 76: (R)-N-(1-(1-Cyclopropyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-
2-yl)-2-fluoro-54trifluoromethyl)benzamide
XRX-100262-00-001
137.2 mg, yield: 12%, white solid.
LCMS (ESl): m/z = 513.1 [M+H]'.
1H-NMR (400 MHz, CD3OD): δ = 0.78-0.91 (m, 4H), 1.03-1.11 (m, 6H), 1.80-1.97 (m, 2H), 2.14-2.48 (m,
4H), 2.97 (s, 3H), 3.46-3.52 (m, 1H), 3.93-3.99 (m, 1H), 4.32-4.34 (m, 1H), 4.57-4.61 (m, 1H), 4.95-5.01 (m, 1H), 7.45-7.50 (m, 1H), 7.89-7.90 (m, 1H), 8.03-8.05 (m, 1H), 8.60 (m, 1H).
Example 77:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
XRX-100288-00-001
7.8 mg, yield: 4%, white solid.
LCMS (ESI): m/z = 557.2 (M+H]+.
1H-NMR (400 MHz, CDaOD): δ = 1.05-1.12 (m, 6H), 1.47-1.57 (m, 2H), 1.75-2.02 (m, 3H), 2.12-2.28 (m, 1H), 2.37-2.68 (m, 3H), 2.96 (s, 3H), 3.50-3.53 (m, 4H), 3.88-4.06 (m, 3H), 4.28-4.36 (m, 1H), 4.54-4.66 (m, 1H), 4.87-5.00 (m, 1H). 7.47-7.60 (m, 1H), 7.90-7.92 (m, 1H), 7.95-7.89 (m, 1H).
Example 78:
2-Fluoro-N-((R)-3-methyl-1-(3-methyl-2,4-dioxo-1-((S)-1-phenylethyl)-1,3,8-trîazaspiro[4.5]decan-8yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
XRX-100290-00-001
45.0 mg, yield: 36%, white solid.
LCMS (ESI); m/z = 577.2 [M+H]\
Ή-NMR (400 MHz, CDsOD): δ = 1.02-1.15 (m, 6H), 1.77-2.23 (m, 8H), 3.00 (s, 3H), 3.41-3.47 (m, 1H),
3.91-3.97 (m, 1H), 4.29-4.32 (m, 1H), 4.49-4.68 (m, 2H), 4.87-4.94 (m, 1H), 7.21-7.50 (m, 5H), 7.88-8.08 (m, 2H), 8.47-8.59 (m, 1H).
Example 79:
(R)-2-FIuoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
XRX-100334-00-001
71.7 mg, yield: 42%, white solid.
LCMS (ESI): m/z = 571.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.04-1.11 (m, 6H), 1.12-1.14 (m, 1H), 1.27-1.30 (m, 2H), 1.61-1.67 (m,
2H), 1.17-2.08 (m, 5H), 2.37-2.44 (m, 1H), 2.99 (s, 3H), 3.12-3.17 (m, 2H), 3.30-3.46 (m, 2H), 3.90-3.97 (m, 3H), 4.30-4.33 (m, 1H), 4.58-4.61 (m, 1H), 4.96-4.98 (m, 2H), 7.45-7.50 (m, 1H), 7.09-7.92 (m, 1H), 8.06-8.07 (m, 1H).
Example 80:
2-Fluoro-N-((R)-3-methyl-1-(3-methyl-2,4-dioxo-1-{(R)-1-phenylethyl)-1,3,8-triazaspiroi4.5]decan-8yl)-1 -oxobutan-2-yl)-5-(trifluoromethyl)benzamide
XRX-100342-00-001
16.0 mg, yield: 14%, white solid.
LCMS (ESI): m/z = 577.2 [M+H]‘.
1H-NMR (400 MHz, CD3OD): δ= 0.95-1.14 (m, 6H), 1.69 (m, 1H), 1.87 (m, 5H), 2.17 (m, 1H), 2.25-2.43 (m, 1H), 3.04 (s, 3H), 3.37-3.61 (m, 1H), 3.90-4.22 (m, 2H), 4.43 (m, 1H), 4.62 (m, 1H), 5.08 (m, 1H), 7.27.61 (m, 7H), 7.72-7.84 (m, 1H), 8.29-8.43 (m, 1H).
Example 81:
(R)-N-(1-(1-{4-(Azetidin-3-ylmethoxy)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait
TFA
Représentative scheme:
OH
Example ÎS-f
HATLI. DI PEA, OCM. r.t
TFA.DCM
Représentative general procedure: tert-Butvl-4-cvano-4-(4-methoxvphenvlamino)piperidine-1-carboxvlate
XRX-100111 -04-01 -a
To a solution of 4-methoxyaniline (2 g, 16 mmol) in acetic acid (20 mL) was added iert-butyl-4oxopiperidine-1-carboxylate (3.5 g, 17.5 mmol). The resulting mixture was cooled to 0°C and trimethylsilyl cyanide (1.9 g, 19 mmol) was added. The solution was stirred ovemight at room température. Saturated aqueous ammonium chloride solution was added (50 mL). The mixture was extracted with ethyl acetate (3 x 50 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : petroleum ether = 1:1 to afford tert-butyl-4-cyano-4-(4-methoxyphenylamino)piperidine1-carboxylate as a white solid (5.0 g, 86%).
LCMS (ESI): m/z = 332.2 (M+Hf.
1H-NMR (300 MHz, DMSO-de): δ = 1.40 (s, 9H), 1.65-1.89 (m, 2H), 2.06-2.19 (m, 2H), 3.01-3.21 (m, 2H) 3.68 (s, 3H), 3.72-3.88 (m, 2H), 5.50 (s, 1H), 6.80 (d, J = 9 Hz, 2H), 6.90 (d, J = 9 Hz, 2H).
tert-Butyl-1-(4-methoxyphenyl)-2,4-dioxo-1,3,8-trîazaspiro[4.5]decane-8-carboxylate
XRX-100111 -04-001 -b
To a solution of tert-butyl-4-cyano-4-(4-methoxyphenyl amino)piperidine-1-carboxylate (2.0 g, 6 mmol) in dichloromethane was added chlorosulfonyl isocyanate (2.3 g, 16 mmol) at 0°C. After stirring for 30 minutes at 0°C, the reaction was quenched with a 5% aqueous hydrochloric acid solution (2 mL). The solvent was removed under reduced pressure and éthanol (10 mL) was added. The mixture was stirred for 30 minutes at 80°C. The solvent was removed under reduced pressure and the residue was dissolved in tetrahydrofuran (20 mL) and the pH of the mixture was adjusted to pH 8 by addition of a 10% aqueous potassium carbonate solution. Then di-fert-butyl-dicarbonate (2.5 g, 11 mmol) in tetrahydrofuran (20 mL) was added. After stirring ovemight, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with ethyl acetate ; petroleum ether= 10:1 to afford tert-butyl-1-(4-methoxyphenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (1.02 g, 45%).
LCMS (ESI): m/z = 376.2 IM+Hf.
tert-Butyl-1-(4-methoxypheny1)-3-methyl-2,4-dioxo-1,3,8-triazaspîro[4.5]decane-8-carboxylate
XRX-100111 -00-001 -c
To a solution of tert-butyl-1-(4-methoxyphenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (1.0 mg, 2.6 mmol) in N,N-dimethylformamide (10 mL) was added sodium hydride (0.2 g, 60% in oil, 5.2 mmol) at 0°C. After stirring for 15 minutes, iodomethane (0.37 g, 6 mmol) was added. The resulting mixture was stirred for 15 minutes. The reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 χ 50 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:3 to afford tert-butyl-1-(4-methoxyphenyl)-
3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (140 mg, 67%).
LCMS (ESI): m/z = 390.2 [M+H]’.
1H-NMR (300 MHz, CDCb): δ = 1.39 (s, 9H), 1.62-1.86 (m, 4H), 3.09 (s, 3H). 3.39-3.56 (m, 2H), 3.86 (s, 3H), 3.89-4.00 (m, 2H), 3.78-3.82 (m, 2H). 6.94 (d, J = 9 Hz, 2H), 7.07 (d, J = 9 Hz, 2H).
Benzyl-1-(4-hydroxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
XRX-100111 -04-001 -d
To a solution of fert-butyl-1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (1.0 g, 2.5 mmol) in dichloromethane (50 mL) was added boron tribromide (4 g, 15 mmol) at 0°C. After stirring ovemight, the reaction was quenched by addition of ice-water (5 mL). To the mixture were added benzyl chlorofonmate (1.56 g, 3.6 mmol) and a 10% aqueous sodium hydroxide solution (12 mL). The mixture was stirred for 2 hours. The organic layer was separated and discarded. The pH of the aqueous layer was adjusted to 2 by addition of 10% aqueous hydrochloric acid solution. The resulting mixture was extracted with dichloromethane (3 * 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was washed with ethyl acetate (30 mL) to afford benzyl-1-(4-hydroxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate as a white solid (620 mg, 59%)
LCMS (ESI): m/z = 410.1 [M+H]+.
Benzyl-1-(4-((1-{tert-butoxycarbonyl)azetidin-3-yl)methoxy)phenyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate
To a solution of benzyl-1-(4-hydroxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (150 mg, 0.367 mmol) in N,N-dimethylfomnamide (15 mL) was added potassium hydride (50 mg, 1.25 mmol) at 0°C. After stirring for 30 minutes at 0°C, to the resulting solution was added terf-butyl-
3-((methylsulfonyloxy)methyl)azetidine-1-carboxylate (243 mg, 0.917 mmol). The resulting mixture was stirred ovemight before the reaction was quenched by addition of ice-water (10 mL). The mixture was extracted with ethyl acetate (3 * 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC (dichloromethane : methanol = 20:1) to afford benzyl-1-(4-((1-(fert-butoxycarbonyl)azetidin-3yl)methoxy)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a coloriess oil (130 mg, 71%).
LCMS (ESI): m/z = 579.2 IM+H]+.
tert-Butyl-3-((4-(3-methyl-2,4-<iioxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenoxy)methyl)azetidine-1carboxylate
N H
XRX-100111-04-001-f
NBoc
To a solution of benzyl-1 -(4-((1 -(fert-butoxycarbonyl)azetidin-3-yl)methoxy)phenyl)-3-methyt-2,4-dioxo-
1,3,8-triazaspiro[4.5]decane-8-carboxylate (130 mg, 0.225 mmol) in methanol (10 mL) was added 5% palladium on carbon (70 mg). The resulting mixture was stirred for 1 hour under a hydrogen atmosphère. The catalyst was removed by filtration and the solvent was removed under reduced pressure to afford fert-butyl-3-((4-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenoxy)methyl)azetidine-1carboxylate as a white solid (31 mg, 100%).
LCMS (ESI): m/z = 445.2 [M+Hf.
(R)-fert-Butyl-3-{(4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2)4dioxo-1,3,8-t ri azaspiro[4.5]decan-1-yl)phenoxy)methyl)azetidine-1-carboxylate
Boc
To a solution of terf-butyl-3-((4-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl) phenoxy)methyl)azetidine-1 -carboxylate (107 mg, 0.240 mmol) in dichloromethane (10 mL) was added (R)-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (80 mg, 0.247 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (128 mg, 0.337 mmol) and N,N-diisopropylethylamine (44 mg. 0.337 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford <R)-tert-butyl-3-((4-(8-(2-(2fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1yl)phenoxy)methyl)azetidine-1-carboxylate as a white solid (80 mg, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 734.1 [M+Hf.
(R)-N-(1-(1-(4-(Azetidin-3-ylmethoxy)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyi-1-oxobutan-2-yl)-2-fluoro-5-(triftuoromethyl)benzamide trifluoroacetic acid sait
To a solution of (R)-ferf-butyl-3-((4-(8-(2-(2-fiuoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenoxy)methy!)azetidine-1-carboxylate (80 mg, crude) in dichloromethane (10 mL) was added trifluoroacetic acid (2 mL). The resulting mixture was stirred for 2 hours. The solvents were removed under reduced pressure and the residue was purified by prep-HPLC (acetonitrile and water, acetonitrile from 30% to 70%) to afford (R)-N-(1-(1-(4-(azetidin-3ylmethoxy)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2fluoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait as a white solid (48 mg, 26% overtwo steps). LCMS (ESl): m/z = 634.0 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.82-1.01 (m, 6H), 1.67-2.11 (m, 5H), 3.09 (s, 3H), 3.38-3.51 (m, 2H), 3.97-4.44 (m, 9H), 4.83-4.90 (m, 1H), 7.18-8.50 (m, 8H).
The following 4 compounds were synthesized following the general procedure described above:
Example 82:
(Rj-N-(1-(1-(4-(cyanomethoxy)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
XRX-100080-00-001
60.3 mg, yield: 25%, white solid.
LCMS (ESl): m/z = 604 [M+H]\ 1H-NMR (400 MHz, CD3OD): δ = 0.79-1.01 (m, 6H), 1.77-2.12 (m, 5H), 3.09 (s, 3H), 3.31-3.33 (m, 1H), 3.95-4.51 (m, 3H), 4.85-4.97 (m, 2H), 5.07 (s, 1H), 7.06-7.46 (m, 5H), 7.87-8.01 (m, 2H), 8.50-8.53 (m, 1H).
Example 83:
(R)-2-Fluoro-N-(3-methyl-1-{3-methyl-1-(4-(oxetan-3-ylmethoxy)phenyl)-2l4-dioxo-1l3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
43.0 mg, yield: 51%, white solid.
LCMS (ESI): m/z = 635 [M+H]\ 1H-NMR (400 MHz, CDsOD): δ = 0.82-1.02 (m, 6H), 1.31-2.20 (m, 6H), 3.08 (s, 3H), 3.41-3.53 (m, 2H),
3.92-3.98 (m, 1H), 4.12-4,64 (m, 6H), 4.85-4.92 (m, 2H), 6.96-8.51 (m, 8H).
Example 84:
(R)-2-Fluoro-N-(1-{1-{4-{2-hydroxyethoxy)phenyl)-3-methyl-2,4-dioxo-1,3)8-triazaspiro[4.5ldecan-8y|)-3-methyl-1-oxobutan-2-yl)-5-(t!ïfiuoromethyl)benzamide
45.0 mg, yield: 19%, white solid.
LCMS (ESI): m/z = 609.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 0.80-1.01 (m, 6H), 1.67-1.88 (m, 2H), 2.05-2.18 (m, 3H), 3.08 (s, 3H), 3.49-3.51 (m, 1H), 3.86-4.05 (m, 4H), 4.11-4.16 (m, 1H), 4.22-4.28 (m, 1H), 4.45 (m, 1H), 4.86-5.01 (m, 1H), 6.94-7.00 (m, 1H), 7.06-7.22 (m, 3H). 7.44-7.49 (m, 1H), 7.94-8.03 (m, 2H).
Example 85:
(R)-N-(1-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5ldecan-8yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait
15.9 mg, yield: 20%, white solid.
LCMS (ESI): m/z = 635.7 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.80-1.01 (m, 6H), 1.66-1.83 (m, 1H), 2.04-2.17 (m, 4H),2.99 (s, 4H), 3.02 (s, 2H), 3.12 (s. 3H), 3.50-3.54 (m, 1H), 3.56-3.63 (m, 2H), 3.99-4.02 (m. 1H). 4.21-4.25 (m, 1H).
4.34-4.50 (m, 3H), 4.82-4.90 (m, 1H), 7.06-7.12 (m, 2H), 7.22-7.29 (m, 2H), 7.41-7.47 (m, 1H). 7.88-8.02 5 (m, 2H).
Example 86:
(R)_N-(1-(1-(4-(Azetidin-3-ylamino)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait
Représentative scheme:
Représentative general procedure: tert-Butyl-4-cyano-4-(4-nitrophenylamino)piperidine-1-€arboxylate
CN ï—NH
BocN
BocN
NO2
XRX-100164-04-001 -a
To a solution of 4-nitroaniline (5 g. 0.036 mol) in acetic acid (80 ml_) was added tert-butyl-4-oxopiperidine1-carboxylate (7.93 g, 0.0399 mol). The resulting mixture was cooled to 0°C and trimethylsilyl cyanide (4.3 g, 0.043 moi) was added, The resulting solution was stirred ovemight at room température. To the solution was added saturated aqueous ammonium chloride solution (50 mL). The mixture was filtered and the filter cake was recrystallized from ethyl acetate to afford fe/t-butyl-4-cyano-4-(4nitrophenyiamino)piperidine-1-carboxylate as a white solid (4 g, 32%).
LCMS (ESI): m/z = 347.2 [M+H]4.
fert-Butyl-1-(4-nitrophenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
O.
BocN
NO2
XRX-1 00164-04-001 -b
To a solution of tert-butyi-4-cyano-4-(4-nitrophenyiamino)piperidine-1-carboxylate (3.8 g, 0.0109 mol) in dichloromethane was added chlorosuifonyl isocyanate (3.8 g, 0.026 mol) at 0°C. After stirring for 30 minutes at 0°C, the reaction was quenched with a 5% aqueous hydrochtoric acid solution (5 mL). The solvent was removed under reduced pressure and éthanol (20 mL) was added. The mixture was stirred for 30 minutes at 80°C. The solvent was removed under reduced pressure and the residue was added to dichloromethane (20 mL). To the resulting suspensions was added sequentially triethylamine (4.4 g, 0.044 mol), di-fert-butyl-dicarbonate (2.39 g, 0.011 mol). After stirring ovemight, the solvent was removed and the residue was recrystallized from ethyl acetate : petroleum ether = 1:2 to afford fert-butyl-1-(4nitrophenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a yellow oil (2.2 g, 52%).
LCMS (ESI): m/z = 391.2 [M+H]4.
tert-Butyl-3-methyl-1-(4-rtitrophenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
XRX-100164-04-001-C
To a solution of tert-butyl-1-(4-nitrophenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5ldecane-8-carboxylate (2.2 g, 5.64 mmol) in N,N-dimethylformamide (15 mL) was added sodium hydrïde (0.237 g, 60% in oil, 6.2 mmol) at 0°C. After stirring for 15 minutes, iodomethane (961 mg, 6.77 mmol) was added. The resulting mixture was stirred for 15 minutes at room température and the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 * 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was recrystallized from ethyl acetate : petroleum ether = 1:2 to afford tert-butyî-3-methyl-1-(4-nitrophenyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxy!ate as a yellow solid (1.66 g, 70%).
LCMS (ESI): m/z = 405.1 [M+H]*.
3-Methyl-1 -{4-nitrophenyl)-1,318-triazaspiroi4.5]decane-2,4-dione hydrochloride
XRX-100164-04-001-d
A solution of fert-butyl-3-methyl-1-(4-nitrophenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (800 mg, 1.98 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 3-methyl-1-(4nitrophenyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride as a white solid (700 mg, some residual solvent), which was used directly without further purification.
LCMS (ESI): m/z = 305.1 IM+Hf.
Benzyl-3-methyl-1-(4-nttrophenyl)-2,4-dioxo-1,3,8-triazaspiro(4.5]decane-8-carboxylate
XRX-100164-04-001-e
To a solution of 3-methyl-1-(4-nitrophenyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (700 mg, 2.05 mmol) in dichloromethane (10 mL) was added sodium carbonate (652 mg, 6.5 mmol) and water (10 mL). To the mixture was added benzyi chloroformate (350 mg, 2.05 mmol) dropwise. The resulting mixture was stirred for 1 hour at room température and the reaction was quenched with ice-water (10 mL). The mixture was extracted with dichloromethane (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was recrystallized from ethyl acetate : petroleum ether = 1 : 2 to afford benzyl-3-methyl-1-(4-nitrophenyl)-2,4dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a yellow solid (810 mg, 90%).
LCMS (ESI): m/z = 439.1 [M+Hf.
Benzyl-1-(4-aminophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
XRX-100164-04-001 -f
To a solution of benzyt-3-methyl-1-(4-nitrophenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (100 mg, 0.28 mmol) in éthanol (10 mL) was added Raney-Ni (0.1 g, 50% in éthanol). After heating to 50°C, to the resulting mixture hydrazine (0.1 g, 2.5 mmol) was added dropwise. Before removing the Raney-Ni by filtration, the reaction mixture was stirred at 50°C for 30 minutes. The solvent was removed under reduced pressure and the residue was used directly without further purification.
Benzyl-1 -(4-(1 -{tert-butoxycarbonyl)azetidin-3-ylamino)phenyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate
NH
BocN—1
XRX-100164-04-001-g
To a solution of tert-butyl-3-oxoazetidine-1-carboxylate (59 mg, 0.343 mmol) and benzyl-1-(4aminophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (140 mg, 0.68 mmol) in dichloromethane (30 mL) was added titaniumisopropoxide (178 mg, 0.68 mmol). The resulting mixture was heated at reflux ovemight. After cooling to room température, to the resulting solution was added sodium triacetoxyborohydride (210 mg, 1.0 mmol). The reaction was stirred for 2 hours. The reaction was quenched with an aqueous sodium hydroxide solution (1.0 M, 10 mL). The mixture was extracted with ethyl acetate (3 χ 10 mL). The combined organic layers were dried overanhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC (ethyl acetate : petroleum ether = 1:1) to afford benzyl-1-(4-(1-(tert-butoxycarbonyl)azetidin-3-ylamino)phenyl)-3-methyl-2,4-dioxo-
1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (30 mg, 15%).
ίθΓί-ΒυίνΙ-3-(4-(3-π)βίΙιν1-2,4-άΐοχο-1,3,8-ίΠ3Ζ35ρΪΓθ[4.5]άβε3η-1-νΙ)ρΙιβηνΐ3πυηο)3Ζβίΐ£ϋηθ-1 carboxylate
XRX-100164-04-001-h
To a solution of benzyl-1-(4-(1-(tert-butoxycarbonyl)azetidin-3-ylamino)phenyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (120 mg, 0.213 mmol) in methanol (10 mL) was added 5% palladium on carbon (10 mg, 50% wet with water). The resulting mixture was stirred under a hydrogen atmosphère for 1 hour. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure to afford terf-butyl-3-(4-(3-methyI-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1yl)phenylamino)azetidine-1-carboxylate as a thick oil (90 mg, crude), which was used directly without any further purification.
(R)-tert-Butyl-3-(4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenylamino)azetidine-1-carboxylate
NH
BocN—J
To a solution of fert-butyl-3-(4-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl) phenylamino)azetidine-1-carboxy!ate (90 mg, 0.21 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (65 mg, 0.21 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-
3-oxide hexafluorophosphate (HATU) (260 mg, 0.68 mmol) and N.N-diisopropylethylamine (180 mg, 1.36 mmol). The resulting mixture was stirred for 2 hours at room température beforethe reaction was quenched with ice-water. The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane ; methanol = 15:1 to afford (R)-tert-butyl-3-(4-(8(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)phenylamino)azetidine-1-carboxylate as a white solid (50 mg, 33%).
LCMS (ESI): m/z = 719.0 [M+Hf.
(R)-N-(1-(1-(4-(Azetidin-3-ylamino)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait
To a solution of (R)-tert-butyl-3-(4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenylamino)azetidine-1-carboxylate (50 mg, 0.21 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (2 mL) at 0°C. The reaction was stirred 3 hours at room température. The solvent was removed under reduced pressure and the residue was purified by prep-HPLC (acetonitrile and water, acetonitrile from 30% to 60%) to afford (R)-N-(1-(1-(4(azetidin-3-ylamino)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5Jdecan-8-yl)-3-methyl-1-oxobutan-2yl)-2-fluoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait as a white solid (17.8 mg, 35%).
LCMS (ESI): m/z = 619.0 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.80-1.01 (m, 6H), 1.68-2.03 (m, 6H), 3.07 (s, 3H), 3.45-3.52 (m, 1H), 3.93-4.46 (m, 7H), 4.83-4.85 (m, 1H), 6.58-6.69 (m, 2H), 7.01-7.07 (m, 2H), 7.41-7.46 (m, 1H), 7.87-8.00 (m, 2H), 8.48-8.53 (m, 1 H).
The following compound was synthesized following the general procedure described above: Example 87:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(4-(oxetan-3-ylamino)phenyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
NH
32.6 mg, yield: 43%, white solid
LCMS (ESI): m/z = 620.0 [M+Hf.
’H-NMR (400 MHz, CDCIa): δ = 0.80-1.01 (m, 6H), 1.67-2.03 (m, 5H), 3.06 (s. 3H), 3.42-3.48 (m. 1H), 3.94-4.53 (m, 7H), 4.88-5.01 (m, 2H), 6.47-6.62 (m, 2H), 6.93-7.01 (m, 2H), 7.41-7.46 (m, 1H), 7.86-7.95 10 (m, 2H).
Example 88:
(R)-N-{1 -(1 -(4-Cyanobenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-3-methyl-1 oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
Représentative scheme:
Représentative general procedure:
Benzyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
XRX-100294-00-001 -a
A mixture of benzyl-4-oxopiperidine-1-carboxylate (11.7 g, 50 mmol), potassium cyanide (4.87 g, 75 mmol) and ammonium carbonate (24 g, 250 mmol) in éthanol (100 mL), was placed in a stainless steel bomb and heated at 110°C ovemight. The reaction mixture was poured into ice-water (300 mL) and the resulting mixture was filtered. The pH of the mixture in water (100 mL) was adjusted to 2 by addition of an aqueous hydrochloric acid solution (6.0 M). The mixture was filtered and the filter cake was recrystallized from methanol : diethyl ether = 1:1 to afford benzyl-2,4-dioxo-1,3,8-triazaspiroI4.5]decane-8-carboxylate as a white solid (10.0 g, 66%).
LCMS (ESI): m/z = 304.1 (M+Hf.
1H-NMR (300 MHz, DMSO-d6): δ = 1.43-1.56 (m, 2H), 1.63-1.85 (m, 2H), 2.45-2.60 (m, 2H), 3.33 (s, 2H), 3.88 (dd, J= 9.7, 4.0 Hz, 2H), 5.09 (s, 2H), 7.20-7.53 (m, 5H), 8.54 (s, 1H), 10.66 (s, 1H).
Benzyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
XRX-100294-00-001 -b
To a solution of benzyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (3.03 g, 10 mmol) in N,Ndimethylformamide (20 mL), was added potassium carbonate (2.76 g, 20 mmol). Afterstimng for 15 minutes, iodomethane (1.42 g, 10 mmol) was added. Before quenching with ice-water (10 mL), the resulting mixture was stirred at room température ovemight. The mixture was extracted with dichloromethane (3 * 150 mL). The combined organic layers were dried overanhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 50:1) to afford benzyl-3-methyl-2,4-dioxo-1,3,8triazasprro[4.5]decane-8-carboxylate as a white solid (1.0 g, 32%).
LCMS (ESI): m/z = 318.1 [M+Hf.
1H-NMR (300 MHz, CDCh): δ = 1.57 (m, 2H), 1.70-1.85 (m, 2H), 2.84 (s, 3H), 3.24 (s, 2H), 3.84-3.90 (m, 2H), 5.10 (s, 2H), 7.29-7.45 (m, 5H), 8.81 (s, 1H).
Benzyl-144-cyanobenzyl)-3-methyl-2l4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of benzyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (110 mg, 0.347 mmol) in N.N-dimethylforrnamide (5 mL), was added césium carbonate (452 mg, 1.39 mmol), and 4(bromomethyl)benzonitrile (136 mg, 0.69 mmol). The resulting mixture was stirred at 80°C for 4 hours, before the reaction was quenched with ice-water (10 mL). The mixture was extracted with dichloromethane (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting (ethyl acetate : petroleum ether= 1:2) to afford benzyl-1-(4-cyanobenzyl)-3-methyl-2,4-dioxo-
1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (130 mg, 86%).
LCMS (ESI): m/z = 433.1 [M+H]1.
1H-NMR (300 MHz, CDCh): δ = 1.70 (m, 4H), 3.07 (s, 3H), 3.52 (s, 2H), 4.11 (dd, J= 14.3 Hz, J = 7.1 Hz, 2H), 4.48 (s, 2H), 5.11 (s, 2H), 7.33-7.42 (m, 2H), 7.55-7.66 (m, 2H).
4-((3-Methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)methyl)benzonitrile hydrobromide
XRX-100294-00-001 -d
To a solution of benzyl-1-(4-cyanobenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (130 mg, 0.3 mmol) in dichloromethane (1 mL) was added hydrobromic acid (2 mL, 38% in acetic acid) at 0°C. Then the reaction was warmed to room température and stirred for 2 hours. The solvent was removed under reduced pressure to afford 4-((3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1yl)methyl)benzonitrile hydrobromide as a white solid (100 mg, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 299.2 [M+H]1.
(R)-N-(1-{1-{4-Cyanobenzyl)-3-methyl-2,4-dioxo-1l3,8-triazaspîro(4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-f1uoro-5-(trifluoromethyl)benzamide
To the mixture of 4-((3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)methyl)benzonitrile hydrobromide (100 mg, crude) was added dichloromethane (5 ml_), (R)-2-(2-fIuoro-5(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (81 mg, 0.26 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (146 mg, 0.38 mmol) and N.N-diisopropylethylamine (83 mg, 0,64 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water. The mixture was extracted with dichloromethane (3 « 10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prepTLC with dichloromethane : methanol = 15:1 to afford (R)-N-(1-(1-(4-cyanobenzyl)-3-methyl-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide as a white solid (56 mg, 41%).
LCMS (ESI): m/z = 588.0 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.89-0.96 (m, 6H). 1.62-2.22 (m, 5H), 2.95 (s, 3H), 3.25-3.31 (m, 1H), 3.75-3.82 (m, 1H), 4.13-4.16 (m, 1H), 4.39-4.54 (m, 3H), 4.74-4.79 (m, 1H), 7.34-7.62 (m, 5H), 7.79-7.95 (m, 2H), 8.35-8.44 (m, 1H).
The followîng 38 compounds were synthesized following the general procedure described above:
Example 89:
(R)-N-(1-(1-Benzyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2 fluoro-5-(trifluoromethyl)benzamide
140.8 mg, yield: 57%, white solid.
LCMS (ESI): m/z = 562.9 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ= 1.00-1.06 (m, 6H), 1.65-1.87 (m, 3H), 2.05-2.17 (m, 1H), 2.30-2.38 (m, 1H), 3.07 (s, 3H), 3.32-3.33 (m, 2H), 3.37-3.44 (m, 1H), 3.87-3.93 (m, 1H), 4.12-4.27 (m, 1H), 4.45-4.72 (m, 2H), 7.21-7.33 (m, 5H), 7.42-7.51 (m, 1H), 7.87-8.10 (m, 2H), 8.50 (m, 1H).
Example 90:
(R)-2-Fluoro-N-(1-(1-(4-fluorobenzyl)-3-methyl-2,4-dioxo-1,3,84riazaspiro[4.5]decan-8-yl)-3-methyl·
1-oxobutan-2-yl)-5-(tri1luoromethyl)benzamide
XRX-100268-00-001
100.0 mg, yield: 45%, white solid.
LCMS (ESI): m/z = 581.1 [M+H]\ 1H-NMR (400 MHz, CD3OD): δ = 1.01-1.07 (m, 6H), 1.66-1.89 (m, 3H), 2.12-2.39 (m, 2H), 3.06 (s. 3H),
3.36-3.44 (m, 1H), 3.87-3.93 (m, 1 H), 4.11-4.32 (m, 1H), 4.48-4.65 (m, 3H), 4.85-4.90 (m, 1H), 6.95-7.10 (m, 2H), 7.37-7.47 (m, 3H), 7.91-8.06 (m, 2H), 8.53 (s, 1H).
Example 91:
(R)-2-Fluoro-N-(1-(1-(4-methoxybenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
XRX-100272-00-001
48.5 mg, yield: 40%, white solid.
LCMS (ESI): m/z = 593.2 [M+Hf.
Ή-NMR (400 MHz, CD3OD): δ = 1.01-1.06 (m, 6H), 1.60-2.38 (m, 5H), 3.32-3.39 (m, 2H), 3.79-3.84 (m,
3H), 3.89-3.93 (m, 1H), 4.11-4.26 (m, 1H), 4.42-4.66 (m, 2H), 6.77-6.90 (m, 2H), 7.24-7.26 (m, 2H), 7.417.53 (m, 1H), 7.44-7.51 (m, 1H), 7.87-7.90 (m, 1H), 8.10-8.12 (m, 1H).
Example 92:
2-Fluoro-N-((2R)-3-methyl-1-(3-methyl-2l4-dioxo-1-(1-phenylethyl)-1,3,8-triazaspiro[4.5]decan-8-yl)-
1-oxobutan-2-yl)-5-{trifluoromethyl)benzamide
XRX-100291 -00-001
27,9 mg, yield: 14%, white solid.
LCMS (ESI): m/z = 577.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.02-1.15 (m, 6H), 1.67-2.18 (m, 5H), 3.00 (s, 3H), 3.07 (s, 3H), 3.413.47 (m, 1H), 3.91-3.97 (m, 1H), 4.29-4.32 (m, 1H), 4.49-4.68 (m, 2H), 4.87-4.94 (m. 1H), 7.21-7.50 (m, 5H), 7.88-8.08 (m, 2H), 8.47-8.59 (m, 1H).
Example 93:
(R)-2-Fluoro-N-(3-methyl-1 -{3-methyl-1 -(4-{methylsulfonyl)benzyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
XRX-100293-00-001
37.5 mg, yield: 40%, white solid.
LCMS (ESI): m/z = 641.2 [M+Hf.
1H-NMR (400 MHz, CDsOD): δ = 0.99-1.07 (m, 6H), 1.75-2.32 (m, 5H), 3.13-3.17 (m, 6H), 3.87-3.93 (m,
1H), 4.25-4.28 (m, 1H), 4.51-4.54 (m, 1H), 4.75-4.65 (m, 2H), 4.84-4.90 (m, 2H), 7.65-7.61 (m, 3H), 8.06
8.08 (m, 3H), 8.47-8.59 (m. 1H).
Example 94:
(R)-2-Fluoro-N-{1-(1-((2-methoxypyridin-4-yl)methyl)-3-methyl-2t4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
XRX-100336-00-001
52.3 mg, yield: 20%, white solid.
LCMS (ESI): m/z = 594.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 1.01-1.07 (m, 6H), 1.83-2.15 (m, 5H), 2.65-2.94 (m, 1H), 3.08 (s, 3H), 3.33-3.44 (m, 1H), 3.94-3.97 (m, 4H), 4.25-4.27 (m, 1H), 4.55-4.64 (m, 2H), 4.84-4.88 (m, 1H), 6.96-7.11 (m, 2H), 7.45-7.47 (m, 1H), 7.91-8.10 (m, 3H).
Example 95:
(R)-2-Fluoro-N-(3-methyl-1 -{3-methyl-1 -((2-methylpyridin-4-yl)methyl)-2,4-dioxo-1,3,8triazaspiro[4.5ldecan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
XRX-100336-00-001
41.6 mg, yield: 43%, white solid.
LCMS (ESI): m/z = 578.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 1.02-1.08 (m, 6H), 1.86-2.24 (m, 5H), 2.73 (s, 3H), 3.09 (s, 3H), 3.433.47 (m, 1H), 3.90-3.96 (m, 1H), 4.26-4.30 (m, 1H), 4.57-4.60 (m, 1H), 4.79-4.84 (m, 3H), 7.45-7.48 (m, 1H), 7.87-8.02 (m, 4H), 8.58-8.65 (m, 1H).
Example 96:
(R)-N-(1-(1-((2,3-Dihydrobenzo[b][1,4Idioxin-6-yl)methyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5Jdecan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
XRX-100340-00-001
38.8 mg, yield: 22%, white solid.
LCMS (ESI): m/z = 621.0 [M+Hf.
1H-NMR (400 MHz, CD3OD): Ô = 1.02-1.07 (m, 6H), 1.61-1.77 (m, 3H), 2.11-2.35 (m, 2H), 3.05 (s, 3H), 3.32-3.37 (m, 2H), 3.87-3.89 (m, 1H), 4.15-4.40 (m. 4H), 4.38-4.49 (m, 3H), 4.87-4.91 (m, 1H), 6.67-6.80 (m. 3H), 7.43-7.49 (m, 1H), 7.89-8.12 (m, 2H).
Example 97:
(R)-2-Fluoro-N-(1-(1-((6-methoxypyridin-3-yl)methyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
XRX-100360-00-001
61.5 mg, yield: 32%, white solid.
LCMS (ESI): m/z = 594.2 [M+H]+.
’H-NMR (400 MHz, CD3OD): δ = 1.03-1.08 (m, 6H), 1.71-1.94 (m, 3H), 2.13-2.18 (m, 1H), 2.34-2.42 (m, 1H), 3.04 (s, 3H), 3.37-3.46 (m, 1H), 3.88-3.94 (m, 4H), 4.18-4.30 (m, 1H), 4.50-4.65 (m, 3H), 4.80 (s, 1H), 6.84-6.87 (m, 1H), 7.43-7.51 (m, 1H), 7.74-8.55 (m, 5H).
Example 98:
(R)-N-(1-(1-((1H-lndazol-5-yl)methyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-
1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamîde
XRX-100362-00-001
2.9 mg, yield: 7%, white solid.
LCMS (ESI): m/z = 603.2 [M+H]+.
1H-NMR (400 MHz, CDsOD): δ = 0.92-1.05 (m, 6H), 1.65-2.42 (m, 5H), 3.09 (s, 3H), 3.33-3.44 (m, 2H), 3.85-4.48 (m, 2H), 4.62-4.79 (m, 2H), 4.80-4.81 (m, 1H), 7.40-7.58 (m, 3H), 7.74-7.75 (m, 1H), 7.23-8.54 (m, 3H).
Example 99:
(R)-N-(1-(1-(4-Chlorobenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiroI4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
XRX-100365-00-001
51.0 mg, yield: 47%, white solid.
LCMS (ESI): m/z = 597.2 [M+H]\ 1H-NMR (400 MHz, CDaOD): δ= 1.02-1.07 (m, 6H), 1.67-2.33 (m, 5H), 3.06 (s, 3H), 3.33-3.41 (m, 1H),
3.90-4.21 (m, 2H), 4.52-4.60 (m, 2H), 4.64-4.87 (m, 2H), 7.24-7.47 (m, 5H), 7.91-8.09 (m, 2H).
Example 100:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(quinoxalin-6-ylmethyl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifIuorometiiyl)benzamide
XRX-100367-00-001
25.0 mg, yield: 20%, white solid.
LCMS (ESI): m/z = 615.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 1.00-1.06 (m, 6H), 1.75-2.38 (m, 5H), 3.11 (s, 3H), 3.42-3.43 (m, 1H), 3.91-4.50 (m, 3H), 4.87-4.79 (m, 2H), 4.90-5.00 (m, 1H), 7.38-7.52 (m, 1H), 7.82-7.94 (m, 2H), 7.98-8.15 (m, 3H), 8.82-8.96 (m, 2H).
Example 101:
(RÏ-N-tl-n-p-CyanobenzylJ-î-methyl-Z^-dioxo-I.S.e-triazaspiro^.Sldecan-S-ylJ-S-niethyl-loxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamîde
28.0 mg, yield: 18%, white solid.
LCMS (ESI): m/z = 588.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 1.01-1.06 (m, 6H), 1.83-2.34 (m, 5H), 3.06 (s, 3H), 3.33-3.43 (m, 1H), 3.90-4.25 (m, 2H), 4.63-4.50 (m, 3H), 4.84-4.86 (m, 1H), 7.47-7.70 (m, 5H), 7.89-8.08 (m, 2H), 8.52 (s, 1H).
Example 102:
(R)-2-Fluoro-N-(1-(1-(imidazo[1 ^-aJpyridin-T-ylmethyO-S-methyl^,4-dioxo-1,3,8triazaspiro[4.5Jdecan-8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
XRX-100368-00-001
26.3 mg. yield: 16%, white solid.
LCMS (ESI): m/z = 603.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.03-1.08 (m, 6H), 1.83-2.03 (m, 3H), 2.12-2.19 (m, 1H), 2.33-2.40 (m,
1H), 3.08 (s, 3H), 3.42-3.49 (m, 1H), 3.89-3.96 (m, 1H), 4.24-4.28 (m, 1H), 4.57-4.60 (m, 1H), 4.69-4.84 (m, 3H), 7.46-7.51 (m, 1H), 7.87-8.21 (m, 6H), 8.30-8.62 (m, 1H).
Exemple 103:
(R)-2-Fluoro-N-(3-methyl-1 -(3-methyl-1 -(3-(methylsulfonyl)benzyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
22.9 mg, yield: 19%, white solid.
LCMS (ESI): m/z = 641.0 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ= 1.02-1.07 (m, 6H), 1.74-1.91 (m,4H), 2.28-2.35 (m, 1H), 3.07-3.14 (m,
6H), 3.43-3.49 (m, 1H), 3.87-3.94 (m. 1H), 4.11-4.28 (m, 2H), 4.51-4.55 (m, 1H), 4.64-4.78 (m, 2H), 7.457.57 (m, 2H), 7.62-7.72 (m, 2H), 7.83-8.09 (m, 3H).
Example 104:
(R)-N-(1-(1-(3-Chlorobenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
13.6 mg, yield: 8%, white solid.
LCMS (ESI): m/z = 597.1 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ= 1.02-1.07 (m, 6H), 1.67-1.85 (m, 3H), 2.05-2.15 (m, 1H), 2.34-2.38 (m, 1H). 3.06 (s, 3H), 3.38-4.44 (m, 1H), 3.86-4.28 (m, 3H), 4.50-4.54 (m. 1H), 4.61-4.71 (m, 1H), 4.86-4.90 (m, 1H), 7.23-7.50 (m, 5H), 7.89-8.02 (m, 1H), 8.09-8.11 (m, 1H), 8.50 (br, 1H).
Example 105:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-{(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)methyl)-
2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
36.0 mg, yield: 15%, white solid.
LCMS (ESI): m/z = 634.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.92-1.06 (m, 6H), 1.68-2.37 (m, 5H), 3.06 (s, 3H), 3.28 (s, 3H), 3.303.36 (m, 2H), 3.86-4.24 (m, 1H), 4.62-4.70 (m, 3H), 4.85-4.87 (m, 1H), 7.06-7.16 (m, 3H), 7.41-7.46 (m,
H), 7.99-8.09 (m, 2H).
Example 106:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyi-1-((2-methyl-1H-benzo[d]imidazol-6-yl)methyl)-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
7.2 mg, yield: 6%, white solid.
LCMS (ESl): m/z = 617.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.02 (m, 6H), 1.31-2.16 (m, 5H), 2.88 (m, 4H), 3.08 (s, 3H), 3.42-4.25 (m, 4H), 4.49-4.75 (m, 2H), 7.47-7.74 (m. 4H), 7.91-8.05 (m, 2H).
Example 107:
(R)-2-Fluoro-N-(1-(1-(2-fluoro-5-methoxybenzyl)-3-methyl-2,4-dioxo-1,3l8-triazaspiro[4.5]decan-8yl)-3-methyl-1-oxobirtan-2-yl)-5-(trifluoromethyl)benzamide
21.4 mg, yield: 18%, white solid.
LCMS (ESl): m/z = 611.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): 6= 1.01-1.04 (m, 6H), 1.71-1.93 (m, 3H), 2.08-2.15 (m, 2H), 3.06 (s, 3H),
3.36-3.43 (m, 1H), 3.71-3.77 (m, 3H), 3.88-3.91 (m, 1H), 4.17-4.27 (m, 1H), 4.48-4.57 (m, 3H), 4.84-4.94 (m, 1H), 6.77-7.01 (m, 3H), 7.43-7.46 (m, 1H), 7.50-8.85 (m, 2H).
Example 108:
(R)-2-Fluoro-N-(1 -(1 -{2-fluoro-4-methoxybenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8yl)-3-methyl-1-oxobutan-2-yl)-54trifluoromethyl)benzamide
22.5 mg, yield: 5.3%, white solid.
LCMS (ESI): m/z = 610.7 [M+HJL
Ή-NMR (400 MHz, CD3OD): δ = 1.01-1.06 (m, 6H), 1.68-1.84 (m, 3H), 2.10-2.28 (m, 2H), 3.03 (s, 3H), 3.36-3.45 (m, 1H), 3.75-3.80 (m, 3H), 3.86-3.90 (m, 1H), 4.16-4.30 (m, 1H), 4.48-4.65 (m, 3H), 4.89-4.95 (m, 1H), 6.54-6.76 (m, 2H), 7.26-7.50 (m, 2H), 7.87-7.92 (m, 1H), 8.02-8.12 (m, 1H), 8.49-8.51 (s, 1H).
Example 109: (RpN-il-Cyclopropyl^a-methyl-Z^-dioxo-l-iquinoxalin-C-ylmethylJ-I.S.e-triazaspiroH.SJdecan-Syl)-2-oxoethyl)-2-fluoro-5-{trifluoromethyl)benzamide
49.2 mg, yield: 34%, white solid.
LCMS (ESI): m/z = 613.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): ô = 0.30-0.63 (m, 4H), 1.11-1.27 (m, 1H), 1.70-1.85 (m, 3H), 2.15-2.21 (m, 1H), 3.14 (s, 3H), 3.41-3.48 (m, 1H), 3.89-3.99 (m, 2H), 4.57-4.90 (m, 4H), 7.24-7.32 (m, 1H). 7.75-7.77 (m, 3H), 7.96-8.14 (m, 2H), 8.40-8.41 (m, 1H), 8.82-8.88 (m, 2H).
Example 110:
(R)-N-(1-Cyclobutyl-2-(3-methyl-2,4-dioxo-1-(qiiinoxalîn-6-ylmethyl)-1,3,8-triazaspiro[4.5]decan-8yl)-2-oxoethyl)-24luoro-5-(trifluoromethyl)benzamide
69.1 mg, yield: 26%, white solid.
LCMS (ESI): m/z = 627.2 [M+Hf.
^-NMR (400 MHz, CD3OD): Ô = 1.73-2.17 (m, 10H), 2.62-2.77 (m, 1H), 3.15 (s, 3H), 3.38-3.49 (m, 1H), 3.89-4.04 (m, 2H), 4.54-4.58 (m, 1H), 4.65-4.95 (m, 2H), 5.05-5.12 (m, 1H), 7.29-7.33 (m, 1H), 7.51-7.58 (m, 1H), 7.73-7.79 (m, 2H), 7.98 (s, 1H), 8.08-8.16 (m, 1H), 8.33-8.43 (m, 1H), 8.82-8.89 (m, 2H).
Example 111:
(R)-2-Fluoro-N43-methyl-1-(3-methyl-2,4-dioxo-1-{pyrimidîn-2-ylmethyl)-1,3,8triazaspiro[4.5]decan-8-yl)-1 -oxobutan-2-yl)-5-(trifluoromethyl)benzamide
16.6 mg, yieid: 12%, white solid.
LCMS (ESI): m/z = 565.1 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.01-1.08 (m, 6H), 1.75-2.36 (m, 5H), 3.05 (s, 3H), 3.42-3.49 (m, 1H), 3.88-3.96 (m, 1H), 4.18-4.27 (m, 1H), 4.46-4.55 (m, 1H), 4.65-4.77 (m, 2H), 4.86-4.89 (m, 1H), 7.33-7.48 (m, 2H), 7.83-8.04 (m, 2H), 8.69-8.77 (m, 2H).
Example 112:
(R)_N-(1-Cyclopentyl-2-(3-methyl-2,4-dioxo-1-{quinoxalin-6-ylmethyl)-1,3,8-triazaspiro[4.5]decan-8yl)-2-oxoethyl)-2-fluoro-5-(trifluoromethyl)benzamide
91.5 mg, yieid: 55%, white solid.
LCMS (ESI): m/z = 641.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): ô = 1.21-1.80 (m, 9H), 1.85-1.95 (m, 3H), 2.30-2.43 (m, 2H), 3.10 (s, 3H), 3.40-3.46 (m, 1H), 3.88-3.95 (m, 1H), 4.17-4.34 (m, 2H), 4.91-5.02 (m, 1H), 7.40-7.45 (m, 1H), 7.85-7.89 (m, 2H), 7.97-8.13 (m, 3H), 8.85-8.90 (m, 2H).
Example 113: (RÏ-N-tl-Cyclopentyl^-tS-methyl-l^-methyl-ÎI^^Itrîazolotl.S-alpyridin^-ynmethylJ^^-dioxo-
1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-2-fluoro-5-(trifluoromethyl}benzamide
CN
13.7 mg, yieid: 5%, white solid.
LCMS (ESI): m/z = 589.2 [M+H]\ 1H-NMR (400 MHz, CD3OD): δ = 1.03-1.08 (m, 6H), 1.78-1.96 (m, 3H), 2.10-2.21 (m, 1H), 2.27-2.35 (m,
1H), 3.05 (s, 3H), 3.32-3.43 (m, 1H), 3.88-3.94 (m, 1H), 4.19-4.29 (m, 1H), 4.34-4.58 (m, 1H), 4.67-4.73 (m, 2H), 4.83-4.85 (m, 1H, contained in solvent signal), 7.43-7.50 (m, 1H), 7.80-7.78 (m, 1 H), 7.85-7.92 (m, 1H). 7.98-8.08 (m, 2H), 8.51-8.55 (m, 1H), 8.71-8.73 (m, 1H).
Example 114:
(/?)-2-ΡΙυθΓθ-Ν-(3-τηθΙΙινΙ-1-{3-ππεΙΐΊνΙ-1-((2-πιθΐΗνΙ-[1,2,4]1ΐΊ3ζοΙο[1,5-a]pyridin-7-yl)methyl)-2,4dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
53.7 mg, yield: 18%, white solid.
LCMS (ESI): m/z = 618.2 [M+Hf.
’H-NMR (400 MHz, CDaOD): δ = 0.98-1.06 (m, 6H), 1.84-1.97 (m, 3H), 2.12-2.16 (m, 1H), 2.26-2.34 (m,
1H), 2.60 (s, 3H), 3.08 (s, 3H). 3.41-3.48 (m, 1H), 3.89-3.96 (m. 1H), 4.19-4.28 (m, 1H). 4.51-4.58 (m.
1H), 4.75-4.80 (m, 2H), 4.84-4.86 (m, 1H, contained in solvent signal), 7.27-7.36 (m, 1H), 7.43-7.48 (m,
1H), 7.71-7.76 (m, 1H), 7.88-7.91 (m, 1H), 8.77-8.71 (m, 1H), 8.06-8.01 (m, 1H).
Example 115:
(RJ-Z-Fluoro-N-fS-methyl-l-tS-methyl-l -((1-methyl-1H-pyrazol-4-yl)methyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifiuoromethyl)benzamide
2.5 mg, yield: 6%, white solid.
LCMS (ESI); m/z = 567.2 [M+H]’.
1H-NMR (400 MHz, CD3OD): δ = 1.04-1.09 (m, 6H), 1.69-1.76 (m, 2H), 1.95-2.03 (m, 1H), 2.14-2.21 (m, 1H), 2.47-2.99 (m, 1H), 3.03 (s, 3H), 3.40-3.46 (m, 1H), 3.81 (s, 3H), 3.86-3.93 (m, 1H), 4.26-4.58 (m, 3H), 4.86-4.95 (m, 2H), 7.46-7.51 (m, 2H), 7.60-7.64 (m, 1H), 7.91 (m, 1H), 8.03-8.11 (m, 1H), 8.55 (m, 1H).
Example 116:
(R)-2-Fluoro-N-{3-methyl-1-(3-methyl-1-((2-methylbenzo[d]oxazol-5-yl)methyl)-2)4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
55.0 mg, yield: 28%, white solid.
LCMS (ESI): m/z = 618.0 [M+H]4.
1H-NMR (400 MHz, CD3OD): δ = 0.94-1.10 (m, 6H), 1.67-1.90 (m, 3H), 2.08-2.40 (m. 2H), 2.59-2.71 (m,
3H), 3.08 (s, 3H), 3.33-3.42 (m, 1H), 3.92-4.26 (m, 3H), 4.48-4.71 (m, 3H), 7.37-7.61 (m, 4H), 7.85-8.06 (m, 2H).
Example 117:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-((4-methylthiazol-2-yl)methyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
40.0 mg, yield: 22%, white solid.
LCMS (ESI): m/z = 584.2 [M+H]4.
1H-NMR (400 MHz, CD3OD): δ = 1.05 (m, 6H), 1.76-2.01 (m, 3H), 2.17-2.19 (m, 2H), 2.39-2.41 (m. 3H),
3.05 (s, 3H). 3.44-3.92 (m, 2H), 4.28-4.57 (m, 2H), 4.85-4.87 (m, 2H), 4.91-5.01 (m, 1H), 7.12-7.15 (m,
1H), 7.46-7.52 (m, 1H), 7.85-8.07 (m, 2H).
Example 118:
(R)-2-Fluoro-N-(3-methyl-1-{3-methyl-1-((2-methylbenzo[d]oxazol-6-yl)methyl)-2,4-dioxo-1,3,8tfïazaspiro[4.5ldecan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
11.5 mg, yield: 11%. white solid.
LCMS (ESI): m/z = 544.1 [M+H]4.
1H-NMR (400 MHz, CD3OD): δ = 0.90-1.03 (m, 6H), 1.65-2.34 (m, 5H), 2.59-2.64 (m, 3H), 3.05 (s, 3H),
3.32-3.40 (m, 1H), 3.85-3.90 (m, 1H), 4.14-4.23 (m, 1H), 4.46-4.68 (m, 1H), 4.72-4.78 (m, 2H), 4.81-4.86 (m, 1H), 7.33-7.42 (m, 1H), 7.46-7.51 (m. 2H), 8.20-8.25 (m, 1H), 7.78-7.80 (m, 2H).
Example 119:
(R)-N-(1-{1-{2-ChlorcM-methoxybenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1 -oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamtde
38.5 mg, yield: 25%, white solid.
LCMS (ESl): m/z = 627.1 [M+H]\ ’H-NMR (400 MHz, CDaOD): δ = 1.00-1.04 (m, 6H), 1.73-1.82 (m, 3H), 2.05-2.14 (m, 2H), 3.06 (s, 3H), 3.32-3.39 (m, 1H), 3.75-3.81 (m, 3H), 3.87-3.90 (m, 1H), 4.22-4.28 (m, 2H), 4.46-4.59 (m, 2H), 4.91-4.93 (m, 1H), 6.78-6.88 (m, 2H). 7.39-7.90 (m, 2H), 8.02-8.04 (m, 1H), 8.10-8.12 (m. 1H).
Example 120:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-((1-methyl-6-oxo-1,6-dihydropyridin-3-yl)methyl)-2,4-dioxoI.S.e-triazaspîro^.Sldecan-e-ylJ-l-oxobutan^-yn-S-ftrifluoromethylJbenzamide
50.0 mg, yield: 27%, white solid.
LCMS (ESl): m/z = 594.2 [M+H]\ 1H-NMR (400 MHz, CD3OD): δ = 1.07-1.09 (m, 6H), 1.69-2.08 (m, 3H), 2.16-2.42 (m, 2H), 3.04 (s, 3H),
3.52-3.91 (m, 6H), 4.31-4.37 (m, 2H), 4.40-4.66 (m, 1H), 4.86-4.90 (m, 1H), 6.53-6.55 (m, 1H), 7.49-7.78 (m, 3H), 7.86-7.95 (m, 1H), 8.11-8.13 (m, 1H).
Example 121:
(RI-N^HHfl-Acetylazetidin-a-ylJmethylH-niethyl^A-dioxo-I.S.S-triazaspiroH.SIdecan-e-ylJ-amethyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
40.0 mg, yield: 32%, white solid.
LCMS (ESI): m/z = 584.2 [M+H]+, 1H-NMR (400 MHz, CD3OD): δ = 1.04-1.16 (m, 6H), 1.77-2.38 (m, 8H), 2.99-3.01 (m, 4H), 3.42-3.56 (m,
4H), 3.76-4.09 (m, 4H), 4.21-4.32 (m, 1H), 4.55-4.62 (m, 1H), 4.89-5.00 (m, 1H), 7.45-7.50 (m, 1H), 7.897.91 (m, 1H), 8.05-8.06 (m, 1H).
Example 122:
(R)-N-(1-(1,3-Dimethyl-2,4-dioxo-1,3T8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 -oxobutan-2-yl)-2fluoro-5-(trifluoromethyl)benzamide
mg, 75% yield, white solid.
LCMS (ESI): m/z = 487.1 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 1.01-1.11 (m, 6H), 1.69-2.19 (m, 5H), 2.85-2.89 (m, 3H), 3.06 (s, 3H), 3.44-3.52 (m, 1H), 3.96-4.13 (m, 2H), 4.67-4.71 (m, 1H). 5.09-5.12 (m, 1H), 7.29-7.34 (m, 1H), 7.52-7.57 (m, 1H), 7.77-7.80 (m, 1H), 8.3 5-8.37 (m, 1H).
Example 123:
(R)-N-(1-(1-Ethyl-3-methyl-2I4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2fluoro-5-(trifluoromethyl)benzamide
mg, 45% yield, white solid.
LCMS (ESI): m/z = 501.2 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 1.02-1.12 (m, 6H), 1.21-1.29 (m, 3H), 1.73-1.91 (m, 3H)„ 2.01-2.19 (m, 2H), 3.05 (s, 3H), 3.26-3.32 (m, 2H), 3.46-3.53 (m, 1H), 4.00-4.12 (m, 2H), 4.67-4.69 (m, 1H), 5.09-5.15 (m, 1H), 7.29-7.35 (m, 1H), 7.53-7.58 (m, 1H), 7.78-7.79 (m, 1H). 8.35-8.36 (m, 1H).
Example 124:
(R)-2-Fluoro-N-(1-(1-isopentyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yi)-3-methyl-1 oxobutan-2-yl)-5-(trifluoromethyl)benzamide
mg, 37% yield, white solid.
LCMS (ESI): m/z = 543.2 [M+Hf.
Ή-NMR (400 MHz, CDCh): ô = 0.91-1.12 (m, 12H), 1.50-1.95 (m, 6H), 2.03-2.18 (m, 2H), 3.15 (s, 3H), 3.18-3.22 (m, 2H), 3.43-3.51 (m, 1H), 3.97-4.10 (m, 2H), 4.67-4.70 (m, 1H), 5.08-5.14 (m, 1H), 7.29-7.34 (m, 1H), 7.46-7.51 (m. 1H). 7.75-7.79 (m, 1H), 8.36-8.37 (m, 1H).
Example 125:
(R)-N-(1-(1-Cyclopentyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3- methyl-1-oxobutan-
2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
mg, 18% yield, white solid.
LCMS (ESI): m/z = 541.2 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 0.94-1.16 (m, 6H), 1.47-1.60 (m, 2H), 1.67-1.98 (m, 7H), 2.06-2.23 (m,
4H), 3.02 (s, 3H), 3.36-.350 (m, 2H), 3.96-4.06 (m, 2H), 4.66-4.69 (m, 1H), 5.09-5.15 (m, 1H), 7.29-7.35 (m, 1H), 7.47-7.58 (m, 1H), 7.76-7.83 (m, 1H), 8.33-8.40 (m. 1H) .
Example 126:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-1-oxobutan-2-yl)-5 (trifluoromethyl)benzamide
mg, 35% yield, white solid.
LCMS (ESI): m/z = 473.1 [M+Hf.
Ή-NMR (400 MHz, CDCh): δ = 1.00-1.09 (m, 6H). 1.70-1.91 (m, 2H), 1.89-2.14 (m, 3H), 3.04 (s, 3H), 3.35-3.60 (m, 1H), 3.75-3.78 (τη, 1H), 4.07-4.11 (m, 1H), 4.12-4.41 (m, 1H), 5.07-5.16 (m, 1H), 7.05 (s, 1H), 7.29-7.37 (m, 1H), 7.58-7.62 (m, 1H), 7.76-7.80 (m, 1H), 8.31-8.36 (m, 1H).
Example 127: (ί?)-ΜθΐηγΙ-4-(8-(2-(2-ίΊυοΓθ-5-(Ιπί1υθΓθΓη6ΐίΊγΙ)Ρθπζ3Γηΐΰο)-3-<ηθΐΚν1δυί3πογΙ)-3-Γη6(ηγΙ-2,4·<1ίοχο-
1,3,8-triazaspiro[4.5]decan-1-yl)phenylcarbamate
Représentative scheme:
Représentative general procedure:
Benzyl-1-{4-(methoxycarbonylamino)phenyl)-3-methyl-2J4-dioxo-1l3,8-triazaspiro[4.5ldecane-8carboxylate
XRX-100262-00-001-a
To a solution of benzyl-1-(4-aminophenyl)-3-methyi-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (prepared as described in Example 86-f) (150 mg, 0.37 mmol) in dichloromethane (15 mL) was added triethylamine (92 mg, 0.92 mmol). The resulting mixture was cooled to 0°C and methyi chloroformate (42 mg, 0.44 mmol) was added. The resulting mixture was stirred for 1 hour. Afterquenching by addition of ice-water (10 mL), the resulting mixture was extracted with dichloromethane (3 χ 10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 20:1 to afford benzyl-1-(4-(methoxycarbonylamino)phenyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate as a white solid (95 mg, 51%).
LCMS (ESI): m/z = 467.2 [M+H]’.
Methyl-4-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenylcarbamate
XRX-100262-00-001-b
To a solution of benzyl-1-(4-(methoxycarbonylamino)phenyi)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (95 mg, 0.20 mmol) in éthanol (15 mL) was added 5% palladium on carbon (15 mg). After stirring for 3 hours, the mixture was filtered. The filtrate was concentrated under reduced pressure to afford methyl-4-(3-methyl-2,4-dioxo-1.3,8-triazaspiro[4.5Jdecan-1yl)phenylcarbamate as a white solid (55 mg, 82%).
LCMS (ESI): m/z = 333.2 [M+H]+.
(R)-Methyl~4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-
1,3,8-triazaspirot4.5Idecan-1-yl)phenylcarbamate
To a solution of methyl-4-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenylcarbamate (55 mg, 0.17 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (51 mg, 0.17 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (90 mg, 0.23 mmol) and N,N-diisopropylethylamine (32 mg, 0.23 mmol). The reaction was stirred for 2 hours at room température before quenching with ice-water (5 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-methyl-4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-rnethylbutanoyl)-3methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenyicarbamate as a white solid (16 mg, 15%). LCMS (ESI): m/z = 622.1 [M+H]\ 1H-NMR (400 MHz, CDaOD): δ = 0.82-1.09 (m, 6H), 1.58-2.47 (m, 5H), 3.08 (s, 3H), 3.43-3.54 (m, 1H), 3.76-3.77 (m, 3H), 3.91-4.01 (m, 1H), 4.16-4.53 (m, 3H), 7.11-7.18 (m, 1H), 7.18-7.23 (m, 1H), 7.40-7.47 (m, 2H), 7.58-7.61 (m, 1H), 7.87-8.00 (m, 2H).
The following compound was synthesized following the general procedure described above;
Example 128:
(R)-N-(1-(1-(4-(Cyclopropanecarboxamido)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
44.2 mg, yield: 22%, white solid
LCMS (ESI): m/z = 632.1 [M+H]’.
1H-NMR (400 MHz, CDaOD): δ = 0.72-1.05 (m, 10H), 1.66-2.27 (m, 6H), 3.08 (s, 3H), 3.46-3.59 (m, 1H), 3,90-3.54 (m, 3H), 4.83-4.87 (m, 1H), 7.09-7.32 (m, 2H), 7.34-7.52 (m, 1H), 7.59-7.74 (m, 2H), 7.81-8.05 (m, 2H).
Example 129:
100 (R)-3-Methyl-N-(2-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxo-1-(tetrahydro-
Représentative general procedure: tert-Butyl-3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate
XRX-000105-00-001-a
To a solution of tert-butyl-4-oxo-1-phenyl-1,3,8-triazaspiroI4.5]decane-8-carboxylate (920 mg, 2.78 mmol) 10 in N,N-dimethylformamide (10 mL) was added sodium hydride (138 mg, 60% in oïl, 3.34 mmol) at 0°C.
After stirring for 15 minutes, iodomethane (789 mg, 5.56 mmol) was added. The resulting mixture was stirred for 15 minutes at room température and the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 χ 50 mL). The combined onganic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:3 to afford tert-butyl-3-methyl-
4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (900 mg. 93%).
LCMS (ESI): m/z = 346.4 [M+Hf.
101 1H-NMR (300 MHz. CDCh): δ = 1.51, (s, 9H), 1.54-1.67 (m, 2H), 2.56-2.57 (m. 2H). 3.01 (s. 3H), 3.503.64 (m. 2H), 3.96-4.12 (m. 2H), 4.69-4.75 (m. 2H), 6.72-6.77 (m, 2H), 6.83-6.87 (m, 1H), 7.22-7.25 (m, 1H), 7.27-7.28 (m, 1H).
3-Methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride
XRX-000106-00-001-b
To a solution of ferî-Butyl-3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate (300 mg, 1.89 mmol) in methanol (50 mL) was added dropwise acetyl chloride (1.49 g, 18.87 mmol). The resulting mixture was stirred for 2 hours. The precipitate was collected by filtration and dried under reduced pressure to afford 3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride as a white solid (173 mg, 70%).
LCMS (ESI): m/z = 246.4 [M+H]*.
Methyl-2-(3-methylbenzamido)-2-{tetrahydro-2W-pyran-4-yl)acetate
XRX-000105-00-001 -c
To a suspension of methyl-2-amino-2-(tetrahydro-2H-pyran-4-yl)acetate hydrochloride (210 mg, 1.0 mmol) in dichloromethane (20 mL) was added triethylamine (303 mg, 3.0 mmol). To the mixture was added dropwise a solution of 3-methylbenzoyl chloride (170 mg, 1.1 mmol) in dichloromethane (5 mL) at 0°C. The mixture was stirred for 1 hour before the reaction was quenched with ice-water (10 mL). The organic iayer was collected and the aqueous layer was extracted with ethyl acetate (3 * 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether= 1:1 to afford methyl-2-(3-methylbenzamido)-2-(tetrahydro-2H-pyran-4yl)acetate as a coloriess oil (200 mg, 68%).
LCMS (ESI): m/z = 292.1 [M+H]*.
1H-NMR (300 MHz, CDCh): δ = 1.45-1.71 (m, 4H), 2.10-2.25 (m, 1H), 2.41 (s, 3H), 3.31-3.46 (m, 2H), 3.80 (s ,3H), 3.91-4.06 (m, 2H), 4.83-4.94 (m, 1H), 6.61-6.75 (m, 1H), 7.31-7.34 (m, 2H), 7.51-7.68 (m, 2H).
102
2-(3-Methylbenzamido)-2-(tetrahydro-2H-pyran-4-yl)acetic acid
XRX-000106-00-001 -d
To a solution of methyl-2-(3-methylbenzamido)-2-(tetrahydro-2H-pyran-4-yl)acetate (200 mg, 0.68 mmol) in methanol (10 mL) was added a 10% aqueous sodium hydroxide solution (5 mL). The reaction was heated at reflux for 2 hours before it was cooled to room température. The pH of the mixture was adjusted to 2 by addition of a 10% aqueous hydrochloric acid solution. The resulting mixture was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure to afford 2-(3methylbenzamido)-2-(tetrahydro-2H-pyran-4-yl)acetic acid as a thick oil (180 mg, crude), which used directly in the next step without further purification.
LCMS (ESI): m/z = 278.1 [M+H]‘.
3-Methyl-N-{2-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxo-1-(tetrahydro-2H- pyran-4-yl)ethyl)benzamide
To a solution of 3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride (106 mg, 0.379 mmol) in dichloromethane (10 mL) was added sequentially 2-(3-methylbenzamido)-2-(tetrahydro-2H-pyran-4yl)acetic acid (70 mg, 0.25 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3oxrde hexafluorophosphate (HATU) (144 mg, 0.38 mmol) and Ν,Ν-diisopropylethylamine (98 mg, 0.75 mmol). The reaction was stirred for 2 hours before it was quenched by addition of with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with ethyl acetate : petroleum ether= 1:1 to afford 3-methyl-N-(2-(3-methyl-4-oxo-1-phenyl-
1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl)benzamide as a white solid (50 mg, 39%).
LCMS (ESI): m/z = 505.2 [M+Hf.
3-Methyl-N-(2-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxo-1-(tetrahydro-2H-pyran-4yl)ethyl)benzamide was separated by chiral-HPLC (column: CHIRALPAK* (Daicei) IB (250 mm x 20 mm, 5 pm). Mobile phase: hexane : éthanol (0.1 %FA) = 70:30, flow rate: 20 mL/min) to afford two isomers. Their confirmations were tentatively assigned as drawn.
(R)-3-Methyl-N-(2-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5Jdecan-8-yl)-2-oxo-1-(tetrahydro2H-pyran-4-yl)ethyl)benzamide
103
Rétention time: 7.481 minutes, ee = 97.1%.
LCMS (ESI): m/z = 505.2 [M+H]+.
1H-NMR (400 MHz, CDCh): S = 1.54-1.90 (m, 7H), 2.42-2.66 (m, 5H), 3.05 (s, 3H), 3.36-3.45 (m, 2H),
3.54-3.64 (m, 2H), 3.97-4.14 (m, 4H), 4.54-4.66 (m, 1H), 4.71-4.76 (m, 2H), 5.17-5.23 (m, 1H), 6.98-7.24 (m, 5H), 7.62-7.66 (m. 4H).
Example 130:
(S)-3-Methyl-N-(2-(3-methyl-4-oxo-1 -phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxo-1 -(tetrahydro2H-pyran-4-yl)ethyl)benzamide
Rétention time: 14.04 minutes, ee = 95%
LCMS (ESI): m/z = 505.2 [M+H]+.
1H-NMR (400 MHz, CDCh): ô = 1.54-1.90 (m, 7H), 2.42-2.66 (m, 5H), 3.05 (s, 3H), 3.36-3.45 (m, 2H),
3.54-3.64 (m, 2H), 3.97-4.14 (m, 4H), 4.54-4.66 (m, 1H), 4.71-4.76 (m, 2H), 5.17-5.23 (m, 1H), 6.98-7.24 (m, 5H), 7.62-7.66 (m, 4H).
The following compound was synthesized following the general procedure described above using chiral amino acid.
Example 131:
(R)-N-(1-Cyclohexyl-2-(3-methyl-4-oxo-1 -phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-6methylptcolinamide trifluoroacetic acid sait
14.6 mg, yield: 20%, white solid.
LCMS (ESI): m/z = 504.2 [M+H]+.
1H-NMR (400 MHz, CDsOD): δ = 1.0-1.44 (m, 5H), 1.51-2.00 (m, 8H), 2.41-2.76 (m, 5H), 3.02 (s, 3H), 3.50-3.55 (m, 1H), 3.96-4.01 (m, 1H), 4.19-4.39 (m, 1H), 4.48-4.50 (m, 1H), 4.75 (m, 2H), 5.07 (m, 1H), 6.56-6.73 (m, 2H), 6.80-7.00 (m, 2H), 7.26-7.35 (m, 1H), 7.53-7.55 (m, 1H), 7.77-8.01 (m, 2H).
104
The following compound was synthesized following the general procedure described for Example 236.
Example 132:
(R)-N,3-Dimethyl-N-(3-methyl-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide
26.4 mg, yield: 58%, white solid.
LCMS (ESI): m/z = 464.2 [M+H]‘.
1H-NMR (400 MHz, CDCh): δ = 1.00-1.04 (m, 6H), 1.75-1.87 (m, 2H), 2.25-2.39 (two singlets, 3H), 2.452.54 (m, 3H), 2.86-2.96 (two singlets, 3H), 3.05 (s, 3H), 3.52-4.75 (m, 6H), 5.26-5.28 (m, 1H), 6.75-7.27 (m, 9H).
Example 133:
5-Ethyi-2-fluoro-N-((2/?,3S)-3-methoxy-1-{3-methyl-4~oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-
y))-1 -oxobutan-2-yl)benzamide
Représentative scheme:
Example 129-b
HCI.dioxane
b a
HATU.DIPEA, DCM, r.t.
105
Représentative general procedure:
tert-Butyl-(2/?,3S)-3-methoxy-1-(3-niethyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1 oxobutan-2-ylcarbamate
XRX-000136-00-001-a
To a mixture of 3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride (prepared as described in Example 129-b) (296 mg, 0.47 mmol) in dichloromethane (30 mL) was added (2R,3S)-2(tert-butoxycarbonylamino)-3-methoxybutanoic acid (100 mg, 0.43 mmol), 1[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (243 mg, 0.64 mmol) and N,N-diisopropylethylamine (139 mg, 1.07 mmol). The reaction was stirred for 2 hours before it was quenched with ice-water (5 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:5 to afford ferf-butyl-(2R,3S)-3-methoxy-1-(3-methyl-4-oxo-1-phenyl-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-ylcarbamate as a coloriess oil (197 mg, 100%).
LCMS (ESI): m/z = 461.2 [M+Hf.
’H-NMR (400 MHz, CDCb): δ = 0.83-1.12 (m, 3H), 1.38 (s, 6H), 1.45 (s, 3H), 1.59-1.64 (m, 4H), 2.83 (s, 3H), 3.06 (s, 1H), 3.14 (s, 2H), 3.34 (s, 2H), 3.30-3.57 (m, 2H), 3.83-4.01 (m, 2H), 4.51-4.75 (m, 2H), 5.47-5.59 (m, 1H), 7.13-7.20 (m, 2H), 7.40-7.52 (m, 3H).
8-((2R,3S)-2-Amino-3-methoxybutanoyl)-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride
XRX-000136-00-001 -b
A solution Of fert-butyl-(2R,3S)-3-methoxy-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-ylcarbamate (197 mg, 0.43 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 8((2R,3S)-2-amino-3-methoxybutanoyl)-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride as a white solid (120 mg, 60%).
LCMS (ESI): m/z = 361.2 [M+Hf.
106
5-Ethyl-2-fluoro-N-((2R,3S)-3-methoxy-1-(3-mettiyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5Jdecane-8y I )-1 -oxobutan-2-yl)benzamide
To a mixture of 8-((2R,3S)-2-amino-3-methoxybutanoyi)-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4one hydrochloride (52 mg, 0.135 mmol) in dichloromethane (10 mL) was added 5-ethyl-2-fluorobenzoic acid (24 mg, 0.144 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (75 mg, 0.196 mmol) and N,N-diisopropylethylamine (51 mg, 0.39 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3x10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified bysilica gel column chromatography eluting with ethyl acetate : petroleum ether= 1:5 to afford 5-ethyl-2-fluoro-N-((2R,3S)-3-methoxy-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8yl)-1-oxobutan-2-yl)benzamide as a coloriess oil (11.2 mg, 15%).
11.2 mg, yield: 15%, white solid LCMS (ESl): m/z = 511.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 1.22-1.31 (m, 6H), 1.66-2.83 (m, 6H), 3.03 (s, 3H). 3.11 (s, 3H), 3.83 (s, 3H), 3.38-4.78 (m, 7H), 5.17-5.3 (m, 1H). 6.73-7.76 (m, 8H).
The following 3 compounds were synthesized following the general procedure described above: Example 134: N-((2R,3S)-3-Methoxy-1-(3-methyl-4-oxo-1-phenyl-1,3l8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2yl)-3-methylbenzamide
10.1 mg, yield: 9%, white solid
LCMS (ESl): m/z = 479 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 1.22-1.27 (m, 3H), 1.70-1.83 (m, 2H), 2.43 (s, 3H), 2.56-2.66 (m, 1H), 2.80-2.94 (m, 1H), 3.06 (s, 3H), 3.41 (s, 3H), 3.46-4.22 (m, 4H), 4.45-4.84 (m, 3H), 5.08-5.51 (m, 1H), 6.85-6.90 (m, 3H), 7.22-7.24 (m, 1H), 7.38-7.50 (m, 3H), 7.67-7.69 (m, 2H).
107
Example 135:
S-Ethyl-N-f^R^SJ-S-nnethoxy-l-p-methyM-oxo-l-phenyl-I.S.e-triazaspiro^.SJdecan-e-yl)-!oxobutan-2-y|)benzamide
9.0 mg, yield: 14%, white solid
LCMS (ESI): m/z = 493.2 [M+H]+.
1H-NMR (400 MHz, CDCh): δ = 1.22-1.26 (m, 6H), 1.66-1.85 (m, 2H), 2.45-2.79 (m, 4H), 2.98 (s, 3H),
3.42 (s, 3H), 3.53-3.64 (m, 1H), 4.03-4.36 (m, 2H), 4.42-4.77 (m, 7H), 5.18-5.29 (m, 1H), 6.69-7.76 (m, 9H).
Example 136:
3-Ethyl-5-fluoro-N-((2R,3S)-3-methoxy-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)1 -oxobutan-2-yl)benzamide
8.0 mg, yield: 12%, white solid
LCMS (ESI): m/z = 511.2 [M+Hf.
1H-NMR (400 MHz, CDsOD): δ = 1.14-1.37 (m, 6H), 1.75-1.81 (m, 2H), 2.50-2.59 (m, 1H), 2.63-2.86 (m, 3H), 3.03 (s, 3H), 3.50 (s, 3H), 3.52-3.59 (m. 1H), 3.74-4.10 (m, 2H), 4.34-4.49 (m, 2H), 4.74-4.77 (m, 2H), 5.21-5.26 (m, 1H), 7.24-7.80 (m, 8H).
The following 8 compounds were synthesized following the general procedure described above using D-Valine:
Example 137:
(R)-2-Methyl-N-(3-methyl-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-
2-yl)isonicotinamide
5.0 mg, yield: 7%, white solid LCMS (ESI): m/z = 464.2 [M+H]*.
108 1H-NMR (400 MHz, CDCh): δ = 1.02-1.09 (m, 6H), 1.24-1.28 (m, 1H), 1.75-2.24 (m, 4H), 2.98-3.06 (m, 6H), 3.51-3.54 (m, 1H), 3.94-4.12 (m, 2H), 4.57-4.62 (m, 1H), 4.72-4.77 (m, 2H), 5.20-5.24 (m, 1H), 5.355.45 (m, 1H). 6.75-6.77 (m, 1 H), 6.84-6.88 (m, 1H), 7.17-7.19 (m, 1H). 7.35-7.37 (m, 2H), 7.82-7.95 (m, 2H), 8.73-8.75 (m, 1H).
Example 138:
(R)-3-Ethyl-N-(3-methyl-1 -(3-methyl-4-oxo-1 -pheny 1-1,3,8-triazaspiro[4.5]decan-8-yl)-1 -oxobutan-2yl)benzamide
10.0 mg, yield: 16%, white solid
LCMS (ESI): m/z = 477.2 [M+H]+.
1H-NMR (400 MHz, CDCb): δ = 1.01-1.14 (m, 6H), 1.25-1.29 (m, 3H), 1.74-1.83 (m, 2H), 2.16-2.18 (m, 1H), 2.68-2.71 (m, 4H), 3.02 (s, 3H), 3.52-3.56 (m, 1H), 3.99-4.08 (m, 2H), 4.54-4.71 (m, 3H), 5.09-5.15 (m, 1H), 6.67-7.24 (m, 6H), 7.34-7.36 (m, 2H). 7.62-7.67 (m, 2H).
Example 139:
(R)-4-Fluoro-3-methyl-N-(3-methyl-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide
20.0 mg, yield: 32%, white solid
LCMS (ESI): m/z = 481.2 [M+Hf.
Ή-NMR (400 MHz, CDCb): δ = 0.98-1.04 (m, 6H), 1.83-1.97 (m, 2H), 2.03-2.23 (m, 1H), 2.46-2.61 (m, 5H), 3.02 (s, 3H), 3.52-3.57 (m, 1H), 4.03-4.06 (m, 2H), 4.57-4.71 (m, 3H), 5.04-5.08 (m, 1H), 6.69-7.13 (m, 6H), 7.65-7.70 (m, 2H).
Example 140: (R)-3-Fluoro-5-methyl-N-(3-methyl-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide
109
13.0 mg, yield: 19%, white solid
LCMS (ESl): m/z = 481.2 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 0.97-1.06 (m, 6H), 1.74-1.79 (m,2H), 1.81-1.83 (m, 1H), 2.40-2.59 (m,
5H), 3.03 (s, 3H), 3.53-3.56 (m, 1H), 4.02-4.05 (m, 2H), 4.57-4.71 (m, 3H), 5.09-5.18 (m, 1H), 6.70-7.39 (m, 8H).
Example 141:
(RJ^-Fluoro-S-methyl-N-P-methyl-l-tS-methyM-oxo-l-phenyl-l ,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide
13.0 mg, yield: 11 %, white solid
LCMS (ESl): m/z = 481.2 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 0.97-1.06 (m. 6H), 1.74-1.79 (m, 2H), 1.81-1.83 (m, 1H), 2.13 (s, 3H), 2.34-2.50 (m, 2H), 3.02 (s, 3H), 3.50-3.54 (m, 1H), 4.03-4.08 (m, 2H), 4.54-4.71 (m, 3H), 5.09-5.18 (m, 1H), 6.67-7.14 (m, 7H), 7.43-7.46 (m, 1H), 7.79-7.80 (m, 1H).
Example 142:
(R)-3-Cyclopropyl-N-(3-methyl-1 -(3-methyl-4-oxo-1 -phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1 oxobutan-2-yl)benzamide
21.0 mg, yield: 29%, white solid
LCMS (ESl): m/z = 489.2 [M+H]+.
1H-NMR (400 MHz, CDCh): δ = 0.73-1.10 (m, 10H), 1.78-1.95 (m, 2H), 2.12-2.15 (m, 1H), 2.60-2.64 (m,
3H), 3.02 (s, 3H), 3.51-3.55 (m, 1H), 4.04-4.07 (m, 2H), 4.59-4.70 (m, 3H), 5.08-5.10 (m, 1H), 6.65-7.99 (m, 9H).
110
Example 143:
(R)-3-Chloro-4-cyano-N43-methyl-1-(3Hmethyl-4-oxo-1-phenyl-1)3,84riazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide
9.9 mg, yield: 15%, white solid
LCMS (ESI): m/z = 509.2 [M+H]+.
1H-NMR (400 MHz, CDCh): δ = 1.02-1.09 (m, 6H), 1.69-2.77 (m, 5H), 3.02 (s, 3H), 3.52-4.34 (m, 4H), 4.74-4.77 (m, 2H), 4.89-4.93 (m, 1H), 6.70-6.78 (m. 2H), 6.86-6.88 (m, 1H), 7.03-7.25 (m, 2H), 7.93-7.96 (m, 2H), 8.09-8.11 (m, 1H).
Example 144:
(R)-5-Ethyl-2-fluoro-N43-methyl-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspîro[4.5]decan-8-yl)-1-
LCMS (ESI): m/z = 495 [M+Hf.
1H-NMR (400 MHz, CDCb): δ = 0.94-1.16 (m, 6H), 1.18-1.38 (m, 3H), 1.60-1.93 (m, 2H), 2.13-2.34 (m, 1H), 2.37-2.62 (m, 1H), 2.62-2.76 (m, 2H), 2.81 (m, 1H), 3.08 (s, 3H), 3.43-3.63 (m, 1H), 3.91-4.10 (m, 1H), 4.20-4.38 (m, 1H), 4.43-4.60 (m, 1H), 4.65-4.76 (m, 2H), 4.96-5.09 (m, 1H), 6.70-6.89 (m, 3H), 7.017.32 (m, 3H), 7.34-7.53 (m, 1H), 7.57-7.71 (m, 1H).
Example 145:
(R)-N-(1-{1-{4-Carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-3-methylbenzamide
111
Représentative scheme:
c d
Représentative general procedure: tert-Butyl-1-(4-carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
XRX-000151-00-001-a
To a solution of terf-butyl-1-(4-cyanophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (prepared as described in Example 179-e) (190 mg, 0.15 mmol) in methanol (15 mL) was added an aqueous sodium hydroxide solution (6 mL, 1.0 M). After stirring for 15 minutes, to the resulting solution was added a 30% aqueous hydrogen peroxide (6 mL) dropwise. The resulting mixture was stirred ovemight. The solvent was removed under reduced pressure and the residue was diluted with water (40 mL) and ethyl acetate (40 mL). The organic layer was collected and dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 200:1 to afford tert-butyl-1-(4-carbamoylphenyl)-3-methyl-4oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (160 mg, 80%).
LCMS (ESI): m/z = 389.1 [M+H]4.
4-(3-Methyl-4-oxo-1,3,8-triazaspîro[4.5]decan-1 -yl)benzamide hydrochloride
XRX-000151-00-001 -b
A solution of te/f-butyl-1-(4-carbamoylphenyl)-3-methy1-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (160 mg, 0.41 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The
112 precipitate was collected by filtration and dried under reduced pressure to afford 4-(3-methyl-4-oxo-1,3,8triazaspiro[4.5Jdecan-1-yl)benzamide hydrochloride as a white solid (120 mg, 90%).
LCMS (ESI): m/z = 289.1 [M+Hf.
(R)-Methyl-2-(2-fluoro-3-methylbenzamido)-3-<Tiethylbutanoate
XRX-000151-00-001-C
To a solution of 2-fluoro-3-methylbenzoic acid (1.54 g, 10 mmol) in dichloromethane (50 mL) was added sequentially D-vaiine methyl ester hydrochloride (1.71 g, 10.2 mmol), 1-[bis(dimethylamino)methylene]1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (4.2 g, 11.0 mmol) and N,Ndiisopropylethylamine (3.9 g, 30 mmol). Before quenching with ice-water (50 mL), the reaction was stimed for 2 hours. The mixture was extracted with dichloromethane (3 χ 100 mL). The combined organic layers were dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:4 to afford (R)-methyl-2-(2-fiuoro-3-methylbenzamido)-3-methylbutanoate as a thick oil (3.5 g, crude), which was used directly without further purification.
LCMS (ESI): m/z = 268.2 [M+Hf.
(R)-2-(2-Fluoro-3-methylbenzamido)-3-methylbutanoic acid
XRX-000151-00-001-d
To a solution of (R)-methyl-2-(2-fluoro-3-methyibenzamido)-3-methylbutanoate(3.9 g, crude) in methanol (30 mL) was added an aqueous lithium hydroxide solution (20 mL, 2.0 M, 0.044 mol). Before quenching with ice-water (20 mL), the reaction was stirred for 1 hour. The pH of the solution was adjusted to 3 by addition of a 5% aqueous hydrochloric acid solution. The mixture was filtered and the filter cake was washed with petroleum ether (30 mL) and dried under reduced pressure to afford (R)-2-(2-fluoro-3methylbenzamido)-3-methylbutanoic acid as a thick oil (2.40 g, 94% overtwo steps).
LCMS (ESI): m/z = 254.1 (M+HJL 1H-NMR (300 MHz, CDCh): δ = 1.05 (t, J= 7.8Hz, 6H), 2.32 (s, 3H), 2.34-2.44 (m, 1H), 4.78-4.82 (m, 1H), 7.06-7.13 (m, 1H), 7.27-7.35 (m. 1H), 7.79-7.91 (m, 1H).
113 (R)-N-(1-(1-(4-Carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-3-methylbenzamide
To a mixture of 4-(3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzamide hydrochloride (100 mg, 0.3 mmol) in dichloromethane (5 mL) was added (R)-2-(2-fluoro-3-methylbenzamido)-3-methylbutanoic acid (94 mg, 0.34 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (177 mg, 0.46 mmol) and N,N-diisopropylethylamine (80 mg, 0.62 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-N-(1 -(1-(4carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-3methylbenzamide as a white solid (11.8 mg, 7.3%).
LCMS (ESI): m/z = 524.2 [M+H]4.
1H-NMR (400 MHz, CD3OD): δ = 0.96-1.25 (m, 6H), 1.68-1.96 (m, 2H), 2.18-2.26 (m, 4H), 2.70-2.71 (m, 1H), 2.89-2.92 (m, 1H), 3.04 (s, 3H). 3.56-3.58 (m, 1H), 3.99-4.03 (m, 1H), 4.37-4.39 (m, 1H), 4.54-4.58 (m, 1H), 4.79-4.82 (m, 2H), 4.95-5.16 (m, 1H), 6.74-6.80 (m, 2H), 7.14-7.17 (m, 1H), 7.38-7.40 (m. 1H), 7.47-7.81 (m, 3H).
The following compound was synthesized following the general procedure described above: Example 146: (R)-N-(1-(1-(3-Carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-3-methylbenzamide
24.2 mg, yield: 17%, white solid.
LCMS (ESI): m/z = 524.0 [M+H]4.
1H-NMR (400 MHz, CDCh): δ = 0.94-1.19 (m, 6H), 1.69-1.86 (m, 2H), 2.17-2.26 (m, 1H), 2.33 (s, 3H), 2.54-2.69 (m, 1H), 2.75-2.87 (m, 1H), 3.07 (s, 3H), 3.49-3.65 (m, 1H), 4.04-4.19 (m, 2H), 4.60-4.67 (m, 1H), 4.78 (s, 2H), 5.01-5.24 (m, 1H), 6.19-6.34 (m, 2H), 6.92-7.00 (m, 1H), 7.09-7.22 (m, 3H), 7.35 (s, 1H), 7.50-7.63 (m, 1H), 7.70-7.85 (m, 1H).
114
Example 147:
(R)_4-(8-(2-(2-Fluoro-3-methylbenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yl)phenylboronîc acid
Représentative scheme:
F O
Br
Example 179-d a
Représentative general procedure:
-(4-Bromophenyl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride
Br
XRX-000152-00-001 -a
A solution of fert-butyl-1-(4-bromophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (prepared as described in Example 179-d) (250 mg, 0.00041 mol) in hydrochtoric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 1-(4-bromophenyl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride as a white solid (180 mg, 85%).
LCMS (ESI): m/z = 324.1,326.1 [M+Hf.
115 (R)-N-(1 -{1 -(4-Bromophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 -oxobutan-
2-yl)-2-fluoro-3-methylbenzamide
Br
To a mixture of 1-(4-bromophenyl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride (167 mg, 0.465 mmol) in dichloromethane (10 mL) was added (R)-2-(2-fluoro-3-methylbenzamido)-3methylbutanoic acid (prepared asdescribed in Example 145-d) (140 mg, 0.511 mmol), 1[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafiuorophosphate (HATU) (292 mg, 0.767 mmol) and N,N-diisopropylethylamine (150 mg, 1.16 mmol). The resulting mixture was stirred for 2 hours before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 * 10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:5 to afford (R)-N-(1-(1-(4-Bromophenyl)-3-methyl-4-oxo-
1,3,8-triazaspiro[4.5]decan-8-y1)-3-methyl-1-oxobutan-2-yl)-2-fluoro-3-methylbenzamide as a colorless oil (220 mg, 85%).
LCMS (ESI): m/z = 559.2, 561.2 [M+Hj*.
(R)-4-(8-(2-(2-FliJoro-3-methylbenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yljphenyIboronic acid
To a solution of (R)-N-(1-(1-(4-bromophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyt-1oxobutan-2-yl)-2-fluoro-3-methylbenzamide (220 mg, 0.39 mmol) in DMSO (10 mL) was added sequentially bis(pinacoiato)diboron (300 mg, 1.18 mmol). tris(dibenzylideneacetone)dipalladium (36 mg, 0.039 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) (46 mg, 0.047 mmol) and potassium acetate (78 mg, 0.788 mmol) under an argon atmosphère. The reaction mixture was stirred at 130°C for 2 hours. After quenching with ice-water (5 mL), the reaction mixture was extracted with ethyl acetate (3*15 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. To the residue were added éthanol (3 mL) and an aqueous hydrochloric acid solution (3 mL, 1.0 M). The resulting mixture was stirred ovemight. The solvents were removed under reduced pressure. The residue was purified by prep-HPLC (acetonitrile and water, acetonitrile from 5% to 75%) to afford (R)-4-(8-(2-(2-fluoro-3-methylbenzamido)-3-methylbutanoyl)-3methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenylboronic acid as a brown oil (14 mg, 7%).
116
LCMS (ESI): m/z = 525.2 [M+H]\ 1H-NMR (400 MHz, CD3OD): Ô = 1.03-1.19 (m, 6H), 1.71-1.82 (m, 2H), 2.20-2.40 (m, 4H), 2.63-2.78 (m, 1H), 2.92-2.96 (m, 1 H), 3.04 (s, 3H), 3.48-3.62 (m, 1H), 4.00-4.03 (m, 1H), 4.29-4.65 (m. 2H), 4.78-4.86 (m, 2H), 4.94-5.03 (m, 1H), 6.72-6.76 (m, 2H), 7.04-7.26 (m, 1H), 7.32-7.63 (m, 2H), 7.82-7.85 (m, 2H).
The following compound was synthesized following the general procedure described above: Example 148:
(R)-3-(8-(2-(2-Fluoro-3-methylbenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yl)phenylborontc acid
OH
B
OH
2.0 mg, yield: 8%, white solid.
LCMS (ESI): m/z = 525.2 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 0.94-1.16 (m, 6H), 1.61-1.95 (m, 3H), 2.09-2.35 (m, 3H), 2.47-2.90 (m, 2H), 2.93-3.16 (m, 3H). 3.55-3.60 (m, 1H), 3.95-4.19 (m, 2H), 4.46-4.84 (m, 3H), 4.98-5.20 (m, 1H), 6.637.19 (m, 4H), 7.34-7,85 (m, 3H).
Example 149: (Rj_4-{8^2-{2-Fluoro-5-(trif)uoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspîro[4.5]decan-1-yl)benzoic acid
COOH
117
Représentative scheme:
Représentative general procedure: fert-Butyl-4-cyano-4-{4-(methoxycarbonyl)phenylamino)piperidine-1-€arboxylate
CN
BocN
COOMe
To a solution of methyl-4-aminobenzoate (16.46 g, 0.109 mol) in acetic acid (160 mL) was added tertbutyl-4-oxopiperidine-1-carboxylate (23.8 g, 0.12 mol). The resulting mixture was cooled to 0°C and trimethylsilyl cyanide (12.95 g, 0.131 mol) was added. The resulting solution was stirred ovemight at room température. Saturated aqueous ammonium chloride solution was added (200 mL). After stirring at room température for 10 minutes, the mixture was filtered. The filter cake was dried under reduced pressure to afford tert-butyl~4-cyano-4-(4-(methoxycarbonyl)phenylamino)piperidine-1-carboxylate as a white solid (39.1 g, 100%).
LCMS (ESI): m/z = 360.2 [M+H]+.
tert-Butyl-4-carbamoyl-4-(4-(methoxycarbonyl)phenylamino)piperidine-1-carboxylate
COOMe
To a solution of tert-butyl-4-cyano-4-(4-(methoxycarbonyl)phenylamino)piperidine-1-carboxylate (20.0 g, 0.0557 mol) in methanol (300 mL) was added an aqueous sodium hydroxide solution (100 mL, 1.0 M). After stirring for 15 minutes, to the resulting solution was added a 30% aqueous hydrogen peroxide solution (8 mL) dropwise. After stirring ovemight, the resulting mixture was filtered. The filter cake was
118 washed with water (3 * 100 mL) and dried under reduced pressure to afford tert-butyl-4-carbamoyi-4-(4(methoxycarbonyl)phenylamino)piperidine-1-carboxylate as a white solid (18.0 g, 79%). LCMS (ESI): m/z = 378.2 [M+H]+.
1H-NMR (400 MHz, DMSO-d6): δ = 1.39 (s, 9H), 1.82-1.92 (m, 4H), 3.14-3.17 (m, 2H), 3.61-3.64 (m, 2H),
3.78 (s, 3H), 6.57 (s, 1H), 6.62-6.70 (m, 2H), 7.15 (s, 1H), 7.41 (s, 1H), 7.62-7.77 (m, 2H).
tert-Butyl-1-(4-{methoxycarbonyl)phenyl)-4-oxo-1,3l8-triazaspiro[4.5ldecane-8-carboxylate
To a solution of fert-butyl-4-carbamoyl-4-(4-(methoxycarbonyl)phenylamino)piperidine-1-carboxylate (20.0 g, 0.053 mol) in triethyl orthoformate (200 mL) was added acetic acid (1 mL, cat.). The resulting mixture was stirred at 150°C for 30 hours. The solvent was removed under reduced pressure. The residue was dissolved in methanol (200 mL). To the resulting solution was added sodium borohydride (2.62 g, 0.069 mol) at 0°C. The resulting mixture was stirred for 30 minutes. The solvent was removed under reduced pressure and the residue was diluted with water (200 mL) and ethyl acetate (150 mL). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (3 χ 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by sîlica gel column chromatography eluting with dichloromethane : methanol = 100:1 to afford tert-butyl-1-(4-(methoxycarbonyl)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (10 g, 48%).
LCMS (ESI): m/z = 390.2 [M+Hf.
1H-NMR (400 MHz, DMSO-d6): δ = 1.40 (s, 9H), 1.72-1.75 (m, 2H), 2.47-2.50 (m, 2H), 3.35-3.42 (m, 2H),
3.78 (s, 3H), 3.97-4.01 (m, 2H), 4.70 (s, 3H). 6.68 (d, J = 8.8 Hz, 2H), 7.75 (d, J= 8.8 Hz, 2H), 8.94 (s, 1H).
tert-Butyi-1-(4-(methoxycarbonyl)phenyl)-3-methyl-4-oxo-1,3l8-triazaspiro[4.5]decane-8carboxylate
To a solution of tert-butyl-1-(4-(methoxycarbonyl)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (1.0 g, 0.00258 mol) in N,N-dimethylformamide (10 mL) was added sodium hydride (180 mg, 60% in oil, 0.00437 mol) at 0°C. After stirring for 15 minutes, iodomethane (0.55 g, 0.00386 mol) was added. The resulting mixture was stirred for 15 minutes at room température and the reaction was
119 quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether= 1:1 to afford fert-butyl-1-(4-(methoxycarbonyl)phenyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decane-8-carboxylate as a white solid (0.95 g, 94%).
LCMS (ESI): m/z = 404.2 [M+Hf.
4-(8-(fert-Butoxycarbonyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid
To a solution of fôrf-butyl-1-(4-(methoxycarbonyl)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (1.0 g, 0.00248 mol) in methanol (10 mL) was added a 15% aqueous sodium hydroxide solution (15 mL). The reaction was heated at reflux for 1 hour before cooling to room température. The pH of the resulting solution was adjusted to 1 by addition of 10% aqueous hydrochloric acid solution. The mixture was fittered and the filter cake was washed with water (10 mL) and then dried under reduced pressure to afford 4-(8-(fert-butoxycarbonyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid as a white solid (0.92 g, 94%).
LCMS (ESI): m/z = 390.2 [M+Hf.
fert-Butyl-1-(4-(benzyloxycarbonyl)phenyl)-3-methyl-4-oxo-1,3I8-triazaspiro[4.5]decane-8carboxylate
To a solution of 4-(8-(fert-butoxycarbonyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid (0.92 g, 0.00236 mol) in N.N-dimethylformamide (10 mL) was added potassium carbonate (0.51 g, 0 00372 mol) and benzyl bromide (0.55 g, 0.00322 mol). Before the reaction was quenched by addition of ice-water (10 mL), the mixture was heated for 2 hours at 50°C. The mixture was extracted with ethyl acetate (3 * 30 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether= 1:1 to afford terf-butyl-1-(4-(benzyloxycarbonyl)phenyl)-3methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (0.9 g, 81%).
LCMS (ESI): m/z = 480.2 [M+Hf.
120 ^-NMR (300 MHz, CDCh): δ = 1.53 (s, 9H), 1.62-1.65 (m, 2H), 2.57-2.79 (m, 2H), 3.03 (s, 3H), 3.66-4.49 (m, 2H), 4.05-4.16 (m, 2H), 4.74 (s, 2H), 5.33 (s, 2H), 6.65 (d, J= 9.1 Hz, 2H), 7.30-7.48 (m, 5H), 7.75 (d, J = 9.1 Hz, 2H).
BenzyM-(3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate hydrochloride
A solution of tert-butyl-1-(4-(benzyloxycarbonyl)phenyi)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (0.9 g, 0.00187 mol) in hydrochloric acid in dioxane (6.0 M, 20 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford benzy!-4(3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate hydrochloride as a white solid (0.92 g, 80%). LCMS (ESI): m/z = 380.2 [M+Hf.
(R)-Benzyl-4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspîro[4.5]decan-1 -yl)benzoate
To a mixture of benzyl-4-(3-methyl-4-oxo-1,3,8-triazaspiroI4.5]decan-1-yl)benzoate hydrochloride (120 mg, 0.28 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(2-fiuoro-5(trifluoromethyl)benzamido)-3-methylbutanoîc acid (prepared as described in Example 28-f) (99 mg, 0.32 mmol), (1-[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (190 mg, 0.50 mmol) and N,N-diisopropytethylamine (150 mg, 1.164 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched by addition of with icewater (5 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLCwith dichloromethane : methanol = 15:1 to afford (R)-benzyl-4-(8-(2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5ldecan-1-yl)benzoate as a thick oü (112 mg, crude).
LCMS (ESI): m/z = 669.2 [M+H]’.
121 (R)-4-(8-(2-(2-Fluoro-5-(tnfluoromethyl)benzamido)-3-methylbutanoyl)-3-methyM-oxo-1l3,8triazaspiro[4.5]decan-1-yl)benzoic acid
COOH
To a solution of ((R)-benzyl-4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate (112 mg, 80% purity, 0.134 mmol) in methanol (15 mL) was added 5% palladium on carbon (50 mg, 50% wet with water). The mixture was stirred under a hydrogen atmosphère for 40 minutes. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (acetonitrile and water, acetonitrile from 20% to 60%) to afford (R)-4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-
1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid as a white solid (64 mg, 38% over two steps).
LCMS (ESI): m/z = 579.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.05-1.28 (m, 6H), 1.68-1.91 (m, 2H), 2.19-2.35 (m, 1H), 2.36-2.82 (m, 1 H), 2.88-3.00 (m, 1H), 3.04 (s, 3H), 3.50-3.63 (m, 1H), 3.92-4.01 (m, 1H), 4.03-4.10 (m, 1H), 4.29-4.48 (m, 1H), 4.50-4.66 (m, 2H), 4.93-5.18 (m, 1H), 6.74-6.79 (m, 2H), 6.79-7.49 (m, 1H), 7.70-7.72 (m, 1H), 7.88-7.89 (m, 1H), 8.02-8.05 (m, 1H).
The following 18 compounds were synthesized following the general procedure described above: Example 150:
(R)-4-{8-{2-(2-Fluoro-3-methylbenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid
COOH
12.0 mg. yield: 28%, white solid.
LCMS (ESI): m/z = 525.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.86-1.25 (m, 6H), 1.60-1.94 (m, 2H), 2.16-2.43 (m, 4H), 2.60-2.85 (m,
1H), 2.85-3.00 (m, 1H), 3.07 (s, 3H), 3.54-3.60 (m, 2H). 4.04-4.36 (m, 2H), 4.60-4.85 (m, 2H), 5.10-5.25 (m, 1H), 6.66-6.71 (m, 2H), 7.00-7.20 (m, 1H), 7.29-7.33 (m, 1H), 7.53-7.73 (m, 1H), 7.73-8.08 (m, 3H).
122
Example 151:
(R)-4-{8-{2-{2-Fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)-2-methoxybenzoic acid
54.9 mg, yield: 27%, white solid.
LCMS (ESI): m/z = 609.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.08-1.17 (m, 6H), 1.76-1.88 (m, 2H), 2.22-2.94 (m, 1H), 2.71-2.88 (m,
2H), 3.05 (s, 3H), 3.55-3.60 (m, 1H), 3.85 (s, 3H), 4.02-4.07 (m, 1H), 4.38-4.40 (m, 1H), 4.56-4.58 (m.
1H), 4.71-4.82 (m, 2H), 5.02-5.05 (m, 1H), 6.20-6.27 (m, 1H), 6.43-6.45 (m, 1H), 7.46-7.50 (m, 1H), 7.57-
7.78 (m, 1H), 7.89 (m, 1H), 8.03-8.04 (m, 1H), 8.63-8.68 (m, 1H).
Example 152:
(RJ^l-^-^-fS-Ethyl^-fluorobenzamidoJ-S-methylbiJtanoylJ-S-methyM-oxo-l ,3,8triazaspiro[4.5ldecan-1 -yl)benzoic acid
COOH
24.0 mg, yield: 31%, white solid.
LCMS (ESI): m/z = 539.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.03-1.34 (m, 9H), 1.64-1.90 (m. 2H), 2.15-2.28 (m, 1H), 2.61-2.74 (m, 3H), 2.84-2.98 (m, 1H), 3.03 (s, 3H), 3.46-3.61 (m, 1H), 3.95-4.11 (m, 1H), 4.31-4.42 (m, 1H), 4.54-4.65 (m, 1H), 4.13-4.84 (m,2H), 4.96-4.98 (m, 1H), 6.52-6.79 (m, 1H), 7.10-7.19 (m, 1H), 7.31-7.40 (m, 1H), 7.61-7.65 (m, 1H), 7.74-7.90 (m, 2H).
Example 153:
(R)_4-(8-(2-(5-Cyclopropyl-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid
23.5 mg, yield: 49%, white solid.
123
LCMS (ESI): m/z = 551.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.55-0.73 (m, 2H), 0.89-1.00 (m, 2H), 1.03-1.04 (m, 3H), 1.09-1.14 (m, 4H), 1.71-1.74 (m, 1H), 1.80-1.84 (m, 1H), 1.91-2.02 (m, 1H), 2.20-2.33 (m, 1H), 2.67-2.83 (m, 1H).2.923.00 (m, 1H), 3.04 (s, 3H), 3.52-3.59 (m, 1H), 3.99-4.05 (m, 1H), 4.33-4.43 (m, 1H), 4.54-4.63 (m, 1H), 4.81-4.83 (m, 1H), 4.97-5.05 (m, 1H), 6.76-6.80 (m, 2H), 7.09-7.29 (m, 2H), 7.46-7.50 (m, 1H), 7.74-7.90 (m, 2H), 8.24-8.32 (m, 1H).
Example 154: (R)-2-Chloro-4-{8-{2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-
1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid
13.0 mg, yield: 12%, white solid.
LCMS (ESI): m/z = 613.0 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.05-1.20 (m, 6H), 1.4-1.88 (m, 2H), 2.22-2.29 (m, 1H), 2.63-2.7 0 (m, 1H), 2.89-2.94 (m, 1H), 3.04 (s, 3H), 3.53-3.60 (m, 1H), 4.01-4.08 (m, 1H), 4.39-4.42 (m, 1H), 4.57-4.59 (m, 1H), 4.80-4.84 (m, 2H). 5.05-5.10 (m, 1H), 6.68-6.72 (m, 1H), 6.79-6.82 (m, 1H), 7.44-7.49 (m, 1H), 7.65-7.67 (m, 1H), 7.88-7.90 (m, 1H), 8.05-8.07 (m, 1H). 8.58-8.67 (m, 1H).
Example 155:
(R)-4-(3-{Cyclopropylmethyl)-8-{2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-4oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid
COOH
36.5 mg, yield: 33%, white solid.
LCMS (ESI): m/z = 619.2 (M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.35-0.38 (m, 2H), 0.63-0.67 (m, 2H), 1.05-1.12 (m, 7H), 1.71-1.92 (m, 2H), 2.23-2.27 (m, 1H), 2.69-2.80 (m, 1H), 2.93-3.00 (m, 1H), 3.31-3.33 (m, 2H), 3.52-3.59 (m, 1H), 3.994.07 (m, 1H), 4.33-4.42 (m, 1H), 4.56-4.60 (m, 1H), 4.94-5.05 (m, 4H), 6.79-6.81 (m, 2H), 7.45-7.47 (m, 1H), 7.73-7.89 (m, 3H), 8.03-8.06 (m, 1H), 8.55-8.67 (m, 1H).
124
Example 156:
(R)_4^8-(2-Cyclopentyl-2-{2-fluoro-5-(trifluoromethyl)benzamido)acetyl)-3-methyl-4-oxo-1l3,8triazaspiro[4.5]decan-1 -yl)benzoic acid
COOH
29.0 mg, yieid: 35%, white solid.
LCMS (ESI): m/z = 605.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): ô = 1.32-1.40 (m, 1H), 1.45-1.58 (m, 1H), 1.65-1.81 (m, 6H), 1.93-1.95 (m, 1H), 2.50-2.56 (m, 1H), 2.67-2.76 (m, 2H), 2.95-3.01 (m, 1H), 3.04 (s, 3H), 3.51-3.60 (m, 1H), 4.00-4.08 (m, 1H), 4.39-4.50 (m, 1H), 4.56-4.59 (m, 1H), 4.83-4.88 (m, 2H, 1H contained in solvent signal), 5.045.07 (m, 1H), 6.74-6.83 (m, 2H), 7.43-7.48 (m, 1H), 7.69-7.71 (m, 1H), 7.86-8.06 (m, 3H).
Example 157:
(R)-N-(1-(1-(4-Carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
23.1 mg, yieid: 9%. white solid.
LCMS (ESI): m/z = 578.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.05-1.20 (m, 6H), 1.73-1.85 (m, 2H), 2.25-2.28 (m, 1H), 2.69-2.73 (m, 1H), 2.95-2.98 (m, 1H), 3.05 (s, 3H), 3.54-3.61 (m, 1H). 4.04-4.05 (m. 1 H). 4.35-4.38 (m. 1H). 4.46-4.49 (m, 1H), 4.56-4.58 (m, 2H), 4.99-5.06 (m, 1H), 6.78-6.81 (m, 2H), 7.46-7.51 (m, 1H), 7.63-7.65 (m, 1H), 7.80-7.82 (m, 1H), 7.88-7.89 (m, 1H), 8.04-8.05 (m, 1H).
125
Example 158:
(R)-4-(8-(2-(2-Fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)-2-methylbenzoic acid
25.0 mg, yield: 32%, white solid.
LCMS (ESl): m/z = 593.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 0.99-1.16 (m, 6H), 1.78-1.80 (m, 2H), 2.22-2.30 (m, 1H), 2.36-2.39 (m, 2H), 2.44-2.59 (m, 2H), 2.63-2.72 (m, 1H), 3.03 (s, 3H), 3.58-3.65 (m, 1H), 3.94-4.10 (m, 1H), 4.31-4.35 (m, 1H), 4.44-4.49 (m, 1H), 4.73-4.78 (m, 2H), 4.98-5.03 (m, 1H), 6.91-7.02 (m, 2H), 7.21 (m, 1H), 7.397.51 (m, 1H), 7.84-8.09 (m, 2H).
Example 159:
(R)-4-(8-{2-{2-Fluoro-5-{trrfluoromethyl)benzamido)-3,3-dimethylbutanoyl)-3-methyM-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid
4.1 mg, yield: 6%, white solid.
LCMS (ESl): m/z = 593.2 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 1.06-1.15 (m, 6H), 1.21-1.23 (m, 2H), 1.27-1.29 (m, 1H), 1.66-1.70 (m, 1H), 1.82-1.85 (m, 1H), 2.70-2.74 (m, 1H), 2.87-2.91 (m, 1H), 3.07 (s. 3H), 3.54-3.57 (m, 1H). 4.12-4.17 (m, 1H), 4.29-4.32 (m, 1H), 4.66-4.69 (m, 1H), 4.76-4.85 (m, 2H), 5.22-5.32 (m, 1 H), 6.59-6.73 (m, 2H), 7.28-7.52 (m, 1H), 7.68-7.98 (m, 4H), 8.33-8.39 (m, 1H).
Example 160:
(R)-4-(8-(2-(3-Chloro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yl)benzoic acid
18.5 mg, yield: 30%, white solid.
126
LCMS (ESI): m/z = 595.1 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.03-1.20 (m, 6H), 1.69-1.90 (m, 2H), 2.27-2.35 (m, 1H), 2.64-2.73 (m, 1H), 2.94-2.99 (m, 1H), 3.04 (s, 3H), 3.51-3.58 (m, 1H). 3.99-4.06 (m, 1H), 4.43-4.60 (m, 2H), 4.80-4.84 (m, 3H, 1H contained in solvent signal), 6.70-6.80 (m, 2H), 7.58-7.61 (m, 2H), 7.87-7.90 (m, 1H), 8.138.17 (m, 2H), 8.82-8.99 (m, 1H).
Example 161:
(R)-4-(3-Metliyl-8-{3-methyl-2-(2-methyl-5-(trifluoromethyl)benzamido)butanoyl)-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yl)benzoic acid
15.0 mg, yield: 35%, white solid.
LCMS (ESI): m/z = 575.2 [M+Hf.
Ή-NMR (400 MHz, CD3OD): δ = 1.13-1.15 (m, 6H), 1.69-1.80 (m, 2H). 2.22-2.35 (m, 1H), 2.50-2.54 (m, 3H), 2.67-2.84 (m, 1H), 3.00-3.13 (m, 4H), 3.54-3.58 (m, 1H), 4.06-4.11 (m, 1H), 4.39-4,43 (m. 1H), 4.544.67 (m, 1H), 4.84-4.92 (m, 2H), 4.94-5.05 (m, 1H), 6.80-6.83 (m, 2H), 7.48-7.53 (m, 1H), 7.64-7.67 (m, 1H), 7.71-7.81 (m, 2H), 7.89-8.00 (m, 1H).
Example 162:
(R)_4_(8-(2-(2-Fluoro-5-(trifluoromethoxy)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8tnazaspiro[4.5]decan-1 -yl)benzoic acid
10.6 mg, yield: 15%, white solid.
LCMS (ESI): m/z = 595.2 [M+H]+.
Ή-NMR (400 MHz, CD3OD): δ = 1.75-1.88 (m, 6H), 1.75-1.78 (m, 2H), 2.25-2.36 (m, 2H), 2.90-2.92 (m, 1H), 3.10 (s, 3H), 3,55-3.59 (m, 1H), 4.01-4.03 (m, 1H). 4.31-4.35 (m, 2H), 4.83-4.85 (m, 1H), 4.96-5.00 (m, 2H), 6.75-6.80 (m. 1H), 7.36-7.90 (m, 5H), 8.56-8.61 (m, 1H).
Example 163:
(R}_4-(8-(2-(2-Fluoro-5-methoxybenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid
127
27.5 mg, yield: 26%, white solid.
LCMS (ESI): m/z = 541.2 [M+H]4.
1H-NMR (400 MHz, CDCh): δ = 1.08-1.27 (m, 6H), 1.68-1.78 (m, 2H), 2.21-2.24 (m, 1H), 2.27-2.77 (m, 1H), 2.88-2.93 (m, 1H), 3.06 (s, 3H), 3.50-3.57 (m, 1H), 3.78-3.82 (m, 3H), 4.03-4.22 (m, 2H), 4.69-4.80 (m, 3H), 5.07-5.21 (m, 1H), 6.50-6.69 (m, 2H), 6.95-7.12 (m, 2H), 7.53-7.84 (m, 2H), 7.94-7.96 (m, 2H).
Example 164:
(R)-4-(8-(2-(1-Admantanecarboxamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yljbenzoic acid
29.9 mg, yield: 54%, white solid.
LCMS (ESI): m/z= 551.2 [M+H]4.
1H-NMR (400 MHz, CDCh): δ = 0.90-1.03 (m, 6H), 1.72-1.97 (m, 16H), 2.15-2.21 (m, 1 H), 2.68-2.83 (m, 3H), 3.04 (s, 3H). 3.50-3.56 (m, 1H). 4.00-4.94 (m, 1H), 4.24-4.26 (m, 1H), 4.52-4.54 (m, 1H), 4.73-4.75 (m, 1H), 4.84-4.86 (m, 2H). 6.77-6.79 (m, 2H). 7.85-7.95 (m, 2H).
Example 165:
(R)jt-(8-(2-(5-(Difluoromethoxy)-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8trîazaspiro[4.5ldecan-1-yl)benzoic acid
COOH
36.0 mg, yield: 51%, white solid.
LCMS (ESI): m/z = 577.2 [M+H]4.
’H-NMR (400 MHz, CDCh): δ = 1.04-1.15 (m, 6H), 1.72-1.81 (m, 2H), 2.24-2.29 (m, 1H), 2.67-2.94 (m, 2H), 3.04 (s, 3H). 3.52-3.59 (m, 1H), 4.03-4.06 (m. 1H), 4.32-4.34 (m, 1H), 4.55-4.58 (m, 1H), 4.86-4.91 (m, 1H), 4.97-5.05 (m, 2H), 6.75-6.77 (m, 2H), 6.85-6.94 (m, 1H), 7.28-7.31 (m, 1H), 7.52-7.55 (m, 1H),
128
7.72-7.79 (m, 1H), 7.88-7.90 (m, 1H), 8.39-8.46 (m, 1H).
Example 166:
(R)-448-(2-{5-(Difluoromethoxy)-2-fluorobenzamido)-3-methylbutanoyl)-3- methyl-2,4-dioxo-1,3,8triazaspiro[4,5]decan-1 -yl)benzoic acid
19.9 mg, 77% yield, white solid.
LCMS (ESl): m/z = 591.1 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ= 0.79-1.01 (m, 6H), 1.71-2.19 (m, 5H), 3.09 (S, 3H), 3.46-3.52 (m, 1H), 3.89-4.04 (m, 1H), 4.15-4.56 (m, 2H). 4.79-4.84 (m, 1H), 6.66-7.00 (m, 1H), 7.21-7.49 (m, 5H), 8.02-8.17 (m, 2H).
Example 167:
(R)-4-(8-(2-(2-Fluoro-5-(trifluoromethoxy)benzamido)-3-methylbutanoyl)-3- methyl-2,4-dioxo-1,3,8triazaspiroi4.5]decan-1-yl)benzoic acid
57.4 mg, 66% yield, white solid.
LCMS (ESl): m/z = 609.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ= 0.80-1.01 (m, 6H), 1.70-2.27 (m, 5H), 3.10 (s, 3H), 3.46-3.54 (m, 1H),
91-3.99 (m, 1H), 4.26-4.58 (m, 2H), 4.78-4.83 (m, 1H), 7.26-7.65 (m, 5H), 8.04-8.16 (m, 2H).
129
Example 168:
(R)-2-(4-(842-(5-Ethyl-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1l3,85 triazaspiro[4.5]decan-1 -yl)phenoxy)acetic acid
Représentative general procedure: tert-Butyl-4-cyano-4-(4-methoxyphenylamino)piperidine-1-carboxylate
To a solution of 4-methoxyaniline (5.0 g, 0.040 mol) in acetic acid (30 mL) was added tert-butyl-4oxopiperidine-1-carboxylate (8.8 g, 0.044 mol). The resufting mixture was cooled to 0°C and trimethylsilyl
130 cyanide (4.36 g, 0.040 mol) was added. The solution was stirred ovemight. Saturated aqueous ammonium chloride solution was added (50 mL). The mixture was filtered, the filter cake was washed with water (3*10 mL) and dried under reduced pressure to afford tert-butyl-4-cyano-4-(4methoxyphenylamino)piperidine-1-carboxylate as a white solid (12.1 g, 93%).
LCMS (ESI): m/z = 332.1 [M+Hf.
tert-Butyl-4-carbamoyl-4-(4-methoxyphenylamino)piperidine-1-carboxylate
To a solution of fert-butyl-4-cyano-4-(4-methoxyphenylamino)piperidine-1-carboxy1ate (3.0 g, 9.06 mmol) in methanol (16 mL) was added an aqueous sodium hydroxide solution (10 mL, 1.0 M). After stirring for 15 minutes, to the resulting solution was added a 30% aqueous hydrogen peroxide solution (10 mL) dropwise. The resulting mixture was stirred ovemight and filtered. The white solid was washed with water (3 « 10 mL) and dried under reduced pressure to afford tert-butyl-4-carbamoyl-4-(4methoxyphenylamino)piperidine-1-carboxy1ate as a white solid (2.8 g, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 350.2 [M+Hf.
tert-Butyl-1-(4-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of fert-butyl-4-carbamoyl-4-(4-methoxyphenylamino)piperidine-1-carboxylate (450 mg, 1.3 mmol) in triethyl orthoformate (4 mL) was added acetic acid (2 drops, cat.). The mixture was heated at 140°C for 30 minutes in a microwave reactor. The solvent was removed under reduced pressure and the residue was dissolved in methanol (10 mL). To the resulting solution was added sodium borohydride (100 mg, 2.6 mmol) at 0°C. The resulting mixture was stirred for 30 minutes. The solvent was removed under reduced pressure and the residue was diluted with water (10 mL) and ethyl acetate (15 mL). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (3 * 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel coiumn chromatography eluting with dichloromethane : methanol = 200:1 to afford fert-butyl-1-(4-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (220 mg, 48%).
LCMS (ES!): m/z = 362.2 [M+H]+.
131 tert-Butyl-1-(4-methoxyphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5ldecane-8-carboxylate
To a solution of tert-butyl-1-(4-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (240 mg, 0.66 mmol) in N.N-dimethylfonmamide (5 mL) was added sodium hydride (82 mg, 60% in oil, 2.04 mmol) at 0°C. After stirring for 15 minutes, iodomethane (600 mg, 4.2 mmol) was added. The resulting mixture was stimed for 1 hour. The reaction was quenched with ice-water (10 mL) and the mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 15:1 to afford tert-butyl-1-(4-methoxyphenyl)-3-methyl-4-oxo-
1,3,8-triazaspiro[4.5]decane-8-carboxylate as a yellow oil (232 mg, 93%).
LCMS (ESI): m/z = 376.1 [M+Hf.
tert-Butyl-1-(4-hydroxyphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of ferf-butyl 1-(4-methoxyphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro(4.5]decane-8-carboxylate (160 mg, 0.42 mmol) in dichloromethane (15 mL) was added boron tribromide (500 mg, 2.0 mmol) at 0°C. After stirring ovemight, the reaction was quenched by addition of ice-water (5 mL). To the mixture was added di-ferf-butyl-dicarbonate (300 mg, 1.37 mmol) and potassium carbonate (1 g, 7.24 mmol). The mixture was stirred for 2 hours. The organic layer was isolated and the aqueous layer was extracted with ethyl acetate (3 χ 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 40:1 to afford tert-butyl-1-(4-hydroxyphenyl)-3-methyl-4-oxo-
1,3,8-triazaspiro(4.5]decane-8-carboxylate as a coloriess oil (110 mg, 72%).
LCMS (ESI): m/z = 362.1 [M+Hf.
132 fert-Butyl-1-{4-{2-ethoxy-2-oxoethoxy)phenyl)-3-methyl”4-oxo-1,3l84riazaspiro[4.5]decane-8carboxylate
To a solution of tert-butyl-1-(4-hydroxyphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (50 mg, 0.14 mmol) in N.N-dimethylformamide (15 mL) was added potassium carbonate (38 mg, 0.28 mmol) and ethyl-2-bromoacetate (50 mg, 0.14 mmol). The resulting mixture was stirred ovemight. After quenching with ice-water (10 mL), the mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with ethyl acetate ; petroleum ether ~ 1:1 to afford tertbutyl-1-(4-(2-ethoxy-2-oxoethoxy)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a coloriess oil (40 mg, 65%).
LCMS (ESI): m/z = 448.2 [M+H]*.
Ethyl-2-(4-(3-methyl-4-oxo-1,3,84riazaspiro[4.5]decan-1 -yl)phenoxy)acetate hydrochloride
A solution of fert-butyl-1-(4-(2-ethoxy-2-oxoethoxy)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (40 mg, 0.089 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford ethyl-2-(4(3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenoxy)acetate hydrochloride as a white solid (31 mg, 100%).
LCMS (ESI): m/z = 348.2 [M+H]*.
(R)-Methyl-2-(5-ethyl-241uorobenzamido)-3-methylbutanoate
To a solution of 5-ethyl-2-fluorobenzoic acid (1.00 g, 5.95 mmol) in dichloromethane (50 mL) was added sequentially D-valine methyl ester hydrochloride (1.2 g, 7.18 mmol), 1- [bis(dimethylamino)methylene]
133
IH-I^.S-triazolo^.S-bJpyridinium-S-oxide hexafluoro phosphate (HATU) (3.4 g, 8.94 mmol) and N,Ndiisopropylethylamine (1.9 g, 14.7 mmol). Before quenching with ice-water (50 mL), the reaction was stirred for 2 hours. The mixture was extracted with dichloromethane (3 * 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:4 to afford (R)-methyl-2-(5-ethyl-2-fluorobenzamido)-3-methylbutanoate as a thick oil (1.6 g, 95%). LCMS (ESI): m/z = 282.2 [M+H]+.
(R)-2-(5-Ethyl-2-fluorobenzamido)-3-methylbutanoic acid
O 'X'
To a solution of (R)-methyl-2-(5-ethyl-2-fluorobenzamido)-3-methylbutanoate (1.6 g, crude) in tetrahydrofuran (20 mL) was added an aqueous lithium hydroxide solution (240 mg in 10 mL of water, 17.8 mmol). Before quenching with ice-water (20 mL), the reaction was stirred for 1 hour. The pH of the solution was adjusted to 3 by addition of a 9% aqueous hydrochloric acid solution. The mixture was filtered and the filter cake was washed with petroleum ether (30 mL) and dried under reduced pressure to afford (R)-2-(5-ethy1-2-fluorobenzamido)-3-methylbutanoic acid as a white solid (1.3 g, 94% overtwo steps).
LCMS (ESI): m/z = 268.1 [M+Hf.
1H-NMR (300 MHz, CDCh): 6 = 1.05 (dd, J= 8.6, 6.9 Hz, 6H), 1.23 (t, J = 7.6 Hz, 3H), 2.31-2.45 (m, 1H), 2.65 (q, J= 7.8 Hz, 2H), 7.01-7.07 (m, 1H), 7.16-7.33 (m, 2H), 7.85-7.93 (m. 1H).
(R)-Ethyl-2-(4-(8-(2-(5-ethyl-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5ldecan-1-yl)phenoxy)acetate
OEt
To a mixture of ethyi-2-(4-(3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenoxy)acetate hydrochloride (31 mg, 0.089 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(5-ethyl-2fluorobenzamido)-3-methylbutanoic acid (24 mg, 0.089 mmol), 1-[bis(dimethylamino)methy1ene]-1H1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafiuorophosphate (HATU) (51 mg, 0.13 mmol) and N,Ndîisopropylethylamine (29 mg, 0.22 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water. The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-ethyl-2-(4-(8-(2-(5-ethyl-2-fiuorobenzamido)-3-methylbutanoyl)-3-methyl-4oxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenoxy)acetate as a coloriess oil (20 mg, 37%).
134
LCMS (ESI): m/z = 597.1 [M+Hf.
(R)-2-(4-{8-{2-(5-Ethyl-2-fluorobenzamido)-3-methyibutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yl)phenoxy)acetic acid
To a solution of (R)-ethyl-2-(4-(8-(2-(5-ethyl-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)phenoxy)acetate (20 mg, 0.03 mmol) in tetrahydrofuran (2 mL) was added an aqueous lithium hydroxide solution (2 mL, 2.0 M). The resulting mixture was stirred ovemight. The pH of the reaction mixture was adjusted to 3 by addition of an aqueous hydrochloric acid solution (2.0 M). The resulting mixture was extracted with ethyl acetate (3x10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-HPLC (acetonitrile and water, acetonitrile from 30% to 70%) to afford (R)-2-(4-(8-(2-(5-ethyl-2fluorobenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenoxy)acetic acid as a white solid (7.0 mg, 39%).
LCMS (ESI): m/z = 569.2 [M+Hf.
1H-NMR (400 MHz, CDCb): δ = 0.99-1.04 (m, 9H), 1.73-2.14 (m, 5H), 2.65-2.67 (m, 2H), 3.02 (s, 3H), 3.57-3.60 (m. 1H), 4.02-4.04 (m, 2H), 4.45-4.66 (m, 5H), 5.06-5.10 (m, 1H), 6.75-7.80 (m, 8H).
The following 3 compounds were synthesized following the general procedure described above:
Example 169:
(R)-N-(1-(1 -(4-(2-Amino-2-oxoethoxy)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-3methyl-1-oxobutan-2-yl)-5-ethyl-2-fluorobenzamide
11.0 mg, yield: 17%, white solid.
LCMS (ESI): m/z = 568.2 [M+Hf.
1H-NMR (400 MHz, CDCb): δ = 0.98-1.05 (m, 6H), 1.23-1.27 (m. 3H), 1.73-1.89 (m, 2H), 2.09-2.27 (m, 3H), 2.64-2.71 (m, 2H), 3.03 (s, 3H), 3.53-3.59 (m, 1H), 4.03-4.06 (m, 2H), 4.39 4.89 (m, 3H), 4.63-4.69 (m, 2H), 5.08-5.15 (m, 1 H), 6.14-6.17 (m, 1H), 6.57-6.61 (m, 1H), 6.77-6.85 (m, 4H), 7.02-7.08 (m, 1H), 7.28-7.32 (m, 1H), 7.51-7.56 (m, 1H), 7.84-7.85 (m, 1H).
135
Example 170:
( R)-N-(1-(1-(4-(Cyanomethoxy)phenyl)-3-<nethyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-5-ethyl-2-fluorobenzamide
2.0 mg, yieid: 4%, white solid.
LCMS (ESI): m/z = 550 [M+H]‘.
1H-NMR (400 MHz, CD3OD): 5 = 0.98-1.00 (m, 6H), 1.24-1.32 (m, 3H), 1.67-1.84 (m, 3H), 2.01-2.21 (m, 4H), 2.47-2.52 (m, 1H), 2.65-2.73 (m, 2H), 3.02 (s, 3H), 3.55-3.65 (m, 2H). 3.95-4.04 (m. 1H). 4.36-4.48 (m, 1H). 4.73-4.75 (m, 2H), 4.79-4.82 (m, 1H), 4.97-5.01 (m, 1H), 6.83-6.89 (m, 3H), 7.03-7.05 (m, 1H), 7.11-7.20 (m,4H), 7.39-7.44 (m, 1H), 7.58-7.61 (m, 1H), 8.18-8.25 (m, 1H).
Example 171:
(R)-N-(1-(1-(4-(2-{Dimethylamino)ethoxy)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait
20.8 mg, yieid: 24%, white solid.
LCMS (ESI): m/z = 621.8 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 0.98-1.06 (m, 6H), 1.75-2.21 (m, 4H), 2.48-2.53 (m, 1H), 2.98 (s, 4H), 3.00 (s, 3H), 3.02 (s, 2H), 3.57-3.61 (m, 3H), 3.93-4.11 (m, 1H), 4.22-4.26 (m, 3H), 4.33-4.40 (m, 1H), 4.69-4.72 (m, 2H), 4.94-4.98 (m, 1H), 6.89-7.06 (m, 4H), 7.47-7.53 (m, 1H), 7.92-7.98 (m, 1H), 8.02-8.06 (m, 1H).
136
Example 172:
(R)-N-(1-(1-(4-Acetamidophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-
Représentative scheme:
Vn >
I ÏN BOCN.J \ nh2
Example 218-d °
Vn' ------ BocN
HCl, dioxane
DCM. TEA
b
nV0H
Example 168-i
O >
V-N ° V Vp
HATU. DCM. DIPEA, r.t.
Représentative general procedure:
fert-Butyl-1-(4-acetamidophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of tert-butyl-1-(4-aminophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (prepared as described in Example 218-d) (150 mg, 0.41 mmol) in dichloromethane (15 mL) was added triethylamine (92 mg, 0.92 mmoi). The resulting mixture was cooled to 0°C and acetyl chloride (42 mg, 0.54 mmol) was added. The reaction was stirred for 30 minutes. Afterthe reaction was quenched by addition of ice-water (10 mL), the mixture was extracted with dichloromethane (3 * 10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:3 to afford tert-butyl-1-(4-acetamidophenyl)-3-methyl-4-oxo-1,3.8triazaspiro[4.5]decane-8-carboxylate as a white solid (95 mg, 51%).
137
LCMS (ESi): m/z = 403.2 [M+Hf.
N-(4-(3-Methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenyl)acetamide hydrochloride
To a solution of ferf-butyl-1-(4-acelamidophenyl)-3-methyl-4-oxo-1,3.8-triazaspiro[4.5]decane-8carboxylate (100 mg, 0.248 mmol) in dioxane (2 mL) was added hydrochloric acid in dioxane (4 mL, 6.0 M). The resulting mixture was stirred for6 hours. The preciprtate was collected by filtration and dried under reduced pressure to afford N-(4-(3-methyl-4-oxo*1,3,8-triazaspiro[4.5]decan-1-yl)phenyl)acetamide hydrochloride as a white solid (80 mg, 95%).
LCMS (ESI): m/z = 303.2 (R)-N-{1-{1-(4-Acetamidophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.S]decan-8-yl)-3-methyl-1oxobutan-2-yl)-5-ethyl-2-fluorobenzamide
To a solution of N-(4-(3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)phenyl)acetamide hydrochloride (69 mg, 0.206 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(5-ethyl-2-fluorobenzamido)-3methylbutanoic acid (prepared as described in Exampie 168-i) (50 mg, 0.187 mmol), 1[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (142 mg, 0.374 mmol) and N.N-diisopropylethylamine (48 mg, 0.374 mmol). The reaction was stirred for 2 hours at room température before quenching with ice-water (5 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-N-(1-(1-(4-acetamidophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8y|)-3-methyl-1-oxobutan-2-yl)-5-ethyl-2-fiuorobenzamide as a white solid (16 mg, 16%).
LCMS (ESI): m/z = 552.2 [M+H]+.
1H-NMR (400 MHz, CDCb): Ô = 1.02-1.07 (m, 6H), 1.20-1.27 (m, 3H), 1.71-1.92 (m, 2H), 2.08-2.11 (m, 3H), 2.17-2.45 (m, 2H), 2.57-2.72 (m, 3H), 3.02 (s, 3H), 3.51-3.58 (m, 1H), 3.95-4.05 (m, 1H), 4.18-4.31 (m, 1H), 4.40-4.48 (m, 1H), 4.73-4.75 (m, 2H), 4.95-4.99 (m, 1H), 6.79-7.62 (m, 8H).
138
The following 3 compounds were synthesized following the general procedure described above: Example 173:
(R)-5-Ethy l-2-fluoro-N-(3-methyl-1 -{3-methyl-1 -(4-{methylsulfonamido)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide
10.6 mg, yield: 10%, white solid.
LCMS (ESI): m/z = 588.2 [M+H]4.
1H-NMR (400 MHz, CD3OD): δ = 1.03-1.08 (m, 6H), 1.22-1.27 (m, 3H), 1.71-1.92 (m, 2H), 2.18-2.53 (m, 2H), 2.66-2.78 (m, 3H), 2.82-2.91 (m, 3H), 3.03 (s, 3H), 3.51-3.58 (m, 1H), 3.95-4.05 (m, 1H), 4.22-4.33 (m, 1H), 4.44-4.51 (m, 1H), 4.75-4.76 (m, 2H), 4.95-4.99 (m, 1H), 6.81-8.31 (m, 8H).
Example 174:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-144-(methylsulfonamido)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
24.6 mg, yield: 22%, white solid.
LCMS (ESI): m/z = 628.2 [M+H]4.
1H-NMR (400 MHz, CD3OD): δ = 1.04-1.09 (m, 6H), 1.72-1.93 (m, 2H), 2.19-2.24 (m, 1H), 2.33-2.49 (m, 1H), 2.68-2.76 (m, 1H), 2.76-2.91 (m, 3H), 3.03 (s, 3H), 3.54-3.60 (m, 1H). 3.97-4.12 (m, 1H), 4.22-4.31 (m, 1H), 4.43-4.51 (m, 1H), 4.74-4.76 (m, 2H), 4.94-5.02 (m, 1H), 6.81-6.91 (m, 2H), 7.07-7.21 (m, 2H), 7.39-7.52 (m, 1H), 7.85-7.95 (m, 1H), 8.04-8.06 (m, 1H), 8.55-8.63 (m, 1H).
139
Example 175:
(R)-Methyi-4-(8-(2-(2-fluoro-5-(trif1uoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)phenylcarbamate
58.4 mg, yield: 27%, white solid.
LCMS (ESI): m/z = 607.8 [M+H]\ 1H-NMR (400 MHz, CD3OD): S= 1.01-1.05 (m, 6H), 1.68-1.87 (m,2H), 2.14-2.51 (m, 3H),2.98 (s, 3H), 3.50-3.56 (m, 1H), 3.70-3.73 (m, 3H), 3.92-4.42 (m, 3H), 4.68-4.71 (m, 2H), 4.95-4.99 (m, 1H), 6.80-6.87 (m, 2H), 7.19-7.44 (m, 3H), 7.86-7.77 (m, 1H), 8.02-8.04 (m, 1H).
Example 176:
(RJ-Z-te-^-tS-Fluoro-S-methylbenzamidoJ-S-methylbutanoylH-oxo-l-phenyl-I.S.etriazaspiro[4.5]decan-3-yl)acetic acid
OH
140
Représentative general procedure:
tert-Butyl-3-(2-ethoxy-2-oxoethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of tert-butyl-4-oxo-1-phenyl-1t3,8-triazaspiro[4.5]decane-8-carboxylate (150 mg, 0.453 mmol) in N,N-dimethylfonmamide (20 mL) was added sodium hydride (20 mg, 60% in oil, 0.5 mmol) at 0°C. After stimng for 30 minutes, ethyl-2-chloroacetate (67 mg, 0.543 mmol) was added. The reaction was stirred ovemight, before quenching with ice-water (10 mL). The resulting mixture was filtered to 10 afford fert-butyl-3-(2-ethoxy-2-oxoethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (164 mg, 87%).
LCMS (ESl): m/z = 418.2 [M+Hf.
Ethyl-2-(4-oxo-1-phenyl-1,3,8-triazaspîro[4.5ldecan-3-yl)acetate hydrochloride
OEt
HCl
To a solution of fert-butyl-3-(2-ethoxy-2-oxoethyl)-4-oxo-l-phenyl-1,3,8-triazaspiro[4.5]decane-8carboxylate (80 mg, 0.192 mmol) in dioxane (2 mL) was added hydrochloric acid in dioxane (4 mL, 6,0 141
M). The resulting mixture was stirred for 6 hours. The preciprtate was collected by filtration and dried under reduced pressure to afford ethyl 2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)acetate hydrochloride as a white solid (65 mg, 97%).
LCMS (ESI): m/z = 318.2 [M+Hf.
(R)-Methyl-2-{3-fIuoro-5-methylbenzamido)-3-methylbutanoate
To a solution of 3-fluoro-5-methylbenzoic acid (1.0 g, 6.49 mmol) in dichloromethane (30 mL) was added sequentially D-valine methyl ester hydrochloride (1.2 g, 7.14 mmol), 1- [bis(dimethylamino)methylene]1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (3.7 g, 9.74 mmol) and N.Ndiisopropylethylamine (2.5 g, 19.48 mmol). Before quenching with ice-water (50 mL), the reaction was stirred for 2 hours. The mixture was extracted with dichloromethane (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate ; petroleum ether = 1:4 to afford (R)-methyl-2-(3-fluoro-5-methylbenzamido)-3-methylbutanoate as a thick oil (0.6 g, 35%). LCMS (ESI): m/z = 268.2 [M+Hf.
(R)-2-(3-Fiuoro-5-methylbenzamido)-3-methylbutanoic acid
To a solution of (R)-methyl-2-(3-fluoro-5-methylbenzamido)-3-methylbutanoate(1.64 g, 6.14 mmol) in tetrahydrofuran (30 mL) was added an aqueous lithium hydroxide solution (0.73 g in 20 mL of water, 30.7 mmol). Before quenching with ice-water (20 mL), the reaction was stirred for 1 hour. The pH of the solution was adjusted to 3 by addition of a 5% aqueous hydrochloric acid solution. The mixture was filtered and the filter cake was washed with petroleum ether (30 mL) and dried under reduced pressure to afford (R)-2-(3-fluoro-5-methylbenzamido)-3-methylbutanoic acid as a thick oil (0.8 g, 53%).
LCMS (ESI): m/z = 254.1 [M+H]+.
142 (R)-Ethyl-2-(8-(2-(3-fluoro-5-methylbenzamido)-3-methylbutanoyi)-4-oxo-1-phenyl-1,3,8tnazaspiro[4.5]decan-3-yl)acetate
To a mixture of ethyl-2-(4-oxo-1-phenyl-1,3,8-triazaspiiO[4.5]decan-3-yl)acetate hydrochloride (65 mg, 0.184 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(3-fluoro-5-methy1benzamido)-3methylbutanoic acid (60 mg, 0.224 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5b]pyridinîum-3-oxide hexafiuorophosphate (HATU) (140 mg, 0.368 mmol) and N,N-diisopropylethylamine (120 mg, 0.920 mmol). The reaction was stirred for 2 hours at room température before quenching with ice-water (5 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried overanhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with ethyl acetate : petroleum ether = 15:1 to afford (R)-ethyl-2-(8-(2-(3-fluoro-5methylbenzamido)-3-methylbutanoyl)-4-oxo-1 -phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)acetate as a white solid (20 mg, 20%).
LCMS (ESI): m/z = 553.2 [M+Hf.
(R)-2-(8-(2-(3-Fluoro-5-methylbenzamido)-3-niethylbutanoyl)-4-oxo-1 -phenyl-1,3,8triazaspiro[4.5]decan-3-yl)acetic acid
To a solution of (R)-ethyl-2-(8-(2-(3-fluoro-5-methylbenzamido)-3-methylbutanoyl)-4-oxo-1-phenyl-1,3,8triazaspiro[4.5]decan-3-yl)acetate (20 mg, 0.036 mmol) in tetrahydrofuran : water = 1:1 (10 mL) was added lithium hydroxide (156 mg, 6.5 mmol). The resulting mixture was stirred ovemight. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL). The pH of the aqueous layer was adjusted to 1 by addition of a 5% aqueous hydrochloric acid solution. The resulting mixture was extracted with ethyl acetate (3 * 10 mL). The combined organic layers were dried over anhydrous sodium sulfate and dried under reduced pressure. The residue was purified by prep-HPLC to afford (R)-2-(8-(2(3-fluoro-5-methyl benzamido)-3-methylbutanoy1)-4-oxo-1 -phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)acetic acid as a white solid (2.7 mg, 15%).
LCMS (ESI): m/z = 525.0 [M+H]+.
1H-NMR (400 MHz, CDCI3): δ = 0.99-1.05 (m, 6H), 1.24-1.28 (m, 1H), 1.77-1.87 (m, 2H), 2.16-2.26 (m, 1H), 2.43-2.44 (m, 3H), 2.55-2.67 (m, 3H), 3.50-3.60 (m, 1H), 3.98-4.13 (m, 3H), 4.33-4.66 (m, 4H), 5.225.30 (m, 1H), 6.68-7.45 (m, 7H).
143
The following 2 compounds were synthesïzed following the general procedure described above: Exampie 177:
( R)-2-Fluoro-3-methyl-N-(3-meth y 1-1-(3-(3-( met hylsulfonyl)propyl)-4-oxo-1-pheny 1-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide
O
35.0 mg, yield: 29%, white solid.
LCMS (ESI): m/z = 587.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.99-1.09 (m, 6H), 1.74-1.87 (m, 2H), 2.16-2.23 (m, 3H), 2.35 (s, 3H), 2.49-2.74 (m, 2H), 3.02 (s, 3H), 3.19-3.24 (m, 2H), 3.50-3.98 (m, 3H), 4.01-4.02 (m, 1H), 4.32-4.35 (m, 1H), 4.47-4.51 (m, 1H), 4.73-4.81 (m, 2H), 4.97-5.00 (m, 1H), 6.71-7.52 (m, 8H).
Example 178: (R)-N-(1-{3-{Cyanomethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2yl)-5-ethyl-2-fluorobenzamide
58.3 mg, yield: 60%, white solid.
LCMS (ESI): m/z = 520.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.03-1.08 (m, 6H), 1.22-1.27 (m, 3H), 1.73-1.95 (m, 2H), 2.16-2.53 (m, 2H), 2.65-2.77 (m, 3H), 3.47-3.57 (m, 1H), 3.93-4.05 (m, 1H), 4.21-4.53 (m, 2H), 4.57-4.58 (m, 2H), 4.844.86 (m, 2H), 4.97-4.99 (m, 1H), 6.75-7.62 (m, 8H).
Example 179: (R)-N-{1-{1-{4-Cyanophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-
2-yl)-2-fluoro-3-methylbenzamide
CN
144
Représentative scheme:
CN
Représentative general procedure: tert-Butyl-4-(4-bromophenylamino)-4-cyanopiperidine-1-carboxylate
CN
Br
To a solution of 4-bromoaniline (4.17 g, 0.024 mol) in acetic acid (100 mL) was added tert-butyl-4oxopiperidine-1-carboxylate (5 g, 0.025 mol). The resulting mixture was cooled to 0°C and trimethylsilyi cyanîde (2.71 g, 0.027 mol) was added. The resulting solution was stirred ovemight. Saturated aqueous ammonium chloride solution was added (50 mL). The mixture was filtered, the filter cake was washed with water (3*10 mL) and dried under reduced pressure to afford tert-butyl-4-(4-bromophenylamino)-4cyanopiperidine-1-carboxy!ate as a white solid (9.0 g, 98%).
LCMS (ESI): m/z = 380.1,383.1 [M+H]4.
1H-NMR (400 MHz, DMSO-de): δ = 1.41 (s, 9H), 1.65-1.85 (m, 2H), 2.28 (d, J= 13.6 Hz, 2H), 3.10-3.16 (m, 2H), 3.76 (d, J= 14.3 Hz, 2H), 6.34 (s, 1H), 6.74-6.91 (m, 2H), 7.27-7.43 (m, 2H).
tert-Butyl-4-(4-bromophenylamino)-4-carbamoylpiperidine-1-carboxylate
Br
To a solution of tert-butyl-4-(4-bromophenylamino)-4-cyanopiperidine-1-carboxylate (4.0 g, 0.011 mol) in methanol (300 mL) was added an aqueous sodium hydroxide solution (36 mL, 1.0 M). After stirring for 15 minutes, to the resulting solution was added a 30% aqueous hydrogen peroxide solution (29 mL)
145 dropwise. The resulting mixture was stirred ovemight and filtered. The precipitate was washed with water (3 x 100 mL) and dried under reduced pressure to afford tert-butyl-4-(4-bromophenylamino)-4carbamoylpiperidine-1-carboxylate as a white solid (3.6 g, 85%).
LCMS (ESI): m/z = 398.2, 400.2 [M+H]+.
Ή-NMR (300 MHz, DMSO-de): δ = 1.39 (s, 9H), 1.59-1.98 (m, 4H), 3.12-3.16 (m, 2H), 3.54-3.60 (m, 2H), 5.92 (s, 1H), 6.53 (d, J= 8.9 Hz, 2H), 7.12 (s, 1H), 7.21 (d, J= 8.9 Hz, 2H), 7.33 (s, 1H).
tert-Butyl-1-(4-bromophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of tert-butyl-4-(4-bromophenylamino)-4-carbamoylpiperidine-1-carboxylate (0.6 g, 0.0015 mol) in triethyl orthofomnate (200 mL) was added acetic acid (1 drop, cat.). The resulting mixture was heated at 170°C for 30 minutes in a microwave reactor. The solvent was removed under reduced pressure. The residue was dissolved in methanol (200 mL) and to the resulting solution was added sodium borohydride (2.62 g, 0.069 mol) at 0°C. The resulting mixture was stirred for 30 minutes. The solvent was removed under reduced pressure and the residue was diluted with water (200 mL) and ethyl acetate (150 mL). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 200:1 to afford tert-butyl-1-(4-bromophenyl)-4-oxo-1,3,8triazaspiro[4.5]decane-8-carboxylate as a white solid (210 mg, 33%).
LCMS (ESI): m/z = 410.1,413.1 [M+Hf.
tert-Butyl-1-(4-bromophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5ldecane-8-carboxylate
To a solution of terf-butyl-1-(4-bromophenyi)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (210 mg, 0.51 mmol) in N,N-dimethylformamide (3 mL) was added sodium hydride (41 mg, 60% in oil, 1.02 mmol) at 0°C. After stirring for 15 minutes, iodomethane (145 mg, 1.02 mmol) was added. The resulting mixture was stirred for 1 hour. The reaction was quenched with ice-water (10 mL) and the mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 15:1 to afford tert-butyl-1-(4-bromophenyl)-3-methyl-4-oxo-
1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (210 mg, 97%).
146
LCMS (ESI): m/z = 424.1, 426.1 [M+H]+.
tert-Butyl-1-(4-cyanophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate °^NZ
BocN
BocN
To a solution of terf-butyl-1-(4-bromophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (100 mg, 0.24 mmol) in Ν,Ν-dimethylfomnamide was added sequentially zinc cyanide (135 mg, 1.18 mmol), tris(dibenzylideneacetone)dipalladium (22 mg, 0.024 mmol), 4,5-bis(diphenylphosphino)-9,9dimethylxanthene (Xantphos) (27 mg, 0.047 mmol) under an argon atmosphère. The reaction mixture was stirred ovemight at 130°C. After quenching with ice-water (5 mL), the reaction mixture was extracted with ethyl acetate (3*15 mL). The combined onganic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:1 to afford fert-butyl-1-(4-cyanophenyl)-3-methyl-4-oxo-
1,3,8-triazaspiro[4.5]decane-8-carboxylate as a brown oil (50 mg, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 371.2 [M+H]+.
4-(3-Methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzonitrile hydrochloride /
CN
A solution of tert-butyl-1-(4-cyanophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (60 mg, 0.16 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 4-(3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzonitrile hydrochloride as a white solid (60 mg, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 271.1 [M+Hf.
147 (R)-N-(1-(1-(4-Cyanophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-
2-yl)-2-fluoro-3-methylbenzamide
CN
To a mixture of 4-(3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzonitrile hydrochloride (55 mg, 0.203 mmol) in dichloromethane (5 mL) was added (R)-2-(2-fluoro-3-methylbenzamido)-3-methylbutanoic acid (prepared as described in Example 145-d) (61 mg, 0.223 mmol), 1-[bis(dimethylamino)methylene]1H-1,2,3-triazolo[4,5-blpyridinium-3-oxide hexafluorophosphate (HATU) (116 mg, 0.304 mmol) and N,Ndiisopropylethylamine (53 mg, 0.406 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water. The mixture was extracted with ethyl acetate (3x10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-N-(1-(1-(4-cyanophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-3-methylbenzamide as a white solid (19 mg, 18%).
LCMS (ESI): m/z = 506.2 [M+H]+.
Ή-NMR (400 MHz, CD3OD): δ = 1.03-1.19 (m, 6H), 1.7-1.82 (m, 2H), 2.20-2.40 (m, 4H), 2.69-2.69-2.73 (m, 2H), 2.81-2.85 (m, 2H), 3.04 (s, 3H), 3.50-3.53 (m, 1H), 3.98-4.03 (m, 1H). 4.36-4.39 (m, 1H), 4.544.59 (m, 1H), 4.79-4.85 (m, 2H), 4.94-4.99 (m, 2H), 6.25-6.78 (m, 2H), 7.14-7.29 (m, 3H), 7.45-7.55 (m, 2H).
The following 12 compounds were synthesized following the general procedure described above: Example 180:
(R)-N-(1-(1-(3-Cyanophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-3-methyH-oxobutan-
2-yl)-2-fluoro-3-methylbenzamide
CN
9.2 mg, 8% yield, white solid.
LCMS (ESI): m/z = 488.0 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.18-1.03 (m, 6H), 1.80-1.65 (m, 2H), 2.20-2.15 (m, 1H), 2.44 (d, J = 4.9 Hz, 3H), 2.60-55 (m, 1H), 2.80-2.78 (m, 1H), 3.08 (s, 3H), 3.63-3.50 (m, 2H), 4.20-4.04 (m, 2H), 4.74-4.62 (m, 2H), 5.18-5.03 (m, 1H), 7.15-6.60 (m, 4H), 7.44-7.30 (m, 2H), 7.67 (d, J = 9.2 Hz, 2H).
148
Example 181:
(R)-N-(1-(1-(4-Chlorophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl) -3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
Cl
45.1 mg, 47% yield, white solid.
LCMS (ESl): m/z = 538.1 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 0.81-1.02 (m, 6H), 1.65-2.21 (m, 5H), 3.08 (s, 3H), 3.46-3.51 (m, 1H), 3.91-3.98 (m, 1H), 4.19-4.30 (m, 1H), 4.41-4.52 (m, 1H), 4.82-4.85 (m, 1H), 7.22-7.54 (m. 5H), 7.88-8.01 (m, 2H), 8.48-8.49 (m, 1H).
Example 182:
(R)-2-Fluoro-N-(1-{1-(4-fluorophenyl)-3-methyl-2,4-dioxo-1,3l8-triazaspiro[4.5]decan-8-yl)-3-methyl-
1-oxobutan-2-yl)-5-(trifiuoromethyl)benzamide
F
47.9 mg, 44% yield, white solid.
LCMS (ESl): m/z = 567.1 [M+Hf.
1H-NMR (400 MHz, CD3OD): ô = 0.80-1.02 (m, 6H), 1.65-2.00 (m, 2H), 2.03-2.21 (m, 3H), 3.08 (s, 3H),
3.45-3.52 (m, 1H), 3.92-3.98 (m, 1H), 4.19-4.30 (m, 1H), 4.41-4.53 (m, 1H), 4.82-4.88 (m, 1H). 7.10-7.14 (m, 1H), 7.23-7.28 (m, 2H), 7,33-7.47 (m, 2H), 7.87-8.01 (m. 2H).
Example 183:
(R)-N-(1-(1-(3l4-Dichlorophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
29.5 mg, 27% yield: 27%, white solid.
LCMS (ESl): mÆ = 617.1 [M+H]+.
149 1H-NMR (400 MHz, CD3OD): δ = 0.83-1.02 (m, 6H), 1.65-1.86 (m, 1H), 1.94-2.22 (m, 4H), 3.08 (s, 3H), 3.32-3.51 (m, 1H), 3.91-3.97 (m, 1H), 4.21-4.31 (m, 1H), 4.43-4.55 (m, 1H), 4.82-4.87 (m, 1H), 7.19-7.27 (m, 1H), 7.38-7.50 (m, 1H), 7.59-7.68 (m, 2H), 7.87-8.02 (m. 2H), 8.47-8,54 (m, 1H).
Example 184:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-p-tolyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxob utan -2-y I )-5-(trifluoro met hy I )be nzamîde
mg, 35% yield, white solid.
LCMS (ESI): m/z = 563.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.78-0.99 (m, 6H), 1.65-2.18 (m, 5H), 2.30-2.41 (m, 3H), 3.08 (s, 3H), 3.44-3.52 (m, 1H), 3.90-3.99 (m, 1H), 4.16-4.50 (m, 2H), 4.84-4.88 (m, 1H), 7.08-7.46 (m, 5H), 7.88-8.02 (m, 2H), 8.43-8.52 (m, 1 H).
Example 185:
(R)-N-(1 -(1 -{1 H-lndol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamîde
mg, 15% yield, white solid.
LCMS (ESI): m/z = 588.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.77-0.83 (m. 2H), 0.89-0.95 (m, 2H), 1.03 (d, J= 6.8 Hz, 2H), 1.83-1.98 (m, 3H), 2.07-2.12 (m, 2H), 3.17 (s, 3H), 3.49-3.55 (m, 1H), 3.97-4.01 (m, 1H). 4.46-4.61 (m, 1.5H), 4.995.02 (m, 1H), 5.37 (s, 0.5H), 6.55-6.61 (m, 1H), 6.90-6.97 (m, 1H), 7.21-7.28 (m, 1H), 7.41-7.48 (m, 3H), 7.70-7.73 (m, 1H), 8.22 (d, J= 4.9 Hz, 1H), 8.32-8.39 (m, 1H).
150
Example 186:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(4-(trifluoromethyl)phenyl)-1,3l8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(tnfluoromethyl)benzamide
172 mg, 52% yield, white solid.
LCMS (ESI): m/z = 617.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ= 0.87-1.05 (m, 6H), 1.75-1.80 (m, 1H), 1.91-2.12 (m, 4H), 3.15 (s, 3H),
3.45-3.53 (m, 1H), 3.99-4.07 (m, 2H), 4.63-4.66 (m. 1H), 5.00-5.03 (m. 1H), 7.24-7.43 (m, 4H), 7.67-7.78 (m. 3H), 8.27-8.36 (m, 1H).
Example 187:
(R)-N-(1-(1-(3-Chlorophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8- yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
120 mg, 79% yield, white solid.
LCMS (ESI): m/z = 583.1 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 0.87-1.05 (m, 6H). 1.77-1.80 (m, 1H). 1.91-2.12 (m, 4H), 3.15 (s, 3H),
3.46-3.53 (m, 1H), 3.98-4.04 (m, 2H), 4.63-4.66 (m, 1H), 4.98-5.01 (m, 1H), 7.05-7.11 (m, 1H), 7.17-7.29 (m. 2H), 7.35-7.46 (m, 3H), 7.75-7.78 (m, 1H), 8.25-8.36 (m, 1H).
Example 188:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-214-dioxo-1-(pyridin-2-yl)-1,3,84riaza- spiro[4.5]decan-8-yl)-1 oxobutan-2-yl)-5-(trifluoromethyl)benzamide
mg, 71% yield, white solid.
LCMS (ESI): m/z = 550.1 [M+H]*.
151 1H-NMR ¢400 MHz, CD3OD): δ = 1.00-1.16 (m, 6H), 1.78-1.92 (m, 2H), 2.18-2.24 (m, 1H), 3.07-3.24 (m,
4H), 3.40-3.52 (m, 2H), 3.98-4.14 (m, 2H), 4.62-4.71 (m, 1H), 5.15-5.20 (m. 1H), 7.01-7.10 (m, 1H), 7.287.35 (m, 1H), 7.53-7.60 (m, 1H), 7.68-7.81 (m, 2H), 7.98-8.26 (m, 2H), 8.35-8.39 (m. 1H).
Example 189:
(RJ^-Fluoro-N-ÎS-methyl-l-tS-methyl-Z^-dioxo-l-tpyrtdin-a-ylJ-I.S.S-triaza- spiro[4.5Idecan-8-yl)-1oxobutan-2-yl)-5-(trif]uoromethyl)benzamïde
LCMS (ESI): m/z = 550.1 [M+H]4.
1H-NMR (400 MHz, CD3OD): δ = 0.88-1.06 (m, 6H), 1.70-1.81 (m, 1H), 1.99-2.23 (m, 4H), 3.18 (s, 3H),
3.48-3.54 (m, 1H), 4.00-4.15 (m, 2H), 4.59-4.70 (m, 1H), 4.86-5.05 (m, 1H), 7.31-7.42 (m, 1H), 7.69-7.78 (m, 2H), 7.85-7.92 (m, 1H), 8.13-8.35 (m. 1H), 8.70-8.77 (m. 1H), 9.31 (s, 1H).
Example 190:
(/3)-2^111(^0-1^-(3411611^1-1-(3-111611^1-2,4-0^0-1-(4-41611161111111^1161^1-1,3,8-triazaspiro[4.5]decan8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
mg, 47% yield, white solid.
LCMS (ESI): m/z = 550.1 [M+H]4.
1H-NMR (400 MHz, CD3OD): δ = 0.75-1.03 (m, 6H), 1.66-2.21 (m, 5H), 3.09 (s, 3H), 3.44-3.53 (m, 1H), 3.91-4.01 (m, 1H), 4.15-4.32 (m, 1H), 4.37-4.54 (m, 1H), 4.83-4.86 (m, 1H), 7.22-7.32 (m2H), 7.37-7.53 (m 3H), 7.84-8.03 (m 2H).
Example 191:
(RJ-N^I-tl-tBenzotdJtl.Sldioxol-S-yO-S-methyl^^-dioxo-l^.e-triazaspiroH.S] decan-8-yl)-3-methyl-
1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethy1)benzamide
152
102.6 mg, 35% yield, white solid.
LCMS (ESl): m/z = 593.1 [M+Hf.
’H-NMR (300 MHz, DMSO-de): δ= 0.92-1.11 (m, 6H), 1.70-178 (m, 2H), 2.07-2.11 (m, 3H), 3.03 -3.12 (m, 5H), 4.13-4.17 (m, 2H). 4.76 (t, 1 H), 6.04-6.10 (m, 2H), 6.87-6.71 (m, 3H), 7.50-7.68 (m, 1H), 8.015 7.74 (m, 2H), 8.34 (d, 1H).
Example 192:
(R)-N-(141-(3-Chlorophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-
2-yl)-3-methylbenzamide
Représentative scheme:
b c
f g
Représentative general procedure: tert-Butyl-4-(3-chlorophenylamino)-4-cyanopiperidine-1-carboxylate
To a solution of 3-chloroaniline (2.0 g, 0.015 mol) in acetic acid (20 mL) was added tert-butyl-4oxopiperidine-1-carboxylate (3.4 g, 0.016 mol). The resulting mixture was cooled to 0°C and trimethylsilyl cyanide (1.86 g, 0.017 mol) was added. The solution was stirred ovemight. Saturated aqueous ammonium chloride was added (50 mL). The mixture was fittered, the filter cake was washed with water
153 (3*10 mL) and dried under reduced pressure to afford fert-butyl-4-(3-chlorophenylamino)-4cyanopiperidine-1-carboxylate as a white solid (5.0 g, 100%).
LCMS (ESI): m/z = 336.1,338.1 [M+Hf.
Ή-NMR (400 MHz, DMSO-d6): δ = 1.41 (s, 9H), 1.64-1.85 (m. 2H), 2.29-2.32 (m, 2H), 3.15-3.17 (m, 2H),
3.77-3.85 (m, 2H), 6.46 (s, 1H), 6.72-6.94 (m, 3H), 7.21-7.29 (m, 1H).
fert-Butyl-4-carbamoyl-4-{3-chlorophenylamino)piperidine-1-carboxylate °<^NH2 / (-NH
BocN
Cl
To a solution of ferf-butyl-4-(3-chlorophenylamino)-4-cyanopiperidine-1-carboxylate (1.0 g, 2.97 mmol) in methanol (16 mL) was added an aqueous sodium hydroxide solution (10 mL, 1.0 M). After stirring for 15 minutes, to the resulting solution was added a 30% aqueous hydrogen peroxide solution (7 mL) dropwise. The resulting mixture was stirred ovemight and filtered. The white solid was washed with water (3x10 mL) and dried under reduced pressure to afford fert-butyl-4-carbamoyl-4-(3chlorophenylamino)piperidine-1-carboxylate as a white solid (1.0 g, crude), which was used directly without any further purification.
LCMS (ESI): m/z- 354.1, 356.1 [M+H]‘.
tert-Butyl-1-(3-chlorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of fert-butyl-4-carbamoyl-4-(3-chlorophenylamino)piperidine-1-carboxy1ate (450 mg, 1.2 mmol) in triethyl orthoformate (4 mL) was added acetic acid (2 drops, cat.). The mixture was heated at 140°C for 30 minutes in a microwave reactor. The solvent was removed under reduced pressure and the residue was dissolved in methanol (10 mL). To the resulting solution was added sodium borohydride (100 mg, 2.6 mmol) at 0°C. The resulting mixture was stirred for 30 minutes. The solvent was removed under reduced pressure and the residue was diluted with water (10 mL) and ethyl acetate (15 mL). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 200:1 to afford terf-butyi-1-(3-chlorophenyl)-4-oxo-l,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (120 mg, 25%).
LCMS (ESI): m/z = 366.1,368.1 [M+H]\ 1H-NMR (300 MHz, CDCb): δ = 1.51 (s, 9H), 1.61-1.76 (m, 2H), 2.47-2.66 (m, 2H), 3.51-3.62 (m, 2H), 3.99-4.16 (m, 2H), 4.73 (s, 2H), 6.57-6.72 (m, 2H), 6.77-6.87 (m, 1H), 7.06-7.21 (m, 1H).
154 tert-Butyl-1-(3-chlorophenyl)-3-methyt-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of tert-butyl-1-(3-chlorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (120 mg, 0.33 mmol) in N,N-dimethylformamide (3 mL) was added sodium hydride (41 mg, 60% in oil, 1.02 mmol) at 0°C. After stirring for 15 minutes, iodomethane (233 mg, 1.64 mmol) was added. The resulting mixture was stirred for 1 hour. The reaction was quenched with ice-water (10 mL) and the mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 15:1 to afford terf-butyl-1-(3-chlorophenyl)-3-methyl-4-oxo-
1,3,8-triazaspiro[4.5]decane-8-carboxylate as a yellow oil (120 mg, 96%).
LCMS (ESI): m/z = 380.1,382.1 [M+H]+.
-(3-Chlorophenyl)-3-methyl-1,3,8-triazaspîro[4.5]decan-4-one hydrochloride
A solution of tert-butyi-1-(3-chlorophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (120 mg, 0.13 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 1-(3-chlorophenyl)-3-methy!-1,3,8triazaspiro[4.5]decan-4-one hydrochloride as a white solid (80 mg, 80%).
LCMS (ESI): m/z = 280.1,282.1 [M+Hf.
(R)-Methyl-3-methyl-2-(3-methylbenzamido)butanoate
To a suspension of (R)-methyl-2-amino-3-methylbutanoate hydrochloride (2.9 g, 17 mmol) in dichloromethane (30 mL) was added N,N-diisopropylethylamine (5.6 g, 40 mmol). To the resulting mixture was added dropwise a solution of 3-methylbenzoyl chloride (3.2 g. 20.6 mmol) in dichloromethane (5 mL) at 0°C. The mixture was stirred for 1 hour before the reaction was quenched with ice-water (10 mL). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (3 * 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl
155 acetate : petroleum ether= 1:10 to afford (R)-methyl-3-methyl-2-(3-methylbenzamido)butanoate as a yellow oil (3.3 g, 78%).
LCMS (ESI): m/z = 250.1 [M+H]+.
1H-NMR (300 MHz, CDCh): δ = 1.01 (t, J= 7.2 Hz, 6H), 2.19-2.36 (m, 1H), 2.42 (s, 3H), 3.79 (s, 3H),
4.59-4.83 (m, 1H), 6.55-6.66 (m, 1H), 7.30-7.38 (m, 2H), 7.56-7.66 (m, 2H).
(R)-3-Methyl-2-(3-methylbenzamido)butanoic acid
To a solution of (R)-methyl-3-methyl-2-(3-methylbenzamido)butanoate (1.5 g, 6 mmol) in tetra hydrofuran (12 mL) was added an aqueous lithium hydroxide solution (8 mL, 2.0 M, 0.016 mol). Before quenching with ice-water (20 mL), the reaction was stirred for 1 hour. The pH of the solution was adjusted to 3 by addition of a 5% aqueous hydrochloric acid solution. The mixture was filtered and the filter cake was washed with petroleum ether (30 mL) and dried under reduced pressure to afford (R)-3-methyl-2-(3methyl benzamido)butanoic acid as a thick oil (1.1 g, 77%).
LCMS (ESI): m/z = 236.1 [M+H]4.
(R)-N-(1-(1-(3-Chlorophenyl)-3-methyM-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 -oxobutan-
2-yl)-3-methylbenzamide
To a mixture of 1-(3-chlorophenyl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride (45 mg, 0.14 mmol) in dichloromethane (5 mL) was added (R)-3-methyl-2-(3-methylbenzamido)butanoic acid (37 mg, 0.16 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (81 mg, 0.21 mmol) and N,N-diisopropylethylamine (46 mg, 0.35 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (5 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-N-(1-(1-(3-chlorophenyl)-
3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-y1)-3-methyl-1-oxobutan-2-yl)-3-methylbenzamide as a white solid (2.1 mg, 3%).
LCMS (ESI): m/z = 497.0, 499.0 [M+H]4.
1H-NMR (400 MHz, CDCh): δ = 0.97-1.15 (m, 6H), 1.64-2.22 (m, 5H), 2.44 (s, 3H), 2.49-2.75 (m, 1H), 3.03 (s, 3H), 3.50-3.65 (m, 1H), 4.10-4.20 (m, 1H), 4.58-4.73 (m, 3H), 5.25-5.50 (m, 1H), 6.92-7.15 (m, 3H), 7.34-7.36 (m, 3H), 7.49-7.70 (m, 2H).
156
The following 16 compounds were synthesized following the general procedure described above:
Example 193:
(R)-N-(1-(1-(4-Chlorophenyl)-3-methyl-4-oxo-1,3l8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-
2-yl)-3-methylbenzamide
8.7 mg, yield: 16%, white solid.
LCMS (ESI): m/z = 496 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 0.89-1.22 (m, 6H), 1.61-1.88 (m, 2H), 2.01-2.27 (m, 1H), 2.30-2.77 (m, 5H), 3.15 (s, 3H), 3.43-3.71 (m, 1H), 3.96-4.23 (m, 2H), 4.50-4.83 (m, 3H), 4.97-5.22 (m, 1H), 6.50-6.76 (m, 2H), 6.91-7.12 (m, 2H), 7.13-7.25 (m, 1H), 7.32-7.46 (m, 2H), 7.58-7.72 (m, 2H).
Example 194:
(R)-N-(1-{1-(3-Bromophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-
2-yl)-3-methylbenzamide
3.0 mg, yield: 5%, white solid.
LCMS (ESI): m/z = 542.2 [M+H]+.
1H-NMR (400 MHz, CDCh): δ = 0.99-1.16 (m, 6H), 1.63-1.88 (m, 2H), 2.15-2.22 (m, 1 H), 2.44 (s, 3H), 2.48-2.82 (m, 2H), 3.05 (s, 3H), 3.55-3.60 (m, 1H), 3.89-4.24 (m, 2H), 4.60-4.71 (m, 3H), 5.00-5.25 (m, 1H), 6.58-6.75 (m, 1H), 6.80-6.96 (m, 1H), 6.96-7.20 (m, 2H), 7.36-7.44 (m,2H), 7.54-7.77 (m, 2H).
Example 195:
(R)-3-Methyl-N-(3-methyl-1-(3-methyl-4-oxo-1-(pyridin-3-yl)-1,3,8-triazaspiro[4.5Idecan-8-yl)-1oxobutan-2-yl)benzamide
6.6 mg, yield: 14%, white solid. LCMS (ESI): m/z = 464 [M+Hf.
157 1H-NMR (400 MHz, CDCh): δ = 1.08-1.13 (m, 6H), 1.66-2.00 (m,2H), 2.14-2.24 (m, 1H), 2.43-2.50 (m, 4H), 2.90-3.05 (m, 1H), 3.10 (s, 3H), 3.53-3.64 (m, 1H), 4.03-4.36 (m, 2H), 4.56-4.98 (m, 4H), 7.07-7.11 (m, 1H), 7.32-7.44 (m, 3H), 7.60-7.65 (m, 2H), 7.96-8.04 (m, 2H), 8.30-8.40 (m, 1H).
Example 196:
(R)-N-(1-(1-(2-Chlorophenyi)-3-methyl-4-oxo-1l3I8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-
2-yl)-3-methylbenzamide
20.0 mg, yield: 23%, white solid.
LCMS (ESI): m/z = 497.2, 499.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.78-1.08 (m, 6H), 1.49-2.31 (m, 5H), 2.43 (s, 3H), 2.97 (s, 3H), 3.464.23 (m, 4H), 4.62-4.77 (m, 2H), 4.79-4.87 (m, 1H), 7.13-7.72 (m, 8H).
Example 197:
(R)-N-(1-(1-(4-Methoxyphenyl)-3-methyl-4-oxo-1,3,84riazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-3-methylbenzamide
23.0 mg, yield: 29%, white solid.
LCMS (ESI): m/z = 493.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 0.89-1.04 (m, 6H), 1.65-2.09 (m, 3H), 2.13-2.31 (m, 2H), 2.42 (s, 3H), 2.99 (s, 3H), 3.45-3.61 (m, 1H), 3.63 (s, 2H), 3.79 (s, 1H), 3.87-4.44 (m, 3H), 4.69-4.71 (m, 2H). 4.91-5.04 (m, 1H), 6.64-6.69 (m, 1H), 6.80-7.06 (m, 3H), 7.32-7.46 (m, 2H), 7.67-7.88 (m, 2H).
Example 198:
(R)_N_(1-(1-(3-Methoxyphenyl)-3-methyl-4-oxo-1,3,8-triazaspiroÎ4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-3-methylbenzamide
13.0 mg, yield: 17%, white solid.
LCMS (ESI): m/z = 493.2 [M+H]+.
158 1H-NMR (400 MHz, CD3OD): δ = 0.93-1.16 (m, 6H), 1.61-2.01 (m, 2H), 1.97-2.20 (m, 1H), 2.24 (s, 3H), 2.48-2.80 (m, 2H), 3.02 (s, 3H), 3.47-3.57 (m, 3H), 3.59 (s, 1H), 3.78 (s, 1H), 3.84-4.60 (m, 3H), 4.75 (m, 1H), 4.90 (m, 1H), 6.21-6.53 (m, 3H), 6.88-7.13 (m, 1H), 7.38 (m, 2H), 7.58-7.74 (m,2H).
Exampie 199:
(R)-N-(1 -(1 -(4-Bromophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 -oxobutan-
2-yl)-3-methylbenzamide
Br
3.2 mg, yieid: 4%, white solid.
LCMS (ESI): m/z = 542.2 [M+Hf.
1H-NMR (400 MHz, CDCb): δ = 1.01-1.14 (m, 6H), 1.66-1.78 (m, 2H), 2.32-2.33 (m, 1H), 2.54-2.63 (m, 4H), 2.72-2.75 (m, 1H), 3.01 (s, 3H), 3.48-4.52 (m, 4H), 4.71-4.73 (m, 2H), 4.92-4.95 (m, 1H), 6.57-6.74 (m, 2H), 7.00-7.03 (m, 2H), 7.33-7.46 (m, 2H), 7.69-7.73 (m, 2H).
Example 200:
(R)-5-Ethyl-2-fluoro-N-(3-methyl-1-(3-methyl-1-(4-(methylsiilfonyl)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide
19.2 mg, yieid: 17%, white solid.
LCMS (ESI): m/z = 573 [M+Hf.
1H-NMR (400 MHz, CDCb): δ = 1.02-1.12 (m, 9H), 1.69-1.70 (m, 1H). 1.80-1.89 (m, 1H), 2.65-2,70 (m, 5H), 2.94 (s, 3H), 3.07 (s, 3H), 3.53-3.60 (m, 1H), 4.08-4.18 (m, 2H), 4.68 (m, 1H), 4.78-4.89 (m, 2H), 5.01-5.21 (m, 1H), 6.74-7.92 (m, 8H).
159
Example 201:
(R)-5-Ethyl-2-fluoro-N-(3-methyl-1-{3-methyl-1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-oxo-1,3,8triazaspiro[4.5ldecan-8-yl)-1-oxobutan-2-yl)benzamide
20.0 mg, yield: 34%, white solid.
LCMS (ESI): m/z = 526.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): Q = 0.84-1.10 (m, 6H), 1.18-1.32 (m, 3H), 1.54-1.75 (m, 1H), 1.77-2.01 (m, 3H), 2.13-2.22 (m, 1H), 2.62-2.77 (m, 2H), 3.09 (s, 3H). 3.48-3.57 (m, 3H), 3.56-3.62 (m, 1H), 3.90-4.07 (m, 1H), 4.15-4.59 (m, 1H), 4.36-4.44 (m, 1H), 4.56-4.61 (m, 2H), 4.87-4.92 (m, 1H), 6.47-6.63 (m, 1H), 7.13-7.21 (m. 1H), 7.40-7.43 (m, 1H), 7.47-7.70 (m, 3H).
Example 202:
(R)-5-Ethyl-2-fluoro-N-(1-(1-{4-methoxyphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)benzamide
65.3 mg, yield: 47%, white solid.
LCMS (ESI): m/z = 525.0 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.88-1.13 (m, 6H), 1.18-1.36 (m, 3H), 1.71-1.92 (m, 2H), 1.93-2.38 (m, 3H), 2.68 (m, 2H), 3.00-3.05 (m, 3H), 3.65 (m, 3H), 3.79 (m, 1H), 3.91-4.09 (m, 1H), 4.20-4.25 (m. 1H), 4.35-4.41 (m, 1H), 4.62-4.76 (m, 2H), 4.94-5.01 (m, 1H), 6.72-6.88 (m, 1H), 6.91-6.98 (m, 2H). 7.13-7.21 (m, 2H), 7.34-7.47 (m, 1H), 7.547.66 (m, 1H).
160
Exampie 203:
(R)-5-Ethyl-2-fluoro-N-(3-methyl-1-(3-methyl-143-methyl-2-oxo-2,3-dihydrobenzo[dIoxazol-5-yl)-4oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1 -oxobutan-2-yl)benzamide
10.0 mg, yield: 19%, white solid.
LCMS (ESI): m/z = 566.0 [M+Hf.
Ή-NMR (400 MHz, CDCb): δ = 0.99-1.06 (m, 6H), 1.22-1.27 (m. 3H), 1.76-1.88 (m, 2H), 2.11-2.37 (m. 3H), 2.65-2.69 (m, 2H), 3.04 (s, 3H), 3.32 (s, 2H), 3.39 (s, 1H), 3.54-3.59 (m, 1H), 4.05-4.07 (m, 2H), 4.53-4.57 (m, 1H), 4.53-4.72 (m, 2H), 5.07-5.10 (m, 1H), 6.41-6.45 (m, 1H), 6.57-6.59 (m, 1H), 6.97-6.99 (m, 1H), 7.04-7.07 (m, 1H), 7.26-7.73 (m, 1H), 7.47-7.49 (m, 1H), 7.77-7.79 (m, 1H).
Example 204:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)^l-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
24.7 mg, yield: 27%, white solid.
LCMS (ESI): m/z = 566.2 [M+H]+.
Ή-NMR (400 MHz, CD3OD): δ = 0.91-1.04 (m, 6H), 1.62-2.18 (m, 5H), 2.97 (s, 3H), 3.52-3.64 (m, 4H), 3.99-4.37 (m, 3H), 4.59-4.63 (m, 2H), 4.87 (m, 1H), 6.48-6.58 (m, 1H), 7.42-7.60 (m 3H), 7.97-8.03 (m, 2H).
161
Example 205:
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(4-(methylsulfonyl)phenyl)-4-oxo-1,3,8triazaspiroI4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
9.3 mg, yield: 6%, white solid.
LCMS (ESl): m/z = 613.2 [M+Hf.
1H-NMR (400 MHz, CDaOD): δ = 1.06-1.19 (m, 6H)T 1.74-1.95 (m, 2H), 2.20-2.33 (m, 1H), 2.66-2.87 (m, 1H), 2.97-3.14 (m, 7H), 3.50-3.61 (m, 1H), 4.02-4.15 (m, 1H), 4.37-4.39 (m, 1H), 4.57-4.60 (m, 1H), 4.834.85 (m, 2H, contarned in solvent signal), 4.95-5.05 (m, 1H), 6.88-6.94 (m, 2H), 7.45-7.52 (m, 1H), 7.627.78 (m, 2H), 7.90-8.09 (m, 2H).
Example 206: (R)-2-Fluoro-N-(1-(1-(imidazo[1l2-a]pyridin-6-yl)-3-methyl-4-oxo-1,3,84riazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trif1uoromethyl)benzamide trifluoroacetic acid sait
6.1 mg, yield: 7%, white solid.
LCMS (ESl): m/z = 575.2 [M+Hf.
1H-NMR (400 MHz, CDaOD): δ= 1.08-1.14 (m, 6H), 1.82-1.94 (m, 2H), 2,17-2.22 (m, 1H), 2.47-2.50 (m, 1H), 2.88-2.91 (m, 1H), 3.07 (s, 3H), 3.56-3.62 (m, 1H), 4.05-4.12 (m, 1H), 4.33-4.36 (m, 1H), 4.61-4.63 (m, 1H), 4.83-4.87 (m, 3H), 7.48-7.52 (m, 1H), 7.72-7.88 (m, 4H), 8.07-8.09 (m, 2H), 8.35 (m, 1H), 8.748.75 (m, 1H).
162
Example 207:
(R)-3-Chloro-N-(3-methyl-1-(3-methyl-1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
59.2 mg, yield: 40%, white solid.
LCMS (ESI): m/z = 582.2 [M+H]+.
Ή-NMR (400 MHz, CD3OD): δ = 0.88-1.06 (m, 6H), 1.56-1.69 (m, 1H), 1.83-1.97 (m, 3H), 2.19-2.21 (m,
1H), 2.97 (s, 3H), 3.51 (s, 3H), 3.55-3.58 (m, 1H), 3.99^.35 (m. 3H), 4.59-4.63 (m. 2H), 4.80-4.82 (m.
1H), 6.46-6.58 (m, 1H), 7.52-7.66 (m, 2H), 7.92-7.94 (m, 1H), 8.08-8.14 (m, 2H).
Example 208:
(R)-N-(1-Cyclopentyl-2-(3-methyl-1-(1-methyl-6-<Jxo-1,6-dihydropyridin-3-yl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-2-fluoro-5-(trifluoromethyl)benzamide
53.3 mg, yield: 31%, white solid.
1H-NMR (400 MHz, CD3OD): δ = 1.31-1.72 (m, 8H), 1.85-1.91 (m, 4H), 2.35-2.39 (m, 1H), 2.96 (s, 3H),
3.50 (s, 3H), 3.52-3.59 (m, 1H), 3.96-3.99 (m, 1H), 4.19-4.36 (m, 2H), 4.59-4.63 (m, 2H), 4.92-4.95 (m, 1H), 6.46-6.58 (m, 1H), 7.42-7.46 (m, 1H), 7.52-7.67 (m, 2H). 7.87-8.00 (m, 2H).
Example 209:
2-Fluoro-N-((2R)-1-(1-(4-methoxyphenyl)-2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
163
Représentative scheme:
Représentative general procedure:
tert-Butyl-1-(4-methoxyphenyl)-2-methyl-4-oxo-1(3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of terï-butyl-4-carbamoyl-4-(4-methoxyphenylamino)piperidine-1-carboxylate (prepared as described in Example 168-b) (300 mg, 0.85 mmol) in triethyl orthoacetate (5 mL) was added acetic acid (1 drop, cat.). The resulting mixture was heated at 170°C for 30 minutes in a microwave reactor. The solvent was removed under reduced pressure and the residue was dissolved in methanol (10 mL). To the resulting solution was added sodium borohydride (50 mg, 0.069 mol) at 0°C. The mixture was stirred for 30 minutes. The solvent was removed under reduced pressure and the residue was diluted with water (10 mL) and ethyl acetate (10 mL). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (3 * 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eiuting with dichloromethane : methanol = 100:1 to afford tert-butyl-1-(4-methoxyphenyl)-2-methyl-4-oxo1 ,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (120 mg, 38%).
LCMS (ESl): m/z = 376.2 [M+Hf.
1H-NMR (300 MHz. CDCh): δ = 1.19 (d, J= 5.3 Hz, 3H), 1.38 (s, 9H), 1.59-1.85 (m, 4H), 3.25-3.27 (m, 1H), 3.80-3.88 (m. 6H), 5.00-5.19 (m, 1H), 6.85 (d, J- 8.9 Hz, 2H), 7.05 (d, J= 8.9 Hz, 2H).
164 tert-Butyl-1-(4-methoxyphenyl)-2,3-dimethyi-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
Ο
To a solution of tert-butyl-1-(4-methoxyphenyl)-2-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (120 mg, 0.32 mmol) in Ν,Ν-dimethylfomnamide (10 mL) was added sodium hydride (20 mg, 60% in oil, 0.52 mmol) at 0°C. After stirring for 15 minutes, iodomethane (282 mg, 1.9 mmol) was added. The resulting mixture was stirred for 15 minutes at room température and the reaction was quenched with icewater (10 mL). The mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:1 to afford ferf-butyl-1-(4-methoxyphenyl)-2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (80 mg, 66%).
LCMS (ESI): m/z = 390.2 [M+H]+.
-(4-Methoxyphenyl)-2,3-dimethyl-1,3,8-triazaspiro[4.5]decane-4-one hydrochloride
A solution of fert-butyl-1-(4-methoxyphenyl)-2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (80 mg, 0.2 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The solvent was removed under reduced pressure to afford 1-(4-methoxypheny!)-2,3-dimethyl-1,3,8triazaspiro[4.5]decane-4-one hydrochloride as a white solid (60 mg, 90%).
LCMS (ESI): m/z = 290.2 [M+Hf.
2-Fluoro-N-((2R)-1-(1-(4-methoxyphenyl)-2,3-dimethyl-4-oxo-1)3)8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
To a mixture of 1-(4-methoxypheny!)-2,3-dimethyl-1,3,8-triazaspiro[4.5]decane-4-one hydrochloride (60 mg, 0.18 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(2-fluoro-5
165 (trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (60 mg, 0.19 mmol), 1-[bis(dimethylamino)methylene]-1H-1l2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (120 mg, 0.31 mmol) and Ν,Ν-diisopropylethylamine (270 mg, 2.0 mmol). The reaction was stirred for 2 hours before the reaction was quenched by addition of ice-water (10 mL), The mixture was extracted with ethyl acetate (3 * 10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford 2-fluoro-N-((2R)-1-(1-(4-methoxyphenyl)-2,3-dimethyl-4-oxo-
1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 -oxobutan-2-yl)-5-(trifluoromethyl)benzamide (6.5 mg, 5.9%). LCMS (ESI): m/z = 579.2 [M+H]‘.
1H-NMR (400 MHz, CD3OD): δ = 0.72-1.01 (m, 6H), 1.18-1.22 (m, 3H), 1.31-1.52 (m, 1 H), 1.78-2.22 (m, 4H), 2.93 (s, 3H), 3.68-3.73 (m, 3H), 3.81-3.82 (m, 1H), 3.97-4.38 (m, 2H), 4.79-4.93 (m, 2H), 5.07-5.12 (m, 1H), 6.76-8.45 (m, 8H),
Example 210:
4-((R)-8-((R)-2-(5-Ethyl-2-fluorobenzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8- triazaspiro[4.5]decan-1 -yl)benzoic acid
Représentative scheme:
2) NaBl-Q. Methanol, r.t
1)CH3CH(Oa)j. HOAc, 17Ü°C
MeQH, reflux
NaOHAvater
Example 149-b
Pd/C. MeOH
chiral prep-HPLC
COOH g
tert-Butyl-1-(4-(methoxycarbonyl)phenyl)-2-methyl-4-oxo-1l3,8-triazaspiro[4.5]decane-8carboxylate
166
COOMe
To a solution of fert-butyl-4-carbamoyl-4-(4-(methoxycarbonyl)phenylamino)piperidine-1-carboxylate (prepared as described in Example 149-b) (500 mg, 0.00136 mmol) in triethyl orthoacetate (5 mL) was added acetic acid (1 drop, cat.). The resulting mixture was heated at 170°C for 30 minutes in a microwave reactor. The solvent was removed under reduced pressure and the residue was dissolved in methanol (10 mL). To the resulting solution was added sodium borohydride (100 mg, 0.0026 mol) at 0°C. The mixture was stirred for 30 minutes. The solvent was removed under reduced pressure and the residue was diluted with water (10 mL) and ethyl acetate (10 mL). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (3 * 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 100:1 to afford fert-butyl-1 -(4(methoxycarbonyl)phenyl)-2-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (223 mg, 41%).
LCMS (ESI): m/z = 404.2 [M+H]+ tert-Butyl-1-(4-(methoxycarbonyl)phenyl)-2,3-dimethyl-4~oxo-1,3,8-triazaspiro[4.5]decane-8 carboxylate
To a solution of tert-butyl-1-(4-(methoxycarbonyl)phenyt)-2-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (500 mg, 1.23 mmol) in N.N-dimethylformamide (10 mL) was added sodium hydride (52 mg, 60% in oil, 1.46 mmol) at 0°C. After stirring for 15 minutes, iodomethane (0.55 g, 3,87 mmol) was added. The resulting mixture was stirred for 15 minutes at room température and the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:1 to afford fert-butyl 1-(4-(methoxycarbonyl)phenyl)-2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate as a white solid (432 mg, 83%).
LCMS (ESI): m/z = 418.2 [M+H]1.
167
4-(8-( tert-Butoxycarbonyl)-2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1 -yljbenzoic acid
To a solution of ferf-butyl-1-(4-(methoxycarbonyl)phenyl)-2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5]decane8-carboxylate (430 mg, 1.02 mmol) in methanol (10 mL) was added a 15% aqueous sodium hydroxide solution (15 mL). The reaction was heated at reflux for 1 hour before cooling to room température. The pH of the resulting solution was adjusted to 1 by addition of 10% aqueous hydrochloric acid solution. The mixture was filtered and the filter cake was washed with water (10 mL) and then dried under reduced pressure to afford 4-(8-(fert-butoxycarbonyl)-2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1 -yljbenzoic acid as a white solid (370 mg, 89%).
LCMS (ESI): m/z = 404.1 [M+Hf.
tert-Butyl-1-(4-(benzyloxycarbonyl)phenyl)-2,3-dimethyl-4-oxo-1l3,8-triazaspiro[4.5]decane-8carboxylate
To a solution of 4-(8-(fert-butoxycarbonyl)-2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid (370 mg, 0.91 mmol) in N.N-dimethylformamide (10 mL) was added potassium carbonate (490 mg, 3.5 mmol) and benzyl bromide (320 mg, 1.7 mmol). Before the reaction was quenched by addition of icewater (10 mL), the mixture was heated for 2 hours at 50°C. The mixture was extracted with ethyl acetate (3 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether= 1:1 to afford fert-butyl-1-(4-(benzyloxycarbonyl)phenyl)-2,3-dimethyl-4-oxo-
1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (391 mg, 89%).
LCMS (ESI): m/z = 494.2 [M+H]T
Benzyl 442,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5ldecan-1-yl)benzoate hydrochloride
168
A solution of teri-butyH-(4-(benzyloxycarbonyl)phenyl)-2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5]decane8-carboxylate (391 mg, 0.79 mmol) in hydrochloric acid in dioxane (6.0 M, 20 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford benzyl-4(2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate hydrochioride as a white solid (312 mg, 92%).
LCMS (ESI): m/z = 394.2 [M+HJT
Benzyl-4-(8-((R)-2-(5-ethyl’2-fluorobenzamtdo)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoate
To a mixture of benzyl-4-(2,3-dimethyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate hydrochloride (312 mg, 0.73 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(5-ethyI-2fiuorobenzamido)-3-methylbutanoic acid (prepared as described in Example 168-i) (195 mg, 0.73 mmol), (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazoloI4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (277 mg, 1.10 mmol) and N,N-diisopropylethylamine (230 mg, 1.78 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched by addition of with icewater (5 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford benzyl-4-(8-((R)-2-(5-ethyl-2fluorobenzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8-triazaspiro{4.5]decan-1-yl)benzoate as a thick oil (251 mg, crude), which was used directly without further purification.
LCMS (ESI): m/z = 644.2 [M+Hf.
(4-(84(R)-245-Ethyl-2-fluorobenzamido)-3-<nethy1butanoyl)-2-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid
169
To a solution of benzyl-4-(8-((R)-2-(5-ethyl-2-fluorobenzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-
1,3,8-triazaspiro[4.5]decan-1-yl)benzoate (251 mg, crude) in methanol (15 mL) was added 5% palladium on carbon (50 mg, 50% wet with water). The mixture was stirred under a hydrogen atmosphère for 40 minutes. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (acetonitrile and water, acetonitrile from 20% to 60%) to afford (4(8-((R)-2-(5-ethyl-2-fluorobenzamido)-3-methylbutanoyl)-2-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1yl)benzoic acid as a white solid (126 mg, 32% overtwo steps).
LCMS (ESI): m/z = 553.1 [M+Hf.
4-{(R)-8-((R)-2-(5-Ethyl-2-fluorobenzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8triazaspiroi4.5]decan-1 -yl)benzoic acid
4-((R)-8-((R)-2-(5-Ethyl-2-fluorobenzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid (126 mg) was separated by chiral prep-HPLC (column: CHIRALPAK* (Daicel) IA (250 mm χ 20 mm, 5 pm). Mobile phase = hexane : éthanol (0.2%EDA-0.2%FA) = 1:1, flow rate: 20 mL/min) to afford as a white solid (31.7 mg, 32%). The conformation was tentatively assigned.
LCMS (ESI): m/z = 553.1 [M+H]+.
Chiral HPLC: (CHIRALPAK*IB (205 mm χ 4.6 mm, 5 pm). Mobile phase = hexane : éthanol (0.2% FA0.2%DEA) = 1:1, rétention time: 6.78 minutes), ee = 96.1%.
1H-NMR (400 MHz, CD3OD): δ = 1.00-1.13 (m, 6H), 1.17-1.32 (m, 4H), 1.43-1.45 (m, 3H), 1.60-1.85 (m, 2H), 2.23-2.35 (m, 1H), 2.65-2.83 (m, 4H), 3.01 (s, 3H), 3.53-3.59 (m, 1H), 4.00-4.05 (m, 1H), 4.34-4.39 (m, 1H), 4.54-4.71 (m, 1H), 5.40-5.59 (m, 1 H), 6.88-7.00 (m, 2H), 7.12-7.19 (m, 1H), 7.35-7.50 (m, 1H), 7.58-7.77 (m, 1H), 7.82-8.01 (m, 2H).
Example 211:
4-((S)-8-((R)-2-(5-Ethyl-2-fluorobenzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yl)benzoic acid
COOH
170
4-((S)-8-((R)-2-(5-Ethyl-2-fluorobenzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid (126 mg) was separated by chiral prep-HPLC (column: CHIRALPAK* (Daicel) IA (250 mm χ 20 mm, 5 pm). Mobile phase = hexane : éthanol (0.2%EDA-0.2%FA) = 1:1, flow rate: 20 mL/min) to afford as a white solid (31.4 mg, 31%). The conformation was tentatively assigned.
LCMS (ESI); m/z = 553.0 [M+Hf.
Chiral HPLC: (CHIRALPAKTB (205 mm χ 4.6 mm, 5 pm). Mobile phase = hexane : éthanol (0.2% FA0.2%DEA) = 1:1, rétention time: 10.578 minutes, ee = 97%.
1H-NMR (400 MHz, CDaOD): δ = 1.03-1.11 (m, 6H), 1.18-1.33 (m, 4H), 1.46-1.49 (m, 3H), 1.54-1.94 (m, 2H), 2.22-2.65 (m, 4H), 2.99 (s, 3H), 3.06-3.08 (m, 1H), 3.57-3.59 (m, 1H), 4.03-4.10 (m, 1H), 4.37-4.44 (m, 1H), 4.52-4.59 (m, 1H), 5.42-5.59 (m, 1H), 6.92-7.00 (m, 2H), 7.17-7.19 (m, 1H), 7.39-7.42 (m, 1H), 7.58-7.77 (m, 1H), 7.82-8.01 (m, 2H).
The following 2 compounds were synthesized following the general procedure described above:
Example 212:
4-((R)-8-((R)-2-(2-Fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yljbenzoic acid
35.6 mg, yield: 23%, white solid.
LCMS (ESI): m/z = 593 [M+H]L
Chiral HPLC: (CHIRALPAK*IB (205 mm χ 4.6 mm, 5 pm). Mobile phase = hexane ; éthanol (0.2% FA0.2%DEA) = 1:1, rétention time: 6.31 minutes, ee = 95.1%.
1H-NMR (400 MHz, CD3OD): δ = 0.99-1.15 (m, 6H), 1.32-1.45 (m, 4H), 1.63-1.87 (m, 2H), 2.26-2.65 (m, 2H), 2.79-2.81 (m, 1H), 2.99 (s, 3H), 3.54-3.59 (m, 1H), 4.06-4.09 (m, 2H), 4.34-4.55 (m, 1H), 5,41-5.59 (m, 1H), 6.89-6.99 (m, 2H), 7.45-7.59 (m, 1H), 7.83-7.99 (m. 3H), 8.02-8.05 (m, 1H).
Example 213:
4-((S)-8-((R)-2-(2-Fluoro-5-{trifluoromethyl)benzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid
35.7 mg, yield: 24%, white solid.
LCMS (ESI): m/z = 593.0 [M+H]+.
171
Chiral HPLC: (CHIRALPAK*]B (205 mm * 4.6 mm, 5 pm). Mobile phase = hexane : éthanol (0.2% FA0.2%DEA) = 1:1, rétention time: 12.7 minutes, ee = 97%.
1H-NMR (400 MHz. CD3OD): δ = 1.04-1.16 (m, 6H), 1.32-1.35 (m, 2H), 1.45-1.74 (m, 4H), 1.95-2.10 (m, 1H), 2.24-2.35 (m, 1H), 2.61-2.81 (m, 1H), 3.04 (s, 3H), 3.59-3.67 (m, 1 H). 4.02-4.37 (m, 2H), 4.53-4.61 (m, 1H), 5.42-5.53 (m, 1H), 6.92-7.01 (m, 2H), 7.48-7.67 (m, 1H), 7.81-7.88 (m, 3H), 8.01-8.07 (m, 1H).
Example 214:
(R)-N-(1 -(1 -(1 H-lndazol-5-yl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 -oxobutan15
2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
Représentative scheme:
SEM-CI
NaH. DMF
H2O2. NaOH
CH3OH. r.t.. 3h
CH(OEt)j
1) HOAc (cat.). 14O°C. ovemight
2) NaBH4, CH3OH
Example 52-a a
HCl. dioxane
172
Représentative general procedure: tert-Butyl-4-cyano-4-(1-{(2-{trimethylsilyl)ethoxy)methyl)-1H-indazol-5-ylamino)piperidine-1carboxylate
To a solution of tert-butyl-4-(1H-indazol-5-ylamino)-4-cyanopiperidine-1 -carboxylate (prepared as described in Example 52-a) (1.0 g, 2.92 mmol) in N.N-dimethylformamide (10 mL) was added sodium hydride (0.175 g, 60% in oil, 4.39 mmol) at 0°C. After stirring for 15 minutes at 0°C, 2-(trimethylsilyl) ethoxymethyl chloride (0.54 g, 3.22 mmol) was added. After stirring for 2 hours, the reaction was quenched by addition of ice-water (20 mL). The mixture was extracted with dichloromethane (3 χ 20 mL). The combined organic layers were washed with brine and dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 100:1 to afford ferf-butyl-4-cyano-4-(1-((2(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-ylamino)piperidine-1-carboxylate as a white solid (280 mg, 21%).
LCMS (ESI): m/z = 472.2 [M+H]+.
1H-NMR (300 MHz, DMSO-ds): δ = 0.01-0.02 (m, 9H), 0.8-0.87 (m, 2H), 1.44-1.45 (m, 9H), 1.82-1.87 (m, 2H), 2.29-2.33 (m, 2H), 3.18-3.25 (m, 2H), 3.49-3.57 (m, 2H), 3.78-3.82 (m, 2H), 5.59-5.70 (m, 2H), 5.95 (s, 1H), 6.94-6.98 (m, 2H). 7.51-7.54 (m, 1H), 8.26 (s, 1H).
fert-Butyl-4-carbamoyl-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-ylamino)piperidine-1carboxylate
To a solution of fert-butyl-4-cyano-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-ylamino) piperidine1-carboxylate (600 mg. 1.73 mmol) in methanol (5 mL) was added an aqueous sodium hydroxide solution (6.67 mL, 1.0 M). After stirnng for 15 minutes, to the resulting solution was added a 30% aqueous hydrogen peroxide solution (5.07 mL) dropwise. After stirring ovemight, the reaction was quenched with ice-water (50 mL) and the mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were washed with brine and dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 100:1 to afford tert-butyl-4-carbamoyl-4-(1-((2-(trimethylsiiyl)ethoxy)methyl)-1H-indazol-5ylamino)piperidine-1-carboxylate as a white solid (500 mg, 80%).
LCMS (ESI): m/z = 490.2 [M+H]*.
173 fert-Butyl-4-oxo-1-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yi)-1,3,8triazaspiro[4.5]decane-8-carboxylate
To a solution of terf-butyl-4-carbamoyl-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5ylamino)piperidine-1-carboxylate (300 mg, 0.613 mmol) in triethyl orthoformate (2 mL) was added acetic acid (1 drop, cat.). The resulting mixture was stirred for 30 minutes at 130°C in a microwave reactor. The solvent was removed under reduced pressure and the residue was dissolved in methanol (10 mL). To the solution was added sodium borohydride (100 mg, 2.63 mmol) at 0°C. The resulting mixture was stirred for 30 minutes. The solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 100:1 to afford tert-butyl-4-oxo-1-(1((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (100 mg, 32%).
LCMS (ESI): m/z = 502.2 [M+Hf.
tert-Butyl-3-methyl-4-oxo-1-(1-((2-(trimethylsily!)ethoxy)methyl)-1H-indazol-5-yl)-1,3,8triazaspiroÎ4.5]decane-8-carboxyIate
To a solution of fert-butyl-4-oxo-1-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)-1,3,8triazaspiro[4.5]decane-8-carboxylate (200 mg, 0.40 mmol) in N.N-dimethylformamide (5 mL) was added sodium hydride (48 mg, 1.2 mol) at 0°C. After stirring for 15 minutes, iodomethane (283 mg, 2.0 mmol) was added. After stirring for 1 hour, the reaction was quenched by addition of ice-water (10 mL). The mixture was extracted with ethyl acetate (3 χ 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 100:1 to afford ferf-butyl-3-methyl-
4-oxo-1-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H’indazol-5-yl)-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (180 mg, 87%).
LCMS (ESI): m/z = 516.2 [M+Hf.
174 ’H-NMR (300 MHz, CDCh) δ = 0.01-0.03 (m, 9H), 0.86-0.95 (m, 2H), 1.44 (s, 9H), 1.69-1.74 (m, 2H), 2.12-2.16 (m, 2H), 2.99 (s, 3H), 3.57-3.62 (m, 4H), 3.82-3.94 (m, 2H), 4.68 (s, 2H), 5.27-5.66 (m, 2H), 7.00-7.08 (m, 2H), 7.61-7.64 (m, 1H), 7.88-7.98 (m, 1H).
1-(1H-lndazol-5-yl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride
A solution of tert-buty1-3-methyl-4-oxo-1-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)-1,3l8triazaspiΓO[4.5]decane-8-carboxylate (180 mg, 0.35 mmol) in hydrochloric acid in dioxane (6.0 M, 20 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 1-(1H-indazol-5-yl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride as a white solid (115 mg, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 285.2 [M+Hf.
(R)-N-(1-(1-(1 H-lndazo!-5-yl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
To a mixture of 1-(1H-indazol-5-yl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride (115 mg, crude) in dichloromethane (10 mL) was added sequentially (R)-2-(2-fluoro-5-(trifluoromethy!)benzamido)-
3-methylbutanoic acid (prepared as described in Example 28-f) (129 mg, 0.34 mmol), 1[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (198 mg, 0.52 mmol), N,N-diisopropylethylamine (109 mg, 0.85 mmol). The reaction was stirred for 2 hours before quenching with ice-water (10 mL). The mixture was extracted with dichloromethane (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 20:1 to afford (R)-N-(1-(1-(1/7-indazol-5-yl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-
2-yl)-2-fluoro-5-(trifluoromethyl)benzamide as a white solid (35 mg, 32%).
LCMS (ESI): m/z = 575.2 [M+Hf.
i|_l-NMR (400 MHz, CD3OD): δ = 0.85-1.06 (m, 6H), 1.82-2.19 (m, 5H), 3.02 (s, 3H), 3.56-3.66 (m, 1H), 3.94-4.34 (m, 3H), 4.75-4.78 (m, 2H), 4.98-5.01 (m, 1H), 7.17-7.53 (m, 4H), 7.80-7.93 (m, 2H), 8.01-8.21 (m, 1H).
The following 2 compounds were synthesized following the general procedure described above:
175
Example 215:
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-
2-yl)-5-ethyl-2-fluorobenzamide
9.5 mg, yield: 10%, white solid.
LCMS (ESI): m/z = 535.0 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 0.94-1.05 (m, 6H), 1.19-1.26 (m, 3H), 1.85-2.11 (m, 5H), 2.61-2.67 (m, 2H), 3.05 (s. 3H). 3.58-3.63 (m, 1H), 3.98-4.05 (m, 2H), 4.27-4.46 (m, 1H), 4.71-4.76 (m, 2H), 5.10 (s, 1H), 7.00-7.12 (m, 2H), 7.28-7.30 (m, 1H), 7.33-7.79 (m, 2H), 7.94-8.02 (m, 2H).
Example 216:
(R)-N-(1-(1-(1 H-Benzo[d]imidazol-6-yl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-3-methyl-1 oxobutan-2-yl)-5-ethyl-2-fluorobenzamide
18.8 mg, yield: 16%, white solid.
LCMS (ESI): m/z = 535.0 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.07-1.11 (m, 6H), 1.17-1.22 (m, 3H), 1.79-1.98 (m, 2H), 2.21-2.31 (m,
1H), 2.44-2.68 (m, 3H), 2.81-2.89 (m, 1H), 3.06-3.07 (m, 3H), 3.52-3.65 (m, 1H), 4.00-4.07 (m, 1H), 4.244.36 (m, 1H), 4.46-4.57 (m, 1H), 4.85-4.87 (m, 2H) 4.93-4.97 (m, 1H), 7.06-9.22 (m, 7H).
Example 217:
(R)-3-Methyl-N-(3-methyl-1-oxo-1-(2-oxo-1-phenyl-3-oxa-1,8-diazaspiro{4.5]decan-8-yl)butan-2 yl)benzamide
Scheme:
176
Experimental procedure:
1-ftert_Butoxycarbonyl)-4-(phenylamino)piperidine-4-carboxylic acid
COOH
To a solution of aniline (10 g, 107 mmol) in tetrahydrofuran (800 mL) was added sodium hydroxide (22 g, 537 mmol) at 0°C. After stirring for 10 minutes at 0°C, to the resulting solution was added fert-butyl-4oxopiperidine-1-carboxylate (42 g, 55 mmol). The resulting suspension was stirred for 20 minutes at 0°C. To the suspension was added chlorofomn (64 g, 537 mmol). The reaction was stirred ovemight before quenching with water (100 mL). The resulting mixture was extracted with ethyl acetate (100 mL). The pH of the aqueous layer was adjusted to 3 by addition of a 5% aqueous hydrochloric acid solution and extracted with ethyl acetate (3 * 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure to afford 1-(fert-butoxycarbonyl)-4(phenylamino)piperidine-4-carboxylic acid as a yellow solid (18 g, 52%).
LCMS (ESI): m/z = 321.2 [M+H]4.
’H-NMR (300 MHz, DMSO-de): δ = 1.39 (s, 9H), 1.82-1.95 (m, 4H), 3.16-3.26 (m, 2H), 3.57-3.61 (m, 2H), 6.52-6.56 (m, 3H), 7.02-7.07 (m, 2H).
tert-Butyl-4-(hydroxymethyl)-4-[phenylamino)piperidine-1-carboxylate
To a solution of 1-(terf-butoxycarbonyl)-4-(phenylamino)piperidine-4-carboxylic acid (2 g, 6.25 mmol) in tetrahydrofuran (10 mL) was added lithium aluminum hydride (4 mL, 2.4 M in tetrahydrofuran, 9.6 mmol).
177
Before quenchîng by sequential addition of ice-water (4 mL), 15% aqueous sodium hydroxide solution (12 mL) and water (4 mL), the reaction was stirred for 2 hours. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:3 to afford tert-butyl-4-(hydroxymethyl)-4(phenylamino)piperidine-l-carboxylate as a yellow oil (580 mg, 30%).
LCMS (ESi): m/z = 307.1 [M+Hf.
tert-Butyl-2-oxo-1-phenyl-3-oxa-1,8-diazaspiro[4.5]decane-8-carboxylate
BocN
To a solution of fert-butyl-4-(hydroxymethyl)-4-(phenylamino)piperidine-1-carboxylate (250 mg, 0.817 mmol) in acetonitrile (5 mL) was added pyridinium chloride (118 mg, 1.01 mmol) and 1,Tcarbonyldiimidazole (265 mg, 1.63 mmol). Before quenchîng by addition of ice-water (4 mL), the reaction was stirred for 2 hours at 70°C. The mixture was extracted with ethyl acetate (3 χ 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:5 to afford the crude product. The crude product was washed with petroleum ether (3 χ 5 mL) to afford fert-butyl-2-oxo-1-pheny1-3-oxa-1,8-diazaspiro[4.5]decane-8-carboxylate as a white solid (170 mg, 62%). LCMS (ESI): m/z = 333.2 [M+H]+.
-Phenyl-3-oxa-1,8-diazaspiro[4.5]decan-2-one hydrochloride
HN
HCl
A solution of tert-butyl-2-oxo-1-phenyl-3-oxa-1,8-diazaspiro[4.5ldecane-8-carboxylate (70 mg, 0.21 mmol) in hydrochioric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried. The crude product was used directly without further purification.
LCMS (ESI): m/z = 233.2 [M+Hf.
(R)-3-Methyl-N-(3-methyl-1 -oxo-1 -(2-oxo-1 -phenyl-3-oxa-1,8-diazaspiro[4.5]decan-8-yl)butan-2yl)benzamide
To a suspension of l-phenyl-3-oxa-1,8-diazaspiro[4.5]decan-2-one hydrochloride (45 mg, crude) and (R)-
3-methyl-2-(3-methylbenzamido)butanoic acid (prepared as described in Example 192-g) (65 mg, 0.274 mmol) in dichloromethane (5 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5
178
b]pyridinium-3-oxide hexafluorophosphate (HATU) (111 mg, 0.316 mmol) and N,N-diisopropylethylamine (82 mg, 0.633 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3x10 mL) and the combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-3methyl-N-(3-methyl-1-oxo-1-(2-oxo-1-phenyl-3-oxa-1,8-diazaspiro[4.5]decan-8-yl)butan-2-yl)benzamide as a white solid (13 mg, 13% over two steps).
LCMS (ESl): m/z = 450.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ = 0.74-0.96 (m, 6H), 1.11-1.28 (m, 1H). 1.46-1.86 (m, 1 H), 1.89-2.30 (m, 3H), 2.37-2.42 (m, 3H), 2.68-2.90 (m, 2H), 3.15-3.31 (m, 1H), 4.35-4.39 (m, 1H), 4.59-4.91 (m, 3H), 6.997.68 (m, 9H).
Example 218:
(R)-2-Fluoro-N-(3-methyl-1-f3-methyl-1-(4-(oxetan-3-ylamino)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
Experimental procedure: tert-Butyl-4-carbamoyl-4-(4-nitrophenylamino)piperidine-1-carboxylate
179
To a solution of tert-butyl-4-cyano-4-(4-nitrophenylamino)piperidine-1-carboxylate (prepared as described in Example 86-a) (9.0 g, 0.0261 mol) in methanol (100 mL) was added an aqueous sodium hydroxide solution (100 mL, 1.0 M). After stirring for 15 minutes, a 30% aqueous hydrogen peroxide solution (76 mL) was added dropwise. After stirring ovemight, the resulting mixture was filtered. The filter cake was washed with water (3 χ 100 mL) and dried under reduced pressure to afford tert-butyl-4-carbamoy!-4-(4nitrophenylamino)piperidine-1-carboxylate as a white solid (5.2 g, 55%).
LCMS (ESI): m/z = 365.2 [M+Hf.
fert-Butyl-1-(4-nitrophenyl)^l-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of terf-butyl-4-carbamoyl-4-(4-nitrophenyiamino)piperidine-1-carboxylate (2.0 g, 0.0055 mol) in triethyl orthoformate (20 mL) was added acetic acid (1 mL, cat). The resulting mixture was stirred at 140°C for 30 minutes in a microwave reactor. The solvent was removed under reduced pressure and the residue was dissolved in methanol (30 mL). To the resulting solution was added sodium borohydride (0.5 g, 0.0132 mol) at 0°C and the mixture was stirred for 30 minutes. The solvent was removed under reduced pressure and the residue was treated with water (20 mL) and ethyl acetate (50 mL). The organic layerwas coliected and the aqueous layerwas extracted with ethyl acetate (3*10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 100:1 to afford fert-butyl-1-(4-nitrophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (1.2 g, 61%).
LCMS (ESI): m/z = 377.4 [M+H]*.
tert-Butyl-3-methyl-1-(4-nitrophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-e-carboxylate
180
To a solution of fert-butyl-1-(4-nitrophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (1.2 g, 0.00319 mol) in N,N-dimethylformamide (10 mL) was added sodium hydride (320 mg, 60% in oil, 0.00798 mol) at 0°C. After stirring for 15 minutes, iodomethane (2.27 g, 0.01598 mol) was added. The resulting mixture was stirred for 60 minutes at room température and the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*15 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether= 1:1 to afford te/ï-butyl-3methyl-1-(4-nitrophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a yellow solid (1.0 g, 81%). LCMS (ESl): m/z = 391.2 [M+H]+.
1H-NMR (400 MHz, CDCh): 0 = 1.55 (s, 9H), 1.67-1.74 (m, 2H), 2.56-2.74 (m, 2H), 3.05 (s, 3H), 3.51-3.65 (m, 2H), 4.06-4.16 (m, 2H). 4.79-4.83 (m. 2H), 6.64-6.67 (m, 2H), 8.11-8.14 (m, 2H).
tert-Butyl-1-(4-arninophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of fert-butyl-3-methyl-1-(4-nitrophenyl)-4-oxo-1,3,8-triazaspiro[4.5ldecane-8-carboxylate (500 mg, 1.281 mmol) in éthanol (10 mL) was added Raney-Ni (0.1 g, 50% in éthanol). After heating to 50°C, hydrazine (1.0 mL) was added dropwise to the resulting suspension. Before removing the Raney-Ni by filtration, the reaction mixture was stirred at room température for 30 minutes. The solvent was removed under reduced pressure and the residue was used directly without further purification.
LCMS (ESl): m/z = 361.2 [M+Hf.
tert-Butyl-3-methyl-1-(4-(oxetan-3-ylamino)phenyl)-4-oxo-1,3l8-triazaspiroI4.5]decane-8carboxylate
To a solution of oxetan-3-one (99 mg, 1.39 mmol) and tert-butyl-1-(4-aminophenyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (100 mg, 0.28 mmol) in 1,2-dichloroethane (30 mL) was added acetic acid (1 drop) at room température. After two hours, to the solution was added sodium triacetoxyborohydride (294 mg, 1.39 mmol) at room température. The mixture was stirred overnight at room température. The reaction was quenched with water (10 mL) and the mixture was extracted with
181 dichloromethane (3*10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 20:1 to afford tert-butyl-3-methyl-1-(4-(oxetan-3-yiamino)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decane-8-carboxylate as a white solid (50 mg, 42%).
LCMS (ESI): m/z = 416.2 [M+H]4.
3-Methyi-1-(4-(oxetan-3-ylamino)phenyl)-1,3,8-triazaspiro[4.5]decan-4-one
HN
NH
To a solution of tert-butyl-3-methyl-1-(4-(oxetan-3-ylamino)phenyi)-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (55 mg, 0.13 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) at room température. The reaction was stirred for 30 minutes at room température. The solvent was removed under reduced pressure and water (5 mL) was added to the residue. The pH of the suspension was adjusted to 11 by addition of a 10% aqueous sodium carbonate solution. The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford 3-methyl-1-(4-(oxetan-3-ylamino)phenyl)-1,3,8triazaspiro[4.5]decan-4-one as the crude product (45 mg, crude) which was used directly without further purification.
(R)-2-Fluoro-N-(3-niethyl-1-(3-methyl-1-(4-(oxetan-3-ylamino)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
NH
182
To a solution of 3-methyi-1-(4-(oxetan-3-ylamino)phenyl)-1,3,8-triazaspiro[4.5]decan-4-one (45 mg, 0.14 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(2-fluoro-5-(trifIuoromethyl)benzamido)-3methylbutanoic acid (prepared as described in Example 28-f) (44 mg, 0.14 mmol), 1[bis(dimethylamino)methylene]-1 Η-Ί ,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (81 mg, 0.21 mmol) and N,N-diisopropylethylamine (46 mg, 0.36 mmol). The resulting mixture was stirred for one hour at room température before the reaction was quenched with ice-water. The mixture was extracted with dichloromethane (3 χ 10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with petroleum ether : ethyl acetate = 1:2 to afford (R)-2-fluoro-N-(3-methyl-1-(3-methyl-1-(4-(oxetan-3ylamino)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide as a white solid (11.5 mg, 13% overtwo steps).
LCMS (ESI): m/z = 606.2 [M+H]\ 1H-NMR (400 MHz, CDCb): ô = 0.88-1.04 (m, 6H), 1.76-2.15 (m, 5H), 3.01 (s, 3H), 3.55-3.60 (m, 2H), 3.92-4.08 (m, 2H), 4.40-4.43 (m, 1H), 4.55-4.65 (m, 5H), 4.94-5.09 (m, 2H), 6.54-6.63 (m, 2H), 6.85-6.87 (m, 2H), 7.26-7.34 (m, 1H), 7.51-7.60 (m, 1H), 7.76-7.77 (m, 1H), 8.34-8.36 (m, 1H).
Example 219:
(R)-2-Fluoro-N-(1-(1-((3-methoxycyclobutyl)methyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
183
Scheme:
DMF, 6C°C. ovemight
1) Pd/C, Ha MeOH
2) (Boc)2O, OCM. TEA
Example Éæ-b c
Pd/C, Hj, MeOH. f.t, ovemight
O Bn
NaH, CHjl. DMF. r.L. ovefnight
1) HCl in dioxane, r t. 0.5h
2) HATU. OIPEA. DCM. r t, 2h
Example 2B-f
Experimental procedure: (3-(Benzyloxy)cyc!obutyl)methanol
To a solution of 3-(benzyloxy)cyclobutanecarboxylic acid (0.5 g, 2.4 mmol) in tetrahydrofuran (10 mL) was added lithium aluminum hydride (2 mL, 2.4 M in tetrahydrofuran) at 0°C dropwise. The reaction was stirred ovemight at room température. After quenching with water (0.2 mL), a 15% aqueous sodium hydroxide solution (0.6 mL) and water (0.2 mL) were added sequentially. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:5 to afford (3(benzyloxy)cyclobutyl)methanol as a colorless oil (420 mg, 90%).
1H-NMR (300 MHz, CDCb): δ = 1.68-2.48 (m, 5H), 2.62-3.57 (m, 2H), 3.88-4.17 (m, 1H), 4.40 (m, 2H), 7.24-7.33 (m, 5H).
184 (3-{Benzyloxy)cyclobutyl)methyl-methanesulfonate
o-s=o
II O
To a solution of (3-(benzyloxy)cyclobutyl)methanol (200 mg, 1.04 mmol) in dichloromethane (10 mL) was added N.N-diisopropylethylamine (201 mg, 1.56 mmol) and methanesulfonyl chloride (142 mg, 1.25 mmol). The reaction was stirred for 0.5 h at room température. Then the reaction was quenched with water (10 mL) and extracted with ethyl acetate (3 χ 10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude (3(benzyloxy)cyclobutyl)methyl-methanesulfonate (270 mg, crude), which was used directly without further purification.
tert-Butyl-3-mettiyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
Boc
To a solution of benzyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (prepared as described in Example 88-b) (1.5 g, 4.7 mmol) in methanol (50 mL) was added 5% palladium on carbon (0.2 g). The reaction was stirred ovemight at room température under a hydrogen atmosphère. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. To the residue was added sequentially dichloromethane (50 mL), triethylamine (0.56 g, 5.6 mmol), di-tert-butyl bicarbonate (1.2 g, 5.6 mmol). The mixture was stirred for 3 hours before the reaction was quenched with a cold 5% aqueous hydrochloric acid solution (10 mL). The organic layerwas collected and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure. To the residue was added ethyl acetate : petroleum ether =1:3(10 mL) and the mixture was stirred at 0°C for 1 hour. The precipitate was collected by filtration and dried under reduced pressure to afford tert-butyl-3-methyl-2,4dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (1.23 g, 92%).
LCMS (ESI): m/z = 284.2 [M+H]+.
tert-Butyl-1-((3-(benzyloxy)cyclobutyl)methyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate
Boc
O
Bn
185
To a solution of (3-(benzyloxy)cyclobutyi)methyl-methanesulfonate (270 mg, crude) in N,Ndimethylformamide (5 mL) was added fert-butyl-3-methyl-2,4-dioxo-1,3,8-triazaspiroi4.5]decane-8carboxylate (283 mg, 1.0 mmol) and césium carbonate (650 mg, 2.0 mmol). Before quenching by addition of ice-water (20 mL), the mixture was stirred at 80°C ovemight. The mixture was extracted with ethyi acetate (3*10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyi acetate : petroleum ether= 1:5 to afford fert-butyl-1-((3-(benzyloxy)cyclobutyl)methyl)-3methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (290 mg, 63%).
LCMS (ESI): m/z = 458.2 [M+H]\ 1H-NMR (300 MHz, CDCh): δ = 1.46 (s, 9H), 1.54-2.68 (m, 8H), 3.01 (s, 3H), 3.31-3.19 (m, 2H), 4.30-3.40 (m, 6H), 4.41-4.39 (m, 2H), 7.33-7.25 (m, 5H).
tert-Butyl-1-((3-hydroxycyclobutyl)methyl)-3-methyl-2,4-dioxo-1,3,8-triazaspîro[4.5]decane-8 carboxylate
To a solution of tert-butyl-1-((3-(benzyloxy)cyclobutyl)methyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro [4.5]decane-8-carboxylate (290 mg, 0.63 mmol) in methanol (10 mL) was added 5% palladium on carbon (30 mg, 50% wet with water). The reaction was stirred ovemight at room température under a hydrogen atmosphère. The catalyst was removed by filtration and the Tilt rate was concentrated under reduced pressure to afford crude tert-butyl-1-((3-hydroxycyclobutyl)methyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro(4.5]decane-8-carboxylate (220 mg, crude), which was used directly without further purification. LCMS (ESI): m/z = 368.2 [M+Hf.
tert-Butyl-1-((3-methoxycyclobutyl)methyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate
To a solution of tert-butyl-1-((3-hydroxycyclobutyl)methyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiroI4.5] decane-8-carboxylate (220 mg, crude) in Ν,Ν-dimethylformamide (5 mL) was added sodium hydride (50 mg, 1.2 mmol) at room température. After stirring for 15 minutes, iodomethane (425 mg, 3.0 mmol) was added. The resulting mixture was stirred ovemight and the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyi acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyi acetate : petroleum ether = 1:3 to afford tert-Butyl-1-((3methoxycyclobutyl)methyl)-3-methyl-2,4-dioxo-1.3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (150 mg, crude), which was used directly without further purification.
186
LCMS (ESI): m/z = 382.2 [M+Hf.
(R)-2-Fluoro-N-(1-(1-((3-methoxycyclobutyl)methyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
A solution of tert-butyl-3-methyl-1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2,4-dioxo-1,3,8triazaspira[4.5]decane-8-carboxylate (150 mg, crude) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The solvent was removed under reduced pressure. To the residue was added dichloromethane (5 mL), (R)-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (121 mg, 0.39 mmol), 1-[bis(dimethylamino)methyleneJ-1H-1,2,3triazolo[4,5-b]pyridinium-3-oxide hexafiuorophosphate (HATLJ) (224 mg, 0.59 mmol) and N,Ndiisopropylethylamine (127 mg, 0.98 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water. The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane . methanol = 15:1 to afford (R)-2-fluoro-N-(1-(1-((3-methoxycyclobutyl)methyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide as a white solid (65.7 mg, 29.5% overthree steps).
LCMS (ESI): m/z ~ 571.2 [M+Hf.
Ή-NMR (400 MHz. CDaOD): δ = 0.98-1.23 (m, 6H), 1.51-2.78 (m, 10H), 2.99 (d, J= 2.8 Hz, 3H), 3.093.27 (m, 3H), 3.27-4.10 (m, 6H), 4.29 (t, J= 13.0 Hz, 1H), 4.59 (d, J= 11.0 Hz, 1 H), 4.99 (d, J = 7.1 Hz, 1H), 7.48 (t. J= 9.4 Hz, 1H), 7.84-7.95 (m, 1H), 7.98-8.18 (m, 1H).
Example 220:
(R)-N-(1-(1-(4-(1H-1,2,4-Triazol-3-yl)phenyl)-3-niethyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3 methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
Représentative scheme:
187
NaH, DMF
CHjl
b
HQ diaxane
HATU. OPEA, DCM
Représentative general procedure: tert-Butyl-1-(4-(methoxycarbonyl)phenyl)-3-methy!^-oxo-1,3,8-triazaspiro[4.5]decane-8 carboxylate
To a solution of fert-butyl-1-(4-(methoxycarbonyl)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (prepared as described in Example 149-c) (1000 mg, 2.57 mmol) in N,N-dimethylformamide (10 mL) was added sodium hydride (138 mg, 60% in oil, 3.34 mmol) at 0°C. After stirring for 15 minutes, iodomethane (550 mg, 3.86 mmol) was added. The resulting mixture was stirred for 15 minutes before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:2 to afford terï-butyl-1-(4-(methoxycarbonyl)phenyl)-3-methyi-4-oxo-1,3,8triazaspiro[4.5]decane-8-carboxylate as a white solid (1000 mg, 96%).
LCMS (ESI): m/z = 404.2 [M+H]+.
4-(8-(tert-Butoxycarbonyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl) benzoic acid
To a solution of fert-butyl-1-(4-(methoxycarbonyl)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (1000 mg, 0.94 mmol) in methanol (20 mL) was added a 15% aqueous sodium hydroxide solution (15 mL) The reaction was heated at reflux for 30 minutes before cooling to room température.
188
The pH of the resulting solution was adjusted to 3-4 by addition of 10% aqueous hydrochloric acid solution. The suspension was filtered. The filter cake was washed with petroleum ether (15 mL) and dried under reduced pressure to afford 4-(8-(tert-butoxycarbonyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-1yl) benzoic acid as a white solid (910 mg, 86%).
LCMS (ESI): m/z = 390.4 [M+HJL tert-Butyl-1 -(4-carbamoylphenyl)-3-methyM-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of 4-(8-(fert-butoxycarbonyl)-3-methyl-4-oxo-1,3,8-triazaspiroi4.5]decan-1-yl) benzoic acid (910 mg 2.34 mmol) in dichloromethane (15 mL) was added sequentially ammonium chloride (751 mg, 14.03 mmol), 1 -[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (1,73 g, 3.51 mmol) and N.N-diisopropylethylamine (1.51 g, 11.69 mmol). The resulting mixture was stirred for 2 hours before the reaction was quenched with ice water (10 mL). The mixture was extracted with dichloromethane (3*15 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 20:1 to afford fert-butyl-1-(4carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (850 mg, 94%).
LCMS (ESI): m/z = 389.2 [M+Hf.
(E)-fert-Butyl-l -(4-(((dimethylamino)methylene)carbamoyl)phenyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decane-8-carboxylate
A solution of tert-butyl-1-(4-carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (400 mg 1.03 mmol) în N,N-dimethylfomnamide/N,N-dimethylacetamide (1:1,10 mL) was stirred at room température ovemight. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:3 to afford (E)-tert-butyl
189
1-(4-(((dimethylamino)methylene)carbamoyl)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate as a yellow solid (290 mg, 85%).
LCMS (ESI): m/z = 444.3 [M+H]*.
tert-Butyl-1 -(4-(1H-1,2,4-triazol-3-yl)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate
To a solution of (E)-fert-butyl-1-(4-(((dimethylamino)methylene)carbamoyl)phenyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (290 mg, 0.65 mmol) in éthanol (20 mL) was added hydrazine hydrate (0.3 mL, 80% in water). The reaction was stinred at room température ovemight. Then the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 20:1 to afford fert-butyl-1-(4-(1H-1,2,4-triazol-3-yl)phenyl)-3methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a thick oil (210 mg, 77%).
LCMS (ESI): m/z = 413.4 (M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 1.52 (s, 9H), 1.61-1.65 (m, 2H), 2.55-2.73 (m, 2H), 3.01 (m, 3H), 3.483.68 (m, 2H), 3.95-4.21 (m, 2H), 4.65-4.73 (m, 2H), 6.71-6.75 (m, 2H), 7.88-7.89 (m, 2H), 8.13 (s, 1H).
H-1,2,4-Triazol-3-yl)phenyl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochioride
A solution of terf-butyl-1-(4-(1 H-1,2,4-triazol-3-yl)phenyl)-3-methy!-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (110 mg, 0.26 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 1-(4-(1 H190
1,2,4-triazol-3-yl)phenyl)-3-methyl-1,3,8-triazaspiro[4.5ldecan-4-one hydrochloride as a white solid (90 mg, 95%).
LCMS (ESI): m/z = 313.4 [M+H]T (R)-N-(1 -{1 H-1,2,4-Triazol-3-yl)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
To a suspension of i-(4-(1H-1,2,4-triazol-3-yl)phenyl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride (90 mg, 0.26 mmol) in dichloromethane (5 mL) was added (R)-2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (82 mg, 0.26 mmol), 1 -[bis(dîmethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (153 mg, 0.40 mmol) and N.N-diisopropylethylamine (104 mg, 0.80 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 χ 10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-N-(1-(1-(4-(1 H-1,2,4-triazol-3-yl)phenyl)-3methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5(trifluoromethyl)benzamide as a white solid (55 mg, 35%).
LCMS (ESI): m/z = 602.2 [M+H]\ 1H-NMR (400 MHz, CDaOD): ô= 1.06-1.20 (m, 6H), 1.76-1.94 (m, 2H), 2.212.32 (m, 1H), 2.64-2.76 (m, 1H), 2.87-3.01 (m, 1H), 3.05 (s, 3H), 3.54-3.58 (m, 1H), 3.99-4.14 (m, 1H), 4.32-4.39 (m, 1H), 4.57-4.60 (m, 1H), 4.85-4.87 (m, 2H), 4.97-4.99 (m, 1H), 6.94-6.97 (m, 2H), 7.44-7.50 (m, 1H), 7.71-7.91 (m, 3H), 8.05-8.06 (m, 1H), 8.81-8.88 (m, 1H).
Example 221:
(R)-Methyl4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methy!-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-1 -yl)benzoate
Représentative scheme:
191
Example 223-c
a
Représentative general procedure:
4-(3-Methyl-2,4-dioxo-1,3l8-triazaspiro[4.5]decan-1-yl)benzoic acid hydrochloride
cooch3
A solution of fert-buty1-1-(4-(methoxycarbonyl)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (prepared as described in Example 223-c) (120 mg, 0.28 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 4-(3-methy1-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid hydrochloride as a white solid (100 mg, 97%).
LCMS (ESI): m/z = 317.1 [M+H]+.
(R)-Methyl-4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-1 -yl)benzoate
COOCH3
To a solution of 4-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid hydrochloride (2) (100 mg, 0.28 mmol) in dichloromethane (5 mL) was added (R)-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3methylbutanoic acid {prepared as described in Example 28-f) (89 mg, 0.28 mmol), 1[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (165 mg, 0.43 mmol) and N,N-diisopropylethylamine (114 mg, 0.86 mmol). The resuiting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prepHPLC (Gradient: 95% water, 5% acetonitrile, 30-50 min gradient to 25% water, 85% acetonitrile) to afford (R)-methyl-4-(8-(2-(2-fluoro-5-(trifIuoromethyl)benzamido)-3-methylbutanoyt)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoate as a white solid (46.1 mg, 27%).
192
LCMS (ESI): m/z = 607.2 [M+H]‘.
^-NMR (400 MHz, CD3OD): δ = 0.81-1.00 (m, 6H), 1.71-1.86 (m, 1H), 1.96-2.22 (m, 4H), 3.11 (s, 3H),
3.49-3.53 (m, 1H), 3.91-3.93 (m, 3H), 3.95-3.97 (m, 1H), 4.15-4.26 (m, 1H), 4.43-4.55 (m, 1H), 4.85-4.87 (m, 1H), 7.33-7.42 (m, 3H), 7.77-7.94 (m, 2H), 8.02-8.07 (m, 2H), 8.13-8.30 (m, 1H).
The following compound was synthesized following the general procedure described above:
Example 222:
(R)-4-(8-(2-(5-Cyclopropyl-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-2>4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid
10.6 mg, 48% yield, white solid.
LCMS (ESI): m/z = 564.7 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.64-0.73 (m, 2H), 0.80-0.90 (m, 2H), 0.94-1.05 (m, 6H), 1.64-1.79 (m, 1H), 1.81-1.91 (m, 1H), 1.91-2.02 (m, 1H), 2.05-2.25 (m, 2H), 3.10 (d, 3H), 3.49-3.50 (m, 1H), 3.75 (m, 1H), 3.94-4.30 (m, 2H), 4.39-4.51 (m, 1H), 4.77-4.87 (m, 1H), 6.99-7.14 (m, 1H), 7.19-7.27 (m,1H), 7.297.37 (m, 2H), 7.43 (dd, 1H), 8.08 (dd, 2H).
Example 223:
(R)_4-(8-(2-(2-Fluoro-5-(trifiuoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8 triazaspiro[4.5]decan-1-yl)benzoic acid
193
Représentative scheme:
Représentative general procedure: fert-Butyl-4-cyano-4-(4-(methoxycarbonyl)phenylamino)piperidine-1-carboxylate
CN
COOCH3
To a solution of methyl-4-aminobenzoate (16.46 g. 0.109 mol) in acetic acid (160 mL) was added tertbutyl-4-oxopiperidine-1-carboxylate (23.8 g, 0.12 mol). The resulting mixture was cooled to 0°C and trimethylsilyl cyanide (12.95 g. 0.131 mol) was added. The resulting solution was stirred ovemight at room température. Saturated aqueous ammonium chloride solution was added (200 mL). After stirring at room température for 10 minutes, the suspension was filtered. The filter cake was dried under reduced pressure to afford tert-butyl-4-cyano-4-(4-(methoxycarbonyl)phenylamino)piperidine-1-carboxy!ate as a white solid (39.1 g, 100%).
LCMS (ESI): m/z = 360.2 [M+H]+.
1H-NMR (300 MHz, DMSO-de): δ = 2.18-2.28 (m, 4H), 2.96-3.25 (m, 4H), 4.25-4.35 (m, 2H), 6.48-6.68 (m, 3H), 7.04-7.18 (m, 2H), 7.40-7.50 (m, 3H), 7.56-7.73 (m, 2H).
194 tert-Butyl-1-(4-(methoxycarbonyl)phenyl)-2,4-dioxo-1,3,8-triazaspîro[4.5]decane-8-carboxylate
To a solution of tert-butyl-4-cyano-4-(4-(methoxycarbonyl)phenylamino)piperidine-1-carboxy1ate (6.0 g 16.7 mmol) in dichloromethane (70 mL) was added chlorosulfonyl isocyanate (4.0 g 28.4 mmol) at 0°C. After stirring for 30 minutes at 0°C, the reaction was quenched with a 5% aqueous hydrochloric acid solution (20 mL). The solvent was removed under reduced pressure and éthanol (35 mL) was added. The suspension was stirred 30 minutes at 80°C. The solvent was removed under reduced pressure and the residue was added to tetrahydrofuran (50 mL) and the pH of the suspension was adjusted to pH 8 by addition of a 10% aqueous potassium carbonate solution. Then di-tert-butyl dicarbonate (6.20 g, 28.4 mmol) in tetrahydrofuran (50 mL) was added. After stirring ovemight, the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether= 10:1 to afford fert-butyl-1-(4-(methoxycarbonyl)phenyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate as a white solid (4.0 g, 60%).
LCMS (ESI): m/z = 404.4 [M+H]4.
tert-Butyl-1-{4-(methoxycarbonyl)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate
COOCH3
To a solution of terf-butyl-1-(4-(methoxycarbonyl)pheny1)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (3.45 g, 8.56 mmol) in N.N-dimethylfomnamide (40 mL) was added sodium hydride (685 mg, 60% in oil, 17.2 mmol) at 0°C, After stirring for 15 minutes, iodomethane (1.83 g, 12.84 mmol) was added. The resulting mixture was stirred for 15 minutes. The reaction was quenched with ice-water (20 mL) and the mixture was extracted with ethyl acetate (3 * 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether= 1:3 to afford tert-butyl-1-(4(methoxycarbonyl)phenyl)-3-methy1-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (3.0 g, 84%). LCMS (ESI): m/z = 418.2 [M+H]4.
4-(8-{tert-Butoxycarbonyl)-3-<Tiethyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1 -yljbenzoic acid
195
To a solution of ferf-butyl-1-(4-(methoxycarbonyl)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane8-carboxylate (1300 mg, 3.12 mmol) in methanol (30 mL) was added a 15% aqueous sodium hydroxide solution (15 mL). The reaction was heated at reflux for 30 minutes before cooling to room température. The pH of the resulting solution was adjusted to 3-4 by addition of 10% aqueous hydrochloric acid solution. The suspension was filtered. The filter cake was washed with petroleum ether and dried under reduced pressure to afford 4-(8-(terf-butoxycarbonyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1yl)benzoic acid as a white solid (1150 mg, 892%).
LCMS (ESI): m/z = 404.4 [M+Hf.
tert-Butyl-1-(4-{(benzyloxy)carbonyl)pheny))-3-methyl-2,4-dioxo-1I3l8-triazaspiro[4.5]decane-8carboxylate
To a solution of 4-(8-(fert-butoxycarbonyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid (400 mg, 0.99 mmol) in N,N-dimethyifomnamide (6 mL) was added potassium carbonate (274 mg,1.99 mmol) and benzyl bromide (177 mg, 1.29 mmol). Before the reaction wasquenched by addition of ice-water (10 mL), the resulting suspension was heated for 2 hours at 50°C. The mixture was extracted with ethyl acetate (3 χ 30 mL) and then the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:2 to afford ferf-butyl-1-(4((benzyloxy)carbonyl)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (500 mg, 91%).
LCMS (ESI): m/z = 493.4 [M+H]*.
1H-NMR (300 MHz, DMSO-de): δ = 1.41 (s, 2H), 1.62-1.86 (m, 4H), 3.13 (s, 3H), 3.53-3.68 (m, 2H), 4.034.13 (m, 2H), 5.41 (s, 2H), 7.26-7.29 (m, 2H), 7.37-7.42 (m, 5H), 8.17-8.19 (m, 2H).
Benzyl-4-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1 -yl)benzoate hydrochloride
196
A solution of fert-butyl-1-(4-((benzyioxy)carbonyl)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane8-carboxylate (120 mg, 0.24 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford benzyl 4(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate hydrochloride as a white solid (110 mg, 98%).
LCMS (ESI): m/z = 393.4 IM+H]+.
(RJ-BenzyM-ie-ÎZ-^-fluoro-S-itrifluoromethylJbenzamidoJ-S-methylbutanoyn-S-methyl-Z^-dioxo-
1,3,8-triazaspiro[4.5]decan-1-yl)benzoate
To a suspension of benzyl 4-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate hydrochloride (90 mg, 0.26 mmol) in dichloromethane (5 mL) was added (R)-2-(2-fluoro-5-(trifIuoromethyl)benzamido)-
3-methylbutanoic acid (prepared as described in Example 28-f) (82 mg, 0.26 mmol), 1[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-blpyridinium-3-oxide hexafluorophosphate (HATU) (153 mg, 0.40 mmol) and N,N-diisopropylethylamine (104 mg, 0.80 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prepTLC with ethyl acetate : petroleum ether = 2:1 to afford (R)-benzyl-4-(8-(2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyt-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1yl)benzoate as a white solid (150 mg, 91%).
LCMS (ESI): m/z = 393.4 [M+Hf.
197 (R)-4-(8-(2-(2-Fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1 -yl)benzoîc acid
COOH
A suspension of (R)-benzyl-4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methyibutanoyl)-3-methyl-
2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate (150 mg, 0.22 mmol) and 5% palladium on carbon (10 mg) in methanol (40 mL) was stirred for 30 minutes under a hydrogen atmosphère. The mixture was filtered and the filter cake was washed with methanol (5*10 mL). The filtrate was concentrated under reduced pressure and the residue was purified by prep-HPLC (Gradient: 95% water, 5% acetonitrile, 3050 min gradient to 25% water, 85% acetonitrile) to afford (R)-4-(8-(2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1yl)benzoic acid as a white solid (55.5 mg, 61%).
LCMS (ESI): m/z = 593.1 [M+H]\ ’H-NMR (400 MHz, CD3OD): δ = 0.80-1.01 (m, 6H), 1.70-1.86 (m, 1H), 1.88-2.24 (m, 4H), 3.10 (s, 3H), 3.47-3.54 (m, 1H), 3.93-3.99 (m, 1H), 4.20-4.31 (m, 1H), 4.43-4.59 (m, 1H), 4.83-4.87 (m, 1H), 7.34-7.46 (m, 3H), 7.85-7.88 (m, 2H), 8.00-8.16 (m, 2H).
Example 224: (R)-N-(1-(1-(4-(2H-Tetrazol-5-yl)phenyl)-3-methyl-2,4-dioxo-1l3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
198
Représentative scheme:
(n-BuJjSnNj toluene
Représentative general procedure:
4-(8-(tert-Butoxycarbonyl)-3-methyl-2,4-dioxo-1,3,84riazaspiro{4.5]decan-1-yl)benzoic acid
COOH
To a solution of fert-butyl-1-(4-(methoxycarbonyl)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane8-carboxylate (prepared as described in Example 223-c) (1300 mg, 3.12 mmol) in methanol (25 mL) was added a 15% aqueous sodium hydroxide solution (7 mL). The reaction was heated at reflux for 30 minutes before cooling to room température. The pH of the resulting solution was adjusted to 3-4 by addition of 10% aqueous hydrochloric acid solution. The suspension was fiitered. The filter cake was washed with water (10 mL) and dried under reduced pressure to afford 4-(8-(tert-butoxycarbonyl)-3methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl) benzoic acid as a white solid (1150 mg, 92%).
LCMS (ESl): m/z = 404.4 [M+Hf.
tert-Butyl-1 -^-carbamoylphenylfS-methyl-Z^-dioxo-l ,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of 4-(8-(tert-butoxycarbonyl)-3-methyl-2.4-dioxo-1,3,8-triazaspiro[4.5]decan-1 -yl)benzoic acid (1000 mg 2.48 mmol) in N,N-dimethylfonmamide (15 mL) was added ammonium chloride (1350 mg, 25.31 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide
199 hexafluorophosphate (HATU) (2400 mg, 6.33 mmol) and N,N-diisopropylethylamine (2180 mg, 16.87 mmol). The resulting mixture was stirred at room température for 24 hours before the reaction was quenched with ice water (15 mL). The organic layer were extracted with ethyl acetate (3 * 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 20:1 to afford tert-butyl-1-(4-carbamoylphenyl)-3-methyi-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate as a white solid (850 mg, 85%).
LCMS (ESI); m/z = 403.4 [M+Hf.
fert-Butyl-1-(4-cyanophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of tert-butyl-1-(4-carbamoylphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxytate (850 mg 2.11 mmol) in dichloromethane (20 mL) was added pyridine (1500 mg 18.98 mmol) and trifluoroacetic anhydride (2120 mg 10.09 mmol). The resulting mixture was stirred at room température for 3 hours before the reaction was quenched with saturated aqueous sodium carbonate solution (20 mL). The mixture was extracted with dichloromethane (3*15 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:1 to afford tert-butyl-1-(4-cyanophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a brown solid (600 mg, 74%).
LCMS (ESI): m/z = 385.4 [M+Hf.
tert-Butyl-1-(4-(2H-tetrazol-5-yl)phenyl)-3-methyl-2,4-dioxo-1I3,8-triazaspiro[4.5]decane-8carboxylate
hn-n
To a solution of tert-butyi-1-(4-cyanophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (50 mg 0.13 mmol) in N,N-dimethylfomnamide (3 mL), was added sodium azide (51 mg .078 mmol), ammonium chloride (42 mg 0.78 mmol), copper iodide (10 mg, cat.), and the mixture was heated at reflux for 2 days. After the reaction was quenched with ice water (10 mL), the mixture was extracted with ethyl acetate (3*15 mL). The combined organic layers were dried over anhydrous sodium sulfate
200 and concentrated under reduced pressure. The residue was purified by silica gel coiumn chromatography eluting with dichloromethane : methanol = 15:1 to afford fert-butyl-1-(4-(2H-tetrazol-5-yl)phenyl)-3-methyl-
2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a thick oil (30 mg, 54%).
LCMS (ESI): m/z = 428.3 [M+H]4.
1H-NMR (400 MHz, CDsOD): δ = 1.38 (s, 9H), 1.76-1.78 (m,2H), 1.79-1.81 (m, 2H), 2.88 (s, 3H), 3.323.54 (m, 2H), 3.98-4.01 (m, 2H). 7.36-7.38 (m, 2H), 8.17-8.19 (m, 2H).
1-(4-(2H-Tetrazol-5-yl)phenyl)-3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride
A solution of fert-butyl-1-(4-(2H-tetrazol-5-yl)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (30 mg, 0.07 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The mixture was concentrated under reduced pressure to afford 1-(4-(2H-tetrazoI-5-yl)phenyl)-3-methyI-
1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride as a white solid (30 mg, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 328.3 [M+H]4.
(R)-N-(1 -(1 -(4-(2H-Tetrazol-5-yl)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yi)-3methyl-1 -oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
HN'n
To a suspension of 1-(4-(2H-tetrazol-5-yl)phenyl)-3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (30 mg, crude) in dichloromethane (5 mL) was added (R)-2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (22 mg, 0.07 mmol), 1-[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (40 mg, 0.11 mmol) and N,N-diisopropylethylamine (28 mg, 0.21 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 10:1 to afford (R)-N-(1-(1-(4-(2H-tetrazol-5-yl)phenyl)-3201 methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5(trifluoromethyl)benzamide as a white solid (2.7 mg, 9%).
LCMS (ESI): m/z = 617.2 [M+Hf.
Ή-NMR (400 MHz, CD3OD): δ = 0.78-0.92 (m, 2H), 0.97-1.02 (m, 4H), 1.37-1.41 (m, 1H), 1.75-1.83 (m,
1H), 1.98-2.24 (m, 3H), 3.12 (s, 3H). 3.48-3.55 (m, 2H), 3.94-4.01 (m, 1H), 4.21-4.57 (m, 1H), 4.80-4.84 (m, 1H), 7.22-7.58 (m, 3H), 7.71-8.01 (m, 2H), 8.05-8.20 (m, 2H).
The following 2 compounds were synthesized following the general procedure described above:
Example 225:
(R)-N-(1-(1-(4-(2H-Tetrazol-5-yl)phenyl)-3-methyl-2,4-dioxo-1l3,8-triazaspiro[4.5] decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethoxy)benzamide
23.6 mg, 19% yield, white solid.
LCMS (ESI): m/z = 633.2 [M+Hf.
Ή-NMR (400 MHz, CD3OD): δ = 0.79-1.00 (m, 6H), 1.75-2.25 (m, 5H), 3.11 (s, 3H), 3.45-3.54 (m, 1H), 3.92-4.03 (m, 1H), 4.21-4.31 (m, 1H), 4.44-4.60 (m, 1H), 4.81-4.87 (m, 1H), 7.14-7.60 (m, 5H), 8.06-8.20 (m, 2H).
Example 226:
(R)-N-(1-(1-(4-(2H-Tetrazol-5-yi)phenyl)-3-methyl-2l4-dioxo-1,3,8-triazaspiro[4.5] decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(difluoromethoxy)-2-fluorobenzamide
22.4 mg, 20% yield, white solid.
LCMS (ESI): m/z = 615.2 [M+Hf.
Ή-NMR (400 MHz, CD3OD): δ= 0.79-1.01 (m, 6H), 1.71-2.17 (m, 5H), 3.11 (s, 3H), 3.47-3.54 (m, 1H), 3.93-4.00 (m, 1H), 4.20-4.55 (m, 2H), 4.81-4.86 (m, 1 H), 6.56-6.93 (m, 1H), 7.03-7.57 (m, 5H), 8.06-8.18 (m, 2H).
202
Example 227:
(R)-N-(1-(1-(4-(2H-Tetrazol-5-yl)phenyl)-3-methyl-4-oxo-1,3,8-tnazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-{trifluoromethyl)benzamide
c
Example 28-f
HATU, DIPEA, DCM
Représentative general procedure:
tert-Butyl-1 -(4-cyanophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of tert-butyl-1-(4-carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (prepared as described in Example 145, or alternatively, as described in Example 220) (320 mg 0.83 mmol) in dichloromethane (50 mL), was added pyridine (652 mg 8.25 mmol), then trifluoroacetic anhydride (866 mg 4.12 mmol). The resulting mixture was stirred at room température for 3 hours before the reaction was quenched with a saturated aqueous sodium carbonate solution (15 mL). The mixture was extracted with dichloromethane (3 χ 15 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica
203 gel column chromatography eluting with ethyl acetate : petroleum ether= 1:1 to afford fert-butyl-1-(4cyanophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a thickoil (207 mg, 68%). LCMS (ESI): m/z = 371.4 [M+H]4.
tert-Butyl-1-(4-(2H-tetrazol-5-yl)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of tert-butyl-1-(4-cyanophenyl)-3-methy1-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (90 mg 0.24 mmol) in toluene (10 mL) was added tributyltin azide (243 mg, 0.73 mmol). The mixture was heated at reflux for 24 hours before the reaction was quenched with ice water (10 mL). The pH of the resulting solution was adjusted to 5-6 by addition of 10% aqueous hydrochloric acid solution. The mixture was extracted with ethyl acetate (3x15 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 10:1 to afford fert-butyl-1-(4-(2H-tetrazol-5yl)phenyl)-3-methy!-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (70 mg, 70%).
LCMS (ESI): m/z = 414.3 [M+H]4.
1H-NMR (400 MHz, CD3OD): δ = 1.54 (s, 9H), 1.65-1.68 (m, 2H), 2.61-2.74 (m, 2H), 3.04 (s, 3H), 3.533.73 (m, 2H), 4.04-4.20 (m, 2H), 4.69-4.75 (m, 2H), 6.73-6.76 (m, 2H), 7.95-7.98 (m, 2H).
-(4-t2H-Tetrazol-5-yl)phenyl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride
A solution of fôrf-butyl-1-(4-(2H-tetrazol-5-yl)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (70 mg, 0.17 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 1-(4-(2H-tetrazol-5yi)phenyl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride as a white solid (58 mg, 98%). LCMS (ESI): m/z = 314.3 [M+H]4.
204 (R)-N-(1 -(1 -(4-{2H-Tetrazol-5-yl)phenyl)-3-mettiyl-4-oxo-1,3,8-triazaspiro[4.5Jdecan-8-yl)-3-methyl-1 oxobutan-2-yl)-2-fluoro-5-{trifluoromethyl)benzamide
h'n-n
To a suspension of 1-(4-(2H-tetrazol-5-yl)phenyl)-3-methyl-1,3,8-triazaspiro[4.5]decan-4-one hydrochloride (58 mg, 0.16 mmol) in dichloromethane (5 mL) was added (R)-2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (63 mg, 0.20 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide-hexafluorophosphate (HATU) (97 mg, 0.25 mmol) and N.N-diisopropylethylamine (67 mg, 0.51 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3x10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 10:1 to afford (R)-N-(1-(1-(4-(2H-tetrazol-5-yl)phenyl)-3methyl-4-oxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5(trifluoromethyl)benzamide as a white solid (10.5 mg, 11%).
LCMS (ESI): m/z = 603.2 [M+HJL 1H-NMR (400 MHz, CD3OD): δ = 1.06-1.33 (m, 6H), 1.73-1.96 (m, 2H), 2.17-2.37 (m, 1H), 2.70-2.81 (m, 1H), 2.90-2.99 (m, 1H), 3.09-3.15 (m, 1H), 3.06 (s, 3H), 3.46-3.65 (m, 1H), 4.02-4.07 (m, 1H), 4.29-4.39 (m, 1H), 4.52-4.64 (m, 1H), 4.99-5.01 (m, 2H), 6.91-6.93 (m, 2H). 7.45-7.50 (m, 1H), 7.68-7.78 (m, 2H),
7.90-8.07 (m, 2H).
Example 228:
(R)-N-(1-(1-(1 H-!ndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)pîcolinamide
205
c
Représentative general procedure:
(R)-Benzyl-5-{8-{2-{tert-butoxycarbonylamino)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate
To a suspension of benzyl-5-(3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)-1H-indazole-1carboxylate hydrochloride (prepared as described in Exemple 52-e) (2.80 g, crude) in dichloromethane (100 mL) was added sequentially (R)-2-(tert-butoxycarbonylamino)-3-methylbutanoic acid (1.54 g, 7.10 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (3.68 g, 9.70 mmol) and N,N-diisopropylethy1amine (2.09 g, 16.16 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water. The mixture was extracted with dichloromethane (3 χ 50 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:1 to afford (R)-benzyl-5-(8-(2(tert-butoxycarbonytamino)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)-1Hindazole-1-carboxylate as a white solid (2.20 g, 54%).
LCMS (ESI): m/z = 655.2 [M+Naf.
1H-NMR (300 MHz, CDCb): 0 = 0.59-1.35 (m, 15H), 1.67-2.13 (m, 5H), 3.08 (s, 3H), 3.34-3.46 (m, 1H), 3.80-3.88 (m, 1H), 4.09-4.14 (m, 2H), 4.69-4.51 (m, 1H), 5.55 (s, 2H), 6.43-6.62 (m, 1H), 7.38-7.42 (m, 4H), 7.54-7.59 (m, 2H), 7.69-7.79 (m, 1H), 8.18-8.31 (m, 2H).
206 (R)-Benzyl-5-(8-(2-amino-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)1H-indazole-1-carboxylate hydrochloride
A solution of (R)-benzyl-5-(8-(2-(fert-butoxycarbonylamino)-3-methy!butanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate (2.20 mg, 3.48 mmol) in hydrochloric acid in dioxane (6.0 Ml, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford (R)-benzyl-5-(8-(2-amino-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate hydrochloride as a white solid (2.00 g, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 533.2 [M+Hf (R)-Benzyl-5-(3-methyl-8-(3-methyl-2-(picolinamido)butanoyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate
To a mixture of (R)-benzyI-5-(8-(2-amino-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate hydrochloride (100 mg, crude) in dichloromethane (10 mL) was added sequentially picolinic acid (23 mg, 0.19 mmol), 1-[bis(dimethylamino)methylenel-1H1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafiuorophosphate (HATU) (106 g, 0.28 mmol) and N,Ndiisopropylethylamine (61 g, 0.47 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water. The mixture was extracted with dichloromethane (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-benzyl-5-(3-methyl-8-(3-methy!-2-(picolinamido)butanoyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)-1H-indazole-1-carboxylate as a thick oil (100 mg, 83%).
LCMS (ESI): m/z = 638.1 [M+Hf.
207 (R)-N-{1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)picolinamide
A mixture of (R)-benzyl-5-(3-methyl-8-(3-methyl-2-(picolinamido)butanoyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)-1/7-indazole-1-carboxylate (100 mg, 0.16 mmol) and 5% palladium on carbon (50 mg) in methanol (10 mL) was stirred for 1 hour under a hydrogen atmosphère. The mixture was filtered and the filtercake was washed with methanol (5*10 mL). The filtrate was concentrated under reduced pressure and the residue was purified by prep-HPLC (Gradient: 95% water, 5% acetonitrile, 3050 min gradient to 25% water, 85% acetonitrile) to afford (R)-N-(1-(1-(1H-indazol-5-yl)-3-methyl-2,4dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)picolinamide as a white solid (27.6 mg, 29%).
LCMS (ESI): m/z = 504.2 [M+H]\ 1H-NMR (400 MHz, CD3OD): G = 0.70-0.94 (m, 6H), 1.71-2.24 (m, 5H), 3.10 (s, 3H), 3.47-3.53 (m, 1H),
3.90-3.98 (m, 1H), 4.13-4.25 (m, 1H), 4.39-4.51 (m, 1H), 4.80-4.82 (m, 1H), 7.12-7.28 (m, 1H), 7.45-8.15 (m, 6H), 8.45-8.62 (m, 1H).
The following 8 compounds were synthesized following the procedure described above: Example 229:
(R)-N-(1 -(1 -(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-3-methyl-1 oxobutan-2-yl)nicotinamide
59.8 mg, yield: 63%, white solid.
LCMS (ESI): m/z = 504.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 0.63-1.02 (m, 6H), 1.06-1.22 (m, 1H), 1.92-2.28 (m, 4H), 3.11 (s, 3H), 3.47-3.52 (m, 1H), 3.91-3.99 (m, 1H), 4.22-4.51 (m, 2H), 4.69-4.80 (m, 1H), 7.17-7.29 (m, 1H), 7.52-7.78 (m, 3H), 8.05-8.15 (m, 2H), 8.60-9.10 (m, 3H).
208
Example 230:
(R)-N-(1-(1-{1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methy!-1 oxobutan-2-yl)cyclohexanecarboxamide
33.8 mg, yield: 36%, white solid.
LCMS (ESI): m/z = 509.2 [M+H]+.
’H-NMR (400 MHz, CDaOD): δ = 0.56-0.89 (m, 6H), 1.31-1.41 (m, 7H), 1.54-1.79 (m, 5H), 1.95-2.27 (m,
4H), 3.10 (s, 3H), 3.43-3.54 (m, 1H), 3.86-3.92 (m, 1H), 4.08-4.53 (m, 3H), 7.19-7.26 (m, 1H), 7.62-7.74 (m, 2H), 8.10-8.18 (m, 1H).
Example 231:
(R)-N41 -(141 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)isonicotinamide
29.8 mg, yield: 31%, yellow solid.
LCMS (ESI): m/z = 504.2 [M+H]*.
1H-NMR (400 MHz, CD3OD): δ = 0.63-0.98 (m, 6H), 1.72-2.24 (m, 5H), 3.11 (s, 3H), 3.46-3.53 (m, 1H),
3.91-3.97 (m, 1H), 4.22-4.52 (m, 2H), 4.71-4.77 (m. 1H). 7.18-7.29 (m, 1H), 7.53-8.14 (m. 5H), 8.66-8.82 (m, 2H).
Example 232:
(R)-N414141H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)pivalamide
33.8 mg, yield: 35%, white solid.
LCMS (ESI): m/z = 483.2 [M+H]*.
209 ^-NMR (400 MHz, CDsOD): δ = 0.57-0.75 (m, 1H), 0.85-0.88 (m, 10H), 1.18-1.33 (m, 4H), 1.71-2.21 (m, 5H), 3.10 (s, 3H), 3.43-3.49 (m, 1H), 3.80-3.92 (m, 1H). 4.07-4.50 (m, 2H), 4.56-4.59 (m, 1 H), 7.09-7.28 (m, 1H), 7.61-7.77 (m. 2H). 8.11-8.14 (m, 1H).
Example 233:
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)benzamide
63.6 mg, yield: 67%, white solid.
LCMS (ESl): m/z = 503.2 [M+H]+.
1H-NMR (400 MHz, CD3OD): δ= 0.61-0.99 (m, 6H), 1.73-2.17 (m, 5H), 3.10 (s, 3H), 3.46-3.52 (m, 1H),
3.90-3.97 (m, 1H), 4.22-4.53 (m, 2H), 4.72-4.74 (m, 1H), 7.13-7.81 (m, 8H), 8.03-8.15 (m, 1H).
Example 234:
(R)-N-(1 -{1 -(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-tnazaspiro[4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)ttiiazole-2-carboxamide
31.5 mg, yield: 35%, white solid.
LCMS (ESl): m/z = 510.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.69-0.98 (m, 6H), 1.70-2.23 (m, 5H), 3.10 (s, 3H), 3.46-3.53 (m, 1H),
3,91-3.98 (m, 1H), 4.12-4.24 (m, 1H), 4.39-4.51 (m, 1H), 4.73-4.78 (m, 1H), 7.14-7.29 (m, 1H), 7.49-7.51 (m, 1H), 7.64-7.67 (m, 1H), 7.76-7.81 (m, 2H), 7.86-7.96 (m, 1H), 8.06-8.15 (m, 1H).
210
Example 235:
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-4-(trifluoromethyl)thiazole-2-carboxamide
30.5 mg, yieid: 34%, white solid.
LCMS (ESI): m/z = 578.1 [M+Hf.
Ή-NMR (400 MHz, CD3OD): δ = 0.69-0.98 (m, 6H), 1.72-2.10 (m, 5H), 3.10 (s, 3H), 3.47-3.53 (m. 1H), 3.89-3.98 (m, 1H), 4.13-4.26 (m, 1H), 4.40-4.52 (m, 1H), 4.73-4.79 (m, 1H), 7.17-7.29 (m, 1H), 7.54-7,77 (m, 2H), 8.06-8.15 (m, 1H), 8.34-8.53 (m, 2H).
Example 236:
(R)-N-(1 -(1 -(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 oxobutan-2-yl)-2-fluoro-N-methyl-5-(trifluoromethyl)benzamide
66.1 mg, yieid: 67%, white solid.
LCMS (ESI): m/z = 603.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 0.57-0.95 (m, 6H), 1.62-1.93 (m, 2H), 2.05-2.40 (m, 3H), 2.50 (s, 2H), 2.80 (s, 1H), 3.11 (s, 3H), 3.49-3.55 (m, 1H), 3.89-3.95 (m, 1H). 4.30-4.55 (m, 2H), 5.11-5.25 (m, 1H), 6.96-8.15 (m,7H).
Example 237:
(R)-4-(3-(2-(Dimethylamino)ethyl)-8-(2-(241 uoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-
2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid trifiuoroacetic acid sait \
N—
211
Représentative scheme:
NaH, DMF
El ample 223-b
d
Représentative general procedure:
tert-Butyl-3-(2-bromoethyl)-1-(4-(methoxycarbonyl)phenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane8-carboxylate
To a solution of tert-butyl-1-(4-(methoxycarbonyl)phenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (prepared as described in Example 223-b) (600 mg, 1.49 mmol) in N,N-dimethylformamide (10 mL) was added sodium hydride (90 mg, 60% in oil, 2.23 mmol) at 0°C. After stirring for 15 minutes, 1,2-dibromoethane (2800 mg, 14.88 mmol) was added. The resulting mixture was stirred ovemight before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3x15 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether= 1:2 to afford fert-butyl-3-(2-bromoethyl)-1-(4-(methoxycarbonyl)phenyl)-2,4dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxy!ate as a white solid (480 mg, 65%).
LCMS (ESI): m/z = 510.1 [M+Hf.
212 tert-Butyl-3-(2-(dimethylamino)ethyl)-1-(4-(methoxycarbonyl)phenyl)-2,4-dioxo-1l3l8triazaspiro[4.5]decane-8-carboxylate
To a solution of terf-butyl-3-(2-bromoethyl)-1-(4-(methoxycarbonyl)phenyl)-2.4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (480 mg, 0.94 mmol) in éthanol (20 mL) was added a 40% aqueous dimethylamine solution (10 mL) and the reaction was stirred ovemight. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 20:1 to afford tert-butyl-3-(2-(dimethylamino)ethyl)-1-(4(methoxycarbonyl)phenyl)-2,4-dioxo-1,3,8-triazaspiroE4.5]decane-8-carboxylate as a thick oil (310 mg, 67%).
LCMS (ESI): m/z = 475.5 [M+Hf.
1H-NMR (400 MHz, CDCh): δ = 1.36 (s, 9H), 1.39-1.45 (m, 2H), 1.65-1.92 (m, 4H), 2.31 (s, 6H), 2.63-2.71 (m, 2H), 3.40-3.58 (m, 2H), 3.88 (s, 3H), 3.90-4.11 (m, 2H), 7.25-7.27 (m, 2H), 8.06-8.09 (m, 2H).
Methyl-4-(3-(2-(dimethylamino)ethyl)-2)4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate hydrochloride
A solution of fôrt-butyl-3-(2-(dimethylamino)ethyl)-1-(4-(methoxycarbonyl)phenyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (310 mg, 0.65 mmol) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford methyl-4-(3-(2-(dimethylamino)ethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1 -yl)benzoate hydrochloride as a white solid (300 mg, crude), which was used directly without any further purification. LCMS (ESI): m/z = 313.4 [M+Hf.
213 (R)-Methyl-4-(3-(2-(dimethylamino)ethyl)-8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3methylbutanoyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate
To a mixture of methyi-4-(3-(2-(dimethylamino)ethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate hydrochloride (300 mg, crude) in dichloromethane (10 mL) was added (R)-2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (201 mg, 0.65 mmol), 1-[bis(dimethyiamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafiuorophosphate (HATU) (372 mg, 0.98 mmol) and N,N-diisopropylethylamine (295 mg, 2.28 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 10:1 to afford (R)-methy 1-4-(3-(2(dimethylamino)ethyl)-8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yi)benzoate as a white solid (390 mg, 93%).
LCMS (ESl): m/z = 313.4 [M+Hf.
(R)-4-(3-(2-(Dimethylamino)ethyl)-8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-
2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid trifluoroacetic acid sait
To a solution of (R)-methyl-4-(3-(2-(dimethylamino)ethyl)-8-(2-(2-fluoro-5-(trifluoromethy1) benzamido)-3methylbutanoyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate (390 mg, 0.59 mmol) in methanol (20 mL) was added a 15% aqueous sodium hydroxide solution (15 mL). The reaction was heated at reflux for 5 minutes before cooling to room température. The pH of the resulting solution was adjusted to 5-6 by addition of 10% aqueous hydrochloric acid. The solvent was removed under reduced pressure. To the residue was added Methanol (50 mL), the resulting solid was removed by filtration. The filtrate concentrated under reduced pressure and the residue was purified by prep-HPLC (Gradient: 95% water, 5% acetonitrile, 30-50 min gradient to 25% water, 85% acetonitrile) to afford (R)-4-(3-(2214 (dimethylamino)ethyl)-8-(2-(2-fluoro-5-(trifIuoromethy[)benzamido)-3-methylbutanoyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid trifluoroacetic acid sait as a white solid (16.6 mg, 5%).
LCMS (ESI): m/z = 650.2 [M+H]+.
Ή-NMR (400 MHz, CD3OD): δ = 0.79-1.03 (m, 6H), 1.71-2.34 (m, 5H), 3.04 (s, 6H), 3.47-3.54 (m, 3H),
3.87-4.05 (m, 3H), 4.20-4.37 (m, 1H), 4.41-4.60 (m, 1H), 4.82-4.86 (m, 1H), 7.36-7.48 (m, 3H), 7.85-8.10 (m, 4H).
Example 238:
(R)-4-(3-(2-(Dimethylamino)ethyl)-8-(2-(2-fluoro-5-(trifluoromethyl) benzamido)-3-methylbutanoyl)4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid trifluoroacetic acid sait
Représentative scheme:
d
215
Représentative general procedure: tert-Butyl-3-(2-bromoethyl)-1-(4-(methoxycarbonyl)phenyl)-4-oxo-1l3>8-triazaspîro[4.5]decane-8 carboxylate
XRX-100151 -04-001-a
To a solution of tert-butyI-1-(4-(methoxycarbonyl)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (prepared as described in Example 149-c) (600 mg, 1.54 mmol) in N.N-dimethylformamide (10 mL) was added sodium hydride (93 mg, 60% in oil, 2.31 mmol) at 0DC. After stirring for 15 minutes, 1,2-dibromoethane (2900 mg, 15.43 mmol) was added. The resulting mixture was stirred ovemight before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3x15 mL). The combined organic layers were dried overanhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 1:1 to afford tert-butyl-3-(2-bromoethyl)-1-(4-(methoxycarbonyl)phenyl)-4-oxo-
1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (540 mg, 70%).
LCMS (ESI): m* = 496.1 [M+Hf. tert-Butyl-3-(2-(dimethylamino)ethyl)-1-{4-(methoxycarbonyl)phenyl)-4-oxo-1,3,8 triazaspiro[4.5]decane-8-carboxylate
XRX-100151-04-001-b
To a solution of fert-butyl-3-(2-bromoethyl)-1-(4-(methoxycarbonyl)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (540 mg. 1.09 mmol) in éthanol (20 mL) was added a 40% aqueous dimethylamine solution (10 mL) and the reaction was stirred ovemight. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 20:1 to afford ferf-butyl-3-(2-(dimethylamino)ethyl)-1-(4(methoxycarbonyl)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a thick oil (340 mg, 69%). LCMS (ESI): m/z = 460.0 [M+Hf.
216 1H-NMR (300 MHz, CDCI3): δ = 1.50 (s, 9H), 1.56-1.61 (m, 2H), 2.23 (s, 6H), 2.48-2.52 (m, 2H), 2.64-2.75 (m, 2H), 2.49-3.52 (m, 4H), 3.85 (s, 3H), 3.96-4.20 (m, 2H), 4.69-4.79 (m, 2H), 6.59-6.62 (m, 2H), 7.827.85 (m, 2H).
Methy1-4-(3-(2-(dimethylamino)ethyl)-4-oxo-1,3,8-triazaspiro[4.5ldecan-1-yl)benzoate hydrochloride
XRX-100560-04-001 -c
A solution of fert-butyl-3-(2-(dimethylamino)ethyl)-1-(4-(methoxycarbonyl)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (340 mg, 0.74 mmoi) in hydrochloric acid in dioxane (6.0 M, 10 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford methyl 4-(3-(2-(dimethylamino)ethyJ)-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate hydrochloride as a white solid (300 mg, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 396.4 [M+Hf.
(R)-Methyl-4-(3-(2-(dimethylamino)ethyl)-8-(2-(2-fluoro-5-(trifluoromethyl)benzamfdo)-3methylbutanoyl)-4-oxo-1,3,8-triazaspîro[4.5]decan-1-yl)benzoate
To a suspension of methyl-4-(3-(2-(dimethylamino)ethyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoate hydrochloride (300 mg, crude) in dichloromethane (10 mL) was added (R)-2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (227 mg, 0.74 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (421 mg, 1.11 mmol) and N,N-diisopropylethylamine (333 mg, 2.58 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 10:1 to afford (R)-methyl-4-(3-(2(dimethylamino)ethyl)-8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methy1butanoyl)-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoate as a white solid (280 mg, 60%).
217
LCMS (ESI): m/z = 650.0 [M+Hf.
(R)-4-(3-(2-(Dimethylamino)ethyl)-8-(2-(2-fIuoro-5-(trifluoromethyl) benzamido)-3-methylbutanoyl)4-oxo-1,3,8-triazaspiro[4,5ldecan-1-yl)benzoic acid trïfluoroacetic acid sait
To a solution of (R)-methyl-4-(3-(2-(dimethylamino)ethyi)-8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3methylbutanoyi)-4-oxo-1,3,8-triazaspiro[4.5jdecan-1-yl)benzoate (280 mg, 0.43 mmol) in tetrahydrofuran (20 mL) was added an aqueous lithium hydroxide solution (2 mL, 1.0 M). The reaction was refluxed for 2 days before cooling to room température. The pH of the resulting solution was adjusted to 3-4 by addition of 10% aqueous hydrochloric acid solution. The solvent was removed rn reduced pressure. To the residue was added Methanol (50 mL), the resulting solid was removed by filtration. The filtrate was concentrated under reduced pressure and the residue was purified by prep-HPLC (Gradient: 95% water, 5% acetonitrile, 30-50 min gradient to 25% water, 85% acetonitrile) to afford (R)-4-(3-(2(dimethylamino)ethyi)-8-(2-(2-fIuoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid trifluoroacetic acid sait as a white solid (25.2 mg, 9%).
LCMS (ESI): m/z = 636.2 [M+H]+.
Ή-NMR (400 MHz, CD3OD): δ = 0.91-1.19 (m, 6H), 1.71-2.06 (m, 2H), 2.18-2.35 (m, 1H), 2.79-3.04 (m, 2H), 3.32 (s, 6H), 3.37-3,47 (m, 4H), 3.89-4.12 (m, 3H), 4.31-4.60 (m, 2H), 4.96-5.09 (m, 2H), 6.77-6.91 (m, 2H), 7.38-7.52 (m, 1H), 7.71-8.04 (m. 4H).
Example 239:
(R^-Fluoro-N-fS-methyl-l-fS-methyl^-dioxo-l-Îpyridin^-yl)- 1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)-5-(trifluoromethyl)benzamide
218
Représentative general procedure: fert-Butyl-4-cyano-4-(2-methoxypyridin-4-ylamino)piperidine-1-carboxylate
CN
To a solution of 2-methoxypyridin-4-amine (15 g, 12 mmol) in acetic acid (50 mL) was added tert-butyl-4oxopipefidine-1-carboxylate (26.6 g, 13 mmol). The resulting mixture was cooled to 0°C and trimethylsilyl cyanide (17.8 g, 18 mmol) was added. The solution was stirred ovemight at room température. Saturated aqueous ammonium chloride solution was added (50 mL). The mixture was extracted with ethyl acetate (3 x 50 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : petroleum ether= 1:1 to afford fert-butyl-4-cyano-4-(2-methoxypyridin-4ylamino)piperidine-1-carboxylate as a white solid (15 g, 37%).
LCMS (ESI): m/z = 333.1 [Μ+ΗΓ.
tert-Butyl-4-carbamoyl-4-(2-methoxypyridin-4-ylamino)piperidine-1-carboxylate
To a suspension of terf-butyl-4-cyano-4-(2-methoxypyridin-4-ylamino)piperidine-1-carboxylate (2 g, 6.0 mmol) in methanol was added sodium hydroxide (0.48 g, 12 mmol). To the resulting mixture was added dropwise hydrogen peroxide (30%, 20 mL) over 30 minutes. After stirring at room température for an additional 1 hour, the reaction was quenched by addition of ice-water (20 mL). The mixture was extracted
219 with ethyl acetate (3 χ 20 mL). The combined organiclayerwas washed with brine (10 mL) and dried over anhydrous sodium sulfate. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 5:1 to afford tert-butyl 4-carbamoyl-4-(2-methoxypyridin-4-ylamino) piperidine-1-carboxylate as a yellow solid (1.9 g, 90%).
LCMS (ESI): m/z = 351.2 [M+H]+.
tert-Butyl-1-(2-methoxypyridin-4-yl)-2,4-dioxo-1,3,84riazaspiro[4.5Jdecane-8- carboxylate
To a solution of tert-butyl-4-carbamoyt-4-(2-methoxypyridin-4-ylamino)piperidine-1-carboxylate (1.9 g, 5.4 mmol) in dimethyl carbonate (20 mL) was added 1 ,Γ-carbonyldiimdazole (2.6 g, 16 mmol) and sodium hydride (0.4 g, 11 mmol). The resulting mixture was heated at 50°C for 3 hours before the reaction was quenched by addition of ice-water (10 mL). The resulting mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were washed with brine (10 mL) and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to afford tert-butyl-1-(2-methoxypyridin-4-yl)-
2,4-dioxo-1)3,8-triazaspiro[4.5] decane-8-carboxylate as a white solid (2 g, crude), which was used directly without any further purification.
LCMS (ESI): m/z = 377.1 [M+Hf.
tert-Butyl-1-(2-methoxypyridin-4-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro [4.5]decane-8-carboxylate
To a solution of tert-butyl-1-(2-methoxypyridin-4-yl)-2,4-dioxo-1,3,8-triazaspiro[4.5] decane-8-carboxylate (2 g, crude) in N,N-dimethylfonnamide (30 mL) was added sodium hydride (0.426 g, 60% in oil, 10.4 mmol) at 0°C. After stirring for 15 minutes, iodomethane (1130 mg, 7.98 mmol) was added. The resulting mixture was stirred for 15 minutes at room température and the reaction was quenched with ice-water (10 mL). The mixture was extracted with ethyl acetate (3 χ 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 50:1 to afford fert-butyl-1 -(2methoxypyridin-4-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro [4.5]decane-8-carboxylate as a yellow solid (2 g, 94% overtwo steps).
LCMS (ESI): m/z = 391.1 [M+Hf.
220 tert-Butyl-1-(2-hydroxypyridin-4-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro [4.5]decane-8-carboxylate
A solution of fert-butyl-1-(2-methoxypyridin-4-y!)-3-methyl-2,4-dioxo-1,3,8-triazaspiro [4.5]decane-8carboxylate (2 g, 5 mmol) was heated at 130°C in a microwave reactorfor 30 minutes. The solvent was removed under reduced pressure. The residue was dissolved in tetrahydrofuran (20 mL). To the resulting mixture was added aqueous sodium hydroxide (2.0 M, 5.1 mL, 10 mmol) and di-fert-butyl-dicarbonate (1.3 g, 6 mmol). The resulting mixture was stirred for 1 hour before it was poured into ice-water (10 mL). The resulting mixture was extracted with ethyl acetate (3 χ 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether= 4:1 to afford tert-butyl1-(2-hydroxypyridin-4-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro [4.5]decane-8-carboxylate as a white solid (250 mg, 13%).
LCMS (ESI): m/z = 377.1 [M+H]4.
tert-Butyl-3-methyl-2,4-dioxo-1-(2-(trifluoromethylsulfonyloxy)pyridin-4-yl) -1,3,8triazaspiro[4.5]decane-8-carboxylate
To a solution of tert-butyl-1-(2-hydroxypyridin-4-yl)-3-methyi-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (200 mg, 0.53 mmol) in dichloromethane (5 mL) was added 1,1,1-trifluoro-N-phenyl-N(trifluoromethylsulfonyl)methanesulfonamide (228 mg, 0.64 mmol), triethylamine (107 mg, 1.0 mmol) and N,N-dimethylpyridin-4-amine (65 mg, 0.53 mmol) at room température. The resulting mixture was stirred for 3 hours before it was diluted with dichloromethane (20 mL). The mixture was washed with brine (20 mL) and dried over anhydrous sodium sulfate. The residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum ether = 3:2 to afford terf-butyl-3-methyf-2,4-dioxo-1(2-(trifluoromethylsuffonyloxy)pyridin-4-yl) -1,3,8-triazaspiro[4.5]decane-8-carboxylate (250 mg, 92%) as a white solid.
LCMS (ESI): m/z = 509.1 [M+H]4.
221 tert-Butyl-3-methyl-2,4-dioxo-1-(pyridin-4-yl)-1,3,8-triazaspiro[4.5] decane-8-carboxylate
To a solution of fe/Ÿ-butyl-3-methyl-2,4-dioxo-1-(2-(trifluoromethylsulfonyloxy)pyridin-4-yl) -1,3,8triazaspiro[4.5]decane-8-carboxylate (250 mg, 0.49 mmol) in N,N-dimethylformamide (30 mL) was added triethyîsilane (114 mg, 0.98 mmol) and 1,1-bis(diphenylphosphino)ferrocene-palladium(ll) dichloromethane complex (201 mg, 0.24 mmol).The resulting mixture was stirred under a nitrogen atmosphère for 3 hours. The reaction was quenched by addition of ice-water (20 mL) and the extracted with ethyl acetate (3 * 20 mL). The combined organic tayers were washed with brine (10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate to afford fert-butyl-3-methyl-2,4-dioxo-1-(pyridin-4yl)-1,3,8-triazaspiro[4.5] decane-8-carboxylate (155 mg, 87%) as a white solid.
LCMS (ESI): m/z = 361.2 [M+H]4.
3-Methyl-1 -(pyridin-4-yl)-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochlorîde
A solution of tert-butyl-3-methyl-2,4-dioxo-1-(pyridin-4-yl)-1,3,8-triazaspiro[4.5] decane-8-carboxylate (155 mg, 0.43 mmol) in hydrochloric acid in dioxane (6.0 M, 20 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 3-methyl-1-(pyridin-4-yl)-1,3,8triazaspiro[4.5]decane-2,4-dione hydrochlorîde as a white solid (142 mg, 100%).
LCMS (ESI): m/z = 261.1 [M+H]4.
(R)-2-Ftuoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(pyridin-4-yl)-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)-5-(trifluoromethyl)benzamide
To a mixture of 3-methyl-1-(pyridin-4-yI)-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochlorîde (150 mg, 0.45 mmol) in dichloromethane (5 mL) was added sequentialiy (R)-2-(2-fluoro-5(trifluoromethyl)benzamido)-3-methylbutanoic acid (prepared as described in Example 28-f) (240 mg, 0.32 mmol), (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (443 mg, 1.17 mmol) and N,N-diisopropy!ethylamine (252 mg, 1.95 mmol).
222
The resulting mixture was stirred for 2 hours at room température before the reaction was quenched by addition of with ice-water (5 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-HPLC (acetonitrile and water, acetonitrile from 5% to 80%) to afford (F?)-2-fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(pyridin-4-yl)- 1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)-5-(trifluoromethyl)benzamide as white solid (110 mg, 26%).
LCMS (ESI): m/z = 550.1 [M+H]4.
1H-NMR (400 MHz, CDCh): δ = 1.09 (m, 6H), 1.97 (m, 2H), 2.35 (m, 2H), 2.98 (m, 1 H). 3.23 (s, 3H), 3.53 (t, J= 12.0 Hz, 1H), 4.08 (t, J= 12.9 Hz, 1H), 4.29 (m, 1H), 4.83 (m, 2H), 7.34 (m, 2H), 7.86 (m, 1H), 8.27 (m, 2H). 8.68 (m, 2H), 10.84 (s, 1H).
Example 240:
(R)-4-(8-(2-(2-Fluoro-5-(trinuoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspîro[4.5]decan-1-yl)pyridine 1-oxide
To a solution of (/?)-2-fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(pyridin-4-yl)- 1,3,8-triazaspiro [4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifiuoromethyl)benzamide (prepared as described in Example 239) (83 mg, 0.15 mmol) in chloroform (5 mL) was added m-chloroperbenzoic acid (53 mg, 0.3 mmol). The resulting mixture was stirred ovemight. The solvent was removed under reduced pressure and the residue was purified by prep-HPLC (acetonitrile and water, acetonitrile from 5% to 80%) to afford (R)-4(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)pyridine 1-oxide as a white solid (70 mg, 82%).
LCMS (ESI): m/z = 566.1 [M+H]4.
1H-NMR (400 MHz, CDCh): δ = 1.07-1.10 (m, 6H), 1.89-2.26 (m, 4H), 2.67 (s, 1H), 3.19 (s, 3H), 3.51 (t. J = 12.5 Hz, 1H), 4.06-4.20 (m, 2H), 4.75-4.88 (m, 2H), 7.29-7.52 (m, 3H), 7.82 (s, 2H), 8.29-8.40 (m, 3H).
Example 241:
(R)-2-Fluoro-N-(1-(1-(4-methoxycyclohexyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(tnfluoromethyl)benzamide
223
Représentative scheme:
CHjCOOH, r.t
PtO2. Hj
Représentative general procedure:
tert-Butyl-1 -(4-methoxycyclohexyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5] decane-8-carboxylate
To a solution of fert-butyl-1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro [4.5]decane-8carboxyiate (prepared as described in Example 168-d) (1.2 g, 3.08 mmol) in acetic acid (15 mL) was added platinum dioxide (50 mg, cat.). The mixture was stirred under a hydrogen atmosphère for 4 hours. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by a gel silica column chromatography eluting with petroleum ether : ethyl acetate 5:1 to afford ferî-butyi-1-(4-methoxycyclohexyl)-3-methy!-2,4-dioxo-1,3,8- triazaspiro[4.5]decane-8carboxylate as white solid (250 mg, 20%) and fert-butyi 1-cyclohexyl-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decane-8-carboxylate (150 mg, 12%) as a white solid.
LCMS (ESI): m/z = 396.1 (Example 241-a) and 366.1 (Example 241-a!) [M+H]+.
1-(4-Methoxycyclohexyl)-3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride)
A solution of tert-butyl 1-(4-methoxycyclohexyl)-3-methyl-2,4-dioxo-1,3,8- triazaspiro[4.5]decane-8carboxylate (250 mg, 0.63 mmol) in hydrochloric acid in dioxane (6.0 M, 20 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 1-(4
224 methoxycyclohexyl)-3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride) as a white solid (170 mg, 85%).
LCMS (ESI): m/z = 296.1 [M+Hf.
(R)-2-Fluoro-N-(1-(1-(4-methoxycyclohexyl)-3-methyl-2,4-dioxo-1,3,8-tfiazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide
To a mixture of 1-(4-methoxycyclohexyl)-3-methyl-1,3,8-triazaspiro [4.5]decane-2,4-dione hydrochloride) (70 mg, 0.17 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(2-fluoro-5(trifIuoromethyl)benzamido)-3-methyl- butanoic acid (prepared as described in Example 28-f) (57 mg, 0.19 mmol), (1-[bis(dimethylamîno)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (96 mg, 0.25 mmol) and Ν,Ν-diisopropylethylamine (150 mg, 1.164 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched by addition of with ice-water (5 mL). The mixture was extracted with ethyl acetate (3 χ 10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-2fluoro-N-(1-(1-(4-methoxycyclohexyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-5-(trifluoromethyl)benzamide (14.6 mg, 15%) as a white solid.
LCMS (ESI): m/z = 585.2 [M+H]\ 1H-NMR (400 MHz, CD3OD): ô = 1.050-1.111 (m, 6H), 1.307-1.439 (m, 5H), 1.713-2.292 (m, 6H), 2.2922.680 (m, 3H), 2.952 (s, 3H), 3.069-3.204 (m, 1H), 3.321-3.33 (m, 3H), 3.368-3.502 (m, 2H), 3.840-4.016 (m, 1H), 4.211-4.02 (m, 1H), 4.518-4.658 (m, 1H), 7.422-7.535 (m, 1H), 7.861-7.943 (m, 1H), 8.006-8.132 (m, 1H).
Example 242:
(R)-N-(1-(1-Cyclohexyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5] decan-8-yl)-3-methyl-1-oxobutan-2yl)-2-fluoro-5-(trifluoromethyl)benzamide
225
Représentative scheme:
HCl, EtOAc
Représentative general procedure:
-Cyclohexyl-3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride
A solution of fert-butyl-1-cyclohexyl-3-methyl-2,4-dioxo-1 ,3,8-triazaspiro[4.5] decane-8-carboxylate (prepared as described in Example 241) (150 mg, 0.41 mmol) in hydrochloric acid in dioxane (6.0 M, 20 mL) was stirred for 30 minutes. The precipitate was collected by filtration and dried under reduced pressure to afford 1-cyclohexyl-3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (90 mg, 73%) as a white solid.
LCMS (ESl): m/z = 266.1 [M+H]+.
(RJ-N-il-fl-Cyclohexyl-S-methyl^^-dioxo-I^.S-triazaspiropLS] decan-8-yi)-3-methyl-1-oxobutan-2yl)-2-fluoro-5-(trifluoromethyl)benzamide
To a mixture of 1-cyclohexyl-3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (90 mg, 0.29 mmol) in dichloromethane (5 mL) was added sequentially (R)-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3methylbutanoic acid (prepared as described in Example 28-f) (98 mg, 0.32 mmol), (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) (165 mg, 0.43 mmol) and N,N-diisopropylethylamine (110 mg, 0.89 mmol). The resulting mixture was stirred for 2 hours at room température before the reaction was quenched by addition of with icewater (5 mL). The mixture was extracted with ethyl acetate (3*10 mL) and the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-TLC with dichloromethane : methanol = 15:1 to afford (R)-N-(1-(1-cyclohexyl-3-methyl-
2,4-dioxo-1,3,8-triazaspiro[4.5] decan-8-yl)-3-methyl-1 -oxobutan-2-yl)-2-fluoro-5(trifluoromethyl)benzamide as a white solid (34.3 mg, 21%).
LCMS (ESl): m/z = 555.2 [M+Hf.
1H-NMR (400 MHz, CDCI3): δ = 1.035-1.121 (m, 6H), 1.225-1.279 (m, 3H), 1.514-1.893 (m, 8H), 2.1592.287 (m, 4H), 2.675-2.902 (m, 1H), 3.013 (s, 3H), 3.384-3.534 (m, 1H), 4.003-4.051 (m, 2H), 4.658226
4.688 (m, 1H), 4.929-5.192 (m, 1H), 7.285-7.350 (m, 1H), 7.482-7.509 (m, 1H), 7.785-7.803 (m, 1 H), 8.389-8.406 (m, 1H).
Example 243:
(R)-M-(3-Methyl-1-(3-methyl-2,4-dioxo-1 -(4-methoxy-d3-phenyl)-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)-3-(trifluoromethyl)-5-fluorobenzamide
ocd3
Représentative scheme:
Représentative general procedure:
tert-Butyl-144-hydroxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
To a solution of fert-butyl-1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (prepared as described in Example 81-c) (0.6 g, 1.54 mmol) in anhydrous dichloromethane (30 mL) was added boron tribromide (3 mL, 1.0 M in dichloromethane) dropwise at 0°C. Then the solution was stirred at room température for 12 hours before the reaction was quenched with water. The aqueous layer was extracted with dichloromethane (30 mL), the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford terf-butyl-1 -(4hydroxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a yellow solid (390 mg, 65%).
227
LCMS (ESI): m/z = 376.2 [M+H]+.
tert-Butyl-1-(4-methoxy-d3-phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8 -carboxylate
To a solution of tert-butyl-1-(4-hydroxyphenyl)-3-methyi-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxylate (0.375 g, 1 mmol) in acetone (30 mL) was added potassium carbonate (0.278 g, 2 mmol) and iodomethane-d3 (0.29 g, 2 mmol), then the resulting mixture was stirred at 60°C for 6 hours. Then the mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with ethyl acetate : petroleum = 1:2 to afford terî-butyl-1-(4-methoxy-d3-phenyl)-3methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxyiate as a white solid (210 mg, 54%).
LCMS (ESI): m/z = 393.2 [M+H]’.
3-Methyl-1-(4-methoxy-d3-phenyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride
Hydrogen chloride gas was bubbled into a stirring solution oftert-butyl-1-(4-methoxy-d3-phenyl)-3-methyl-
2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (0.21 g, 0.54 mmol) in ethyl acetate (10 mL) for 0.5 hours. Then the mixture was concentrated under reduced pressure to afford 3-methyl-1-(4-methoxy-d3phenyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride as a white solid (0.17 g, 100%).
LCMS (ESI): m/z = 293.2 [M+H]*.
(R)-N-(3-Methyl-1-(3-methyl-2,4-dioxo-1-(4-methoxy-d3-phenyl)-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)-3-(trifluoromethyl)-5-fluorobenzamide
To a solution of 3-methyl-1-(4-methoxy-d3-phenyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (0.17 g, 0.53 mmol), (R)-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoic acid (0.196 g, 0.64 mmol) (prepared as described in Example 28-f) and triethylamine (0.16 g, 1.6 mmol) in dichloromethane (20 mL) was added 1-ethyl-3-(3-dimethyllaminopropyi)carbodiimide hydrochloride (EDCI) (0.153 g, 0.8 228 mmol) and 1-hydroxbenzotriazole (HOBT) (0.108 g, 0.8 mmol), then the resulting mixture was stirred at room température for 4 hours before the reaction was quenched with water (20 mL). The aqueous layer was extracted with ethyl acetate (3 * 20 mL), the combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 70:1 to afford (R)-A/-(3-methyl-1-(3-methyl-
2,4-dioxo-1-(4-methoxy-d3-phenyl)-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-3-(trifluoromethyl)-5fluorobenzamide as a white solid (0.1 g, 33%).
LCMS (ESI): m/z = 582.2 [Μ+ΗΓ.
1H-NMR (400 MHz, CDaOD): δ = 8.05-7.85 (m, 2H), 7.44 (dd, J= 20.0, 11.1 Hz, 1H), 7.22 (d, J= 8.8 Hz, 1 H), 7.13 (d, J = 8.8 Hz, 1 H), 7.04 (d, J = 8.8 Hz, 1 H), 6.91 (d, J = 8.8 Hz, 1 H), 4.85 (s, 1 H), 4.45 (dd, J = 35.0, 13.1 Hz, 1H),4.23 (dd, J= 30.7, 14.0 Hz, 1H), 3.95 (t, J = 13.1 Hz, 1H), 3.49 (dd, J= 14.4,11.6 Hz, 1H), 3.08 (s, 3H), 2.22-1.99 (m, 3H), 1.96-1.81 (m, 1H), 1.71 (td, J= 13.1, 4.8 Hz, 1 H), 1.05-0.73 (m, 6H).
The following compound was synthesized following the procedure described above: Example 244:
(R)-N-(3-Methyl-1-(3-niethyl-2,4-dioxo-1-(4-ethoxyphenyl)-1,3,8-triazaspiro[4.5]decan-8-yi)-1oxobutan-2-yl)-3-(trifluoromethyl)-5 -fluorobenzamide
OEt mg, 23% yield, white solid.
LCMS (ESI): m/z = 593.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 8.02-7.90 (m, 2H), 7.47-7.37 (m, 1H), 7.20 (d, J= 8.8 Hz, 1H), 7.11 (d, J = 8.8 Hz, 1 H), 7.03 (d, J = 8.8 Hz, 1 H), 6.89 (d, J = 8.8 Hz, 1 H), 4.49 (d, J = 13.4 Hz. 1 H), 4.27 (d, J = 13.9 Hz, 1H), 4.12 (d, J = 7.1 Hz, 2H), 4.10-3.90 (m, 3H), 3.49 (t, J= 12.8 Hz, 1H), 3.08 (s, 3H), 2.25-2.05 (m, 2H), 1.94 (m, 1H), 1.71 (m, 1H), 1.44-1.30 (m, 4H), 1.27 (dd, J = 16.9, 9.8 Hz, 3H), 1.07-0.76 (m, 7H).
Exampie 245:
(R)-W-(1-(1-(Benzo[d]oxazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
229
Représentative scheme:
HC(OMo)3
MejSiCN
HOAc
Représentative general procedure:
5-Nitrobenzo[d]oxazole
A solution of 2-amino-4-nitrophenol (600 mg, 3.9 mmol) in trimethyl orthoformate (30 mL) was stirred at reflux for 12 hours. The reaction mixture was slowly poured into ice-cold water (100 mL) and extracted with ethyl acetate (100 mL). The organic layer was concentrated under reduced pressure and the residue was purified by silica gel column chromatography efuting with dichloromethane : methanol = 30:1 to afford
5-nitrobenzo[dJoxazole as a white solid (530 mg, 83%).
LCMS (ESI): m/z = 164.0 [M+Hf.
Benzo[d]oxazol-5-amine
To a solution of 5-nitrobenzo[d]oxazole (530 mg, 3.23 mmol) in methanol (30 mL) was added palladium on carbon (100 mg, dry, 5%). The mixture was stirred under a hydrogen gas atmosphère at room température for 12 hours. The catalyst was removed by filtration and the filtrate was concentrated to dryness under reduced pressure to afford benzo[d]oxazo1-5-amine as a yellow solid (430 mg, 100%). LCMS (ESI): m/z= 134.1 [M+H]+.
230 tert-Butyl-4-(benzo[d]oxazol-5-ylamîno)-4-cyanopiperidine-1-carboxylate
I
Boc
A mixture of benzo[d]oxazol-5-amine (430 mg, 3.2 mmol) and tert-butyl-4-oxopiperidine-1-carboxylate (637 mg, 3.2 mmol) in acetic acid (10 mL) was stirred at 0°C for 15 minutes, then trimethylsilyl cyanide (317 mg, 3.2 mmol) was added. The reaction mixture was stirred for 4 hours at room température. Then the mixture was slowly poured into concentrated aqueous ammonium hydroxide solution (30 mL) and extracted with ethyl acetate (50 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 40:1 to afford tert-butyl-4-(benzo[d]oxazol-5-ylamino)-4cyanopiperidine-1-carboxylate as a white solid (500 mg, 46%).
LCMS (ESI): m/z = 342.2 [M+H]+.
tert-Butyl-1 -(3-amino-4-hydroxyphenyl)-2,4-dioxo-1,3,8-triazaspiro[4,5]decane-8- carboxylate
To a solution of tert-butyl-4-(benzo[d]oxazol-5-ylamino)-4-cyanopiperidine-1-carboxy1ate (500 mg, 1.5 mmol) in dichloromethane (30 mL) was added chlorosulfonyl isocyanate (0.31 mL, 1.65 mmol) dropwise over 15 minutes at 0°C. The mixture was stimed for 1 hour at room température and then concentrated under reduced pressure. The residue was dissolved in 1.0 M aqueous hydrochloric acid solution (20 mL) and stirred at reflux for 1 hour. Then the pH of the solution was adjusted to pH 9 by addition of solid potassium carbonate. To the solution was added di-tert-butyI dicarbonate (360 mg, 1.65 mmol) and the reaction mixture was stirred for 12 hours. The mixture was extracted with dichloromethane/methanol = 10:1 (60 mL), the organic layer was dried over anhydrous sodium sulfate and concentrated to dryness to afford fert-butyl-1-(3-amino-4-hydroxyphenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a brownish solid (crude, 500 mg, 88%).
LCMS (ESI): m/z = 376.2 [M+H]*.
tert-Butyl-1-(benzo[d]oxazol-5-yl)-2,4-dioxo-1,3,8-triazaspiro[4.5] decane-8-carboxylate
To a solution of ferf-butyl-1-(3-amino-4-hydroxyphenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carboxyiate (500 mg, 1.3 mmol) and ammonium chloride (53 mg, 0.15 mmol) in éthanol (30 mL) was
231 added trimethyl orthoformate (5 mL), Then the mixture was stirred for 12 hours at 60°C. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 20:1 to afford fert-butyl-1-(benzo[d]oxazol-5yl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (470 mg, 94%).
LCMS (ESI): m/z = 386.2 [M+H]*.
tert-Butyl-1-(benzo[d]oxazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8- carboxylate
To a mixture of fert-butyl-1-(benzo[d]oxazol-5-yl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (470 mg, 1.2 mmol) and potassium carbonate (337 mg, 2.4 mmol) in N,N-dimethylfoimamide (10 mL) was added iodomethane (190 mg,1.34 mmol) and then the mixture was stirred for 1 hour at room température. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane : methanol = 20:1 to afford fert-butyi-1-(benzo[d]oxazol-5yl)-3-methy1-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate as a white solid (347 mg, 72%).
LCMS (ESI): m/z = 400.2 [M+H]*.
14Benzo[d]oxazol-5-yl)-3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride
ferf-Butyl-1-(benzo[d]oxazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxyiate (347 mg, 0.87 mmol) was dissolved in a solution of hydrochloric acid in ethyl acetate (2.0 M, 10 mL). The mixture was stirred for 4 hours at room température before it was concentrated under reduced pressure to afford cnjde 1-(benzo[d]oxazol-5-yl)-3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride as a white solid (247 mg, 95%), which was used directly in the next step without further purification.
LCMS (ESI): m/z= 300.1 [M+H]*.
(R)-N-(1-(1-(Benzo[d]oxazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-niethyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
232
To a mixture of 1-(benzo[d]oxazol-5-yl)-3-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride (247 mg, 0.82 mmol), (R)-2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoic acid (252 mg, 0.82 mmol) (prepared as described in Example 28-f), 1-ethyl-3-(3-dimethyllaminopropyl)carbodiimide hydrochloride (250 mg, 1.3 mmol), and /V-hydroxybenzotriazole (176 mg, 1.3 mmol) in dichloromethane (20 mL) was added triethylamine (0.5 mL) at room température. The mixture was stirred at room température for 5 hours, before it was washed with water (30 mL). The organic layer was concentrated to dryness under reduced pressure and the residue was purified by silica gel column chromatography eluting with dichloromethane : methanol : ammonium hydroxide = 20:1:0.1 to afford (R)-N-(1 -(1 (benzo[d]oxazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2fluoro-5-(trifluoromethyl)benzamide as a yellow solid (16.6 mg, 3.4%).
LCMS (ESI): m/z = 589.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 8.55 (s, 1H), 8.06-7.74 (m, 3H), 7.73-7.66 (m, 1H), 7.43 (dd, J = 18.7, 9.0 Hz, 1H), 7.37-7.28 (m, 1H), 4.86-4.78 (m, 1H), 4.58-4.37 (m, 1H), 4.34-4.15 (m, 1H), 3.97 (t, J= 12.0 Hz, 1H), 3.51 (t, J= 12.0 Hz, 1H), 3.12 (s, 3H), 2.32-1.87 (m, 4H), 1.83-1.67 (m, 1H), 0.99 (t, J= 6.2 Hz, 4H), 0.87 (d, J = 6.7 Hz. 1 H), 0.73 (d, J = 6.7 Hz, 1 H).
The following compound was synthesized following the procedure described above:
Example 246:
(R)-N-(1-{1-(2-Methylbenzo[d]oxazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1 -oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide
mg, 36% yield, white solid.
LCMS (ESI): m/z = 603.2 [M+Hf.
1H-NMR (400 MHz, CD3OD): δ = 7.92-7.82 (m, 1H), 7.74 (dd, J = 24.9, 7.4 Hz, 1H), 7.63-7.41 (m, 2H), 7.33 (t, J = 9.5 Hz, 1 H), 7.22 (dd, J = 8.6, 1.9 Hz, 1 H), 4.83 (d, J = 7.8 Hz, 1 H), 4.47 (dd, J = 43.4, 13.8 Hz, 1 H), 4.24 (dd, J = 29.4, 12.7 Hz, 1 H), 3.96 (t, J = 13.3 Hz, 1 H), 3.51 (t, J = 13.8 Hz, 1 H), 3.11 (s, 3H), 2.66 (d, J = 26.8 Hz, 3H), 2.27-2.08 (m, 2H), 2.06-1.96 (m, 1H), 1.80-1.60 (m, 1H), 1.00-0.71 (m, 6H).
Anaiytical conditions
Unless otherwise noted, al) solvents, chemicals, and reagents were obtained commercialfy and used without purification. The 1H-NMR spectra were obtained in CDCb, DMSO-de, CD3OD, or acetone-ds at 25°C at 300 MHz or 400 MHz on an OXFORD (Varian) with chemical shift (δ, ppm) reported relative to TMS as an internai standard. HPLC-MS chromatograms and spectra were obtained with an Agilent 12006110 System. Prep-HPLC instruments were Gilson GX-281 (Gilson) and P230 Préparative Gradient System (Gradient: 95% water, 5% acetonitrile, 30-50 min gradient to 25% water, 75% acetonitrile). The microwave instrument was a CEM Discover SP.
233
Biological Properties
The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confinmed by pharmacological in vitro assays. The following assays and their respective methods are carried out with the compounds according to the present invention. Activity possessed by the compounds may be demonstrated in vivo. Those ski lied in the art will appreciate that a variety of assay formats may be used to détermine the activity of the compounds of this invention.
Autotaxin LPC Cascade Assay:
Assay Buffer:
100 mM Tris-HCI, pH = 9
500 mM NaCI mM MgCh mM CaCh
0.05% Triton X 100
Reagents:
Enzyme | Source | Stock conc | Working conc. | Final conc. |
Autotaxin | X-Chem | 4.6 pM | 20 nM | 5 nM |
LPC | Sigma L5254 | 8 mM in assay buffer | 400 pM | 100 pM |
Choline Oxidase | Sigma C5896 | 50U/mL in water | 0.8 U/mL | 0.1 U/mL |
HRP | Sigma P8375 | 1000U/mL in water | 8 U/mL | 1 U/mL |
Ampliflu Red | Sigma 90101 | 100 mM in DMSO | 400 pM | 50 pM |
HA130 and Test Compounds:
Highest final concentration is 10 M for HA130 (Echelon, B-0701) and 30 M for test compounds. Préparé a 1 mM stock of HA130 and a 3 mM stock of each compound in 100% DMSO. Perform a 1:3 serial dilution in DMSO (transfer 5 I of compound to 10 I of DMSO). Add 240 I of buffer to generate a top working concentration of 40 Μ (HA130) and 120 M (test compound) in 4% DMSO.
Ampliflu Red — Préparé a stock of 5 mM from 100 mM in 100% DMSO. Further dilate to a working concentration of 400 μΜ in buffer (8% DMSO).
Together with compound this yields a 2% DMSO final concentration.
Chotine Oxidase/HRP - 0.8 U/mL CO and 8 U/mL HRP.
Assay Conditions:
Add 5 I of ATX and 5 I of compound in a 384 weli plate (Coming 3676). Incubate for 10 mins at RT. Add 5 I of LPC and incubate for 1 hr on the plate shaker. Préparé the CO/HRP and AR immediately prior to use.
234
Add 2.5 I of CO/HRP and follow with 2.5 I AR. Note order of addition, CO/HRP mix before AR. Read fluorescence intensity (ex/em: 530/590 nm) kinetically for 30 min at RT on the Tecan M1000.
Table 1 : IC50 ATX Activity Values For Examples 1-246
ICM (nM) | Examples |
>1000 | 2, 11, 15, 16, 17, 19, 22, 34, 35, 36, 38. 53, 61,65, 67, 68, 69, 70. 71, 72, 73, 74, 75, 78, 80, 81,85. 86. 87, 93. 106, 111, 113, 114, 115, 117, 121, 122, 123, 126, 130, 132, 137, 143, 146, 148, 158, 159, 164, 180, 195, 217, 219, 228, 229, 230, 231,232, 233, 234, 235, 236, 240, 241. |
>500 <1000 | 3, 9, 23, 29, 30. 33. 46. 47, 63, 66, 76, 77. 79, 82, 92, 95, 102, 103, 120, 127, 128, 129, 145, 161, 176, 188, 189. |
>0 <500 | 1,4, 5, 6, 7, 8, 10, 12, 13, 14, 18, 20, 21,24, 25, 26, 27, 28, 31,32, 37, 39, 40, 41,42, 43, 44, 45, 48, 49, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60. 62, 64, 83. 84, 88, 89, 90, 91,94, 96, 97, 98, 99, 100, 101, 104, 105, 107, 108, 109, 110, 112, 116, 118, 119, 124, 125, 131, 133, 134, 135, 136, 138, 139, 140, 141, 142, 144, 147, 149, 150, 151, 152, 153, 154, 155, 156, 157, 160, 162, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 177, 178, 179, 181, 182, 183, 184, 185, 186, 187, 190, 191, 192, 193, 194, 196, 197, 198, 199, 200, 201,202, 203, 204, 205, 206, 207, 208, 209, 210, 211,212, 213, 214, 215, 216, 218, 220, 221, 222, 223, 224, 225, 226, 227, 237, 238. 239, 242, 243, 244, 245, 246. |
Further Assays:
An inhibitor of autotaxin is expected to show bénéficiai effects in human diseases by inhibiting autotaxin in human plasma and tissues as well as in animal models used to recapitulate such human 10 diseases where the disease is caused, mediated and/or propagated by increased LPA levels and/orthe activation of ATX. Such diseases which hâve been reported in the literature include but are not limited to: chronic inflammation, chronic obstructive pulmonary disease (COPD), arthritis, fibrosis, thrombosis, cholestatic pruritus, septic shock, inflammatory bowel disease, asthma, LPS induced lung inflammation, neuropathie pain, atherosclerosis and cardiovascular disease, multiple sclerosis, bone development and 15 cancer. Literature référencés which describe human diseases where the disease is caused, mediated and/or propagated by increased LPA levels and/or the activation of ATX, autotaxin and LPA and inhibition thereof in in vitro models and animal models used to mimic human diseases caused, mediated and/or propagated by increased LPA levels and/or the activation of ATX include: J Lipid Res. 2014 Mar
235
18;55(7):1192-1214, Cancer Res 2009; 69 (13), 5441; The Journal of Pharmacology and Experimental Therapeutics, 2010, 334 (1), 310; PLOS ONE, 2014, 9 (4), e93230; Biochem. Soc. Trans. 2014, 42, 125; FASEB J. 2014, 28(6), 2655; Arthritis Rheum, 2011,63(5), 1405; Cell Cycle, 2009, 8 (22), 3695; Mol Carcinog, 2009, 48(9), 801; Clin Cancer Res. 2013 19(23), 6461; Annu Rev Pharmacol ToxicoL 2010, 50, 157; Mol Cancer Ther 208, 7(10), 3352; Front Oncol. 2013, 3, 236; Biomol Ther (Séoul). 2015, 23(1), 1; Osteoarthritis Cartilage 2015, 23(2), 308; Biochim Biophys Acta. 2015,1851(1), 61; J Lipid Res. 2014, 55(7), 1192; FEBS Lett. 2014, 588(16), 2712; Future Med Chem. 2013, (16), 1935; Biochim Biophys Acta. 2014,1841(1), 88; Biochim Biophys Acta. 2013,1831(1), 42; Am J RespirCell Mol Biol. 2012, 47(5), 563; Am J Respir Cell Mol Biol. 2012, 47(5), 566; Acta Diabetol. 2013, 50(3), 363; Clin Chim Acta. 2012, 413(23-24), 1817; Clin Chim Acta. 2011,412(13-14), 1201; Life Sci. 2007, 81(12), 1009; Mol Pain 2011, 7, 33; Mol Pain 2010, 6, 78; Biochimie. 2010, 92(6), 698; J Pharmacol ExpTher. 2010, 333(2), 540; Mol Pain. 2009, 5, 64; Neuroscience 2008,152(2), 296; Mol Pain 2008, 4, 6; J Neuroimmunol. 2014, 273(1-2), 120; PLoS One. 2013, 8(7), e70941 ; Nat Rev Rheumatol. 2012, 8(6), 307; J Exp Med. 2012, 209(5), 925; CurrOpin Investig Drugs. 2010,11(5), 515; Atherosclerosis. 2013, 229(1), 192; J Biol Chem. 2009, 284(11), 7385; Cuit Drug Targets 2008, 9(8), 698; Gastroenterology 2010, 139(3), 1008; Lab Invest. 2013, 93(5), 508; J Immunol. 2014, 192(3), 851; Am J Respir Crit Care Med. 2013, 188(8), 889; Am J RespirCrit Care Med. 2013, 188(8), 928; Cell Metab. 2011, 13(5), 592; Exp Cell Res. 2014Nov25. pii: S0014-4827(14)00506-0; Biochem J. 2014, 463(1), 157; Biochim Biophys Acta. 2013, 1831(1), 74; Hepatology 2012, 56(4), 1391; Biochem Soc Trans. 2012, 40(1), 31; Enzyme Res. 2011, 2011:194857.
Compositions:
The présent invention includes pharmaceutical compositions comprising a compound or pharmaceuticaîly acceptable sait thereof of the invention, which is formulated for a desired mode of administration with or without one or more pharmaceuticaîly acceptable and useful carriers.
The compounds can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
The pharmaceutical compositions of the invention comprise a compound of the invention (or a pharmaceuticaîly acceptable sait thereof) as an active ingrédient, optional pharmaceuticaîly acceptable carrier(s) and optionally other therapeutic ingrédients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parentéral (încluding subeutaneous, intramuscular, and intravenous) administration, atthough the most suitable route in any given case will dépend on the particular host, and nature and severity of the conditions for which the active ingrédient is being administered. The pharmaceutical compositions can be conveniently presented in unit dosage form and prepared by any of the methods weli known in the art of pharmacy.
Compounds of the invention can be combined as the active ingrédient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of fomns depending on the form of préparation desired for administration, e.g., oral or parentéral (încluding intravenous). Thus, the pharmaceutical compositions of the invention can be presented as discrète units suitable for oral administration such as capsules, cachets ortablets each containing a predetermined amount of the active ingrédient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid,
236 as an oil-in-water émulsion, or as a water-in-oil liquid émulsion. In addition to the common dosage fomns set out above, the compound represented by Formula I, or a phamnaceutically acceptable sait thereof, can also be administered by controlled release means and/ordelivery devices. The compositions can be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingrédient with the carrier that constitutes one or more necessary ingrédients. In general, the compositions are prepared by uniformly and intimately admixing the active ingrédient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired présentation.
The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnésium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oii, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
A tabfet containing the composition of this invention can be prepared by compression or molding, optionally with one or more accessory ingrédients or adjuvants. Compressed tablets can be prepared by compressing, in a suitable machine, the active ingrédient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05 mg to about 5 g of the active ingrédient and each cachet or capsule preferably containing from about 0.05 mg to about 5 g of the active ingrédient.
A formulation intended for the oral administration to humans may contain from about 0.5 mg to about 5 g of active agent, compounded with an appropriate and convenient amount of carrier matériel which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about 1 mg to about 2 g of the active ingrédient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
Compounds of the invention can be provided for formulation at high purity, for example at least about 90%, 95%, or 98% pure by weight.
Pharmaceutical compositions of the invention suitable for parentéral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for exampie, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycots, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
Pharmaceutical compositions of the invention suitable for injectable use include stérile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of stérile powders for the extemporaneous préparation of such stérile injectable solutions or dispersions. In ail cases, the final injectable fonm must be stérile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved againstthe contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, éthanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycot), vegetable oils, and suitable mixtures thereof.
Pharmaceutical compositions of the invention can be in a form suitable fortopical use such as, for example, an aérosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions
237 can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable sait thereof, via conventions! processing methods. As an example, a cream orointment is prepared by admixing hydrophilic matériel and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.
Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is préférable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other matériels commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.
In addition to the aforementioned carrier ingrédients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingrédients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like. Furthermore, other adjuvants can be included to renderthe formulation isotonie with the blood of the intended récipient.
Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.
L/ses:
Compounds ofthe présent invention inhibitthe activity of ATXin animais, including humans, and are useful in the treatment and/or prévention of various diseases and conditions such as cancer, lymphocyte homing and inflammation, neuropathie pain, fibrotic diseases, thrombosis, and cholestatic pruritus which are caused, mediated and/or propagated by increased LPA levels and/or the activation of ATX. In particular, compounds of the invention, and compositions thereof, are inhibitors of ATX, and are useful in treating conditions modulated, at least in part, by ATX.
In some embodiments, the invention includes a method of treating cancer comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
In some embodiments, the invention includes a method of treating a cancer mediated at least in part by ATX comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of Formula I.
In some embodiments, the invention includes a method of treating or a method of manufacturing a médicament for treating a cancer, such as those described herein, which is mediated at least in part by ATX, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
In some embodiments, the invention includes a method of treating lymphocyte homing and inflammation comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
In some embodiments, the invention includes a method of treating lymphocyte homing and inflammation mediated at least in part by ATX comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of Formula I.
238
In some embodiments, the invention includes a method of treating or a method of manufacturing a médicament for treating lymphocyte homing and inflammation, such as those described herein, which is mediated at least in part by ATX, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
In some embodiments, the invention includes a method of treating neuropathie pain comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
In some embodiments, the invention includes a method of treating neuropathie pain mediated at least in part by ATX comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of Formula I.
In some embodiments, the invention includes a method of treating or a method of manufacturing a médicament for treating neuropathie pain, such as those described herein, which is mediated at least in part by ATX, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
In some embodiments, the invention includes a method of treating fibrotic diseases comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
In some embodiments, the invention includes a method of treating fibrotic diseases mediated at least in part by ATX comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of Formula I.
In some embodiments, the invention includes a method of treating or a method of manufacturing a médicament for treating a fibrotic disease, such as those described herein, which is mediated at least in part by ATX, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
In some embodiments, the invention includes a method of treating thrombosis comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
In some embodiments, the invention includes a method of treating thrombosis mediated at least in part by ATX comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of Formula I.
In some embodiments, the invention includes a method of treating or a method of manufacturing a médicament for treating thrombosis, such as those described herein, which is mediated at least in part by ATX, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
in some embodiments, the invention includes a method of treating cholestatic pruritus comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
In some embodiments, the invention includes a method of treating cholestatic pruritus mediated at least in part by ATX comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of Formula I.
In some embodiments, the invention includes a method of treating or a method of manufacturing a médicament for cholestatic pruritus, such as those described herein, which is mediated at least in part
239 by ATX, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention.
The compounds of Formula I of the invention are useful in the treatment of a variety of cancers, including, but not limited to, solid tumors, sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, rhabdomyosarcoma, glioblastoma, neuroblastome, teratocarcinoma, hematopoietic malignancy, and malignant ascites. More specifically, the cancers include, but not limited to, lung cancer, bladder cancer, pancreatic cancer, kidney cancer, gastric cancer, breast cancer, colon cancer, prostate cancer (including bone métastasés), hepatocellular carcinoma, ovarian cancer, esophageal squamous cell carcinoma, melanoma, an anaplastic large cell lymphoma, an inflammatory myofibroblastic tumor, and a glioblastoma.
In some embodiments, the above methods are used to treat one or more of bladder, colorectal, non-small cell lung, breast, or pancreatic cancer. In some embodiments, the above methods are used to treat one or more of ovarian, gastric, head and neck, prostate, hepatocellular, rénal, glioma, or sarcoma cancer.
In some embodiments, the invention includes a method, including the above methods, wherein the compound is used to inhibit cellular épithélial to mesenchymal transition (EMT).
In some embodiments, the method further comprises administering at least on additional active agent. In some embodiments, the invention includes a method of treating cancer comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or sait of the invention, wherein at least one additional active anti-cancer agent is used as part of the method.
In some embodiments, the invention includes a method of treating the disease described herein mediated at least in part by ATX comprising administering to a mammal in need thereof a therapeutically effective regimen comprising a compound or sait of Formula I and at least one additional active agent. Generally, dosage levels on the order of from about 0.01 mg/kg to about 150 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or altematively about 0.5 mg to about 7 g per patient per day. For example, inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune System, disease and conditions of the Central Nervous System (CNS), may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or altematively about 0.5 mg to about 3.5 g per patient per day.
It is understood, however, that the spécifie dose level for any particular patient will dépend upon a variety of factors including the âge, body weight, general health, sex, diet, time of administration, route of administration, rate of excrétion, drug combination and the severity of the particular disease undergoing therapy.
General Définitions and Abréviations:
Except where otherwise indicated, the following general conventions and définitions apply. Unless otherwise indicated herein, language and terms are to be given their broadest reasonable interprétation as understood by the skilled artisan. Any examptes given are nonlimiting.
Any section headings or subheadings herein are for the readerts convenience and/or formai compliance and are non-limiting.
A recitation of a compound herein is open to and embraces any material or composition containing the recited compound (e.g., a composition containing a racemic mixture, tautomers, epimers,
240 stereoisomers, impure mixtures, etc.). In that a sait, solvaté, or hydrate, polymorph, or other complex of a compound includes the compound itself, a recitation of a compound embraces materials containing such forms. Isotopically labeled compounds are also encompassed except where specifrcally excluded. For example, hydrogen is not limited to hydrogen containing zéro neutrons. For example, deuterium is referred to herein as “D and means a hydrogen atom having one neutron.
The term “active agent of the présent invention means a compound of the invention in any sait, polymorph, crystal, solvaté, or hydrated form.
The term “pharmaceutically acceptable salt(s) is known in the art and includes salts of acidic or basic groups which can be présent in the compounds and prepared or resulting from pharmaceutically acceptable bases or acids.
The term “substituted’ and substitutions contained in formulas herein refer to the replacement of one or more hydrogen radicals in a given structure with a specified radical, or, if not specified, to the replacement with any chemically feasible radical. When more than one position in a given structure can be substituted with more than one substituent selected from specified groups, the substituents can be eitherthe same or different at every position (independently selected) unless otherwise indicated. In some cases, two positions in a given structure can be substituted with one shared substituent. It is understood that chemically impossible or highly unstable configurations are not desired or intended, as the skilled artisan would appreciate.
In descriptions and daims where subject matter (e.g„ substitution at a given molecular position) is recited as being selected from a group of possibilities, the recitation is specifically intended to inciude any subset of the recited group. In the case of multiple variable positions or substituents, any combination of group or variable subsets is also contemplated.
Unless indicated otherwise, a substituent, diradical or other group referred to herein can be bonded through any suitable position to a referenced subject molécule. For exemple, the term “indolyl includes 1indolyl, 2-indolyl, 3-indolyl, etc.
The convention for describing the carbon content of certain moieties is “(Ca-t>) or “Ca-CtT meaning that the moiety can contain any number of from “a to “b” carbon atoms. Coalkyl means a single covalent chemical bond when it is a connecting moiety, and a hydrogen when it is a terminal moiety. Similarly, “x-y” can indicate a moiety containing from xto y atoms, e.g.,s6heterocydoalkyl means a heterocycloalkyl having either five or six ring members. ’Cx-y’ may be used to define number of carbons in a group. For example, “Co-izalkyl means alkyl having 0-12 carbons, wherein Coalkyl means a single covalent chemical bond when a linking group and means hydrogen when a terminal group.
The term “absent, as used herein to describe a structural variable (e.g., “—R— is absent) means that diradical R has no atoms, and merely represents a bond between other adjoining atoms, unless otherwise indicated.
Unless otherwise indicated (such as by a connecting “-), the connections of compound name moieties are at the rightmost recited moiety. That is, the substituent name starts with a terminal moiety, continues with any bridging moieties, and ends with the connecting moiety. For example, “heteroarylthioCi^alkyl is a heteroaryl group connected through a thio sulfur to a Ci-4 alkyl, which alkyl connects to the chemical species bearing the substituent.
The term “aliphatic” means any hydrocarbon moiety, and can contain linear, branched, and cyclic parts, and can be saturated or unsaturated.
241
The terni “alkyl” means any saturated hydrocarbon group that is straight-chain or branched. Examples of alkyl groups include methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, tert-butyl, pentyl, and the like.
The terni “alkenyl means any ethylenically unsaturated straight-chain or branched hydrocarbon group. Représentative examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or
3-butenyl, and the like.
The term “alkynyl means any acetylenically unsaturated straight-chain or branched hydrocarbon group. Représentative examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, or
3-butynyl, and the like.
The temn “alkoxy means —O-alkyl, —O-alkenyl, or —O-alkynyl. “Haloalkoxy” means an —O(haloalkyl) group. Représentative examples include, but are not limited to, trifluoromethoxy, tribromomethoxy, and the like.
“Haloalkyl means an alkyl, preferably lower alkyl, that is substituted with one or more same or different halo atoms.
“Hydroxyalkyl means an alkyl, preferably lower alkyl, that is substituted with one, two, orthree hydroxy groups; e.g., hydroxymethyl, 1 or 2-hydroxyethyl, 1,2-, 1,3-, or 2,3-dihydroxypropyl, and the like.
The temn “alkanoyl means —C(O)-alkyi, —C(O)-alkenyl, or—C(O)-alkynyl.
“Alkylthio means an —S-(alkyl) or an —S-(unsubstituted cycloalkyl) group. Représentative examples include, but are not limited to, methylthio, ethyithio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.
The term cyclic means any ring System with or without heteroatoms (N, O, or S(0)o-2), and which can be saturated, partially saturated, or unsaturated. Ring Systems can be bridged and can include fused rings. The size of ring Systems may be described using terminofogy such as “x-ycyclic, which means a cyclic ring System that can hâve from x to y ring atoms. For example, the term “g-wcarbocyclic means a 5,6 or 6,6 fused bicyclic carbocyclic ring System which can be saturated, unsaturated or aromatic. It also means a phenyl fused to one 5 or 6 membered saturated or unsaturated carbocyclic group. Nonlimiting examples of such groups include naphthyl, 1,2,3,4 tetrahydronaphthyl, indenyi, indanyl, and the like.
The term “carbocyclic means a cyclic ring moiety containing only carbon atoms in the ring(s) without regard to aromaticity. A 3-10 membered carbocyclic means chemically feasible monocyclic and fused bicyclic carbocyclics having from 3 to 10 ring atoms. Similariy, a 4-6 membered carbocyclic means monocyclic carbocyclic ring moieties having 4 to 6 ring carbons, and a 9-10 membered carbocyclic means fused bicyclic carbocyclic ring moieties having 9 to 10 ring carbons.
The term “cycloalkyl means a non-aromatic 3-12 carbon mono-cyclic, bicyclic, or polycyclic aliphatic ring moiety. Cycloalkyl can be bicycloalkyl, polycycloalkyl, bridged, or spiroalkyl. One or more of the rings may contain one or more double bonds but none of the rings has a completely conjugated pielectron System. Examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, adamantane, cycloheptane, cycloheptatriene, and the like.
The term “unsaturated carbocyclic” means any cycloalkyl containing at least one double or triple bond. The term “cycloaikenyl means a cycloalkyl having at least one double bond in the ring moiety.
242
The ternis “bicycloalkyl” and “polycycloalkyl mean a structure consîsting of two or more cycloalkyl moieties that hâve two or more atoms in common. If the cycloalkyl moieties hâve exactly two atoms in common they are said to be “fused. Examples include, but are not limited to, bicyclo[3.1.0]hexyl, perhydronaphthyl, and the like. If the cycloalkyl moieties hâve more than two atoms in common they are said to be “bridged. Examples include, but are not limited to, bicyclo[2.2.1]heptyl (“norbomyl), bicyclo[2.2.2]octyl, and the like.
The terni “spiroalkyl means a structure consîsting of two cycloalkyl moieties that hâve exactly one atom in common. Examples include, but are not limited to, spiro[4.5]decyl, spiro[2.3]hexyl, and the like.
The terni “aromatic means a planar ring moieties containing 4n+2 pi électrons, wherein n is an integer.
The term “aryl means aromatic moieties containing only carbon atoms in its ring System. Nonlimiting examples include phenyl, naphthyl, and anthracenyl. The ternis “aryl-alkyl” or “arylalkyl or “aralkyl refer to any alkyl that fornis a bridging portion with a terminal aryl.
“Aralkyi means alkyl that is substituted with an aryl group as defined above; e.g., —CHî phenyl, —(CH2)2phenyl, —(CH2)3 phenyl, CH3CH(CH3)CH2phenyl, and the like and dérivatives thereof.
The term “heterocyclic means a cyclic ring moiety containing at least one heteroatom (N, O, or S(O)d-2), including heteroaryl, heterocycloalkyl, including unsaturated heterocyclic rings.
The term “heterocycloalkyl means a non-aromatic monocyclic, bicyclic, or polycyclic heterocyclic ring moiety of 3 to 12 ring atoms containing at least one ring having one or more heteroatoms. The rings may also hâve one or more double bonds. However, the rings do not hâve a completely conjugated pielectron System. Examples, without limitation, of heterocycloalkyl rings include azetidine, oxetane, tetrahydrofuran, tetrahydropyran, oxepane, oxocane, thietane, thiazolidine, oxazolidine, oxazetidine, pyrazolidine, isoxazolidine, isothiazolidine, tetrahydrothiophene, tetrahydrothiopyran, thiepane, thiocane, azetidine, pyrrolidine, piperidine, N-methylpiperidine, azepane, 1,4-diazapane, azocane, [1,3]dioxane, oxazolidine, piperazine, homopiperazine, morpholine, thiomorpholine, 1,2,3,6-tetrahydropyridine and the like. Other examples of heterocycloalkyl rings include the oxidized forms of the sulfur-containing rings. Thus, tetrahydrothiophene-1 -oxide, tetrahydrothiophene-1,1-dioxide, thiomorpholine-1-oxide, thiomorpholine-1,1 -dioxide, tetrahydrothiopyran-1 -oxide, tetrahydrothiopyran-1,1 -dioxide, thiazolidine-1oxide, and thiazolidine-1,1-dioxide are also considered to be heterocycloalkyl rings. The term “heterocycloalkyl also includes fused ring Systems and can include a carbocyclic ring that is partially or fully unsaturated, such as a benzene ring, to form benzofused heterocycloalkyl rings. For example, 3,4dihydro-1,4-benzodioxine, tetrahydroquinoline, tetrahydroisoquinoline and the like. The term “heterocycloalkyl also includes heterobicycloalkyl, heteropolycycloalkyl, or heterospiroalkyl, which are bicycloalkyl, polycycloalkyl, or spiroalkyl, in which one or more carbon atomfs) are replaced by one or more heteroatoms selected from O, N, and S. For example, 2-oxa-spiro[3.3]heptane, 2,7-diazaspiro[4.5]decane, 6-oxa-2-thia-spiro[3.4]octane, octahydropyrrolo[1,2-a]pyrazine, 7-azabicyclo[2.2.1]heptane, 2-oxa-bicyclo[2.2.2]octane, and the like, are such heterocycloalkyls.
Examples of saturated heterocyclic groups include, but are not limited to oxiranyl, thiaranyl, aziridinyl, oxetanyl, thiatanyl, azetidinyl, tetrahydrofuranyï, tetrahydrothiophenyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, 1,4-dioxanyl, 1,4-oxathianyl, morpholinyï, 1,4
243 dithianyl, piperazinyl, 1,4-azathianyl. oxepanyl, thiepanyl, azepanyl, 1,4-dioxepanyl, 1,4-oxathiepanyl, 1.4oxaazepanyl, 1,4-dithiepanyl, 1,4-thieazepanyl, 1,4-diazepanyl.
Non-aryl heterocyclic groups include saturated and unsaturated Systems and can include groups having only 4 atoms in their ring System. The heterocyclic groups include benzo-fused ring Systems and ring Systems substituted with one or more oxo moieties. Recitation of ring sulfur is understood to include the sulfide, sulfoxide or sulfone where feasible. The heterocyclic groups also include partially unsaturated orfuily saturated 4-10 membered ring Systems, e.g., single rings of 4 to 8 atoms in size and bicyclic ring Systems, including aromatic6-membered aryl or heteroaryl rings fused to a non-aromatic ring. Also included are 4-6 membered ring Systems (“4-6 membered heterocyclic”), which include 5-6 membered heteroaryls, and include groups such as azetidinyl and piperidinyl. Heterocyclics can be heteroatomattached where such is possible. For instance, a group derived from pyrrole can be pyrrol-1-yl (Nattached) or pyrrol-3-yl (C-attached). Other heterocyclics include imidazo(4,5-b)pyridin-3-yl and benzoimidazol-1-yl.
Examples of heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyï, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyi, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pynrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3dioxolanyl, pyrazolinyl, dithianyl, dithiolanyI, dihydropyranyl, dihydrothienyl, dihydrofuranyi, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-îndolyl, quinoliztnyl, and the like.
The term “unsaturated heterocyclic means a heterocycloalkyl containing at least one unsaturated bond. The term “heterobicycloalkyl” means a bicycloalkyl structure in which at least one carbon atom is replaced with a heteroatom. The term “heterospiroalkyl means a spiroalkyl structure in which at least one carbon atom is replaced with a heteroatom.
Examples of partially unsaturated heteroalicyclic groups include, but are not limited to: 3,4dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, 2H-pyranyl, 1,2,3,4-tetrahydropyridinyl, and 1,2,5,6tetrahydropyridinyl.
The terms “heteroaryl” or “hetaryl” mean a monocyclic, bicyclic, or polycyclic aromatic heterocyclic ring moiety containing 5-12 atoms. Examples of such heteroaryl rings include, but are not limited to, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyI, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyI. The terms “heteroaryl” also include heteroaryl rings with fused carbocyclic ring Systems that are partially orfuily unsaturated, such as a benzene ring, to form a benzofused heteroaryl. For example, benzimidazole, benzoxazole, benzothiazole, benzofuran, quinoline, isoquinoline, quinoxaline, indazole, imidazo[1,2a]pyridine, 3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl, 2-methyî-2H-indazol-5-yl, 3methylimidazo[1,5-a]pyridine, 2-methyl-1H-benzo[d]imidazole, 1 H-pyrrolo[2,3-b]pyridine. 3,4-Dihydro-2Hbenzo[b][1,4]oxazine, 2-oxo-2,3-dihydrobenzo[d]oxazole, 3-oxo-3.4-dihydro-2H-benzo[b][1,4]oxazine, 2,3Dihydrobenzo[b][1,4]dioxine, 2-methyl-[1,2,4]triazolo[1,5-a]pyridine, and the like. Furthermore, the terms “heteroaryl include fused 5-6, 5-5, 6-6 ring Systems, optionally possessing one nitrogen atom at a ring junction. Examples of such hetaryl rings include. but are not limited to, pyrrolopyrimidinyl. imidazo[1,2ajpyridinyl, imidazo[2,1-b]thiazolyl, imidazo[4.5-b]pyridine, pyrrolo[2,1-f][1,2,4]triazinyl, and the like.
244
Heteroaryl groups may be attached to other groups through their carbon atoms or the heteroatom(s), if applicable. For exampte, pyrrofe may be connected at the nitrogen atom or at any of the carbon atoms.
Heteroaryls include, e.g., 5 and 6 membered monocyclics such as pyrazinyl and pyridinyl, and 9 and 10 membered fused bicyclic ring moieties, such as quinolinyl. Other examples of heteroaryl include quinolin-4-yl, 7-methoxy-quinolin-4-yl, pyridin-4-yl, pyridin-3-yl, and pyridin-2-yl. Other examples of heteroaryl include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furanyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolîzinyl, phthalazinyl, pyridazinyl, triazinyl, tsoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyï, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, and the like. Examples of 5-6 membered heteroaryls include, thiophenyl, isoxazolyl, 1,2,3-triazolyl, 1,2,3-oxadiazolyl, 1,2,3-thiadîazolyl, 1,2,4-triazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-oxadiazolyl, 1,2,5-thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,2,4 oxadiazolyl, 1,2,5-triazinyl, 1,3,5-triazinyl, 6-oxo-1,6dihydropyridine, and the like.
“Heteroaralkyl group means alkyl, preferably lower alkyl, that is substituted with a heteroaryl group; e.g., —CH2 pyridinyl, —(CH2)2pyrimidinyl, —(CHîjsimidazoiyl, and the like, and dérivatives thereof.
A pharmaceutically acceptable heteroaryl is one that is sufficiently stable to be attached to a compound of the invention, formulated into a pharmaceutical composition and subsequently administered to a patient in need thereof.
Examples of monocyclic heteroaryl groups include, but are not limited to: pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, 1-oxa-2,3-diazolyl, 1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl, 1-thia-2,3-diazolyl, 1-thia-
2,4-diazolyl, 1 -thia-2,5-diazolyl, 1-thia-3,4-diazoiyl tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl.
Examples of fused ring heteroaryl groups include, but are not limited to: benzoduranyï, benzothiophenyl, indolyl, benzimidazolyl, indazolyl, benzotriazolyl, pyrro1o[2,3-b]pyridinyl, pyrro!o[2,3c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, pyrazolo[4,3-d]pyridinyl, pyrazolo[4,3-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, isoindolyl, indazolyl, purinyl, indolinyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, pyrazolo[1,5ajpyridînyl, pyrrolo[1,2-b]pyridazinyl, imidazo[1,2-c]pyrimidinyl, quinolinyl, isoquinolinyl, cinnolinyl, azaquinazoline, quinoxalinyl, phthalazinyl, 1,6-naphthyridinyl, 1,7-naphthyridinyl, 1,8-naphthyridinyl, 1,5naphthyridinyl, 2,6-naphthyridinyl, 2,7-naphthyridinyl. pyrido[3,2-d]pyrimidinyl, pyrido[4,3-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, pyrido[2,3-b]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl, pyrimido[2,3-b]pyrazinyl, pyrimido[4,5-d]pyrimidinyl.
“Arylthio means an —S-aryl or an —S-heteroaryl group, as defined herein. Représentative examples include, but are not limited to, phenyithio, pyridinylthio, furanylthio, thienylthio, pyrimidinylthio, and the like and dérivatives thereof.
The term “9-10 membered heterocyclic” means a fused 5,6 or 6,6 bicyclic heterocyclic ring moiety, which can be saturadated, unsaturated or aromatic. The term “9-10 membered fused bicyclic heterocyclic” also means a phenyl fused to one 5 or 6 membered heterocyclic group. Examples include benzofuranyl, benzothiophenyl, indolyl, benzoxazolyl, 3H-imidazo[4,5-c]pyridin-yl, dihydrophthazinyl, 1Himidazo[4,5-c]pyridin-1-yl, imidazo[4,5-b]pyridyl, 1,3 benzo[1,3]dioxolyl, 2H-chromanyl, isochromanyl, 5oxo-2,3 dihydro-SH-n.Slthiazolop^-alpyrimidyl, 1,3-benzothiazolyl, 1,4,5,6 tetrahydropyridazyl,
245
1,2,3,4,7,8hexahydropteridinyl, 2-thioxo-2,3,6,9-tetrahydro-1 H-purin-8-yl, 3,7-dihydro-1 H-purin-8-yl, 3,4dihydropyrimidin-1-yl, 2,3-dihydro-1,4-benzodioxinyl, benzo[1,3]dioxolyl, 2H-chromenyl, chromanyl, 3,4dihydrophthalazinyl, 2,3-ihydro-1H-indolyl, 1,3-dihydro-2H-isoindol-2-yl, 2,4,7-trioxo-1,2,3,4,7,8hexahydropteridin-yl, thieno[3,2-d]pyrimidinyl, 4-oxo-4,7-dÎhydro-3H-pyrrolo[2,3-d]pyrimidin-yl, 1,3dimethyl-6-oxo-2-thioxo-2,3,6,9-tetrahydro-1 H-purinyl, 1,2-dihydroisoquinolinyl, 2-oxo-1,3-benzoxazolyl, 2,3-dihydro-5H-1,3-thiazolo-[3,2-a]pyrimidinyl, 5,6,7,8-tetrahydro-quinazoiinyl, 4-oxochromanyl, 1,3benzothiazolyl, benzimidazolyl, benzotriazolyl, purinyl, furyIpyridyl, thiophenylpyrimidyl, thiophenylpyridyl, pyrrolylpiridyl, oxazolylpyridyl, thiazolylpiridyl, 3,4-dihydropyrimidin-1-yl imidazolylpyridyl, quinoliyl, isoquinolinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pyrazolyl[3,4]pyridine, 1,2-dihydroisoquinolinyl, cinnolinyl, 2,3-dihydro-benzo[1,4]dioxin4-yl, 4,5,6,7-tetrahydro-benzo[bJ-thiophenyl-2-yl, 1,8naphthyridinyl, 1,5-napthyridinyl, 1,6-naphthyridinyl, 1,7-napthyridinyl, 3,4-dihydro-2H-1,4-benzothiazine,
4,8-dihydroxy-quinolinyl, 1-oxo-1,2-dihydro-isoquinolinyl, 4-phenyl-[1,2,3]thiadiazolyl, and the like.
The term “aryloxy means an —O-aryl or an —O-heteroaryl group, as defined herein. Représentative examples include, but are not limited to, phenoxy, pyridinyloxy, furanyloxy, thienyloxy, pyrimidinyloxy, pyrazinyloxy, and the like, and dérivatives thereof.
The term “oxo” means a compound containing a carbonyl group. One in the art understands that an “oxo requires a second bond from the atom to which the oxo is attached.
The term “halo or “halogen” means fluoro, chloro, bromo, or iodo.
“Acyl means a —C(O)R group, where R can be seiected from the nonlimiting group of hydrogen or optionally substituted Iower alkyl, trihalomethyl, unsubstituted cyctoalkyl, aryl, or other suitable substituent.
“Thioacyl” or “thiocarbonyl means a—C(S)R group, with R as defined above.
The term “protecting group means a suitable chemical group that can be attached to a functional group and removed at a later stage to reveal the intact functional group. Examples of suitable protecting groups for various functional groups are described in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2d Ed., John Wiley and Sons (1991 and later éditions); L. Fieser and M. Fieser, Fieser and Fieseris Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Raquette, ed. Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995). The tenm “hydroxy protecting group”, as used herein, untess otherwise indicated, inciudes Ac, CBZ, and various hydroxy protecting groups famiiiarto those skilled in the art including the groups referred to in Greene.
The term “linear structure” means a moiety having substituents that do not cyclize to form a ring System. A représentative example inciudes, but is not limited to, a compound including -NR5R6 where any atoms of “R5 and any atoms of “R6 do not connect to form a ring.
As used herein, the term “pharmaceutically acceptable sait means those salts which retain the biological effectiveness and properties of the parent compound and do not présent insurmountable safety ortoxicity issues.
The terni “pharmaceutical composition means an active compound in any form suitable for effective administration to a subject, e.g., a mixture of the compound and at least one pharmaceutically acceptable carrier.
As used herein, a “physiologically/phanmaceutically acceptable carrier” means a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
246
A “pharmaceutically acceptable excipient means an inert substance added to a pharmaceutical composition to furtherfacilitate administration of a compound. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose dérivatives, gelatin, vegetable oils and polyethylene glycols.
The term “substituted and substitutions contained in formulas herein refer to the replacement of one or more hydrogen radicals in a given structure with a specified radical, or, if not specified, to the replacement with any chemically feasible radical. When more than one position in a given structure can be substituted with more than one substituent selected from specified groups, the substituents can be eitherthe same or different at every position (independently selected) unless otherwise indicated. In some cases, two positions in a given structure can be substituted with one shared substituent. It is understood that chemically impossible or highly unstable configurations are not desired or intended, as the skilled artisan would appreciate.
The terms “treat, “treatment, and “treating means reversing, alleviating, or inhibiting the progress of the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. “Preventing” means partially or completing treating before the disorder or condition occurs.
“Therapeutically effective amount’ means that amount of the compound being administered which will relieve to some extent one or more of the symptoms of the disorder being treated, or resuit in inhibition ofthe progress orat least partial reversai ofthe condition.
NMR Nuclear magnetic résonance
MDP(S) Mass-directed HPLC purification (System) LC/MS Liquid chromatography mass spectrometry
LDA Lithium diisopropylamide fert-BuOH fert-Butanol
AcOH Acetic acid
CDl 1,1'-Carbonyldiimidazole
DCE 1,1-Dichloroethane DCM Dichloromethane DMF Dimethylformamide THF Tetrahydrofuran MeOH Methanol
EtOH Ethanol
EtOAc Ethyl acetate
MeCN Acetonitrile
DMSO Dimethylsulfoxide
Boc tert-Butyloxycarbonyl
DME 1,2-Dimethoxyethane
DMF N,N-Dimethylformamide DIPEA Diisopropylethylamine PS-DIEA Polymer-supported diisopropylethylamine PS—pph3-Pd Polymer-supported Pd(PPh3)4
247
LAH Lithium aiuminum hydride
EDC 1-(3-Dimethylaminopropyl)-3-ethyicarbodiimide
HATU: 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate
HOBt 1-Hydroxybenzotnazole
DMAP 4-Dimethylaminopyridine
SEM-Ct 2-(Trimethyisilyl)ethoxymethyl chloride
TBTU 0-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
TEMPO 2,2,6,6-Tetramethylpiperidine-1-oxyl
TFA (A) Trifluoroacetic acid (anhydride)
TLC Thin layer chromatography
TMSCN Trimethylsilyl cyanide
Min Minute(s)
NMO N-Methylmorpholine N-oxide h Hour(s) d Day(s)
RT, R.T., r.L, r.t or rt Room température îr Rétention time
Claims (46)
1. A compound according to Formula I:
l or a pharmaceutically acceptable sait thereof, wherein:
X1 and X2 are each independently setected from one or more of Ci.2aikyi, C=O, NR3, or O;
X3 is independently selected from one or more of Ci-zaikyi, C=O, NR3, O, or CR10R11;
m and n are each independently selected from 0,1 or 2;
R1 is selected from Co-iaalkyl—, C3-i2cycloalkyl-Co-i2alkyl-, C3-i2heterocycloalkyl-Co.i2alkyl-, aryl— Co-i2alkyl-, aryl-C3-t2cycloalkyl-, aryl-Ca-uheterocycloalkyl-, heteroaryl-Co-i2alkyl-, heteroarylC3-i2cycloalkyl- or heteroaryl-C3-i2heterocycloalkyl-, any of which is optionally substituted with one or more independent G1 substituents;
R2 is selected from Co-i2alkyl-, C3-i2cycloalkyl-Co-i2alkyl-, Ca-^heterocycloalkyl-Co-^alkyl-, arylCo-i2alkyl-, aryl-C3-i2cycloalkyl-, aryl-C3-i2heterocycloalkyl-. heteroaryl-Co-i2alkyl-, heteroarylC3-i2cycloalkyl-, or heteroaryl-C3-i2heterocycloalkyl-, any of which is optionally substituted with one or more independent G2 substituents;
R2a is selected from Co-nalkyl-, C3-i2cycloalkyl-Co-i2alkyl-, C3-i2heterocycloalkyl-Co-i2alkyi-, arylCo-i2alkyl-, aryl-C3i2cycloalkyi-, aryl-Crj-iaheterocycloalkyl-, heteroaryl-Co-iaalkyl-, heteroarylC3-i2Cycloalkyi-, or heteroaryl-C3-i2heterocycloalkyl-, any of which is optionally substituted with one or more independent G2a substituents;
R2 and R2a are each independently a linear structure, or, R2 and R2a are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)mi;
R3 is selected from Co-i2alkyl—, C3.i2cycloalkyl-Co-i2alkyl-, C3-i2heterocycloalkyl-Co-i2alkyl-, arylCo-i2a)kyl-, aryl-Cs-^cycloalkyl-, aryl-C3-i2heterocycloalkyl-, heteroaryl-Co-i2alkyl-, heteroarylC3-i2cycloalkyl~, or heteroaryl-C3-i2heterocycloalkyl-, any of which is optionally substituted with one or more independent G3 substituents;
R4 is selected from Co-^alkyl-, C3-i2cycloalkyl-Co-i2alkyl-, C3.i2heterocycloalkyl-Co-i2alkyl-, arylCo-i2alkyl-, aryl-C3.i2cycloalkyl-, aryl-C3-i2heterocycloalkyi-, heteroaryl-Co-i2alkyl-, heteroarylC3-i2CycloalkyJ-, heteroaryl-C^nheterocycloalkyl-, or pyridine-N-oxide, any of which is optionally substituted with one or more independent G4 substituents;
G1, G2, G2a, G3, and G4 are each independently selected from one or more of H, D, halo, -CN, CD3, -OCDs, -oxo-, —CFs, -OCF3, -OCHF2, -NR5R6, -NO2. -B(OH)2, -PO(OR12)2, PO(OR12)R13, -CONR12OH, -Co-i2alkyl, -C2-i2alkenyl, -C2-i2alkynyl, C3-i2cycloalkyl-Co-i2alkyl-,
249
C3-i2heterocycloalkyl-Co-i2alkyl-, aryl-Co i^alkyl—, heteroaryl-Coi2alkyl-, -OCo-nalkyl, S(O)mR13, -C(O)R12, -C(O)NR12R13, -C(O)-C(O)NR12R13, -C(O)OR12, -C(O)-C(O)OR12, OC(0)R12, -NR12C(O)R13, -NR12C(O)OR13, -NR13S(O)2R13, -(CR14R15)C(O)R13, (CR14R15)C(O)OR12, -(CR14R15)C(O)NR12R13, -(CR14R15)niS(O)2NR12R13, -(CR14R15)niNR12R13, (CR14R15)niOR12, -(CR14R15)niS(O)n2R12 -NR16C(O)NR12R13, -NR16S(O)2NR12R13 orNR16S(O)NR12R13, any of which is optionally substituted with one or more independent Q1 substitueras;
Q1 is selected from H, D, halo, —CN, —CD3, —OCD3, —oxo—, —CF3, —OCF3, —OCHF2, —NO2, — B(OH)2, -PO(OR17)2, -PO(OR17)R18, NR17R18, -CONR17OH, Co-i2alkyl-, -C2-12 alkenyl, -C2. i2alkynyl, aryl-Co-i2alkyl-, heteroaryl-Co-i2alkyl-, C3-i2cycloalkyl~Co-i2alkyl-, C3i2heterocycloalkyl-Co-i2alkyl-, aryl-Coi2cycloatkyl-, heteroaryl-C3-i2cycloalkyl-, C3i2heterocycloalkyl~C3-i2cycloalkyl-, C3-i2cycloaikyl-C3-i2cycloalkyl-, Ci-i2alkyl-C3uheterocycloalkyl-, C3-i2heterocycloalkyl-C3-i2heterocycloalkyl-, aryl-C3-i2heterocycloalkyl-, heteroaryl-C3-i2heterocycloalkyl-, -OCo-i2alkyl, -C(O)-C(0)NR17R18, -C(O)-C(O)OR17, OC(O)R17, -NR17C{O)R18, -NR17S(O)2R16, -(CR19R20)raC(O)R17, -(CR19R20)n3C(O)OR17, (CR19R20)n3C(O)NR17R18, -(CRl9R20)n3S(O)2NR17R18, -(CR19R2O)n3NR17R18, -(CR19R20)n3OR17, (CR19R20)n3S(O)n4R17, -NR21C(O)NR17R18, -NR21S(O)2NR17R18 or-NR21S(Q)NR17R18, any of which is optionally substituted with one or more independent Q2 substituents;
Q2 is selected from one or more of H, D, halo, —CN, —oxo—, —CD3, -OCD3, —CF3, —OCF3, — OCHF2, -NO2, -B{OH)2, -PO(OR27)2, -PO(OR27)R28, -CONR27OH, -CONR27R20Co-i2alkyl-, -C2. 12 alkenyl, -C2-i2 alkynyl, -OCo-i2alkyl, aryl-Cü i2alkyl—, heteroaryl-Co-^alkyl-, C3-i2cycloalkyl-Cûi2alkyl-, C3-i2heterocycloalkyl-Co-i2alkyl-, aryl-Co-i2cycloalkyl-, heteroaryl-Cs-izcycloalkyl-, C3i2heterocycloalkyl-C3-i2cycloalkyl-, C3-i2cycloalkyl-C3-i2cycloalkyl-, Ci-i2alkyl-C3. i2heterocycloalkyl-, C3.i2heterocycloalkyl-C3-i2heterocycloalkyl-, aryl-Ca-izheterocycloaikyl-, heteroaryl-C3.i2heterocycloalkyl—, -C(O)-C(O)NR27R28, -Co-i2alkylC(0)OR27, -C(O)-C(O)OR27, OC(O)R27, -NR27C(O)R28, -NR27C(O)OR28, -NR27S(O)2R2B, -(CR^R^nsCtOR27, (CR29R30)n5C(O)OR27, -(CR29R3O)n5C(O)NR27R28, -(CR29R33)[!5S(O)7NR27R2B, (CR29R^n5NR27R28, -(CR29R30)n5OR27, -(CR29R30)n5S(O)n6R27, -NR30C(O)NR27R28, NR3QS(O)2NR27R20 or-NR^S(O)NR27R20 substituents, any of which may be optionally substituted;
R5, R6( rio_ ru, R12, R13, R14, R15, and R16 are each independently selected from one or more of H, Ci-salkyl—, C^ecycloalkyl-Co-ealkyl-, C^eheterocycloalkyl-Co-ealkyl-, aryl-Co^alkyl-, aryl-Csscycloalkyl-, aryl-Ca-aheterocycloalkyl-, heteroaryl-Ci-ealkyl-, heteroaryl-Csacycloalkyl- or heteroaryl-C^heterocycloalkyl-, any of which may be optionally substituted;
R17, R18, R19, R2Q, R21, R27, R28, R29, and R30 are each independently selected from H, Ci^alkyl-, Cyacycloalkyl-Coealkyl-, C-^heterocycloalkyl-Co-ealkyl-, aryl-Coealkyl-, aryl-Cs-acycloalkyl-, aryl—Caeheterocycloalkyl—, heteroaryl—Ci-ealkyl—, heteroaryl—Csscycloalkyl— or heteroaryl—C3. sheterocycloalkyl-, any of which may be optionally substituted;
-NR5R6 and -NR12R13 are each independently a linear structure, or, R5 and R6, or R12 and R13, respectively, are taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additionai heteroatoms selected from O, N, or S(O)m2;
250
-CR10R11 and -CR14R15 are each independently a linear structure, or, R10 and R11, or R14 and R'5 respectively, are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more heteroatoms selected from O, N, or S(O)m3;
-CR19R20 is a linear structure, or, R19 and R20 are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(0)m4;
-NR17R18 is a linear structure, or, R17 and R18 are taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)ms;
-CR29R30 is a linear structure, or, R29 and R30 are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)me;
-NR27R20 is a linear structure, or, R27 and R38 are taken together with the nitrogen atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m7;
wherein m1, m2, m3, m4, m5, m6, m7, n1, n2, n3, n4, n5 and n6 are each independently selected from 0, 1 or 2;
or a pharmaceutically acceptable sait, solvaté or a prodrug thereof.
2. The compound or sait of any one of the preceding daims, wherein:
R1 is selected from one of Cs-ecydoalkyl—Ctxaalkyl—, Cs-eheterocycloalkyl—Cosalkyl—, aryl—Coaalkyl-, or heteroaryl-Cosalkyl-;
G1 is selected from one of H, halo, -CN, -oxo-, -CF3, -OCF3, -OCHF2, -NR4 5RS, -NO2, -OCoealkyl, -S(O)niR12, -B(OH)2, -Cosalkyl, -C2-8alkenyl, -C2-âalkynyl, Csscycloalkyl-Cosalkyl-.Cl· Bheterocycloalkyl-Co-salkyl—, aryl-Co ealkyl—, or heteroaryl-Cosalkyl—.
3. The compound or sait of any one of the preceding daims, wherein G1 is selected from 0 to 3 of H, halo, -CN, -oxo-, -CF3, -OCF3, -OCHF2, -NR5R6, -NO2, -OCo-ealkyl, -S(O)niR12, -B(OH)2, -Coealkyl, —Cs-salkenyl, —C2salkynyl, Csscycfoalkyl—Cosalkyl—.Cssheterocycloalkyl—Cosalkyl—, arylCosalkyl-, or heteroaryl-Cosalkyl-.
4. The compound or sait of any one of the preceding daims, wherein:
R2 is selected from Cosalkyl-, Cascydoalkyl-Cosalkyl-, or Cssheterocycloalkyl-Cosalkyl-;
R2a is Cosalkyl-;
G2 is selected from one or more of H, halo, -CN, -CD3, -OCD3, -CF3, -OCF3, -OCHF2, or -OCoealkyl;
R2 and R2a are each independently a linear strudure, or, R2 and R2a are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, or N.
251
5. The compound or sait of any one of the preceding daims, wherein G2 is selected from 0 to 3 of H, halo, -CN, -CD3, -OCÛ3, ~CF3, -OCF3, -OCHF2, or-OC^alkyl.
6. The compound or sait of any one of the preceding daims, wherein:
R3 is selected from Coealkyl-, CMCydoalkyl-Coealkyl-, or C^aheterocycloalkyl-Co-salkyl-;
G3 is selected from one or more of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF3, OCHF2, -NR5R6, -Co-aalkyl, -C2-ealkenyl, -Cj-ealkynyl, -OCMalkyl, -S(O)niR10 * 12, -C(O)R12, C(O)NR12R13, or-C(0)OR12
7. The compound or sait of any one of the preceding daims, wherein G3 is selected from 0 to 3 of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF31 -OCHF2, -NR5R6, -Co-aalkyl, -Cs aalkenyl, Czealkynyl, -OCo-salkyî, -S(O)mR12, -C(O)R12, -C(O)NR12R13, or-C(0)OR12
8. The compound or sait of any one of the preceding daims, wherein:
R4 is selected from Co-aalkyl-, Cs-ecydoalkyl-Cs-aalkyl-, Cs-eheterocycloalkyl-Co-aalkyl-, aryl-Cosalkyl-, heteroaryl-Coaalkyl-, heteroaryl-Co-ecycloalkyl-, heteroaryl-Coaheterocycloalkyl-, or pyridine-N-oxide;
G4 is selected from one or more of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF3, OCHF2, -NR5R6, -NOz, -B(OH)2, -CONR12OH, -Ccwalkyl, Cs-scycloalkyl-Cc-salkyl-, C3aheterocycloalkyl—Cn aalkyl—, aryl—Co-aalkyl—, heteroaryl—Co-aalkyl—, —OCo-aalkyl, —S(O)niR12, C(O)R12, -C(O)NR12R13, -C(O)-C(O)NR12R13, -C(O)OR12, -C(O)-C(O)OR12, -OC(O)R12, NR12C(O)R13, -NR12C(O)OR13, -(CR14R1S)C(O)R13, -(CR14R1s)ntS(O)2NR12R13. (CR14R15)mNR12R13, -(CR14R15)mOR12, -<CRl4R15)niS(O)n2 R12, or-NR16C(C)NR12R13.
9. The compound or sait of any one of the preceding daims, wherein G4 is selected from 0 to 3 of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF31 -OCHF2, -NR5R6, -NO2, -B(OH)2, CONR12OH, -Co-aalkyl, Ca-ecycloalkyl-Coaalkyl- C^heterocycloalkyl-Co aalkyl-, aryl-C^aalkyl-, heteroaryl—Co-aalkyl—, -OCo-aalkyl, —S(O)niR12, —C(O)R12, —C(O)NR12R13, —C(O)-C(0)NR12R13, C(O)OR12, -C(O)-C(O)OR12, -OC(O)R12, -NR12C(O)R13, -NR12C(O)OR13, -(CR14R15)C(O)R13, (CR14R15)niS(O)2NR12R13, -(CR14R15)mNR12R13, -(CR14R15)niOR12, -(CR14R15)niS(O)n2 R12, orNRieC(O)NR12R13
10. The compound or sait of any one of the preceding daims, wherein:
Q1 is seleded from H, D, halo, —CN, —CD3, —OCD3, —oxo—, —CF3, —OCF3, -OCHF2, NR17R18, Coaalkyl-, aryl-Co aaikyl-, heteroaryl-Co-aalkyl-, Cs^cydoalkyl-Co-aalkyl-, Cs-eheterocydoalkyl-Coaalkyl-, aryl-Co-acydoalkyl-, heteroaryl-Ca-scydoalkyl-, Cs-aheterocycloalkyl-Cs-acycloaikyl-, C3ecycloalkyl-C^ecycloalkyl-, Ct-salkyl-Ca-eheterocycloalkyl-, Cs-aheterocycloalkyl-Caaheterocycloalkyl-, aryl-C^heterocydoalkyl-, heteroaryl-Ca-aheterocydoalkyl-, -OCo-aalkyl, C(O)-C(O)NR17R18, -C(O)-C(O)OR17, -OC(O)R17, -NR17C(O)R18, -NR17S(O)2R18, (CR19R20)n3C(O)R17, -(CR19R20)n3C(O)OR17, -(CRl9R20)n3C(O)NR’7R18. (CR19R20)n3S(O)2NR17R18, -(CR19R20)n3NR17R18, -(CR19R20)n3OR17, -(CR1sR2û)n3S(O)n.R17, NR21C(O)NR17R1B, -NR21S(O)2NR17R18, or-NR21S(0)NR17R18
252
11. The compound or sait of any one of the preceding daims, wherein:
R1 is selected from one of CsiCydoalkyl-Co-ealkyl-, Cseheterocycloalkyl-Coealkyl-, aryl-Cc eaikyi-, or heteroaryl-Co-ealkyl-;
G1 is selected from one of H, halo, -CN, -oxo-, -CF3, -OCFs, -OCHF?, -NR5R6, -NO2, -OCoealkyl, -S(O)niR12, -B(OH)î, -Co-ealkyl, -Ci-ealkenyl, -02-ealkynyl, Cs-ecycloalkyl-CMalkyl-.Cseheterocycloalkyl-Coealkyl-, aryl-Co-ealkyl-, or heteroaryl-Co-ealkyl-.
12. The compound or sait of any one of the preceding daims, wherein G1 is selected from 0 to 2 of H, halo, -CN, -oxo-, -CF3, -OCF3, -OCHF2, -NR5R6, -NO2, -OCo^alkyl, -S(O)mR12, -B(OH)2, -Cosalkyl, -Cî-ealkenyl, -C2-ealkynyl, Ca-ecycloalkyl-CMalkyl-Cjeheterocycloalkyl-Co-ealkyl-, arylCœalkyl-, or heteroaryl-Coeaikyl-.
13. The compound or sait of any one of the preceding daims, wherein:
R2 is selected from Co^alkyl-, CMcycloalkyl-Co^alkyl-, or Cs-eheterocycloalkyl—Coealky!-;
R2a is Co-ealkyl-;
G2 is selected from one or more of H, halo, -CN, -CD31 -OCD3. -CF3, -OCF3, -OCHF2, or -OCoealkyl;
R2 and R2a are each independently a linear structure, or, R2 and R2a are taken together with the carbon atom to which they are attached to form a 3-12 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, or N.
14. The compound or sait of any one of the preceding daims, wherein: R2 and R2a are each independently a linear structure, or, R2 and R2a are taken together with the carbon atom to which they are attached to fonm a 4-6 membered saturated or unsaturated ring, wherein said ring optionally indudes one or more additional heteroatoms selected from O, or N.
15. The compound or sait of any one of the preceding daims, wherein G2 is selected from 0 to 2 of H, halo, -CN, -CDj, -OCD3, -CF3, -OCF3, -OCHF2, or-OCw>alkyl.
16. The compound or sait of any one ofthe preceding daims, wherein:
R3 is selected from Cc^alkyl-, Cs-ecydoalkyl-Co-salkyl-, or C^heterocycloalkyl-Coealkyl-;
G3 is selected from one or more of H, D, halo, —CN, —CDa, —OCDs, —oxo—, —CF3, —OCF3, OCHF2, -NR5R6, —Coealkyl, -C2-6alkenyl, -Ca-ealkynyl, -OCo-ealkyl, -S(O)niR’2, -C(O)R12, C(O)NR12R13, or-C(O)QR12
17. The compound or sait of any one of the preceding daims, wherein G3 is selected from 0 to 2 of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF3, -OCHF2, -NR5R6, —Co-ealkyl, -C2-ealkenyl, C2-6alkynyl, -OCwalkyl, -S(O)mRÎ2, -C(O)R12, -C(O)NR12R13, or-C{0)OR12
253
18.
19.
20.
21.
The compound or sait of any one of the preceding daims, wherein:
R4 is selected from C06a1kyI—, C^cydoalkyl-Co-ealkyl-, C^heterocycloalkyl-Coealkyl-, aryl-Ctr ealkyl-, heteroaryl-Ccwalkyl-, heteroaryl-Cs^cycloalkyl-, heteroaryl-Cs^heterocydoalkyl-, or pyridine-N-oxide;
G4 is selected from one or more of H, D, halo, -CN, -CD3, -OCD3, -oxo-, -CF3, -OCF3, OCHF2, -NR5R6, -NO2. -B(OH)2, -CONR12OH, -Co^aikyl, C^scydcalkyl-Co^alkyl-, C3eheterocycloalkyl-Ctwalkyl-, aryl—Coealkyl—, heteroaryl-Coealkyl-, -OCo-salkyî, -S(O)mR12, C(O)R12, -C(O)NR12R13, -C(O)-C(O)NR12R13, -C(O)OR12, -C(O)-C(O)OR12, -OC(O)R12, NR12C(O)R13, -NR12C(O)OR13, -(CR14R15)C(O)R13, -(CR14R15)mS(O)2NR12R13, (CR14Rl6)mNR12R13, -(CR14R15)mOR12, -(CR14R15)niS(O)n2 R12, or -NR18C(O)NR12R13.
The compound or sait of any one of the preceding daims, G4 is selected from 0 to 2 of H, D, halo, -CN, -CDs, -OCDs, -oxo-, -CF3, -OCF3. -OCHF2, -NR5R6, -NO2, -B(OH)2. -CONR12OH, -Co. 6alkyl, C^cycloalkyl-Coealkyl-, C^heterocycloalkyl-Coealkyl-, aryl-Coealkyl-, heteroaryl-Coealkyl-, -OCo-ealkyl, -S(O)niR12, -C(O)R12, -C(O)NR12R13, -C(O)-C(O)NR12R13, -C(O)OR12, C(O)-C(O)OR12, -OC(O)R12, -NR12C(O)R13, -NR12C(O)OR13, -(CR14R15)C(O)R13, (CR14R15)niS(O)2NR12R13, -(CR14R15)mNR12R13, -(CR14R15)mOR12, -(CR14R15)mS(O)n2 R12, orNR16C(O)NR12R13.
The compound or sait of any one of the preceding daims, wherein:
Q1 is selected from H, D, halo, —CN, —CDa, —OCD3, —oxo—, —CF3, —OCF3, —OCHF2, NR17R18, Coealkyl—, aryl-Ca-salkyl-, heteroaryl-Coealkyl—, Cs-ecycloalkyl-Co-ealkyl-, Cs-eheterocycloalkyl-Ccsalkyl—, aryl-C&icydoalkyl-, heteroaryl-C^cycloalkyl-, C^heterocycloalkyl-C^cycloalkyl-, C3. çcycloalkyl-Ca-scycloalkyl-, Ci^alkyl-C^heterocycloalkyl-, Cs^heterocycloalkyl-Cssheterocycloalkyl-, aryl-C3.6heterocycloalkyl-, heteroaryl-C^eheterocydoalkyl-, -OCoealkyl, C(O)-C(O)NR17R18, -C(O)-C(O)OR17, -OC(O)R17, -NR17C(O)R18, -NR17S(O)2R18, (CR19R20)n3C(O)R17, —(CR19R20)n3C(O)OR17, -(CRl9R2û)n3C(O)NR17R18, (CR19R20)n3S(O)2NR17Rie, -(CR1sR20)n3NR17R18, -(CR19R20)n3OR17, -(CR19R20)n3S(O)n4R17, NR21C(O)NR17R18, -NR21S(O)2NR17R18, or-NR21S(0)NR17R18.
The compound or sait of any one of the preceding daims, wherein:
R2 is selected from methyl, ethyl, propyl, isopropyl, or one of the following groups:
254 and R2a is selected H, methyl, ethyl, propyl, isopropyl; or
R2 and R2a are taken together with the carbon atom to which they are attached to form one of the following groups:
22. The compound or sait of any one of the preceding daims, wherein:
R1 is selected from one of Cecycloalkyl-Coealkyl-, Ceheterocycloalkyl-Co-ealkyl-, 6-memberedaryl-Cœalkyl-, or 6-membered-heteroaryl-CoOalkyl-, wherein the 4-position of R1 is hydrogen, and wherein R1 is optionally substituted by one or more G1 substituents at the 2, 3, 5 and 6 positions.
23. The compound or sait of any one of the preceding daims, wherein:
-NR5R6 and -NR12R13 are each independently a linear structure, or, R5 and R6, or R12 and R13, respectively, are taken together with the nitrogen atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m2;
-CR10R11 and -CR14R15 are each independently a linear structure, or, R10 and R”, or R14 and R15 respectively, are taken together with the carbon atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more heteroatoms selected from O, N, or S(O)m3;
-CR19R20 is a linear structure, or, R19 and R20 are taken together with the carbon atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m< -NR17R1S is a linear structure, or, R17 and R18 are taken together with the nitrogen atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m5;
_Cr29r3û js a ijneac structure, or, R29 and R30 are taken together with the carbon atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)me;
-NR27R28 is a linear structure, or, R27 and R2B are taken together with the nitrogen atom to which they are attached to form a 4-8 membered saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(0)m7;
wherein m2, m3, m4, m5, m6, and m7 are each independently selected from 0,1 or 2.
255
24. The compound or sait of any one of the preceding daims, which is represented by the Formula la:
o la wherein X3 is selected from C=O, or CR10R11.
25. The compound of claim 24, wherein R2a is hydrogen.
26. The compound of claim 24 or 25, wherein R2 is Ci-valkyl-, Cs-iscycloalkyl-, or Ci-iîheteroalkyl any of which is optionally substituted with one or more independent G2 substituents.
27. The compound of any one of daims 24 to 26, wherein R1 is aryl or heteroaryl, any of which is optionally substituted with one or more independent G1 substituents.
28. The compound of claim 27, wherein R1 is aryl.
29. The compound of claim 28, wherein the 4-position of said aryl is H. and wherein the 2. 3, 5 and 6 positions of said aryl are optionally substituted by one or more G1 substituents.
30. The compound of daim 29, wherein said 2, 3, 5, and 6 positions are optionally substituted with halo, Ci ealkyl, Ci-cheteroalkyl, or Cs-ecycloalkyl.
31. The compound of any one of daims 24 to 30, wherein R3 is Ci.12a!kyl or Cvizheteroalkyl.
32. The compound of any one of daims 24 to 31, wherein R4 is Ci-1 ?alkyl, CMCydoalkyl, aryl, heteroaryl, aryl-Ci-ealkyl, heteroaryl-Ci-ealkyl, or C3-12heterocycloa!kyl, any of which is optionally substituted with one or more independent Q1 substituents.
33. The compound of any one of daims 24 to 32, wherein X3 is C=O.
34. The compound of any one of daims 24 to 32, wherein X3 is CR10R11 wherein R10 is hydrogen and R11 is hydrogen or methyl.
35. The compound or sait of any one of the preceding daims, which is represented by the Formula
Ih:
256
Rs
lh wherein X3 is selected from C=O, or CR10R11.
36. The compound or sait of any one of the preceding daims, wherein the 4-position of the phenyl ring in Formula lh is H, and wherein the 2, 3, 5 and 6 positions of the phenyl ring in Formula lh are optionally substituted by one or more G1 substituents.
37. The compound or sait of any one of the preceding daims, wherein R3 is selected from methyl, ethyl, propyl, isopropyl, -(CH2)i-3-cydopropyl, Ca-ecydoalkyl, -(CH2)i-3CN, -(CH2)i 3C(O)OH, or (CH2)i-3S(O)2Me.
38. The compound or sait of any one of the preceding daims, wherein:
X1 is selected from Ci-2aikyi or C=O;
X2 is selected from Ci-2aikyi, NR3, or O;
X3 is selected from C=O or CR10R11;
R10 and R11 are each independentiy equal to H or Ci-ealkyl;
m and n are each equal to 1.
39. The compound or sait of any one of the preceding daims, wherein the compounds of Formula I are inhibitors of ATX.
40. A compound selected from: (R)-N-(1-Cyclohexyl-2-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-
3-methylbenzamide;
(R)-3-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl) benzamide ;
(R)-2-Fluoro-3-methyl-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8yl)-1-oxobutan-2-yl)benzamide;
2-Fluoro-3-methyl-N-((2R,3R)-3-methyl-1-(3-methy!-2,4-dioxo-1-phenyl-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxopentan-2-yl)benzamide;
(R)-N-(1-(3-(Cyanomethyl)-1-(4-methoxyphenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-ethyl-2-fluorobenzamide;
(R)-2-Fluoro-N-(1-(1-(3-fluoro-4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan8-yl)-3-methy!-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(4-Cyanophenyl)-3-methyf-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
257 (R)-N-(1-(1-(3-Cyanophenyl)-3-methyi-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fiuoro-N-(3-methyl-1-(3-methyl-1-(4-(methylsulfonyl)phenyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(1-(1-(3-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-rTtethyl-1-(3-methyl-1-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazoi-5-yl)-2,4dioxo-1,3,8-triazaspiroI4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1 -(3-methyl-1 -(1-methyl-1 H-indazol-5-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(2-methyl-2H-indazol-5-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(1-(1-(imidazo[1,2-a]pyridin-6-yl)-3-methyi-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyi)benzamide trifluoroacetic acid sait;
(R)-2-Fiuoro-N-(3-methyl-1-(3-methyl-1-(3-(methylsulfonyl)phenyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-y[)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methy[-1-(1-methy!-1H-pyrazol-3-yl)-2,4-dioxo-1,3,8triazaspiro{4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(1-methyl-1H-pyrazol-4-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-5-Ethyl-2-fluoro-N-(3-methyl-1-(3-methyl-1-(3-methylimidazo[1,5-a]pyridin-6-yl)-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1 -<3-methyl-1 -(2-methyl-1 H-benzo[d]imidazol-6-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide trifluoroacetic acid sait; (R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3,8triazaspiro[4.5ldecan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzannide;
(R)_N-(1 -(1 -(3,4-Dihydro-2H-benzo[b][1 l4]oxazin-7-yl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide; (R)-2-Fluoro-N-(3-methyl-1-(3-methy!-2,4-dioxo-1-(6-oxo-1,6-dihydropyridin-3-yl)-1,3,8triazaspiro[4.5]decan-8-yi)-1-oxobutan-2-yl)-5-(trifluoromethyi)benzamide;
(R)-2-Fiuoro-N-(3-methyH-(3-methyl-1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-Cyclopentyi-2-(3-methyl-1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(1-(1-(6-methoxypyridin-3-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-
3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(4-(trifluoromethoxy)phenyl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(5-benzofuran)-1,3,8-triazaspiro[4.5]decan-8yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-1,3,8triazaspiro[4.5]decan-8-yi)-1-oxobutan-2-yi)-5-(trifluoromethyl)benzamide;
258 (R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7yl)-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyi)benzamide;
(R)-5-Ethyl-2-fluoro-N-(3-methy!-1-(3-methyl-2,4-dioxo-1-(2-oxo-213-dihydrobenzo[d]oxazol-6-yl)-
1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
(RJ-N-tl-il-tlH-BenzoIdltl^.SJtriazol-S-yO-S-methyl^^-dioxo-I.S.e-triazaspiro^.SJdecan-S-yQ-Smethyl-1-oxobutan'2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(3-Methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobiitan-2yl)-3-(trifluoromethyl)benzamide;
(R)-3-Ethyl-2-fluoro-N-(3-methyi-1-(3-methyl-2,4-dioxO'1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)1-oxobutan-2-yl)benzamide;
(R)-3,4-Dichloro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide;
(R)-2,5-Dichloro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide;
5-Ethyl-2-fluoro-N-((2R,3S)-3-nriethoxy-1-(3-methyl-2,4-dioxo-1-pheriyl-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
3-Ethyl-5-fIuoro-N-((2R,3S)-3-methoxy-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
(RJ-S-Ethyl^-fluoro-N-ÎS-methyl-l-iS-methyl^^-dioxo-l-phenyl-I.S.e-trlazaspiroK.Sldecan-e-yl)1 -oxob ut a n-2-y I) be nza m ide ;
5-Ethyl-2-fluoro-N-((2R,3R)-3-methoxy-1-(1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
3-Fluoro-N-((2R,3R)-1-(1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-
3-methyl-1-oxopentan-2-yl)-5-methyIbenzamide;
(R)-5-Cyclopropyl-2-fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-ptienyl-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
(Ri-S-Chloro^-fluoro-N-p-methyl-l-iS-methyl^Adioxo-l-phenyl-l.S.e-triazaspiroH.Sldecan-ey l)-1 -oxobutan-2-yl)benzamide; (R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)-5-(trifluoroiriethyl)benzaTnide;
(R)-5-Cyclopropyl-2-fluoro-N-(1-(1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)benzamide;
(R)-3-Ethyl-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-phenyH,3,8-triazaspiro[4.5]decan-8-yl)-1· oxobutan-2-yi)benzamide;
(R)-3-Ethyl-5-fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)’ 1 -oxobutan-2-yl)benzamide;
(Rj-S.S-Dichloro-N-p-methyl-l-ÎS-methyl^.A-dioxo-l-phenyl-I.S.e-triazaspiroH.SJdecan-e-yD-loxobutan-2-yl)benzamide;
5-ΟνοΙορΓθρνμ2-ΑυθΓθ-Ν-((2Ρ,3Β)-3-ηΊβίΡθχν-1-(1-(4-πιβίΡθχνρήΘΠνΙ)-3-ΓηβΙΙψΙ-2,4-Λοχο-1,3,8triazaspira[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
259 (R)-5-Ethyl-2-fluoro-N-(1-(1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8yl)-3-methyl-1-oxobutan-2-yl)benzamide;
(R)-2-Fluoro-N-(1-(1-(4-methoxyphenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyi)benzamide;
(R)-N-(1-(1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzannide;
(R)-N-(1-(1-(1H-lndazol-6-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspîro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yi)-3-methyl-1oxobutan-2-yl)-5-cyclopropyl-2-fluorobenzamide;
(R)-N-(1-(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-nnethyl-1oxobutan-2-yl)-5-ethyl-2-fluorobenzamide;
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyi-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-methylbenzamide;
(R)-N-(2-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-cyclopentyl-2oxoethyl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(2-(1-(1H-lndazol-5-yl)-3-methyl-2l4-dioxo-1,3l8-triazaspiro[4.5]decan-8-yl)-1-cyclobutyl-2oxo et h y I )-2-fI u oro-5- (trifl uoromethy I) benzam id e ;
(R)-N-(1-(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-3-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methy!-1oxobutan-2-yl)-3-chloro-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-methyl-5-(trifluoromethyl)benzamide;
(R). n-(1 -(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethoxy)benzamide;
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-methoxybenzamide;
(R)-N-(1-(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-5-(difluoromethoxy)-2-fluorobenzamide;
(R)-N-(1-(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2,5-dichlorobenzamide;
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2,5-difluorobenzamide;
(R) -N-(1-(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobiitan-2-yl)-1-admantanecarboxly amide;
(RJ-N-il-il-tlH-Indazol-S-yO-S-methyl^^-dioxo-I.S.S-triazaspiro^.SJdecan-e-yO-S-methyl-loxobutan-2-y!)-2-chloro-5-(trifluoromethyl)benzamide;
(S) -N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-tnazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-y!)-2-fluoro-5-(trifluoromethyl)benzamide;
N-(2-(1-(1H-lndazot-5-yl)-3-methyi-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-2fluo ro-5-(trifl uoromet hy I) ben za mid e ;
260
N-(1-(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8carbonyl)cyclopropyl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(1 -(1 -(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1 -oxopropan-2yl)-2-fl uoro-5-(trifluoromethyl) benza mide;
N-(3-(1-(1H-lndazol-5-yi)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-cart>onyl)oxetan-3yi)-2-fluoro-5-(trifluoromethyl)benzamide;
|ψ(1-(1-(1 H-lndazoi-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-2-methyl-1oxopropan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(Cyclopropylmethyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-Cyclopropyl-3-mettiyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxo buta n-2-yl)-2-fluoro-5-(t riflu o romethyl) be nza mide; (R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,3,8triazaspira[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
2-Fluoro-N-((R)-3-methyl-1-(3-methyl-2,4-dioxo-1-((S)-1-phenylethyl)-1,3,8-triazaspiro[4.5]decan8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
2- Fluoro-N-((R)-3-methyl-1-(3-methyl-2,4-dioxo-1-((R)-1-phenylethyl)-1,3,8-triazaspiro[4.5]decan8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(4-(Azetidin-3-ylmethoxy)phenyl)-3-melhyl-2,4-dioxo-1,3,8-triazaspiro[4.5ldecan-8-yl)-
3- methyl-1-oxobutan-2-yl)-2-fiuoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait;
(R).N-(1-(1-(4-(cyanomethoxy)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(Ρ)-2-Ρ1υ0Γ0-Ν-(3^βΙήνΙ-1-(3^β^Ι’1-(4-(0χβΐ3Π-3-νΐΓΤΐθΙΙΐ0χν)ρΙ1βπνΙ)-2,4-ΡΪ0Χ0-1,3,8triazaspiro|4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(1 -(1-(4-(2-hydroxyethoxy)phenyl)-3-methyl-2l4-dioxo-1,3,8-triazaspiro[4.5]decan8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait;
(R)-N-(1-(1-(4-(Azetidin-3-ylamino)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(4-(oxetan-3-ylamino)phenyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(l-(l-(4-Cyanobenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yi)-3-methyI-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-Benzyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(1-(1-(4-fluorobenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethy1)benzamide;
(R)-2-Fluoro-N-(1-(1-(4-methoxybenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
261
2-Fluoro-N-((2R)-3-methyl-1-(3-methy[-2,4-dioxo-1-(1-phenylethyl)-1,3,8-triazaspiro[4.5]decan-8yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1 -(3-methyl-1 -(4-(methylsulfonyl)benzyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(1-(1-((2-methoxypyridin-4-yl)methyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-y!)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-((2-methylpyridin-4-yl)methyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifIuoromethyl)benzamide;
(R)-2-Fiuoro-N-(1 -(1 -((6-methoxypy ridin-3-yl)methyl)-3-methy l-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoronnethyl)benzamide;
(R)-N-(1-(1-((1H-lndazol-5-yl)methyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(4-Chlorobenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yO-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(quinoxalin-6-ylmethyl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(3-Cyanobenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methy[-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(1 -(1 -(imidazo[1,2-a]pyridin-7-ylmethyl)-3-methy l-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-(3-(methylsulfonyl)benzy[)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(3-Chlorobenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifiuoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-((3-methyl-2-oxo-2,3-dihydrobenzoidloxazol-5-yl)methyl)-
2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide; (R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-((2-methyl-1H-benzo[d]imidazol-6-yi)methyl)-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(1-(1-(2-fluoro-5-methoxybenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyi)benzamide;
(R)-2-Fluoro-N-(1-(1-(2-fluoro-4-methoxybenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoronnethyl)benzamide;
(R)-N-(1-Cyclopropyl-2-(3-methy!-2,4-dioxo-1-(quinoxalin-6-yimethyl)-1,3,8-triazaspiro[4.5]decan8-yl)-2-oxoethyl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(1-Cyclobutyl-2-(3-methyi-2,4-dioxo-1-(quinoxa!!n-6-ylmethyl)-1,3,8-triazaspiro[4.5]decan-8yl)-2-oxoethyl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dîoxo-1-(pyrimidin-2-ylmethyl)-1l3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluorometliyl)benzamide;
(R)-N-(1-Cyclopentyl-2-(3-methyl-2,4-dioxo-1-(quinoxalin-6-ylmethyl)-1,3,8-triazaspiro[4.5]decan8-yl)-2-oxoethyl)-2-fluoro-5-(trifluoromethyl)benzamide;
262 (R)-N-(1-Cyclopentyl-2-(3-methyl-1-((2-methyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)methyl)-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxoethyt)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1 -(3-methyl-1 -<(2-methyi-[1,2,4]triazolo[1,5-a]pyridin-7-yl)methyt)-2,4dioxo-1,3,8-triazaspiro[4.5]decan-8-yi)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-((1-methyl-1H-pyrazo!-4-yl)methyl)-2,4-dîoxo-1l3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-((2-methylbenzo[d]oxazol-5-yl)methyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-((4-methylthiazol-2-yl)methyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yi)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-rnethyl-1-(3-methyl-1-((2-methylbenzo[d]oxazoi-6-yl)methyl)-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(2-Chloro-4-methoxybenzyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-1-((1-methyl-6-oxo-1,6-dihydropyridin-3-yl)methyt)-2,4dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-((1-Acetylazetidin-3-yl)methyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yJ)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(Ρ)-Ν-(1-(1,3-Οΐηΐ61ϊιγΙ-214-ΰίοχο-1,3,8-ΙΠ3ζ35ρΐΐΌ[4.5]ΰ6θ3η-8-γΙ)-3-ΓηβίΜγΙ-1-οχοΡυί3Π-2-γΙ)-2fluoro-5-(trifluoromethy[)benzamide;
(R)-N-(1 -(1 -Ethyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1 -oxobutan-2-yl)2-fluoro-5-(trïfluorornethyl)benzamide;
(R)-2-Fluoro-N-(1-(1-isopentyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-y!)-3-methyl-1oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-Cyclopentyl-3-methyl-2,4-dioxo-1É3,8-triazaspiro[4.5]decan-8-yl)-3-methyI-1oxobutan-2-yl)’2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyi-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-2yl)-5-(trifluoromethyi)benzamide;
(R)-Methyl-4-(8-(2-(2-fluoro-5-(trifluoiOmethyl)benzainido)-3-methylbirtanoyl)-3-methyl-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-1-yl)phenylcarbamate;
(R)-N-(1-(1-(4-(Cydopropanecarboxamido)phenyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4,5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzannide;
(R) -3-Methyl-N-(2-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxo-1-(tetrahydro2H-pyran-4-yi)ethyl)benzamide;
(S) -3-Methyl-N-(2-(3-methyl-4-oxo-1-pheny!-1,3,8-triazaspiro[4.5]decan-8-yl)-2-oxo-1-(tetrahydro2H-pyran-4-yl)ethyl)benzamide;
(R)-N-(1 -Cyclohexyl-2-(3-methyl-4-oxo-1-phenyl-1,3l8-triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-6methylpicolinamide trifluoroacetic acid sait;
(R)-N>3-Dimethyl-N-(3-methyl-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide;
5-Ethyl-2-fluoiO-N-«2R,3S)-3-methoxy-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane8-y1)-1-oxobutan-2-yl)benzamide;
263
N-((2R,3S)-3-Methoxy-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxobutan-
2- yl)-3-methylbenzamide;
3- Ethyl-N-((2R,3S)-3-methoxy-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide;
3-Ethyl-5-fluoro-N-((2R,3S)-3-methoxy-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8y l)-1 -oxobutan-2-yi) benzamide;
(R)-2-Methyl-N-(3-methyl-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)isonicotinamide;
(R)-3-Ethyl-N-(3-methyt-1 -(3-methyl-4-oxo-1 -phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1 -oxobutan2-yl)benzamïde;
(R)-4-Fiuoro-3-methyl-N-(3-methyl-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-
1-oxobuta n-2-yl) benzamide;
(R)-3-Fluoro-5-methyl-N-(3-methyl-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)1 -oxobuta n-2-y I) benzamide;
(R)-2-Fluoro-5-methyl-N-(3-methyl-1-(3-methyl-4-oxo-1-phenyl-1 ,3,8-triazaspiro[4.5]decan-8-yl)1-oxobutan-2-yl)benzamide;
(R)-3-Cyclopropyl-N-(3-methyl-1-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide;
(R)-3-Ch[oro-4-cyano-N-(3-methyl-1-(3-methyi-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide;
(R)-5-Ethyl-2-fluorO-N-(3-methyl-1-(3-methy1-4-oxo-1 -phenyl-1,3,8-triazaspiro[4.5]decan-8-yi)-1oxobutan-2-yl) benza mide;
(R)-N-(1-(1-(4-Carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro(4.5]decan-8-yl)-3-methyl-1oxobuta n-2-yl)-2-fluoro-3-methyl benzamide;
(R)-N-(l-(l-(3-Carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methy!-1oxob uta π-2-y l)-2-fl uoro-3-methyl be nzam id e;
(R)-4-(8-(2-(2-Fluoro-3-methylbenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)phenylboronic acid;
(R)-3-(8-(2-(2-Fluoro-3-methylbenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)phenylboronic acid;
(R)-4-(8-(2-(2-F1uoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyi-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yi)benzoic acid;
(R)-4-(8-(2-(2-Fluoro-3-methylbenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-4-(8-(2-(2-Fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methy!-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)-2-methoxybenzoic acid;
(R)-4-(8-(2-(5-Ethyl-2-fluorobenzamido)-3-methyibutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-4-(8-(2-(5-Cyclopropyl-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-113,8triazaspîro[4.5]decan-1 -yi)benzoic acid;
(R)-2-Chloro-4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-
1,3,8-triazaspiro[4.5]decan-1-yl)benzoîc acid;
264 (R)-4-(3-(Cyclopropylmethyl)-8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-4oxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-4-(8-(2-Cyclopentyl-2-(2-fluoro-5-(trifluoromethyl)benzamido)acetyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-N-(1-(1-(4-Carbamoylphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yi)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-4-(8-(2-(2-Fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8trîazaspiro[4.5]decan-1-yl)-2-methylbenzoic acid;
(R)-4-{8-(2-(2-Fluoro-5-(trifIuoromethyi)benzannido)-3,3-dimethylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-4-(8-(2-(3-Chloro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yl)benzoic acid;
(R)-4-(3-Methyl-8-(3-methyl-2-(2-methyl-5-(trifluoromethyl)benzamido)butanoyl)-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-4-(8-(2-(2-Fluoro-5-(trifiuoromethoxy)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-4-(8-(2-(2-Fluoro-5-methoxybenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-4-(8-(2-(1-Admantanecarboxamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-4-(8-(2-(5-(Difluoromethoxy)-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-4-(8-(2-(5-(Difluoromethoxy)-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-l-yl)benzoic acid;
(R)-4-(8-(2-(2-Fluoro-5-(trifluoromethoxy)benzannido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoicacid;
(R)-2-(4-(8-(2-(5-Ethyl-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yl)phenoxy)acetic acid;
(R)-N-(1-(1-(4-(2-Amino-2-oxoethoxy)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-ethyl-2-fluorobenzamide;
(R)-N-(1-(1-(4-(Cyanomethoxy)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl1-oxobutan-2-yl)-5-ethyl-2-fluorobenzamide;
(R)-N-(1-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8y|)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide trifluoroacetic acid sait; (R)-N-(1-(1-(4-Acetamidophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-5-ethyl-2-fluorobenzamide;
(R)-5-Ethyl-2-fluoro-N-(3-methy1-1 -(3-methyl-1-(4-(methyisulfonamido)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
(R)-2-Fluora-N-(3-methyl-1-(3-methyl-1-(4-(methylsulfonamido)phenyl)-4-oxo-1,3,8triazaspiro[4.5Idecan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-Methyl-4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-4-oxo-
1,3,8-triazaspiro[4.5]decan-1-yl)phenyicarbamate;
265 (R)-2-(8-(2-(3-F!uoro-5-methylbenzamido)-3-methyibutanoyl)-4-oxo-1-phenyl-1,3,8triazaspiro[4.5]decan-3-yl)acetic acid;
(R)-2-Fluoro-3-methyl-N-(3-nnethyl-1-(3-(3-(methylsulfonyl)propyl)-4-oxo-1-phenyl-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
(R)-N-(1-(3-(Cyanomethyl)-4-oxo-1-phenyl-1,3,8-triazaspirO[4.5]decan-8-yl)-3-methyl-1-oxobutan-
2-yl)-5-ethyl-2-fiuorobenzamide;
(R)-N-(1-(1-(4-Cyanophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobuta π-2-y l)-2-fluo ro-3-m et hylbe nzam id e;
(R)-N-(1-(1-(3-Cyanophenyl)-3-methyl-4-oxo-1,3É8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-3-methylbenzamide;
(R)-N-(1-(1-(4-Chlorophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(1-(1-(4-fluorophenyl)-3-methyl-2,4-dioxo-1,3<8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluo(Omethyl)benzamide;
(R)-N-(1-(1-(3,4-Dichlorophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yi)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-FluorO-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-p-tolyl-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)-5-(trifiuoromethyl)benzamide;
(R)-N-(1-(1-(1 H-lndol-5-yl)-3-methyl-2,4-dioxo-1 t3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(4-(trifluoromethyl)phenyl)-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide; (R)-N-(1-(1-(3-Chlorophenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8- yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(pyridin-2-yl)-1,3,8-triazaspiro[4.5]decan-8-y[)1-oxobutan-2-yl)-5-(trifluoromethyl)benzannide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(pyridin-3-yl)-1,3.8-triazaspiro[4.5]decan-8-yl)1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyl-2,4-dioxo-1-(4-deuterium-phenyl-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifltioromethyl)benzamide;
(R)-N-(1-(1-(Benzo[d][1,3]dioxol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yi)-2-fluoro-5-(trifluoromethyi)benzannide;
(R)-N-(1-(1-(3-Chlorophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-3-methylbenzannide;
(R)-N-(1-(1-(4-Chlorophenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobuta π-2-y i)-3-m ethy I benzam id e ;
(R)-N-(1-(1-(3-Bromophenyl)-3-methyi-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-3-methylbenzamide;
(R)-3-Methyl-N-(3-methyl-1-(3-methyl-4-oxo-1-(pyridin-3-yl)-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)benzamide;
(R)-N-(1-(1-(2-Chlorophenyl)-3-methyi-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-y!)-3-methylbenzamide;
266 (R)-N-(1-(1-(4-Methoxyphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-3-methyibenzarnide;
(R)-N-(1-(1-(3-Methoxyphenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-3-methyl benzamide ;
(R)-N-(1-(1-(4-Bromophenyl)-3-methyl-4-oxo-1,3,8-triazaspirci[4.5]decan-8-y!)-3-methyl-1oxobutan-2-yl)-3-methyl benzamide;
(R)-5-Ethyl-2-fluoro-N-(3-methyl-1-(3-methyl-1-(4-(methyisulfonyl)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
(R)-5-Ethyl-2-fluoro-N-(3-methyl-1-(3-methyl-1-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-oxo-
1.3.8- triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)benzamide;
(R)-5-Ethyl-2-fluoro-N-(1-(1-(4-methoxypheny!)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-
3- methyl-1-oxobutan-2-yl)benzamide;
(R)-5-Ethyl-2-fluoro-N-(3-methyl-1-(3-methyl-1-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-
4- oxo-1,3,8-tfiazaspiro[4.5]decan-8-yl)-1-oxobiitan-2-yl)benzamide;
(R)-2-Fluoro-N-(3-methyl-1-(3-methyi-1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifiuoromethyl) benzamide;
(R)-2-Fluoro-N-(3-methyl-1 -(3-methyl-1 -(4-(methylsulfonyl)phenyl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-2-Fluoro-N-(1-(1-(imidazo[1,2-a]pyridin-6-yÎ)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-
3- methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide trifluoroacetic acid sait;
(R)-3-Chloro-N-(3-methyl-1-(3-methyl-1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyi)benzamide;
(R)-N-(1-Cyclopentyl-2-(3-methy 1-1-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-oxo-1,3,8triazaspiro[4.5]decan-8-yl)-2-oxoethyl)-2-fluoro-5-(trifluoromethyl) benzamide;
2-Fluoro-N-((2R)-1-(1-(4-methoxyphenyl)-2,3-dimethyl-4-oxo-1.3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(trifluoromethyl) benzamide;
4- ((R)-8-((R)-2-(5-Ethyl-2-fluorobenzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8- triazaspiro[4.5]decan-1-yl)benzoic acid;
4-((S)-8-((R)-2-(5-Ethyl-2-fiuorobenzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-1,3,8triazaspiro[4.5]decan-1 -yl)benzoic acid;
4-((R)-8-((R)-2-(2-F!uoro-5-(trifluoromethyi)benzamido)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-
1.3.8- triazaspiro[4.5]decan-1-yl)benzoic acid;
4-((S)-8-((R)-2-(2-Fluoro-5-(trifluoromethyl)benzamîdo)-3-methylbutanoyl)-2,3-dimethyl-4-oxo-
1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-N-(1 -(l-(lH-lndazol-5-yl)-3-methyl-4-oxo-1.3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl) benzamide;
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyi-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-rnethyl-1oxobutan-2-yl)-5-ethy!-2-fluorobenzamide;
(R)-N-(1 -(1 -(1 H-Benzo[d]imidazol-6-yl)-3-methy1-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl1-oxobutan-2-yl)-5-ethyl-2-fluorobenzamide;
(R)-3-Methyl-N-(3-methyi-1-oxo-1-(2-oxo-1-phenyl-3-oxa-1,8-diazaspiro[4.5]decan-8-yl)butan-2yl) benzamide;
267 (R^-Fluoro-N-iS-melhyl-l-n-methyi-l-^-ioxetan-S-yîaminoiphenylH-oxo-IAStriazaspiro[4.5]decan-8-yl)-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide; (R)-2-FIuoro-N-(1 -(1 -((3-methoxycyclobuty l)methyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide; (R)-N-(1-(1-(4-(1H-1,2,4-Triazoi-3-yl)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzaniide;
(R)-Methyl-4-(8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-mettiyl-2,4-dioxo-
1,3,8-triazaspiro[4.5]decan-1-yl)benzoate;
(R)-4-(8-(2-(5-Cyclopropyl-2-fluorobenzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1 -yl)benzoic acid;
(R)-4-(8-(2-(2-Fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)benzoic acid;
(R)-N-(1-(1-(4-(2H-Tetrazol-5-yl)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(4-(2H-Tetrazol-5-yl)phenyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yî)-3methyl-1-oxobutan-2-yi)-2-fluoro-5-(trifluoromethoxy)benzamide;
(R)-N-(1-(1-(4-(2H-Tetrazo!-5-yl)pïienyl)-3-mettiyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-5-(difluoromethoxy)-2-fluorobenzamide;
(R)-N-(1 -(1 -(4-(2H-Tetrazol-5-yl)phenyl)-3-methyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(1 H-lndazol-5-yl)-3-methyt-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)picolinamide;
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxo b uta n-2-y i)n icoti nam i d e ;
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3>8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)cyclohexanecarboxamide;
(R)-N-(l-(l-(lH-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)isonicotinamîde;
(R)-N-(1-(1-(1 H-Indazol-S-yO-S-methyl^^dioxo-I.S.e-triazaspiro^.SJdecan-e-yO-S-methyl-loxobutan-2-yl)pivalamide;
(R)-N-(1-(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-1riazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutart-2-yl)benzamide;
(R)-N-(1-(1-(1 H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobuta n-2-yl)t hiazo I e-2-carboxam id e ;
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-4-(trifluoromethyl)thiazole-2-carboxamide;
(R)-N-(1-(1-(1H-lndazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-N-methyl-5-(trifluoromethyl)benzamide;
(R)-4-(3-(2-(Dimethylamino)ethyl)-8-(2-(2-fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-
2,4-dioxo-1,3,8-triazaspiro[4.5]decan-1-yl)benzoic acid trifluoroacetic acid sait;
(R)-4-(3-(2-(Dimethylamino)ethyl)-8-(2-(2-fluoro-5-(trifluoromethyl) benzamido)-3methylbutanoylH-oxo-I.S.S-triazaspiroH.Sldecan-l-ylJbenzoic acid trifluoroacetic acid sait;
268 (R)-2-Fluoro-N-(3-methyl-1-(3-methyi-2,4-dioxo-1-(pyridin-4-yl)- 1,3,8-triazaspiro[4.5]decan-8-yl)1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-4-(8-(2-(2-Fluoro-5-(trifluoromethyl)benzamido)-3-methylbutanoyl)-3-methyl-2,4-dioxo-1,3,8triazaspiro[4.5]decan-1-yl)pyridine 1-oxide;
(R)-2-Fluoro-N-(1-(1-(4-methoxycyclohexyl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-
3-methyl-1-oxobutan-2-yl)-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-Cyclohexyl-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5] decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(3-Methyl-1-(3-methyl-2,4-dioxo-1-(4-methoxy-d3-phenyl)-1,3,8-triazaspiro[4.5]decan-8-yl)1-oxobutan-2-yl)-3-(trifluoromethyl)-5-fluorobenzamide;
(R)-N-(3-Methyl-1-(3-methyl-2,4-dioxo-1-(4-ethoxyphenyl)-1,3,8-triazaspiro[4.5]decan-8-yl)-1oxobutan-2-yl)-3-(trifluoromethyl)-5-fluorobenzamide;
(R)-N-(1-(1-(Benzo[d]oxazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3-methyl-1oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
(R)-N-(1-(1-(2-Methylbenzo[d]oxazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-3methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide;
or a pharmaceutically acceptable sait thereof.
41. A pharmaceutical composition comprising the compound or sait of a compound according to any one of daims 1 to 40, formulated with or without one or more pharmaceutical carriers.
42. A method for the treatment of at least one of cancer, lymphocyte homing, chronic inflammation, neuropathie pain, fibrotic diseases, thrombosis, and cholestatic pruritus mediated at least in part by ATX comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of daims 1 to 40 or a pharmaceutical composition of daim 41.
43. A method for the treatment of at least one of cancer, lymphocyte homing, chronic inflammation, neuropathie pain, fibrotic diseases, thrombosis, and cholestatic pruritus comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of daims 1 to 40 or a pharmaceutical composition of daim 41 that binds to and inhibits ATX providing a réduction in LPA levels.
44. A method of treating fibrosis, inflammation, cancer, angiogenesis, or pain in a mammal comprising administering a therapeutically effective amount of a compound according to any one of daims 1 to 40, or a pharmaceutically acceptable sait thereof or a pharmaceutical composition of daim 41, to the mammal in need thereof.
45. A method of treating lung fibrosis, asthma, chronic obstructive pulmonary disease (COPD), rénal fibrosis, acute kidney injury, chronic kidney disease, liver fibrosis, skin fibrosis, fibrosis of the gut, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer,
269 colon cancer, bowel cancer, head and neck cancer, melanoma, multiple myeloma, chronic lymphocytic leukemia, B cell lymphoma, T cell lymphoma, cancer pain, tumor metastasis, transplant organ rejection, scleroderma, ocular fibrosis, âge related macular degeneration (AMD), diabetic retinopathy, collagen vascular disease, atherosclerosis, Raynaud's phenomenom, rheumatoid arthritis, osteoarthritis or neuropathie pain in a mammal comprising administering a therapeutically effective amount of a compound according to any one of daims 1 to 4, or a pharmaceutically acceptable sait thereof or a pharmaceutical composition of daim 41, to the mammal in need thereof.
46. The method according to any one of daims 42 to 45, comprising administering to the mammal one or more additional therapeutically active agents selected from; corticosteroids, immunosuppressants, analgésies, anti-cancer agents, anti-inflammatories, non-steroidal antiinflammatories, dual cyclooxygenase-1 and -2 inhibitors, cyclooxygenase-2 sélective inhibitors, TNFa blockers, kinase inhibitors, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists, leukotriene formation inhibitors, prostaglandin receptor antagonists, prostaglandin formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase A1 inhibitors, phospholipase A2 inhibitors, lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, and LPA receptor antagonists.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/975,123 | 2014-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA18996A true OA18996A (en) | 2019-11-22 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10233182B2 (en) | Substituted spirocyclic inhibitors of autotaxin | |
AU2018217488B2 (en) | Aminotriazolopyridines as kinase inhibitors | |
EP3743430B1 (en) | Aminopyrrolotriazines as kinase inhibitors | |
KR102516711B1 (en) | P2x7 modulators | |
JP6592008B2 (en) | Substituted N- (2-amino) -2-oxoethylbenzamide inhibitors of autotaxin and their preparation and use in the treatment of LPA-dependent or LPA-mediated diseases | |
JP7112488B2 (en) | Heterocyclic compounds as protein kinase inhibitors | |
WO2014074657A1 (en) | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | |
CA3038756A1 (en) | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors | |
AU2019228568A1 (en) | Piperidinyl-3-(aryloxy)propanamides and propanoates | |
CA3074059A1 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
TW202122382A (en) | Hydantoin derivative | |
KR102133595B1 (en) | Heterocyclic compound as a protein kinase inhibitor | |
OA18996A (en) | Substituted Spirocyclic Inhibitors of Autotaxin | |
KR102112336B1 (en) | Heterocyclic compound as a protein kinase inhibitor | |
RU2783723C2 (en) | Heterocyclic compound as protein kinase inhibitor | |
EA042342B1 (en) | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | |
EA041386B1 (en) | SPIROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
NZ787918A (en) | Pyridopyrimdinone CDK2/4/6 inhibitors |